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ABSTRACT 
Epilepsy is the most common serious disease of the brain. Magnetic Resonance 
Spectroscopy (MRS) is a novel imaging technique that offers the opportunity for co-
localising biochemical information relating to metabolites specific to the study of 
epilepsy with high resolution MRI. 
 
Aims:   
The work included in this thesis was undertaken with two fundamental aims. The first 
was to apply a standardised MRS methodology in order to gain reproducible semi-
quantitative information about the variation of relevant neuro-metabolites such as 
gamma amino butyric acid (GABA), glutamate (as glutamate plus glutamine [GLX]), 
N acetyl aspartate (NAA), myo-inositol (Ins) and creatine plus phosphocreatine (Cr) 
within epilepsy syndromes or pathological groups. The second main aim was to test a 
series of hypotheses relating to the regulation of the concentrations of these 
metabolites in the region of epileptic seizures, immediately following seizures and 
associated with particular medical and surgical treatment interventions.  
 
Methods: 
Seven experiments were performed in this thesis. In all seven studies the findings in 
the patient groups were compared against results from an acquired control group 
made up of healthy volunteers. 
 
In the first experiment [3.1] twenty patients with temporal lobe epilepsy, with (10), 
and without hippocampal sclerosis were studied using multi voxel magnetic resonance 
spectroscopic imaging (MRSI) sequences in order to examine for differences in the 
obtained metabolites N acetyl aspartate (NAA), creatine plus phosphocreatine (Cr), 
choline containing compounds (Cho), GLX and myo-inositol (Ins) across the 
pathological groups and against a control population. 
 
In experiments [3.2], [3.3], [3.4] and [3.6] an MRS protocol that incorporated a 
double quantum filter acquisition sequence was applied in order to allow 
measurement of GABA+ (a combined measure of GABA plus homocarnosine) in 
addition to measurement of the metabolites examined in [3.1]. Studies were 
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performed in the occipital lobes in patients with idiopathic generalised epilepsy (IGE) 
(n =10) or occipital lobe epilepsy (n = 10) [3.2], in the frontal lobes in patients with 
IGE (n = 21) and within regions of the MRI visible pathology in patients with large 
focal malformations of cortical development (MCD, n =10) [3.4]. In the last 
experiment using this technique patients with hippocampal sclerosis and temporal 
lobe epilepsy (n = 16) were studied in the ipsilateral and also in the contralateral 
temporal lobes and following temporal lobe surgery (n = 10) [3.6]. 
 
In experiment [3.5] ten patients were examined whilst taking and when not taking 
sodium valproate in order to further examine for an effect of this medication on the 
measured metabolite concentrations. 
 
In experiment [3.7] ten patients were studied immediately after an epileptic seizure 
and then again during a subsequent inter-ictal period in order to examine for an 
influence of the recent seizure on the measured concentrations of the main 
metabolites.  
  
Results: 
MRSI in the temporal lobes in patients with temporal lobe epilepsy identified low 
NAA in the anterior hippocampus that was most severe in those patients with 
hippocampal sclerosis. GLX elevation was a feature in the patients without 
hippocampal sclerosis. Metabolic abnormality was most marked in the anterior 
compared to the posterior hippocampal regions. 
 
GABA+ levels were elevated in patients with MCD and in the ipsilateral temporal 
lobe in temporal lobe epilepsy associated with hippocampal sclerosis but levels were 
not altered in patients with IGE or OLE. GLX was also elevated in MCD in the region 
of MRI visible abnormality and in IGE patients when measured in the frontal lobes. 
Low NAA was a feature of TLE and MCD. Patients with IGE showed normal NAA 
levels in the occipital lobes but reduced frontal lobe concentrations. 
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Cr concentrations were abnormal in the immediate post ictal period but normalised 
within 120 minutes. NAA was not altered and no significant change in lactate 
concentrations was observed. 
 
Finally sodium valproate treatment was associated with a reduction in the levels of Ins 
and with unchanged NAA and GLX levels. 
 
Main Conclusions: 
MRS techniques demonstrate metabolite abnormalities in epileptic patients. NAA is 
the most sensitive metabolite marker of chronic pathology but levels are insensitive to 
recent seizure history. These findings repeat earlier observations of the usefulness of 
NAA measurement in the assessment of chronic epilepsy whilst illustrating ongoing 
uncertainty as to the correct patho-physiological interpretation of reduced NAA 
levels.  
 
Measurable changes in the combined Cr signal are detectable whilst elevated lactate is 
not reliably observed following brief epileptic seizures at 1.5T. This finding indicates 
a potential role for MRS in functional activation studies. 
 
Malformations of cortical development have abnormal levels of both GABA+ and 
GLX and MCD sub-types may well demonstrate different metabolite profiles. This 
finding suggests that MRS could be a useful tool in the MRI classification of MCD 
and in the pre-surgical assessment of patients with focal malformations. 
 
Following successful temporal lobe surgery levels of NAA remain unchanged but 
NAA/Cr levels appear to normalise in the contralateral temporal lobe. 
 
NAA and GLX/NAA levels were altered in the frontal lobes but not in the occipital 
lobes in Idiopathic Generalised Epilepsy. This finding provides imaging support for 
frontal lobe dysfunction as a cause or consequence of IGE.  
 
Metabolite levels are affected by administered antiepileptic drugs. Sodium valproate 
reduces the levels of MRS visible Ins levels whilst topiramate and gabapentin appear 
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to be associated with higher GABA+ levels. These findings may be of major 
importance in the assessment of treatment effect or in the investigation of patients 
with possible drug resistance. The effect of valproate on Ins levels may become 
particularly interesting in the light of a growing understanding of the role of astrocyte 
dysfunction in a range of neurological conditions which include migraine, epilepsy, 
Alzheimer’s disease, motor neurone disease and in ischaemic lesions.
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1.1 Introduction and Background 
 
1.1.1 Background 
This thesis investigates the application of an MRI technology, Magnetic Resonance 
Spectroscopy (MRS), to the study of epilepsy. Prior to the period during which this 
work was undertaken several groups had reported MRS findings in patients with 
epilepsy. These studies, which had generally reported on only the major visible 
metabolites and which had used metabolite ratios rather than individual metabolite 
concentrations, had indicated that MRS may be a sensitive tool for the in vivo 
assessment of biochemical disturbance associated with epilepsy [for a summary of 
the available evidence prior to the period of this thesis see(Duncan, 1996;Kuzniecky, 
1999)].  This thesis builds on that preliminary evidence and takes advantage of 
developments in scanner hardware and pulse sequences which allowed the semi-
quantification of neuro-metabolites such as glutamate and γ-amino butyric acid 
(GABA) that are of fundamental importance to understanding epilepsy. 
 
The work included in this thesis was undertaken based upon several hypotheses. 
Namely that: 
 
I     Cortical excitability in idiopathic generalised epilepsy (IGE) is associated with 
reduced concentrations of GABA and / or raised concentrations of glutamate and 
glutamine in the cerebral cortex. 
 
II In patients with focal seizures, there will be a disturbance in GABA and / or 
glutamate levels in the region of the epileptic focus compared to healthy controls 
measured in the same anatomical region. 
 
III There will be measurable metabolite abnormalities in epileptogenic 
malformations of cortical development as a consequence of the abnormal 
development of this tissue. 
 
IV There will be a measurable disturbance of brain metabolites at the site of 
interictal epileptiform activity that will help to characterise the epileptic focus. 
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V  Immediately following focal seizures there will be a transient disturbance in those 
measurable metabolites relevant to cell energetics and neurotransmission such as 
lactate, GABA, glutamate and glutamine and phosphocreatine. 
 
In order to evaluate these hypotheses the work has necessarily covered a wide range 
of epilepsy syndromes and seizure types which are briefly introduced in this 
Introduction. Other sections of this chapter are intended to introduce the underlying 
principles and techniques of MRS relevant to my work and to present the published 
work from other experimenters in the field that sets the foundation on which this 
work has been based.  
 
MRS is potentially a uniquely important imaging tool: an MRS experiment can 
provide simultaneous in vivo data relating to neuronal function and / or cell loss, 
glial function, and neurotransmitter cycling in regions of interest mapped directly 
upon structural MR volumetric images. MRS measured metabolite concentrations 
also appear to be sensitive to exogenous factors such as concomitant antiepileptic 
medications and endogenous factors such as recent seizure history. The Results and 
Discussion Chapters of this thesis consider these themes further while the key 
measured metabolites and some fundamental considerations relating to cell 
energetics and neurotransmitter cycling in the human brain are briefly introduced 
first in this Introduction.     
Finally, this work is an investigation of epilepsy and epileptic syndromes and for 
this to be informative a clear understanding of the classification of epileptic seizures 
and syndromes is necessary from the outset.  
 
1.1.2 Classification of epileptic seizures and syndromes 
Epilepsy is a condition characterised by the occurrence of recurrent epileptic 
seizures of primary cerebral origin. Epileptic seizures consist of a paroxysmal 
dysfunction of cerebral neuro-physiological function and, in general, have a 
correlate on the electroencephalogram (EEG). 
 
The International League Against Epilepsy (ILAE) first introduced a classification 
of the epilepsies in 1970(Merlis, 1970) with subsequent revisions occurring in 1985 
and in 1989(The International League Against Epilepsy, 1989). Classification of 
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seizure type was revised in 1981. In 2001 the ILAE published a proposed new 
diagnostic scheme for people with epileptic seizures and epilepsy(Engel, Jr., 
2001)which described an approach to classification based upon five components or 
axes: ictal phenomenology, seizure type, syndrome, aetiology and impairment. 
Seizure type was divided into self-limited seizures (incorporating generalised 
seizures and focal onset seizures); continuous seizure types incorporating focal and 
generalised status epilepticus; and precipitating stimuli for reflex seizures. In 2006 
the ILAE decided to defer introduction of a new classification system but recognised 
that the 1989 classification system was imperfect(Engel, Jr., 2006). In this system an 
epilepsy syndrome is a complex of signs and symptoms that define a unique 
epilepsy condition and is more than just the seizure type (e.g. Idiopathic Generalised 
Epilepsy is an epilepsy syndrome characterised by a cluster of signs and symptoms 
occurring together). An epilepsy disease is a pathological condition with a single 
specific well defined aetiology (e.g. Unverricht-Lundborg)  
 
In 2009 the ILAE organised for consultation on a revised terminology for the 
orgnisation of the epilepsies(ILAE Commission on Classification and Terminology, 
2009). The revised terminology will make a number of changes to the above 
classification system. Amongst these changes is the recognition that generalised 
seizures may originate at some location but rapidly engage bilaterally distributed 
networks whilst focal seizures may be discretely localised or more widely 
distributed in networks limited to one hemisphere but will have onset that is 
consistent from one seizure to another. The use of the term “syndrome” will be 
restricted to a group of clinical entities that are reliably identified by a cluster of 
electro-clinical characteristics. Underlying aetiology will be grouped as Genetic, 
Structural / Metabolic and Unknown. 
 
 
 
 
 
 
 
 
P a g e  | 27 
 
Seizure classification will also change with a new structure for the description of 
generalised seizures  
GENERALIZED SEIZURES 
Tonic Clonic (in any combination) 
Absence:             
Typical 
Atypical 
Absence with special features 
                           Myoclonic absence 
                           Eyelid myoclonia 
Myoclonic           
Myoclonic 
            Myoclonic atonic 
            Myoclonic tonic 
Clonic 
Tonic 
Atonic 
The description of focal seizures will also change so that the current concepts of 
“simple” and “complex” partial seizures and secondarily generalised seizures will be 
revised to reflect the often difficult distinction between strictly “simple” and 
“complex” seizures. 
The old concept of an “epileptic disease” will be lost and syndromic classification as 
“electroclinical” syndromes will be tighter and will represent distinctive disorders 
identifiable on the basis of a typical age onset, specific EEG characteristics, seizure 
types, and often other features which, when taken together, permit a specific 
diagnosis. Other common entities which will represent electro-clinical syndromes 
but which do represent common clinical entities such as mesial temporal lobe 
epilepsy will be referred to as Constellations. Epilepsies secondary to specific 
structural or metabolic lesions or conditions and Epilepsies of Unknown Cause will 
represent the remaining two classification groups. The terminology “Idiopathic 
Generalised Epilepsy” for the cluster of epilepsy syndromes described in Section 1.3 
will remain for the time being but with the recognition that the term “idiopathic” is 
now inaccurate and out-dated. 
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1.2 Neurotransmission 
 
1.2.1 Introduction 
1.2.2 Energetics of neurotransmission 
1.2.3 Glutamate metabolism 
1.2.4 Glutamate receptor function 
1.2.4.1 AMPA receptors  
1.2.4.2 Kainate Receptors 
1.2.4.3 NMDA Receptors 
1.2.5 Glutamate and epilepsy 
1.2.6 GABA metabolism 
1.2.7 GABA receptors  
1.2.7.1 GABAA receptors 
1.2.7.2 GABAB receptors 
1.2.7.3 GABAc receptors 
1.2.8 GABA and Epilepsy 
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1.2.1 Introduction 
Several of the neuro-metabolites that are visible to MRS play an important role in 
the fundamental processes of brain cells, including energy balance and signalling. 
These metabolites include glutamate, glutamine, γ-amino butyric acid (GABA), 
lactate and creatine (Creat) plus phosphocreatine (PCreat). Glutamate and GABA 
are respectively the principal excitatory and inhibitory neurotransmitters in the brain 
and the study of both is fundamental to an understanding of epilepsy.  
 
1.2.2 Energetics of neurotransmission 
Brain metabolism accounts for 20% of the body’s resting metabolism(Leonard et al., 
2007). MRS studies have shown that glucose utilisation is closely linked to the rate 
of brain glutamate – glutamine cycling between neuronal and glial compartments 
and indicate that up to 75% of total energy expenditure in grey matter is devoted to 
cell to cell signalling(Pellerin et al., 1998;Sibson et al., 1998a;Sibson et al., 
1998b;Rothman et al., 1999;Attwell and Laughlin, 2001).  
 
Under normal conditions the brain derives almost all of its energy from the oxidation 
of glucose(Simpson et al., 1978). For this it needs a continuous supply of glucose 
and oxygen delivered by the blood supply through a rich network of vessels. 
Maintenance of bio-energetic homeostasis requires that the metabolic rate varies 
rapidly in response to abrupt changes in cell energy demand. Glycolysis is the series 
of enzyme catalysed reactions in the cytosol responsible for the breakdown of 
glucose with the formation of two molecules of ATP and pyruvate. In the presence 
of oxygen the pyruvate so formed would normally enter the Krebs cycle 
(tricarboxylic acid cycle [TCA]) and undergo oxidative phosphorylation. 
 
Glucose is transported into neurones and astrocytes by several members of the 
GLUT family of membrane spanning proteins. In the brain the important 
transporters are GLUT1 (present on astrocyte cell membranes) and GLUT3 (present 
on neuronal cell membranes)(Maher et al., 1994). They show maximum transport 
rates several orders of magnitude higher than seen with non-brain located glucose 
transporters so glucose transport is not usually a rate limiting step for 
glycolysis(Maher et al., 1994). Astrocytes are ideally positioned to sense increases 
in synaptic activity and increase glucose uptake. These cells cover the surface of the 
intra-parenchymal capillaries with specialised processes called astrocytic end feet 
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and GLUT1 are expressed on these feet(Morgello et al., 1995) suggesting that 
astrocytes may be a likely site of prevalent glucose uptake. Other astrocyte processes 
wrapped around synaptic contacts possess receptors and reuptake sites for 
neurotransmitters.  
 
The conventional view that brain energy metabolism is almost exclusively aerobic 
was challenged by the observation of a decoupling of O2 consumption  from glucose 
utilisation in activated brain tissue(Fox and Raichle, 1986;Villringer and Dirnagl, 
1995). Further support for these observations was obtained from MRS work in 
humans (Frahm et al., 1996; Prichard et al., 1991; Sappey-Marinier et al., 1992), and 
in animals (Fellows et al., 1993; Hu and Wilson, 1997b), showing an increase in 
tissue or extracellular lactate during cerebral activation and in turn this has led to a 
detailed discussion as to the potential role of lactate as a neuronal fuel in activated 
brain tissue. Most discussion has centred around a proposal by Pellerin and 
Magistretti and referred to as the astrocyte–neuron lactate shuttle (ANLS) 
hypothesis (Pellerin and Magistretti, 1994, 2003) which has sought to link export of 
astrocyte produced lactate via aerobic glycolysis (i.e. glycolysis derived lactate 
despite the presence of oxygen) to neurons with glutamate-glutmamine cycling 
between these two cell compartments. 
 
This hypothesis was based in large part on work performed using 
13
C MRS by 
Sibson and others where rates of total glutamate to glutamine cycling were measured 
against neuronal glucose oxidation rates in anaesthetised rats and at different levels 
of electrical activity  and which found a linear relationship above electrical baseline 
with a slope of 1 indicating a 1:1 relationship(Sibson et al., 1997;Sibson et al., 
1998a;Sibson et al., 1998b;Rothman et al., 1999). This was combined with glial 
culture studies performed which described glial glutamate uptake(Flott and Seifert, 
1991),  co-transport with Na
+
 stimulated glial glycolysis(Kimelberg et al., 1989) and 
lactate production(Ercinska and Silver, 1987). In this theory the two ATP 
equivalents produced per glucose molecule were in principle sufficient to maintain 
active glutamate clearance from the extracellular space and recycling to the neurone 
(one used for pumping of Na
+
/K
+
 ions and one for glutamine synthesis). 
 
Lactate normally represents a metabolic dead end unless it is converted back to 
pyruvate. This can only be accomplished with the enzyme lactate dehydrogenase 
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(LDH) which has several isoforms each representing a tetrameric combination of 
two different polypeptide chains. LDH5 is found in tissues producing lactate while 
tissues containing predominantly the LDH1 isoform are more oxidative and 
consume lactate by favouring conversion to pyruvate. These properties have 
significance for cell physiology. Increase in brain adenosine diphosphate (ADP) 
concentration stimulates glycolysis by activation of the regulatory enzyme 
phosphofructokinase. When maximally stimulated the rate of formation of pyruvate 
can rise to close to the maximum rate at which it can enter the tricarboxylic acid 
(TCA) cycle. The increase stimulates pyruvate conversion into lactate as well as its 
transport into the mitochondrial matrix and export into the circulation. The greater 
the equilibrium lactate/pyruvate ratio the more slowly this rise occurs. For cells with 
a greater proportion of LDH5 isoforms than LDH1 there is a much higher rate of 
increase of conversion into lactate. There is evidence that mRNA for LDH1 alone is 
expressed in neurones while astrocytes appear to express both LDH1 and LDH5 and 
their corresponding mRNA(van Hall G., 2000).  
 
The ANLS hypothesis has been the subject of an intense debate during the last 
decade [for example: (Magistretti et al., 1993;Magistretti and Pellerin, 1997;Pellerin 
et al., 1998;Magistretti and Pellerin, 1999;Magistretti et al., 1999;Magistretti and 
Pellerin, 2000;Pellerin et al., 2001;Chih et al., 2001;Dienel and Hertz, 2001;Pellerin 
and Magistretti, 2003;Mangia et al., 2003a;Mangia et al., 2003b;Hertz, 2004;Pellerin 
et al., 2007;Simpson et al., 2007;Mangia et al., 2009). Several of these authors have 
disputed the validity of the ANLSH(Chih et al., 2001;Gruetter, 2002;Hertz and 
Hertz, 2003;Mangia et al., 2009)  and in particular the requirement of the hypothesis 
that neurones preferentially utilise astrocyte derived lactate ahead of glucose in 
oxidative metabolism and the assumption that astrocytic oxidative phosphorylation 
does not play a part in these energy transactions. However there remains general 
agreement that there is a link between the rate of glutamate-glutamine cycling and 
the TCA flux of the neuron even if this relationship does not fit the 1:1 association 
necessary for the ANLSH.  
 
The energy currency of cells, adenosine triphosphate (ATP), is the link between 
energy utilising and energy producing processes. Brain energy metabolism normally 
maintains constant concentration of ATP as the processes that restore this metabolite 
are sensitive to increased ATP utilisation. Observations in heart and brain suggest 
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that even a tenfold increase in cellular work output can be sustained with minimal 
ATP concentration fluctuation(Petroff et al., 1984;Young et al., 1985). Both short 
term and longer term regulatory mechanisms are used to maintain a constant 
concentration of ATP. One important short term mechanism for maintaining ATP 
concentration is by hydrolysis of PCreat(Fedosov, 1994;Friedman and Roberts, 
1994;Wallimann et al., 1998;Brustovetsky et al., 2001;Neumann et al., 2003). More 
sustained increases in rates of ATP utilisation are balanced by increases in rates of 
glycolysis and oxidative phosphorylation. 
 
The enzyme creatine kinase (CK) catalyses the inter-conversion of ADP and PCreat 
with ATP and Creat according to the reaction: 
    
ADP + PCreat  ATP + Creat      
 
Only after PCreat is reduced by 70 - 80% is ATP concentration lowered, in parallel 
with the accumulation of ADP and, later on, AMP(Hilberman et al., 1984). The 
transfer of energy from the mitochondrial matrix to the cytoplasm is achieved via a 
creatine phosphate energy shuttle system(Bessman and Geiger, 1981). CK isoforms 
are present both within mitochondria and also within the cytosol. Intracellular 
compartmentation of these enzymes helps to establish a buffering system for cellular 
energy stores and a shuttle for high-energy phosphates from the mitochondria to the 
cytosol. At the outer surface of the inner mitochondrial membrane a mitochondrial 
isoform of CK (MtCK) is coupled both structurally and functionally to the adenine 
nucleotide translocator(Jacobus and Lehninger, 1973;Moreadith and Jacobus, 1982). 
As ATP derived from oxidative phosphorylation enters the inter membranous space 
of mitochondria MtCK preferentially transfers the gamma phosphoryl to creatine 
and ADP is recycled back to the matrix(Wallimann et al., 1998) whilst cytosol 
located CK isoforms (BCK) can both utilise PCreat to convert ADP to ATP and 
convert ATP to PCreat for energy storage(Fedosov, 1994). In most regions of the 
brain BCK is concentrated in synaptic regions indicating the importance of the 
shuttle in the metabolic support of synaptic transmission(Friedman and Roberts, 
1994). 
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1.2.3Glutamate metabolism 
The amino acid L-glutamate is the major mediator of excitatory signals in 
mammalian central nervous system.  Glutamate and -amino butyric acid (GABA), 
its conjugate inhibitory neurotransmitter, constitute the principal transmitters in 
more than 90% of cortical neurons in the adult mammalian brain (Nicholls, 1989, 
1993) and glutamate is probably involved in most aspects of normal brain function 
including cognition, memory and learning(Fonnum, 1984;Collingridge and Lester, 
1989;Headley and Grillner, 1990). Most neurons, and some glial cells have 
glutamate receptors in their plasma membranes  but receptor concentration differs 
greatly in these cell types; glutamatergic neurons possess ~80% , whereas 
GABAergic neurons contain  between 2% to 10% and astrocytes  ~10% of total 
tissue glutamate (Storm-Mathisen et al, 1983; Ottersen and Storm-Mathisen, 1984; 
Korf and Venema, 1983; Van den Berg and Garfinkel, 1971; Patel et al, 1974; 
Ottersen et al, 1992; Lebon et al, 2002). 
 
The brain contains huge amounts of glutamate, about 5–15 mmol per kg wet 
weight(Schousboe, 1981), but only a tiny fraction of this glutamate is normally 
present in the extracellular compartment. The concentrations in the extracellular 
fluid, which represents 13–22% of brain tissue volume, and in the cerebrospinal 
fluid (CSF) are normally around 3–4 μM and around 10 μM, respectively(Lehmann 
et al., 1983;Hamberger and Nystrom, 1984). Consequently, the concentration 
gradient of glutamate across the plasma membranes is several thousand-fold. The 
highest concentrations are found inside nerve terminals(Ottersen et al., 1992;Storm-
Mathisen et al., 1992). 
 
The distribution of glutamate is in a dynamic equilibrium which is highly sensitive 
to changes in the energy supply. Glutamate is continuously being released from cells 
and removed from the extracellular fluid. Synaptically released glutamate is taken 
up mainly by astrocytes, driven by the co-transport with each glutamate of 3 Na
+
 and 
1 H
+
 and the counter transport of 1 K
+
(Levy et al., 1998). Approximately one third 
of the glutamate so taken up by the neighbouring astrocytes is converted into 
glutamine (de Barry J. et al., 1983) in a process requiring 1 ATP per glutamate. One 
quarter of the glutamate remains as glutamate, 1/5 is converted to alpha-
ketoglutarate by GAD and the other 1/5 may be transaminated by aspartate. 
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Glutamine may leave the astrocyte and enter neurons without consuming energy. In 
the neuron the glutamine may be converted into glutamate and repackaged in 
synaptic vesicles. This packaging is powered by vesicular H
+–ATPase. At least one 
H
+
 is pumped to accumulate a glutamate anion. This requires hydrolysis of 1/3 ATP 
molecule. An extra 1.14 ATP/glutamate may be hydrolysed to counteract leakage 
from the vesicle. For the average 4.000 glutamate molecules per vesicle, 11, 000 
ATP are required. Other energy requirements are due to activation of post synaptic 
receptors in the post-synaptic neuron, pre-synaptic Ca
2+
 fluxes and the vesicular 
release mechanism, the energy need to maintain action potentials and the energy 
expended on the resting potential. In total the energy expended per vesicle of 
glutamate released is 1.64 x 10
5
 ATP molecules(Attwell and Laughlin, 2001). 
 
This trafficking of glutamate and glutamine between astrocytes and neurons has 
been proposed to be a major pathway by which transmitter glutamate is recycled. It 
is commonly referred to as the glutamine–glutamate cycle. The concept of a 
compartmentation of glutamate into two pools was introduced in the early seventies 
based on 14C tracer studies (van den Berg and Garfinkel, 1971) and the notion of a 
predominantly glial synthesis of glutamine a little later when glutamine synthetase 
was shown immunocytochemically to be a glial enzyme(Martinez-Hernandez et al., 
1977;Erecinska and Silver, 1990) (Westergaard et al., 1995). Glutamine is normally 
present in the extracellular fluid at around 200–500 μM (Gjessing et al., 
1972;Hamberger and Nystrom, 1984). This does not compromise neurotransmission 
because glutamine does not activate glutamate receptors.  
 
Following the release of glutamate from a pre-synaptic nerve terminal, glutamate 
will diffuse into the synaptic cleft and interact with glutamate binding proteins 
(transporters and receptors) present there, e.g. AMPA and NMDA receptors. The 
diffusion will continue out of the cleft and glutamate may interact with metabotropic 
glutamate receptors along the spine and nerve terminal membranes and come within 
reach of glial glutamate transporters.  
 
Metabotropic glutamate receptors located pre-synaptically on glutamatergic and on 
some GABAergic nerve terminals modulate the release of the transmitter(Sanchez-
Prieto et al., 1996;Scanziani et al., 1997;Vogt and Nicoll, 1999). This implies that 
glutamate transporters are indirectly involved in the control of transmitter release 
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because they control the amount of glutamate that reaches the pre-synaptic 
receptors. In line with this, inhibition of glutamate uptake has been reported to cause 
decreased synaptic release of glutamate and GABA(Maki et al., 1994;Semyanov and 
Kullmann, 2000) (Maki et al., 1994) due to increased activation of these receptors.  
 
The concentrations of glutamate transporter molecules in brain tissue are very high. 
It has been shown that 15, 000 and 21, 000 glial glutamate transporter molecules are 
present per μm3 tissue in the striatum radiatum of hippocampus CA1 and the 
molecular layer of cerebellum, respectively(Lehre and Danbolt, 1998).  
 
The glutamate concentration profile within the synaptic cleft depends on the amount 
of glutamate released into the cleft, on the speed with which it is released and on 
how fast it is removed from the cleft. The removal depends on uptake and on 
diffusion which again depends on the water concentration, the tortuosity of the 
extracellular space and the interaction with glutamate binding sites. Regulation of 
this activity can  be modulated at many levels, e.g. DNA transcription, mRNA 
splicing, protein synthesis, protein targeting, and actual amino acid transport and 
associated ion channel activities(Gegelashvili and Schousboe, 1998;Sims and 
Robinson, 1999). 
 
Failure of regulation may lead to the ‘deleterious network hypothesis’(Ying, 1998) 
in which high extracellular glutamate can activate glutamate receptors causing 
further glutamate release. Glutamate receptor activation increases energy 
consumption and free radical production which may in turn impair energy 
production and glutamate uptake and possibly even reverse the transporter direction 
leading to an escalating positive feedback of glutamate release. The influx of ions 
may cause oedema(Kimelberg et al., 1995) and ischaemia and the formation of 
highly reactive compounds such as the superoxide anion radical (O
2-
), hydroxyl 
radicals, H2O2 and peroxynitrite (for review, see (Fridovich, 1997;Koppenol, 1998) 
leading to neuronal injury or death(Gotz et al., 1994;Dawson and Dawson, 
1996;Delanty and Dichter, 1998). Regulation failure secondary to down-regulation 
of glial glutamate transporters has been described in a variety of situations, e.g. after 
transient ischemia, in amyotrophic lateral sclerosis, and after traumatic brain injury.  
 
 
P a g e  | 36 
 
 
1.2.4 Glutamate receptor function 
Glutamate exerts its effects by action on glutamatergic receptors of which there are 
ionotropic and metabotropic receptor subtypes. Each of the two main families of 
glutamate receptors comprises three functionally defined groups of receptor. These 
are made up of numerous individual subunits, each encoded by a different gene. 
Ionotropic sub-types include three classes originally named after selective agonists: 
N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) and kainate (Ka). As many as ten distinct subfamilies of 
ionotropic glutamate receptor genes have been identified, based on evidence from 
molecular biology experiments.  
 
1.2.4.1 AMPA receptors  
AMPA receptors are the receptors responsible for most rapid excitatory transmission 
within the vertebrate CNS. The associated channels are rapidly activated and 
inactivated, and appear to be present on all neurons within the CNS. AMPA 
receptors can be activated following the binding of L-glutamate and other agonists, 
such as quisqualate and domoic acid, as well as AMPA. The affinity of AMPA 
receptors for L-glutamate, the endogenous amino acid that represents the most likely 
candidate in mediating neurotransmission at these receptors, is much lower than is 
the affinity at NMDA receptors. 
 
Four glutamate receptors (GluR 1 to GluR 4) have been cloned and identified as 
subunits which have the electrophysiology and pharmacology of the AMPA 
receptor. AMPA receptors are widely present throughout the brain, although there 
are regional differences in the relative amounts of each receptor.  
 
1.2.4.2 Kainate Receptors 
The distinguishing hallmark of the electrophysiology of kainate receptors is that, in 
general, for vertebrate CNS neurons, there is no agonist-induced desensitization. 
However, like the AMPA receptor subfamily, the kainate receptors are coupled to 
ion channels that are permeable to monovalent cations and have reversal potentials 
near   0 mV. Often, these receptors are considered, along with AMPA receptors, to 
be simply non-NMDA receptors, as both types have overlapping pharmacologic and 
electrophysiological profiles. 
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In situ hybridization studies have led to the discovery of different distributions 
throughout the brain for mRNA encoding the glutamate receptors GluR 5, 6, and 7 
respectively. In contrast to GluR5 and GluR6, GluR7 receptors are not present in 
high numbers in the hippocampus, although they have been found in the granule 
cells of the dentate gyrus. Messenger RNA for both GluR6 and GluR7 is present in 
high abundance in brain regions that have been found to be profoundly sensitive to 
destruction following kainic acid treatment. These areas include the hippocampus, 
cortex, cerebellum, and reticular thalamic regions. KA1 is expressed at high levels in 
only CA3 pyramidal cells and dentate granule cells, whereas KA2 is found in 
virtually all brain regions. There is evidence to support the hypothesis that the KA2 
receptor is co-expressed in some areas with GluR6 and GluR5, and that KA1 may be 
co-expressed with GluR6 in the hippocampus. 
 
1.2.4.3 NMDA Receptors 
Agonists at the NMDA receptor include N-methyl-D-aspartate, glutamate, and a 
variety of other excitatory amino acids. As with the non-NMDA receptor, the 
NMDA receptor possesses two agonist-binding sites. The NMDA receptor is also 
distinguished by the fact that it has an absolute requirement for a co-agonist, glycine. 
If the glycine site on the receptor is blocked or unoccupied, binding of glutamate to 
the receptor will not result in the channel opening. In addition to its co-agonist 
requirement, the NMDA receptor has been shown to be modulated by Mg
2+
, H
+
, 
Zn
2+
, polyamines and steroids. 
 
The behaviour of the activated NMDA receptor-channel complex differs 
dramatically from that of the non-NMDA receptor. Activation of the channel is 
much slower, with the time to the peak current being often tens of milliseconds. 
Desensitization at NMDA receptors during exogenous application of agonist takes 
several hundred milliseconds to develop, whereas desensitization at AMPA 
receptors occurs within 5–10 ms.  
 
Another difference between non-NMDA and NMDA receptors is the voltage-
sensitive block of Mg
2+
 at the NMDA receptor. In addition, single-channel 
experiments have revealed that once agonist has bound to the NMDA receptor, the 
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channel can open and close repeatedly for up to several hundred milliseconds, 
resulting in long-lasting currents. 
 
1.2.4.4 Metabotropic receptors (MGluR) 
These receptors, unlike their ionotropic counterparts, are not comprised of subunits 
that form an integral ion channel; instead, they are comprised of polypeptides that 
have a trans-membrane spanning domain with a large extracellular NH2 terminal 
region. When an agonist binds to the mGluR, activation of a variety of G-proteins 
occurs. This G-protein coupled activation then results in a diverse biochemical 
cascade that can result in the modulation of a variety of cellular functions, such as 
current flow through voltage-gated ion channels. To date, within the three groups of 
receptors, eight subtypes of the mGluR have been cloned and correspond to a novel 
gene family of G-protein coupled receptors. Activation of this class of glutamate 
receptors has been implicated in a variety of CNS functions, including different 
forms of synaptic plasticity and excitotoxicity. 
 
1.2.5 Glutamate and epilepsy 
Elevated glutamate concentrations have been observed in most(Perry et al., 
1975;Sherwin et al., 1988;Petroff et al., 1989) but not all(Peeling and Sutherland, 
1993;van Gelder and Sherwin, 2003) ex-vivo studies of resected epileptic tissue.  
 
In patients with refractory complex partial seizures requiring depth electrode 
insertion for further electrographic investigation, During and Spencer were able to 
implant micro-dialysis probes bilaterally along the hippocampi. Their measurements 
of glutamate and GABA concentrations in relation to the electrographic onset of 
spontaneous seizures showed a significant increase in glutamate concentration 
directly before seizure onset on the epileptogenic side. The non-epileptogenic side 
showed a smaller increase in glutamate concentration beginning after seizure onset 
and an associated rise in GABA concentration.(During and Spencer, 1993). During 
and Spencer were also able to report the observation that the glutamate levels fell 
slower indicating impaired removal from the extra cellular space 
 
Other groups have found similar. Wilson (Wilson et al 1996 add) found elevated 
glutamate, aspartate and GABA in the epileptogenic hippocampus whilst Thomas 
and Philips found similar with spontaneously vigorous hippocampal epileptiform 
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activity increased by more than 23 fold, 19 fold and 10 fold compared to cases with 
minimal hippocampal activity. 
 
Glutamate acting on AMPA, NMDA and probably also mGluR1 receptors is thought 
to play an important role in cell death subsequent to status epilepticus. The primary 
mechanism involved is ionic disequilibrium related to the excessive entry into the 
cell of Na
+
 and Ca
2+
 through ligand gated voltage sensitive channels. Raised 
intracellular Ca
2+
 activates various enzymes (e.g. proteases, phospholipases, nitric 
oxide synthesis or endonucleases) that contribute to cell death(Meldrum, 2000).  
 
Agonists acting at GluR are pro-convulsant following intra-cerebral or systemic 
injection. Antibodies to GluR3, as found in sera of subjects with Rasmussen’s 
encephalitis, enhance neuronal excitability and are associated with seizures. Kainate 
and domoate, which are synthesised by marine plants, induce limbic seizures 
apparently by acting at high-affinity kainite receptors in the CA3 subfield of the 
hippocampus. Pre-synaptically they inhibit GABA release; post-synaptically they 
are depolarising. Seizures can also be induced by agonists acting on the NMDA 
receptors and type 1 metabotropic receptors whilst NMDA and AMPA receptor 
antagonists are powerful anticonvulsants in a range of animal models(Meldrum and 
Chapman, 1999). 
 
For these reasons precise regulation of glutamate is crucial in healthy tissue and 
likely to be impaired in epileptogenic tissue. MRS allows the in vivo study of 
glutamate (in this thesis as the combined signal of glutamate plus glutamine [GLX]) 
and measurement of GLX in different epileptic disorders is an important part of this 
thesis.  
 
1.2.6 GABA metabolism 
The role of GABA as an inhibitory neurotransmitter in the mammalian brain was 
firmly established by the mid-1970s.  It is estimated that between 17% and 50% of 
all synapses in the brain are GABAergic (Bloom and Iversen, 1971; Mody et al., 
1994). GABA exerts its effect through GABAA, GABAB and GABAC receptors (see 
below). The clinical importance of the GABAergic system is reflected in the wide 
range of drugs modifying GABAergic transmission (mainly GABAA receptors), 
including anticonvulsants (benzodiazepines and barbiturates), steroids, anaesthetics, 
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and anxiolytics. The paramount importance of GABA metabolism is reflected in the 
multiple roles attributed to GABAergic transmission including the modulation of 
cortical excitability, anxiety levels, feeding and drinking behaviour, circadian 
rhythms, cognition, vigilance, memory and learning [reviewed by (Sieghart et al., 
1999)]. In the developing brain, however, it is now established that GABA-mediated 
signalling can be excitatory and has been implicated in the regulation of several 
phases of brain development from cell proliferation to circuit refinement(Ben Ari, 
2001;Ben Ari, 2002;Ben Ari et al., 2004). GABAergic transmission may also 
sometimes become excitatory in adults, for example in patients with mesial temporal 
lobe epilepsy (mTLE)(Fujiwara-Tsukamoto et al., 2003;Ben-Ari, 2006). In 
microdialysis experiments of epileptogenic hippocampi epileptic seizures were 
associated with large increases in glutamate but also with elevation of GABA 
indicating ictal activation of GABAergic pathways. 
 
The evidence for the role of GABA as an important inhibitory neurotransmitter 
began to accumulate when GABA was localised to mammalian nerve terminals and 
antibodies raised to GABAergic enzymes were shown to localise to inhibitory nerve 
terminals [for recent review of GABA metabolism and mechanisms of action see 
(Schousboe and Waagepetersen, 2007)]. Glucose is the principal precursor for 
GABA production in vivo although pyruvate and other amino acids also can act as 
precursors. GABA is formed in vivo by a metabolic pathway referred to as the 
GABA shunt. The shunt is a closed loop process with the dual purpose of producing 
and conserving the supply of GABA. The first step in the synthesis of GABA from 
tricarboxylic acid intermediates is the transamination of alpha ketoglutarate to 
glutamic acid by GABA-Transaminase (GABA-T). Glutamic acid is then 
decarboxylated to form GABA by glutamic acid decarboxylase (GAD). GAD 
appears only to be expressed in GABAergic cells. Two forms of GAD have been 
identified – GAD65 and GAD67. GABA is metabolised by GABA-T to form 
succinic semialdehyde in a process that results in the transfer of an amino group 
from GABA to alpha ketoglutarate thereby reforming glutamic acid. 
 
GABA formed in this process is concentrated within synaptic vesicles by action of a 
vesicular neurotransmitter transporter (VGAT) and vesicle release at the pre-
synaptic terminal occurs by calcium-dependent exocytosis although non-vesicular 
GABA release has also been demonstrated. After release into the synaptic cleft, 
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extracellular GABA is removed (and the GABA signal terminated) by re-uptake into 
neurons and uptake into glia by plasma-membrane GABA transporters. These 
transport systems are both temperature and ion dependent processes. The 
transporters are capable of bidirectional neurotransmitter transport. They have an 
absolute requirement for extracellular Na
+
 and an additional dependence on Cl
-
 ions. 
The ability of the reuptake system to transport GABA against a concentration 
gradient had been demonstrated using synaptosomes. The driving force for this 
reuptake process is supplied by the movement of Na
+
 down its concentration 
gradient. GABA taken back up into the neuron is available for re-release but GABA 
taken up by glial cells is metabolised to succinic semialdehyde and cannot be 
resynthesised in this compartment due to lack of GAD. GABA is returned to the 
neuronal pool following transfer of glial glutamine and conversion by glutaminase to 
glutamate and re-entry to the GABA shunt. 
 
In the neocortex, most GABA-containing neurons are local interneurons which vary 
according to morphology, intrinsic membrane properties and synaptic connectivity. 
GABA synapses are present in all neocortical layers and are observed most 
frequently on cell somata, proximal dendrites and axon initial segments but also on 
distal dendrites and dendritic spines.   
 
1.2.7 GABA receptors 
The actions of GABA are mediated through GABAA, GABAB and GABAC 
receptors.  
 
1.2.7.1 GABAA receptors 
The GABAA receptor is a multi-subunit, heteromeric ion channel directly activated 
by the transmitter, GABA. There are usually five subunits, although a minority may 
have four subunits only. The exact subunit composition determines the physiological 
and pharmacological properties of the receptor(Barnard et al., 1998). Ligand binding 
is followed by conformational change in the channel protein that allows a net inward 
or outward flow of ions through the membrane-spanning pore of the channel. The 
directionality of flow depends on the electrochemical gradient of the particular 
permanent ion. Most GABAA receptors carry primarily chloride ions and there is 
now evidence that these receptors undergo a switch during development with respect 
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to their response to GABA signalling consequent upon intracellular chloride 
concentrations. With maturation neuronal [Cl
-
] decreases and the GABAA reversal 
potential becomes more negative allowing the effect of GABA to become 
progressively more inhibitory(Ben Ari, 2002). Consistent with this finding is the 
observation that cation-chloride co-transporters are expressed differentially in the 
cortex as development continues. In the embryonic brain a Na
+
-K
+
-Cl
-
 co-transporter 
(NKCC1) is dominantly expressed and acts to increase intracellular Cl
-
, whilst with 
maturity an outwardly directed co-transporter (KCC2) plays an increased role. 
Consequently in immature brain tissue (and tissue demonstrating impaired neuronal 
development such as may be found in some types of malformations of cortical 
development) or within areas of epileptic tissue associated with structural 
reorganisation the response to GABA stimulation may not be inhibitory. This 
interaction between altered GABAergic signalling and the interneuron connectivity 
of GABA releasing neurons has been shown in hippocampal slices to support 
pathological synchronisation of aberrant discharges(Cohen et al., 2003).  
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Figure 1.2.1 Sub-unit stoichiometry, arrangement, membrane position and binding sites of 
the GABAA receptor 
 
1.2.7.2 GABAB receptors 
GABAB receptors are less numerous than GABAA receptors but are still widely 
distributed in the brain. In contrast to GABAA receptors, they are metabotropic 
(Sivilotti and Nistri, 1991) and are thought to have pre-synaptic locations where they 
impair release of both excitatory and inhibitory neurotransmitter from vesicles.  
 
 
 
γx 
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αx 
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-
] 120 mmol/l 
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-
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GABA benzodiazepines 
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1.2.7.2 GABAC receptors 
GABAC receptors are ionotropic and composed of ρ sub units (Cutting et al., 1991). 
These subunits can form homo- or hetero-oligomeric channels with other ρ subunits 
but do not seem to combine with GABAA receptor subunits. 
 
1.2.8 GABA and Epilepsy 
It has long been known that enhancing central nervous system GABA levels with 
GABA transaminase inhibitors or succinic semi-aldehyde inhibitors has an anti-
convulsant effect and also that lowering these levels produces seizures. In 1995 
During and Spencer performed micro-dialysis experiments which demonstrated 
reduced GABA/glutamate ratios in the ictal temporal lobe(During and Spencer, 
1993) and Petroff and co-workers have authored a number of MRS studies over 
several years that report low levels of GABA in patients with epilepsy(Petroff et al., 
1996b;Petroff et al., 1999a;Petroff et al., 2000) and increasing GABA levels with 
improved seizure control or GABAergic antiepileptic medications such as 
topiramate or vigabatrin(Petroff et al., 1996a;Petroff et al., 1996b;Petroff et al., 
1999c;Petroff et al., 2000).  
 
Several antiepileptic drugs in widespread use have actions mediated by an alteration 
of the GABA receptor system. Post-synaptic GABAA receptor currents are enhanced 
by barbiturates and benzodiazepines. Pre-synaptic GABA release is likely modified 
by the antiepileptic drug vigabatrin. The uptake of GABA has been shown to be 
modified by compounds such as tiagabine. Valproic acid has been suggested either 
to enhance the release of GABA or to enhance postsynaptic GABA responses whilst 
topiramate may increase GABA mediated Cl
- 
influx. 
 
This complex role of GABA in guiding brain development, regulating synchronous 
cell discharge and blocking excitatory pathways would indicate that simple 
reduction in GABA concentrations is probably an inadequate explanation for many 
epileptic disorders. However GABA metabolism is clearly extremely important to 
the regulation of cell signalling and the measurement of GABA levels in several 
epileptic disorders is one of the main aims of this thesis.  
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1.3.1 Introduction 
 
The Commission on Classification of the International League Against Epilepsy 
currently describes Idiopathic Generalised Epilepsy as follows: 
 
“Idiopathic generalised epilepsies are forms of generalised epilepsies in which all 
seizures are initially generalised (absences, myoclonic jerks and generalised tonic 
clonic seizures), with an EEG expression that is a generalised bilateral, synchronous, 
symmetrical discharge … The patient usually has a normal inter-ictal state, without 
neurological or neuro-radiological signs. In general, inter-ictal EEGs show normal 
background activity and generalised discharges, such as spikes, polyspike spike-
wave, and polyspike-wave > 3 Hz… No aetiology can be found other than a genetic 
predisposition towards these disorders.”(The International League Against Epilepsy, 
1989) 
 
The seizures of IGE are typical absences, myoclonic jerks and generalised tonic 
clonic seizures. 
 
Typical absence seizures are brief (lasting for seconds) generalised epileptic seizures 
of abrupt onset and abrupt termination. They manifest clinically with impairment of 
consciousness (absence) and EEG with generalised 3-4 Hz spike and slow wave 
discharges. Impairment of consciousness is variable and automatisms may be seen. 
Typical absence seizures are easily precipitated by hyperventilation in untreated 
patients. Absences may remit with increasing age or be life-long. 
 
Myoclonic jerks are shock like irregular and often arrhythmic clonic-twitching 
movements that may be singular or repetitive of variable amplitude and force. The 
myoclonic jerks of IGE mainly occur on awakening and are precipitated by sleep 
deprivation fatigue, excitement or distress. They may also often be precipitated by 
photic stimulation. The patient is fully aware of myoclonic jerks except when these 
occur during absence seizures.  
 
Generalised tonic clonic seizures (GTCS) in IGE are generalised from onset. They 
are the same irrespective of epilepsy type. They are never preceded by the focal 
subjective symptoms (aura) of focal onset seizures. The occurrence of GTCS in IGE 
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does not have diagnostic significance but does influence the morbidity and 
mortality. 
 
The 2001 ILAE Task Force on Classification recognises the following IGE sub-
syndromes(Engel, Jr., 2001): 
 
Benign Myoclonic Epilepsy in Infancy 
Epilepsy with myoclonic-astatic seizures 
Childhood absence epilepsy 
Epilepsy with myoclonic absences 
Idiopathic Generalised Epilepsies with variable phenotypes 
 Juvenile absence epilepsy 
 Juvenile myoclonic epilepsy 
 Epilepsy with generalised tonic-clonic seizures only 
Generalised epilepsy with febrile seizures plus (syndrome in development)  
 
This classification system has been controversial. Revised systems for Childhood 
Absence Epilepsy (CAE)(Loiseau and Panayiotopoulos, 2005) and for Juvenile 
Absence Epilepsy (JAE)(Wolf, 1999) have been proposed. The argument for tighter 
classification is that this will improve prognostication in patients fulfilling the 
criteria at the expense of a higher number of unclassifiable cases. In the revised 
classification system the occurrence of myoclonus other than prior to or during the 
active stage of the absence is a contraindication to the diagnosis of CAE. All the 
patients included in the current work were classified according to the 1989 ILAE 
Classification. 
 
1.3.2 Pathophysiology of Generalised Spike Wave Discharges (SWD)  
There has been historical debate as to the origin of SWD. Following the initial 
analysis of EEG in patients with absence seizures by Jasper and Kershman in 
1941(Jasper HH and Kershman J, 1941) and the observation of abrupt onset of EEG 
spike and wave discharge in both hemispheres a sub-cortical origin of the seizure 
activity was proposed and formalised in the centrencephalic theory by Penfield in 
1952(Penfield W, 1952). In 1968 Gloor proposed the cortico-reticular hypothesis of 
SWD generation (namely that SWD result from an abnormal interaction of 
ascending inputs from midbrain and midline thalamic reticular systems and a 
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diffusely hyper excitable cortex)(Gloor, 1968). Buzsaki later updated the earlier 
centrencephalic theory of Penfield to suggest a “thalamic clock” trigger to seizure 
onset based on experimental observations of the development of high voltage 
spindle field potentials in the thalamic reticular nucleus which preceded the EEG 
changes of typical absence seizures(Buzsaki, 1991). 
 
Since then a number of neurobiological studies of the neuronal activity behind the 
ictal EEG manifestation of absence epilepsy have been reported. Meeren and co-
workers have reported a series of experiments performed on Wistar Albino Glaxo / 
Rijswijk (WAG/Rij) rats (reviewed (Meeren et al., 2002) finding that typical 
absence seizures appear to require both an intact thalamus and in particular reticular 
thalamic nucleus; a functionally intact cortex; and that seizures appeared to have 
reliable onset in the somatosensory cortex before spreading to other cortical regions 
and to the thalamus,  so initiating a cascade within the thalamocortical network 
which transforms the spike into a spike wave complex – the “cortical focus 
theory”(Meeren et al., 2005).  
 
Blumenfeld has recently reviewed the current evidence and considers that the spike-
wave discharge should be considered a final common output resulting from intrinsic 
brain circuit oscillation between excitation and inhibition and triggered by a range of 
causes. The author asserts the requirement for an intact cortex, thalamus and 
thalamo-cortical interconnection for the occurrence of spontaneous discharges but 
finds no evidence to support a requirement in all cases for onset to arise in cortex or 
thalamus(Blumenfeld, 2005).  
 
1.3.3 Genetics of IGE 
The majority of individuals with IGE have a complex genetic etiology(Ottman, 
2005) for which the underlying genetic alterations remain largely unknown. 
Heritability estimates are >80% and risk for first-degree relatives can be as high as 
9%(Helbig et al., 2008). Twenty percent of children of parents with IGE manifest 
GSWD activity in their EEG, and multiple spike-and-wave (“polyspike”) activity 
occurs in 15% of family members with myoclonic seizures. Numerous genes have 
now been identified that are linked to various patterns of epilepsy. All the genes 
identified so far for monogenic epilepsy syndromes cause disorders of ion channels 
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giving rise to the opinion that IGE could represent a channelopathy(Kaneko et al., 
2002;Hirose et al., 2005;Reid et al., 2009). 
 
Interest has recently focussed on a microdeletion syndrome associated with 
generalised epilepsy, learning difficulties and schizophrenia. The microdeletion site 
is in the region 15q13.3 which contains several genes incuding the CHRNA7 gene 
encoding for the alpha7 sub-unit of the nicotinic acetylcholine receptor which may 
be a candidate gene for the epilepsy phenotype. CHRNA7 is highly expressed in the 
thalamus potentially indicating a role in modulating thalamocortical activity. The 
deletion is very uncommon in the general population but occurred fifty fold more 
frequently in individuals with IGE in a study by Helbig and colleagues(Helbig et al., 
2009) a result which was later confirmed in an independent IGE sample(Dibbens et 
al., 2009). Further screening for possible microdeletion “hot-spots” by Kovel and 
colleagues has shown additional sites at 15q11.2 and 16p13.11(de Kovel et al., 
2010). 
 
 
Cloning of epilepsy genes in large families with monogenic inheritance has further 
identified several rare gene variants including mutations in CACNA1H(Chen et al., 
2003) which impair calcium channel function. CACNA1H is associated with CAE 
in the Chinese Hans. Cumulative evidence from studies using both human and 
animal subjects suggests that thalamic T-channels are necessary for the regulation of 
spike-and-wave discharges(Kim et al., 2001) and disruption of this function might 
predispose to generalised discharges. Functional variants of the CACNA1H cause 
different IGE types(Heron et al., 2007) 
 
Genetic loci for JME have been mapped at 5q12-q14(Kapoor et al., 2007), 5q34 
(Cossette et al., 2002), 6p21.2–p11(Liu et al., 1995) and 15q14(Elmslie et al., 1997) 
and individual genes that have been identied for JME are: GABRA1 (gamma-amino 
butyric acid A receptor, alpha 1) at 5q34(Cossette et al., 2002), and EFHC1 (EF-
hand domain containing 1) at 6p12–p11(Suzuki et al., 2004). In addition, genetic 
associations have been observed between JME and gene polymorphisms at BRD2 
(bromodomain containing 2) at 6p21.3(Pal et al., 2003) and CX36 (connexin-36) at 
15q14(Mas et al., 2004). 
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1.3.4 Pathology of IGE 
The concept that IGE may be associated with microscopic abnormality in cortical 
grey matter and / or adjacent white matter continues to be debated following reports 
by Janz and colleagues of cortical and sub-cortical dystopic neurones 
(“microdysgenesis”) in a large percentage of a limited number of pathological 
specimens from patients with IGE(Meencke and Janz, 1984;Meencke and Janz, 
1985).Lyon and Gastaut have considered that these reported findings can also occur 
in neurologically normal controls(Lyon G and Gastaut H, 1985) whilst a controlled 
and blinded histological study did not replicated earlier findings of microdysgenesis 
and increased frontal neuronal density(Opeskin et al., 2000). 
 
1.3.5 Imaging in Idiopathic Generalised Epilepsy 
Despite grossly normal structural MRI on visual assessment the evidence from 
quantitative MRI, PET, SPECT, functional MRI (fMRI) and from MRS is that IGE 
is associated with imaging abnormalities that often involve frontal and thalamic 
regions and which provides support for current thalamocortical models(Blumenfeld, 
2005) of generalised spike wave discharges. (For a review of this literature see 
Duncan(Duncan, 2005).)  
 
Quantitative MRI has shown increased grey matter content in studies of patients 
with IGE. Woermann and colleagues found abnormal cerebral grey matter in 8 out 
of 20 patients with juvenile myoclonic epilepsy (JME), 1 of 10 patients with 
childhood absence epilepsy (CAE), 4 of 10 patients with juvenile absence epilepsy 
(JAE), and 2 out of 5 patients with GTCS on awakening, but in none of the 30 
control subjects(Woermann et al., 1998b). Voxel based morphology (VBM) 
methods have shown increased grey matter in the medial frontal regions in patients 
with JME(Woermann et al., 1999a;Woermann et al., 1999b;Kim et al., 2007) and 
superior mesiofrontal regions in Absence Epilepsy patients(Betting et al., 2006) and 
decreased thalamic grey matter bilaterally(Kim et al., 2007) in patients with JME. 
Thalamic atrophy was found in a group of CAE patients(Chan et al., 2006) and in a 
mixed population of IGE patients(Helms et al., 2006). 
 
PET imaging of 
11
C flumazenil binding has shown diffuse reduction of cortical 
binding in a mixed group with generalised epilepsy(Savic et al., 1990) and decreased 
binding in the thalami(Savic et al., 1994). Regional increase in thalamic blood 
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flow(Prevett et al., 1995a) and unchanged flumazenil binding(Prevett et al., 1995b) 
is described during absence seizures. Studies of opioid receptor binding using 
11
C 
diprenorphine has indicated a faster elimination of 
11
C diprenorphine from 
association areas of neocortex but not thalamus, basal ganglia, or cerebellum 
following hyperventilation-induced serial absences in IGE(Bartenstein et al., 1993). 
 
Most recently the consistent finding of decreased cortical BOLD signal and a 
corresponding increased thalamic BOLD signal has been widely reported using 
continuous EEG-correlated fMRI during generalised SWD(Salek-Haddadi et al., 
2003;Aghakhani et al., 2004;Hamandi et al., 2006;Hamandi et al., 2008) with some 
evidence that these changes precede the generalised SWD and may commence in the 
thalamus(Moeller et al., 2008). Schmuel and colleagues have inferred from fMRI 
experiments performed in the visual cortex that the negative BOLD reaction occurs 
as a consequence of reduced synaptic activity rather than spiking activity thereby 
indicating cortical deactivation with generalised SWD and increased activity in the 
thalamus (Shmuel et al., 2006).  
 
Magnetic Resonance Spectroscopy has also shown a thalamocortical pattern of 
abnormality in IGE patients. Savic and colleagues reported a 10% reduction in 
frontal NAA in patients with JME compared to controls (Savic et al., 2000a) while 
Mory and colleagues have reported low NAA/Cr in the thalamus also in JME 
patients (Mory et al., 2003). Petroff has reported low occipital GABA in JME 
patients but did not measure levels in thalamus or in frontal regions(Petroff et al., 
2001a). 
 
1.3.6 Idiopathic Generalised Epilepsy Sub-syndrome description 
1.3.6.1 Childhood Absence Epilepsy (CAE) 
CAE has peak age of onset at 6–7 years. It is characterised by very frequent (several 
to many per day) absences. During adolescence GTCS may occur but otherwise 
there is remission or rarely persistence of absences as the only seizure type. The 
absences of CAE are easily precipitated by hyperventilation. During a typical 
absence the impairment of consciousness is severe. Automatisms occur in two thirds 
of the seizures but are not stereotyped. The duration of absences in CAE is short, 
typically 10-12 seconds. The interictal EEG is normal whilst the ictal EEG shows 
generalized, spike and slow wave complexes at 3 Hz. 
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1.3.6.2 Juvenile Absence Epilepsy 
The first manifestation occurs around puberty whilst the absences usually occur 
sporadically in comparison to CAE. GTCS precede the absence manifestations more 
often than in CAE and occur more frequently. Occasionally myoclonic jerks are 
seen. As with CAE there is usually severe impairment of consciousness but the 
absences last longer than for CAE (approximately 16 seconds). The EEG features 
are similar to those observed in CAE. Remission with increasing age is uncommon.  
 
1.3.6.3 Juvenile Myoclonic Epilepsy (JME) 
JME (Janz Syndrome) appears around puberty and is characterized by seizures with 
bilateral, single or repetitive arrhythmic, irregular, myoclonic jerks. GTCS may 
occur but absences are infrequent and usually associated with mild reduction in level 
of consciousness. Seizures are most common shortly after awakening and are often 
precipitated by sleep deprivation. The background EEG activity is usually normal. 
The characteristic ictal EEG pattern is one of a bilateral symmetric polyspike-wave 
complex with fronto-central accentuation. The spikes have a frequency of 10–16 Hz. 
Up to 40% of JME patients may display photosensitivity. It is accepted that relapse 
occurs in up to 100% of patients if the antiepileptic drug treatment is discontinued, 
even after many years of complete seizure control. 
 
1.3.6.4 Idiopathic Generalised Epilepsy with Generalised Tonic Clonic Seizures 
only 
Epilepsy with Grand Tonic Seizures on Awakening has a wide range of onset 
between 17 and 31 years and is characterised by GTCS occurring exclusively or 
predominantly shortly after awakening, regardless of the time of day. If other 
seizures occur, they are mostly absence or myoclonic, as in juvenile myoclonic 
epilepsy. Seizures may be precipitated by sleep deprivation. Patients are often 
photosensitive. EEG shows generalised discharges of spike / multiple spike slow 
waves in approximately half of patients studied. 
 
1.3.7 Epileptic syndromes associated with photosensitivity 
Photosensitivity or photoparoxysmal response (PPR) is an abnormal, highly 
hereditary electroencephalographic (EEG) trait characterized by the occurrence of 
spikes or spike-wave discharges in response to visual stimulation(Fisher et al., 
2005). Although PPR has been found rarely in subjects without epilepsy it is a more 
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common feature of idiopathic generalised epilepsies (IGE), in which a PPR may be 
observed in 40–90% of the patients(Wolf and Goosses, 1986;Appleton et al., 
2000;Lu et al., 2008). Functional imaging studies performed by Moeller and 
colleagues has shown that intermitant photic stimulation causing photoparosysmal 
response is associated with activation in the parietal cortex adjacent to the 
intraparietal sulcus in five subjects and in the premotorcortex in all 6 subjects 
occurring 3 seconds prior to the SWD and deactivation in all areas at the time of 
SWD. These results were considered to suggest that PPR is a cortical phenomenon 
with involvement of the parietal and frontal cortices(Moeller et al., 2009). 
 
Photosensitivity is best demonstrated with EEG with appropriate intermittent photic 
stimulation (IPS) eliciting an abnormal PPR. PPR broadly are broadly categorised 
as: 
 
1 A generalised spike / spike-wave response that is highly associated with 
clinical seizures, particularly if the response outlasts the stimulus, and 
may be associated with clinical events such as brief myoclonic jerks. 
2 Spike / polyspike discharges induced in posterior regions of the EEG 
only. Approximately 50% of subjects with this result will have epileptic 
seizures. 
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1.4.1 Introduction  
 
Focal epilepsies may be symptomatic, cryptogenic or idiopathic. Ictal symptoms, 
particularly at outset are determined by localisation and not by aetiology. Focal 
epilepsies account for up to 70% of all epilepsies and half of these arise from the 
temporal lobes. High resolution MRI and advanced MR sequences that include MRS 
are often directed to the investigation of subjects with focal epilepsy, particularly if 
initially labelled  ‘MRI negative’, because these investigations may yield the 
underlying aetiology and perhaps ’surgical cure’. Focal epilepsy with ictal onset 
within the frontal or parietal lobes was not specifically studied in this thesis and 
therefore not covered in this Introduction. 
 
1.4.2Temporal Lobe Epilepsy (TLE) 
TLE is the most common form of focal epilepsy. Mesial temporal lobe epilepsy 
(mTLE) is a specific form of epilepsy which is usually associated with hippocampal 
sclerosis (HS) although dual pathology can often be identified in resected surgical 
specimen(Spencer and Huh, 2008). Patients with mTLE typically have medically 
refractory seizures but a good outcome following anterior temporal lobe resections, 
with some 53-84% of patients reporting seizure freedom for at least 1 year after 
anteromesial temporal lobe resection (recently reviewed by Spencer and Huh 
(Spencer and Huh, 2008). 
 
1.4.2.1 Pathology and pathophysiology in TLE 
HS is typically unilateral and diffuse(Quigg et al., 1997a) but more localised damage 
may occur(Woermann et al., 1998a). Bilateral damage is seen but is usually 
asymmetrical with the greater degree of atrophy on the epileptogenic side(Quigg et 
al., 1997b). HS is described histo-pathologically by the presence of neuronal loss 
and gliosis which is usually most severe in the CA (cornu ammonis) and sector 
CA1(Sommer W, 1880) and to a lesser extent in CA3 and CA4. CA2 pyramidal 
cells are typically resistant to damage(Spielmeyer, 1925). A discrete form of HS is 
end folium sclerosis in which hippocampal damage is centred on the hilus and 
dentate gyrus. End folium sclerosis is undetectable on low field strength MRI scans. 
There is evidence that HS can follow prolonged febrile convulsions in infancy, early 
childhood or possibly status epilepticus in older individuals(Falconer et al., 
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1964;Kuks et al., 1993;Nohria et al., 1994;Wieshmann et al., 1997). Progressive 
atrophy with continued seizures is reported in some (Van Paesschen W. et al., 
1997a;Briellmann et al., 2002;Fuerst et al., 2003) but not all  studies(Liu et al., 
2005) 
 
The mechanism for the development of HS is probably related to toxic release of 
excitatory amino acid neurotransmitters (glutamate, aspartate) and calcium-mediated 
neuronal death(Sloviter and Dempster, 1985) with particular damage recorded in the 
vulnerable CA3 pyramidal cells and dentate hilar neurons(Sloviter, 1996). CA2 
might be relatively resistant due to a higher abundance of calcium binding proteins 
in its pyramidal cells(Sloviter et al., 1991). This process may well occur in the 
context of pre-existing abnormalities either acquired during prolonged febrile 
convulsion or as a consequence of underlying congenital malformation of neural 
development(Baulac et al., 1998;Fernandez et al., 1998). 
 
Following an initial insult abnormal mossy fibre sprouting leads to the formation of 
aberrant excitatory pathways. Mossy fibres are the axons of the excitatory granule 
cells in the dentate gyrus. They terminate at the dendrites of the pyramidal neurons 
of the neighbouring fields CA3 and CA4. Sprouting of the mossy fibres results in 
additional aberrant innervation of other granule cells in the dentate gyrus and of 
pyramidal neurons in CA1 and CA2, resulting in abnormal feedback and feed-
forward excitation(Babb et al., 1992;Mathern et al., 1995).  
 
Other pathological processes are also important. Sloviter et al. have proposed the 
"dormant basket cell" hypothesis, stating that loss of excitatory input to GABAergic 
interneurons causes a net disinhibition of granule cells resulting in increased 
excitability of these cells(Sloviter et al., 1991).  
 
1.4.2.2 Clinical features of mesial TLE 
Although the majority of children who suffer from febrile convulsions will not 
develop epilepsy there is a strong association of history of febrile convulsion in 
patients with mTLE secondary to HS particularly if the convulsion was 
prolonged(Cendes, 2004;Huang and Chang, 2009;Dube et al., 2009). Seizure onset 
is typically in the second half of the first decade of life. There may then be a seizure-
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free period of several years with antiepileptic drugs before seizures return and the 
epilepsy becomes refractory. 
 
Typical seizures associated with mTLE are briefly described as follows. Patients 
may experience auras (simple partial seizures) in isolation or which evolve to altered 
awareness as complex partial seizures (CPS) or secondarily generalised seizures. 
Seizures are generally longer in duration than frontal lobe seizures; usually lasting 
more than 2 minutes, have a more gradual onset and offset, and a slower evolution. 
 
Typical auras comprise visceral, cephalic, gustatory, dysmnestic, affective, 
perceptual or autonomic symptoms. Ascending epigastric sensations are particularly 
common. Autonomic symptoms include changes in skin colour, blood pressure, 
heart rate, and pupil size. There is usually no or only severely reduced speech, but 
occasionally repetitive vocalisation with formed words may occur if the seizure 
originates in the non-dominant temporal lobe. An intense sense of fear may arise 
without an obvious trigger. Other affective symptoms occurring in TLE include 
depression, anger and irritability and, more rarely, elation, erotic thoughts, serenity 
or exhilaration. 
 
Motor arrest, or a 'motionless stare' is a prominent feature of the progression of the 
SPS to a CPS. When the aura is short, unreported or absent, this is often the first 
manifestation of a seizure noticed by eyewitnesses. Automatisms may then be 
observed. Automatisms which are defined as 'a more or less coordinated involuntary 
motor activity occurring during the state of clouding of consciousness either in the 
course of, or after, an epileptic seizure, usually followed by amnesia of the event' are 
usually oro-alimentary or gestural. The former include lip-smacking, chewing and 
swallowing and the latter include fumbling, fidgeting, repetitive motor actions, 
undressing, walking, and sexually-directed actions. They can sometimes be 
prolonged or semi-purposeful, e.g. rearranging items on a desk. Limb automatisms 
are usually ipsilateral to the focus, with contralateral dystonic posturing. 
Vocalisation of identifiable words suggests a non-dominant seizure focus. 
Secondary generalisation is much less common than in extra-temporal lobe epilepsy. 
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1.4.2.3 EEG features of mesial TLE 
The EEG in mTLE typically shows anterior or mid-temporal spikes. These are best 
shown on superficial sphenoidal or zygomatic electrodes. Intermittent or persistent 
slow activity may be present over the temporal lobes. The EEG abnormalities can be 
unilateral or bilateral, but are usually more marked ipsilateral to the focus. 
 
1.4.2.4 MRI features of mesial TLE 
MRI will frequently reveal the cause of the mTLE.  HS is the most commonly 
identified pathology. It is demonstrated by a reduced hippocampal volume (on T1 
weighted images) and an increased signal on T2-weighted MRI scans(Jackson et al., 
1990;Van Paesschen W. et al., 1997b;Jackson and Connelly, 1999). The 
hippocampus is a curved structure with its concave surface facing the brainstem and 
with its longitudinal axis at approximately 35° to the traditionally used axial imaging 
plane for MRI, the orbito-meatal line. Imaging sensitivity for abnormality is 
improved by acquiring the coronal images perpendicular to the long axis of the 
hippocampus. In equivocal cases sensitivity can be further increased if hippocampal 
volume and T2 relaxation times are quantified using established protocols(Free et al., 
1995;Duncan et al., 1996). 
 
1.4.2.5 Clinical features of neo-cortical TLE 
In neocortical TLE, there is usually a detectable structural pathology, for example 
glioma, angioma, hamartoma, dysembryoplastic neuroepithelial tumour (DNET), 
malformations of cortical development or post-traumatic change. In contrast to 
mTLE, there is no association with a history of febrile convulsions. Clinically, 
consciousness may be preserved for longer than in a typical mesial temporal lobe 
seizure. Simple auditory phenomena such as humming, buzzing or hissing may be 
reported in seizures arising in the superior temporal gyrus whilst seizures arising 
from the Sylvian region can start with olfactory hallucinations which are usually 
unpleasant in quality. More complex hallucinatory or illusionary states occur with 
phenomenology related to their origin with association areas and may include 
distortion of size or shape, complex visual or auditory disturbance. Affective, 
visceral or psychic auras may occur but are less common than in mTLE. The 
automatisms can be unilateral and have more prominent motor manifestations than 
in mTLE.  
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1.4.2.6 EEG features of neo-cortical TLE 
The interictal EEG in neocortical TLE often shows spikes over the temporal region, 
maximal over the lateral convexity rather than infero-mesial electrodes.  
 
1.4.2.7 Imaging features of neocortical TLE 
Standard MRI sequences may demonstrate extra-hippocampal structural lesions 
responsible for the epilepsy if they are present.  Hippocampal volumes and T2 
measurements on MRI may be normal but can show subtle abnormality with 
advanced imaging modalities. 
 
1.4.3 Occipital lobe epilepsy (OLE) 
Occipital onset seizures account for approximately 10% of epilepsies but are less 
prevalent in neurosurgical series. Seizures may arise spontaneously from an epileptic 
focus or be triggered by external visual stimuli. Occipital epilepsies may be 
idiopathic or symptomatic. Idiopathic occipital seizures usually start in late 
childhood whilst symptomatic seizures may start at any age. Typical clinical 
manifestations are mainly visual or oculomotor.  
 
Idiopathic photosensitive occipital epilepsy (IPOE) is an uncommon focal epilepsy 
beginning in late childhood or adolescence and marked by seizures that are triggered 
by environmental photic stimulation such as the television(Guerrini et al., 
1995;Yalcin et al., 2000). These seizures are usually diurnal, last minutes to hours 
and rarely secondarily generalize(Yalcin et al., 2000). Electro-clinical overlap 
between IPOE and JME is described in four families by Taylor and 
colleagues(Taylor et al., 2004). 
 
Malformations of cortical development are relatively common causes of 
symptomatic occipital lobe epilepsy whilst a number of processes including 
eclampsia, malignant hypertension, mitochondrial cytopathies and progressive 
myoclonic epilepsies such as Lafora disease are all preferentially associated with 
occipital onset seizures. 
 
Visual symptoms include elementary and occasionally complex visual 
hallucinations, blindness, visual illusions and palinopsia. Elementary visual 
hallucinations are the most common manifestation of occipital lobe seizures. They 
usually take the form of small multi-coloured patterns that appear in the periphery of 
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the temporal visual field, become larger as the seizure progresses, and may move 
across the visual field. They are brief, lasting typically less than 3 minutes. They do 
not have the linear, zigzag, achromatic or black and white characteristics of visual 
aura associated with migraine. More complex visual hallucinations may occur from 
the outset of the seizure but more typically follow from elementary symptoms. 
“Blurring” of vision may be a common initial seizure manifestation.  Ocular 
symptoms include tonic deviation of the eyes, oculoclonic or nystagmoid 
movements and repetitive eyelid closure or eyelid fluttering are all reported. 
Secondary generalisation may occur. 
 
1.4.3.1 EEG in Occipital lobe epilepsy 
In symptomatic cases the EEG is often abnormal with posterior lateralised slow 
waves. Unilateral occipital spikes and occasional occipital paroxysmal bursts may 
occur and there may be a positive photoparoxysmal response. Ictal EEG usually 
manifests with paroxysmal fast activity that is localised to the occipital regions with 
occasional anterior spreading and generalisation.  
 
1.4.3.2 Imaging features in occipital lobe epilepsy 
High resolution MRI is mandatory as this may detect a structural lesion that itself 
requires treatment. Additionally, research MRI sequences that may be more 
sensitive for pathology than conventional MRI are often also performed for subjects 
with “MRI Negative” focal epilepsy.     
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1.5 Malformations of cortical development (MCD) 
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1.5.1 Introduction 
 
The favoured term of “malformation of cortical development” (MCD) encompasses 
many disorders that differ in their clinical presentation, associated pathology and 
genetic basis. MCD may be the consequence of a variety of inherited or acquired 
insults. Several sub-types of MCD are well described and MCD in general are 
associated closely with refractory epilepsy and learning disability. MCD are 
otherwise rare in the general population. Focal cortical dysplasia (FCD) is probably 
the most common of the recognised MCD although in all sub-groups the true 
prevalence is not known. 
 
In contrast to surgical treatment of refractory focal epilepsy associated with 
hippocampal sclerosis where excellent seizure outcome might occur in a high 
proportion of cases, surgical treatment of MCD is often unsuccessful. Sisodiya has 
reviewed the available literature and has found that seizure freedom (Engel class I) 
at 2 years occurred in approximately 40% of surgically treated MCD patients. This 
compares to figure of between 70-80% for mesial temporal lobe epilepsy associated 
with hippocampal sclerosis(Sisodiya, 2000). 
 
An explanation for the poor surgical outcome in these patients is likely to be a 
consequence of functional cortical abnormality in subjects with MCD that extends 
outside the area of visible structural abnormality. Indeed EEG is often non-localising 
in patients with MCD(Palmini et al., 1991a;Palmini et al., 1991b;Raymond et al., 
1995;Dubeau et al., 1998;Sisodiya, 2000) whilst PET studies(Hammers et al., 2001), 
MRS studies(Woermann et al., 2001b) and volumetric MRI or DWI(Eriksson et al., 
2001) have all identified abnormal signal outside the area of MR visible 
abnormality.  
 
A further limitation when contemplating surgical treatment of MCD is that the 
region of the visible MCD may still have some residual level of “normal” biological 
function. For example Leblanc showed that electro-stimulation of a posterior 
temporal lobe dysgenetic region caused interference with speech(Leblanc et al., 
1995).  
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The classification of MCD is based upon the concept that cerebral cortical 
development consists of three major processes: cell proliferation and apoptosis; 
neuronal migration; and cortical organisation. 
  
1.5.2 Normal brain development  
The nervous system develops from a thickening of the ectoderm, the neural plate, 
which appears at day 13 post conception and gradually expands towards the 
primitive streak. By the end of the 3rd week post conception the lateral edges of the 
neural plate become elevated and approach each other in the midline to form the 
neural tube the rostral end of which will ultimately develop into the brain. 
 
Around day 28, three primary brain vesicles appear: prosencephalon, mesencephalon 
and rhombencephalon. By about day 35, the first and third of these vesicles have 
both grown into two vesicles. The resulting five secondary brain vesicles are: 
  
1. Telencephalon (ultimately forming the cortex, striatum and olfactory system) 
2. Diencephalon (ultimately forming thalamus, hypothalamus and sub thalamus) 
3. Mesencephalon (ultimately forming the midbrain) 
4. Metencephalon (ultimately forming the pons and cerebellum) 
5. Myelencephalon (ultimately forming the medulla oblongata). 
 
1.5.2.1 Normal microscopic development of the neocortex 
Most of the cells destined to eventually become cortical neurones or glial cells are 
derived by proliferation of neuroepithelial cells in the cortical ventricular or sub-
ventricular zone (germinal matrix). The highest rate of cell division occurs in the 
second trimester of gestation. The number of cells created is far larger than the final 
number of neurons in the adult brain. Many cells undergo programmed (apoptotic) 
cell death, particularly if appropriate synaptic contacts have not been formed.  
 
Four anatomical migratory pathways have classically been described: via the corpus 
pontobulbare to the pontine and medullary nuclei; via the corpus gangliothalamicum 
to the basal ganglia and thalamus; to the cerebellum; and centrifugal migration from 
the cortical ventricular zone to the cerebral cortex. Errors in the development of cells 
involved in this latter pathway result in the most commonly observed MCD. 
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Neurones that are generated in the ventricular zone migrate along radial glial fibres 
towards the pial surface. The earliest neurones form the pre-plate at embryonic 
weeks 8 to 9. Through weeks 10-18 accumulation of newly migrated cells forms the 
cortical plate within the pre-plate and dividing it into the outer marginal zone and 
the inner sub-plate. Neurons arriving subsequently in the cortical plate penetrate 
both the sub-plate and the previously deposited cortical plate neurones in an “inside-
out” formation. Pyramidal cells and neuroglial cells form via this process. Cells that 
will eventually become non-pyramidal GABAergic cortical inhibitory inter-neurones 
are generated from a distinct proliferative zone in the ganglionic eminence of the 
ventral telencephalon. In contrast to the radial migration of pyramidal cells these 
non-pyramidal cells use tangential migratory pathways. They first appear in the 
marginal zone in the form of Cajal-Retzius cells. These cells release signalling 
compounds such as Reelin that are important in facilitating the migration of 
neurones to the cortical plate. 
 
1.5.2.2 Normal microscopic development of the archicortex 
Neuroblasts that will form the hippocampus are also generated in the ventricular 
zone.  They migrate to the cortical plate which in this area is designated the 
"ammonic plate" [(Stanfield and Cowan, 1988), reviewed by (Raymond et al., 
1995)]. In contrast to the development of the neocortex, the migrating neurons 
dissociate themselves earlier from the radial glial fibres and accumulate in the 
deeper aspects of the ammonic plate. During a subsequent phase, these neurons are 
reorganised to more superficial positions so that the formation of Ammon's Horn 
follows an inside-out gradient similar to that of the neocortex, to form the 
archicortex. The development of the dentate gyrus is different in many ways. 
Neurogenesis occurs initially in the ventricular zone, but a second, sub-pial germinal 
centre develops at a later stage and appears to become the dominant germinal centre 
(Schlessinger et al., 1975). Another difference is the assembly of the laminar 
architecture which follows an outside-in pattern, with neurons arriving later being 
added to the deeper layers. Tangential migration may be more important than radial 
migration. During maturation of the archicortex, the dentate granule cell layers and 
the hippocampal pyramidal cell layers which are originally in continuity become 
separated, probably in the course of the complex folding of the hippocampus 
(Duvernoy, 1998; Klingler, 1948; Stanfield and Cowan, 1988). Unlike neocortical 
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development, granule cell generation continues well into postnatal life, with the peak 
of neurogenesis in the early postnatal period (Schlessinger et al., 1975). 
 
1.5.3 Abnormal cortical development resulting in MCD. 
MCD are classified according to the scheme proposed by Barkovich and colleagues. 
This classification broadly categorises MCD according to failure at different stages 
of cortical development - neuronal proliferation and eventual apoptosis of selected 
cells; neuronal migration; and cortical organisation(Barkovich et al., 2001).  
 
1.5.3.1 Proliferation and differentiation 
1.5.3.1.1 Focal Cortical Dysplasia (FCD) 
FCD describes a localised MCD with characteristic histological appearance (Taylor 
et al., 1971). FCD are likely to represent the most common form of focal 
developmental disorder associated with intractable epilepsy(Kuzniecky and 
Barkovich, 2001) but the true prevalence is not known. Sisodiya found FCD to be 
the most common form of MCD in surgical series (Sisodiya, 2000) although this 
will have been influenced by selection bias. FCD seems to be rare in persons without 
epilepsy and absent in 500 controls in one series (Wolf et al., 1995) and not seen in 
170 controls in the National Society for Epilepsy MRI study (Everitt et al., 1998). 
 
Macroscopically FCD have smooth cortex with lack of sulci, coarse gyri and 
blurring of the grey-white matter junction (Thom, 2001). Histology (Norman et al., 
1995d; Prayson and Estes, 1995; Taylor et al., 1971) shows, beneath a molecular 
layer that is usually normal, cortical laminar architectural disorganisation with 
hypercellular cortex, possibly with persistent columnar alignment. Clusters of 
atypical neurons and glia can occur within the cortex, and heterotopic nerve cells 
may also be present in increased numbers in the underlying juxtacortical white 
matter.  
 
Cytology (Norman et al., 1995d; Thom, 2001) shows aberrant differentiation of 
nerve cells which are described as bizarre and cytomegalic and scattered in all 
cortical layers. They maintain an overall pyramidal shape and are usually greater 
than 20 microns. These nerve cells often appear randomly orientated, with loss of 
the normal vertical polarity of the apical dendrites. In a large proportion of cases, 
abnormal and enlarged astrocytic cells of up to 50µm in diameter are present. These 
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are mostly called "balloon cells", but other terms include "balloon cell glia", 
"grotesque cells", "dysplastic glial cells" or "uncommitted cells". Their appearance 
is intermediate between nerve cell and astrocyte. Glassy cytoplasm is abundant, 
nuclei are large and sometimes multiple. They are preferentially located in the 
deeper regions of the cortex or in the juxtacortical white matter. They resemble 
similar cells seen in cortical tubers in tuberous sclerosis and subependymal giant cell 
astrocytoma. A frequently used classification system is based on the absence (FCD 
type I) or presence (FCD type II) of these balloon cells (Kuzniecky and Barkovich, 
2001).  
 
Other lesions may coexist with FCD. Tumours have been reported [e.g. (Daumas-
Duport et al., 1988; Prayson and Estes, 1995; Prayson et al., 1993)]. Hippocampal 
sclerosis is relatively frequently found, in 9% (Prayson and Estes, 1995) and 12% 
(Wolf et al., 1995) respectively in two series.  
 
FCD may have a genetic inheritance, particularly when diffuse lesions are seen, as 
suggested by a case report of two brothers (Kuzniecky, 1994). Histological 
similarities with the cortical tubers of tuberous sclerosis and FCD have been noted, 
and FCD has been suggested to be a "forme fruste" of tuberous sclerosis (Palmini et 
al., 1991b). However the common presentation of FCD without evident family 
history suggests that environmental factors are usually a factor. 
 
The onset of epilepsy in patients with FCD is usually in the first decade. Seizures are 
often refractory despite treatment with antiepileptic drugs (Kuzniecky and 
Barkovich, 2001). MRI features are blurring of the grey-white matter interface, focal 
thickening of the cortex, gyral thickening and abnormal T2 signal, particularly in the 
underlying white matter (Kuzniecky and Barkovich, 2001).  
 
1.5.3.2 Neuronal migration 
Disorders of neuronal migration can occur and can be genetically determined. 
Filamin 1 is a large actin-binding / cross linking protein whose gene is located on 
chromosome Xq28. It plays an important role in migration. Defects may be inherited 
or due to sporadic mutations, and lead to migrational defects in females, while 
affected males foetuses generally do not survive to term. Other factors such as 
integrins, Ra1A and presenilin 1 may be involved in the initiation of migration 
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(reviewed by (Gleeson and Walsh, 2000)). Insight into the mechanisms of migration 
between the ventricular zone and the cortical plate comes from two disorders where 
migration is arrested part way between source and target, Lissencephaly type I and 
band heterotopia (BH). 
 
1.5.3.2.1 Lissencephaly 
Lissencephaly can be caused by mutations in at least two genes. The LIS1 gene is 
located on chromosome 17p13.3 (Cardoso et al., 2002; Dobyns et al., 1991). Its 
autosomal mode of inheritance causes haplo-insufficiency in affected individuals 
and the Lissencephaly phenotype (severe mental retardation and intractable 
epilepsy), suggesting that two wild type copies of the gene are necessary for normal 
cortical development. LIS1 probably exercises its role in migration through 
interaction with the microtubule cytoskeleton (Morris et al., 1998). 
 
In males, a second Lissencephaly locus on the X chromosome, termed DCX gene, 
leads to a phenotype that is similar to the one caused by the LIS1 mutation. Affected 
females, however, retain a working copy of the gene and have a band heterotopia 
together with a milder phenotype.  
 
Lissencephaly type II (cobblestone Lissencephaly) in humans, the related Fukuyama 
disease (Kobayashi et al., 1998) and Walker-Warburg syndrome (Kanoff et al., 
1998) all produce disruptions of the architecture of the developing cerebral wall and 
severe disorders of neuronal migration. The pial limiting membrane is defective, and 
neurons migrate out of the CNS and into the meninges [reviews by (Gleeson and 
Walsh, 2000; Golden, 2001)].  
 
1.5.3.2.2 Subependymal nodular heterotopia (SEH) 
Grey matter accumulation between the ependyma lining the lateral ventricles and the 
cortex is described as heterotopic, as compared to the normotopic overlying cortical 
grey matter. SEH are characterised by periventricular (subependymal) collections of 
neurons which form nodules.  
 
The nodules measure typically 2-10mm in diameter (Eksioglu et al., 1996), but may 
merge to form an irregular band of overlapping nodules (Raymond et al., 1994b). 
They may be unilateral or bilateral, and in published series comprising 7 
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(Huttenlocher et al., 1994), 8 (Barkovich and Kjos, 1992a), 13 (Raymond et al., 
1994b), 20 (Raymond et al., 1995) and 33 patients (Dubeau et al., 1995), 
respectively, they were seen bilaterally in 40-100%. While the whole length of the 
ventricles may be involved, the trigones and occipital horns are more commonly 
involved (Raymond et al., 1995). Frontal and temporal horns are less frequently 
involved, and the third and fourth ventricles are spared.  
 
SEH are among the more common forms of MCD encountered in adult epilepsy 
patients, accounting for 20/100 patients with MCD in the National Hospital series 
(Raymond et al., 1995), but again the true prevalence is not known. SEH has 
occasionally been seen in people undergoing MRI as “healthy controls” (Raymond 
et al., 1995) (Dubeau et al., 1995). There is a female preponderance. The gene, 
FLN1 (named after its gene product, filamin), has been linked to Xq28, and affected 
hemizygous males in typical pedigrees do not appear to survive gestation. 
  
SEH can be associated with other CNS malformations, for example Chiari Type II 
malformations or agenesis of the corpus callosum, and metabolic disorders such as 
Zellweger’s syndrome or neonatal adrenoleukodystrophy [reviewed by (Kuzniecky 
and Barkovich, 2001)]. In Dubeau's series of 33 patients with SEH, 13 also had sub-
cortical nodular heterotopia (Dubeau et al., 1995), and this combination was present 
in 2 of 20 patients in Raymond's series as well (Raymond et al., 1995). These cases 
were mostly unilateral, and abnormalities of the overlying cortex were frequently 
seen. Hippocampal sclerosis is described in association with SEH (Dubeau et al., 
1995; Raymond et al., 1994b). 
  
The heterotopia are composed of islands of relatively mature cells which resemble 
cortical neurons rather than the neurons of deep grey nuclei, in keeping with their 
likely provenance. They contain multiple neuronal types but no dysplastic nerve 
cells, and calcifications are not seen. Synaptophysin immunohistochemistry has 
shown dense pre-synaptic terminals around the heterotopic cells (Eksioglu et al., 
1996) but the origin of these afferents is not established. A study of nodular 
heterotopia in four children using dye tracing methods has shown limited 
connectivity of neurons between nodules (Hannan et al., 1999), for which there is 
indirect evidence through functional imaging studies that show task-induced 
activation in heterotopic gray matter (Pinard et al., 2000; Richardson et al., 1998a; 
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Spreer et al., 2001). The detailed autopsy study in children (Hannan et al., 1999) 
showed abnormal calretinin-positive neurons in the nodules and far less arborisation 
of dendritic trees. The interneurons in the nodules appeared generally immature. 
 
Epilepsy is common (Raymond et al., 1995). As the onset of seizures is typically in 
the second decade of life, relatively later than in other forms of MCD, the 
prevalence of epilepsy may be underestimated in series including young patients. 
Learning difficulties may not be present in milder cases (Raymond et al., 1995) but 
become more likely with bilateral and more extensive SEH (Kuzniecky and 
Barkovich, 2001).  
 
Focal, multifocal and generalized seizures can occur and at the severe end of the 
spectrum, infantile spasms and Lennox-Gastaut syndrome are seen (Golden, 2001). 
Epileptic phenomena are frequently discordant or contralateral to the side or location 
of the lesion (Raymond et al., 1995). There is direct evidence for epileptogenicity of 
heterotopic neuronal clusters (Francione et al., 1994; Kothare et al., 1998; Mattia et 
al., 1995; Palmini et al., 1995; Sisodiya et al., 1999a). 
 
On MRI, the isolated or confluent nodules are seen as isointense to normotopic grey 
matter on all standard MR sequences but are most readily seen on T1 weighted 
images (Raymond et al., 1995). Coexisting hippocampal sclerosis (dual pathology) 
is relatively frequent (Cendes et al., 1995; Raymond et al., 1995). 
 
1.5.3.2.3 Subcortical heterotopia (SCH) 
SCH are characterised by collections of neurons in the hemispheric white matter. 
These are separated from both the ventricles and the cortex through white matter. 
SCH are rare, accounting for only 3/100 malformations in the National Hospital 
series (Raymond et al., 1995). 
 
The nodules are of widely varying size, from less than 5mm to 20 or more mm in 
diameter. Abnormalities of the overlying cortex may be present [e.g. (Battaglia et 
al., 1996; Guerrini et al., 1996)]. Histology shows unlayered neurons which may 
look normal on inspection (Battaglia et al., 1996), but closer study suggests an 
imbalance between excitation and inhibition within the heterotopia (Hannan et al., 
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1999). SCH are often sporadic, indicating that somatic rather than germ line 
mutations may be involved (Kuzniecky and Barkovich, 2001). 
 
Epilepsy is common and usually develops early in life (Kuzniecky and Barkovich, 
2001). Patients with small unilateral subcortical heterotopia may be neurologically 
normal (Barkovich and Kjos, 1992a), whereas patients with extensive unilateral 
heterotopia are likely to present with hemi-plegia. At the severe end of the spectrum, 
patients with bilateral, large or spatially extended lesions may present with moderate 
to severe developmental delay and neurological deficits (Kuzniecky and Barkovich, 
2001). Heterotopic grey matter (Francione et al., 1994; Kothare et al., 1998; 
Sisodiya et al., 1999a) may be intrinsically epileptogenic. 
 
On MRI, the subcortical nodules are seen as isointense to normotopic grey matter 
(Raymond et al., 1995). The overlying cortex may look normal but may also be thin 
with small gyri and shallow sulci. Coexisting abnormalities are frequent, Kuzniecky 
and Barkovich claim that an agenetic or hypogenetic corpus callosum is present in 
approximately 70% of affected brains (Kuzniecky and Barkovich, 2001), and other 
malformations, particularly SEH, are frequently seen (Cendes et al., 1995; Raymond 
et al., 1995). 
 
1.5.3.2.3 Band Heterotopia (BH)  
BH usually affects the fronto-central and/or parieto-occipital areas with sparing of 
the temporal, inferior frontal and cingulate/medial frontal cortices. They are rare in 
adult epilepsy patients, accounting for 8/100 patients with MCD in the National 
Hospital series (Raymond et al., 1995). 
 
The bands are composed of differentiated, randomly orientated neurons of all types, 
accompanied by glial cells. In most cases, the overlying cortex shows the normal 
six-layered architecture, but layers V and VI may be poorly delineated and merge 
with the subcortical white matter and the lateral parts of the bands. 
  
A developmental link between Lissencephaly and BH was reported in a study of two 
families. Females had BH and hemizygous male offspring had Lissencephaly 
(Pinard et al., 1994). Subsequently, mutations of the gene, named DCX after its gene 
product, doublecortin, or XLIS after the mode of transmission, have been identified 
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on the X chromosome (Des Portes et al., 1998). Mutations have also been seen in 
some sporadic cases where DCX mutations account for some 85% of cases, whereas 
mutations have been found in 11 of 11 pedigrees with X-linked transmission of 
laminar heterotopia [reviewed by (Ross and Walsh, 2001)]. Doublecortin is a 
microtubule-associated protein expressed by migrating neurons (Gleeson et al., 
1999). While its precise function is unknown, it is thought to play a role in 
regulation of the microtubule cytoskeleton (Gleeson and Walsh, 2000). 
 
Most if not all subjects with BH develop epilepsy within the first two decades. A 
variety of seizure types is seen, including infantile spasms, Lennox-Gastaut 
syndrome, or other forms of secondary generalized, focal or multifocal epilepsy. On 
MRI, the BH are usually bilateral and approximately symmetrical. As with the other 
heterotopia, they are isointense to normotopic grey matter on all sequences. 
Typically, the medial border of the lamina is smooth, whereas the lateral border 
follows the white matter into the crowns of the gyri. The cortex overlying the 
laminae may appear macrogyric. Patients with the DCX/XLIS mutation show an 
anterior>posterior gradient of severity which is in contrast to that seen in LIS1 
patients. 
 
1.5.3.3 Abnormal post-migrational cortical organisation  
1.5.3.3.1 Polymicrogyria (PMG) 
PMG arises when neurons move out to the cortical surface but organise abnormally 
to produce multiple small gyri. It may be focal but is often bilateral, occurring 
predominantly in perisylvian, frontal, parieto-occipital or mesial occipital 
areas(Kuzniecky and Barkovich, 2001).  
  
PMG is characterised by many small microgyri separated by shallow sulci, 
abnormally thin cortex which appears thickened through the juxtaposition of the 
tightly packed microgyri, neuronal heterotopia and often enlarged ventricles 
(Kuzniecky and Barkovich, 2001). Two patterns are recognised, four-layered 
polymicrogyria, in which there is a molecular layer, an organised outer layer, a cell 
sparse layer and a disorganised inner layer, and an unlayered (disorganised) form. 
These two forms likely reflect the timing of the causative insult during 
corticogenesis (Norman et al., 1995c). Associated MCD may be present, including 
neural and glial leptomeningeal ectopia, areas resembling FCD, clefts, and 
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calcification. There is an excess of reelin immunopositive Cajal-Retzius cells in the 
region of the malformation which may be part of the malformation or may represent 
a reaction to an area of cortical injury (Eriksson et al., 2001b). Bilateral perisylvian 
polymicrogyria is relatively frequent and considered a discrete congenital syndrome 
by some (Kuzniecky et al., 1993a) but not others (Raymond et al., 1995). 
 
PMG is generally considered to be due to environmental insults rather than genetic 
causes, and diffuse PMG has been associated with intrauterine cytomegalovirus 
(CMV) infection (Barkovich, 1995), toxoplasmosis, syphilis, or maternal hypoxia. 
The environmental hypothesis is further strengthened by the rat freeze model where 
a focal freezing injury leads to the formation of microgyri (Dvorák and Feit, 1977; 
Jacobs et al., 1999a) and epilepsy through hyperexcitability caused by reorganisation 
of neural networks in perilesional areas (Jacobs et al., 1999b; Jacobs et al., 1999c). 
Lesion experiments suggest mechanisms that interfere with radial glial function, but 
this need not be the mechanism in all cases (Ross and Walsh, 2001). 
 
However familial cases do occur and several genes have been implicated (Ferrie et 
al., 1995)(Barkovich et al., 1999). An autosomal recessive inheritance is possible in 
purely frontal polymicrogyria. Genetic heterogeneity has also been indicated in 
kindreds with perisylvian polymicrogyria, with both X-linked (Cardoso et al., 2000; 
Guerreiro et al., 2000; Leventer et al., 2000; Yoshimura et al., 1998) and autosomal 
(dominant with incomplete penetrance, or recessive) patterns (Borgatti et al., 1999; 
Leventer et al., 2000). The genetic locus for bilateral perisylvian polymicrogyria has 
recently been mapped to Xq28 by linkage analysis in five families (Villard et al., 
2002). No inheritance pattern was discernible in nine individuals with parieto-
occipital polymicrogyria (Guerrini et al., 1997). 
 
Epilepsy associated with learning difficulties is common. Neurological signs are 
more likely to occur when the abnormality is located in or near eloquent cortex 
(Raymond et al., 1995). The polymicrogyria may be visible on high resolution MRI 
or be indistinguishable from macrogyria / pachygyria (Raymond et al., 1995). 
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1.5.3.3.2 Schizencephaly (SHZ) 
SHZ describes full-thickness clefts of the cerebral hemisphere lined by grey matter 
which may appear normal or be polymicrogyric. SHZ may be "closed-lipped" (type 
I) when the edges of the cleft are in apposition to each other or "open-lipped" (type 
II) when the appearance is that of a wide cleft. It may be unilateral or bilateral. 
  
SHZ is thought to be among the rarer forms of MCD (Sisodiya, 2000). Only two 
patients out of 100 with MCD in the National Hospital series fulfilled the criteria for 
true SHZ(Raymond et al., 1995). 
 
Apart from the cleft, the neuropathological appearance corresponds to 
polymicrogyria and indeed SHZ has been suggested to be an extreme form of 
polymicrogyria (Barkovich and Kjos, 1992c) and similar aetiological factors seem 
likely. Other areas of the brain, outside the SHZ, may be histologically abnormal 
(Packard et al., 1997). 
 
While most cases are sporadic, a minority of cases of open-lipped (type II) severe 
SHZ are due to germ line mutations in EMX2 (Brunelli et al., 1996), a homeobox 
gene involved in cell fate determination [reviewed by (Ross and Walsh, 2001)]. 
  
Neurological signs are common, and may be accompanied by learning difficulties, 
the severity of which is usually related to the type of defect, with open-lipped (type 
II) defects and bilateral clefts leading to more severe clinical pictures (Barkovich 
and Kjos, 1992c; Kuzniecky and Barkovich, 2001). Epilepsy seems to be the rule 
and is often intractable. MRI may be able to clearly show the polymicrogyric nature 
of the thickened grey matter lining the clefts (Raymond et al., 1995). 
 
1.5.3.4 Other relevant MCD sub-types 
1.5.3.4.1 Microdysgenesis 
Sometimes histological examination identifies abnormal cortical formation despite 
normal prior neuro-imaging studies and normal macroscopic pathological 
examination. Whether these microscopic abnormalities represent a distinct 
pathological process or part of the normal continuum is often debated, but a 
combination of abnormal histological features has been described in pathological 
tissue from subjects with epilepsy and labelled as microdysgenesis. 
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The original description was based upon the study of eight autopsy specimens from 
patients with IGE(Meencke and Janz, 1984). Seven of the eight showed similar 
qualitative histopathological abnormalities that included an excess of nerve cells in 
the subpial region and the molecular layer of the cortex, increased numbers of 
heterotopic nerve cells in the adjacent white matter and blurring of the cortical 
laminae 1 and 2(Meencke and Janz, 1984). Meencke later used a morphometric 
method to study neuronal densities in the molecular layer of frontal cortical 
specimens from epilepsy patients and found increased neuronal densities compared 
to age matched controls. Further studies have also reported increased white matter 
neuronal densities in subjects with epilepsy(Emery et al., 1997) or abnormal 
clustering of cortical neurones in layers II-IV in specimens from temporal lobe 
epilepsy patients with poor post-operative outcome following temporal lobe surgery. 
In contrast, some authors have argued against the presence of microdysgenesis in 
patients with epilepsy(Palmini et al., 1995;Opeskin et al., 2000). 
 
Increased numbers of heterotopic nerve cells described in microdysgenesis might 
represent arrested migration of nerve cells destined for the cortex or neurones that 
failed to undergo programmed cell death. By definition microdysgenesis is not 
observable using conventional MRI sequences. Research morphometric imaging 
methods have shown increased grey matter volumes in subjects with IGE compared 
to controls(Woermann et al., 1999b) which would be consistent with the initial 
observations of microdysgenesis in this population by Meencke and Janz.  Features 
commonly accepted to represent subtle MCD include neuronal clustering, 
mislamination, abnormal cortical myelinated fibres, and an excess of neurons in 
cortical layer I and the subcortical white matter(Sisodiya, 2004). 
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1.6 Magnetic Resonance Imaging 
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1.6.1 Introduction 
 
Magnetic resonance imaging (MRI) involves the application of alternating magnetic 
fields and radiofrequency (RF) electromagnetic waves. It was first developed in 
1946 independently by Bloch and co-workers at Stanford and by Purcell at Harvard. 
In 1967 Jackson produced the first signals from a live animal. 
 
This Section and the following Section describing the underlying concepts of MRS 
(1.7) are intended to contain sufficient physics to allow an appreciation of the 
methodologies used in this thesis. A more complete description of the physics of 
MR imaging techniques may be found by reference to dedicated texts (for example 
see(Tofts, 2003)) 
 
1.6.2 Physics of nuclear magnetic resonance imaging (MRI) 
A fundamental property of protons and neutrons is that they possess an angular 
momentum, which is often referred to as spin. Not all nuclei have a net spin. 
Specifically any nucleus with an even atomic number and an even charge number 
has no spin. If a nucleus does have net spin, the fact that it carries a positive charge 
results in a non-zero nuclear magnetic moment and an associated resonant frequency 
dependent on the strength of the external magnetic field. Table 1.6.1 shows the 
natural abundance, nuclear spin and resonant frequency at 1 Tesla for several such 
nuclei. 
 
Table 1.6.1 Natural abundance, nuclear spin and resonant frequency at 1 Tesla for 
several nuclei commonly studied in vivo. 
 
Nucleus Natural Abundance (%) Spin (I) Resonant Frequency 
1
H (hydrogen) 99.9 ½ 42.6 MHz 
13
C (carbon) 1.1 ½ 10.7 MHz 
31
P (phosphorus) 100 ½ 17.25 MHz 
 
Hydrogen has the highest resonant frequency because it has the strongest magnetic 
moment. It is also naturally abundant and these properties make it the ideal nucleus 
for MRI techniques. 
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Magnetic field theory dictates that a nucleus with a magnetic moment can occupy 
(2I + 1) energy levels, where I is the spin number of the nucleus. For the nuclei in 
the table above I = ½ and the energy level diagram will therefore consist of two 
levels. In the lower energy state the nuclear moment lies parallel to the external field 
while the higher energy state has a moment that lies anti-parallel to the external 
field. Within a sample subjected to an external field at physiological temperatures 
there is only a small imbalance between the population of nuclei that occupies the 
lower energy state and the population that occupies the higher state. If the sample is 
then excited by an additional radiofrequency (RF) magnetic field providing precisely 
the difference in energy between the two levels, energy transitions between the two 
levels can be induced that perturb the net magnetisation so that a signal can be 
produced. The relationship between the frequency of the resulting signal and the 
static external field is given by the Larmor equation as follows: 
 
ν = (γ/2)B0            [Eqn 1.6.1] 
 
where B0 is external magnetic field strength in Tesla, and γ/2 is the gyro-magnetic 
ratio in MHz /Tesla for the spin under consideration. ν is the resonant frequency of 
the material studied and is shown by this relationship to be dependent on the applied 
external field. 
 
The application of an RF pulse that causes resonance to occur is termed excitation. 
This absorption of energy causes an increase in the “spin-down” hydrogen nuclei 
population (that is the population of nuclei that occupy the higher energy spin state 
with net moment anti-parallel to the applied field), as a proportion of the “spin-up” 
(the population in the lower energy state with moment parallel to the applied field) 
nuclei transition to the higher energy state. 
  
The RF pulse generally used for MR imaging is in the form of a rotating magnetic 
field, denoted by B1, which is applied for a short time in the plane perpendicular to 
the main field (B0). To tip the net nuclear magnetisation (M), this B1 field must 
rotate precisely at the precession frequency of the protons. The first result of 
resonance is that the net magnetisation moves out of alignment away from B0. The 
angle to which the magnetisation moves out of alignment is called the flip angle. 
The magnitude of the flip angle depends on the magnitude and duration of the RF 
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pulse. Usually the flip angle chosen is 90 degrees, i.e. the magnetisation is given 
enough energy by the RF pulse to move through 90 degrees relative to B0. B0 is 
aligned along the longitudinal axis and the plane at 90 degrees to the longitudinal 
axis B0 is termed the transverse plane. 
  
Immediately following excitation the magnetic moments of the hydrogen nuclei 
within the transverse plane move in phase with each other: their precessional paths 
around B0 are aligned.  
 
The most basic MR experiment is to perturb the nuclear magnetic moment into the 
transverse plane using a brief RF pulse (B1), and then to observe the signal induced 
by Faraday’s law of induction in a receiver coil. An oscillating signal is induced in 
the coil that decays under an exponential envelope (the free induction decay).  The 
detected signal can be analysed for its frequency components by means of Fourier 
transform. 
 
1.6.2.1 T1 Relaxation 
RF stimulation causes a proportion of the exposed nuclei to absorb energy, lifting 
them to the excited state. The nuclei in this state can return to the ground state only 
by dissipating their excess energy. Spin lattice relaxation (T1 relaxation) depends on 
energy transfer to the surrounding environment (i.e. when a stimulated proton 
encounters another magnetic field nearby). Relaxation recovery is an exponential 
process with the T1 time being the recovery time constant.  
 
1.6.2.2 T2 relaxation / decay 
T2 relaxation is also called spin-spin relaxation. T2 relaxation results from any 
intrinsic process that causes the spins to lose their phase coherence in the transverse 
plane. Most frequently it results from static or slowly fluctuating local magnetic 
field variations within the tissue itself. As with the T1 recovery this rate of transverse 
signal decay is exponential and by convention has time constant T2.  
 
In biological tissues the main contribution to T2 relaxation is from the relatively 
static magnetic field from neighbouring protons. In rigid molecules such as 
membrane phospholipids, where molecular motions are extremely slow, T2 
relaxation is very rapid and the transverse magnetisation may decay so rapidly that 
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signal is not detected by the receiver coil. Alternatively, when molecules are moving 
rapidly, any short local field inhomogeneity experienced by an excited proton will 
average to zero over a short time and the T2 relaxation times are correspondingly 
much longer. 
 
1.6.2.3 Repetition Time (TR) 
The time between repeated RF excitation pulses is called the repetition time (TR). 
The TR determines the amount of relaxation that is allowed to occur between the 
end of one RF pulse and the application of the next. Longer repetition times allow 
more T1 relaxation and this property can be used to exploit the contrast between 
tissues with different T1. 
  
1.6.2.4 The Spin-Echo Sequence  
In practice the net transverse magnetisation shrinks more rapidly than expected from 
T2 relaxation alone and is characterised by time constant T2* where T2 can be 
thought of as the natural or true spin-spin relaxation of the tissue and T2* as the 
“observed” relaxation due to both spin-spin relaxation effects as well as other causes 
of spin dephasing (principally due to inhomogeneities in the main magnetic field). 
However, a 180 degree RF pulse applied at time T after the 90 degree excitation 
pulse can re-establish phase coherence at time 2T as a spin echo. The amplitude of 
the transverse magnetisation at the echo peak depends on TE and T2 of the tissue. In 
a spin echo this amplitude is proportional to e 
– TE/T
2. If TE equals T2 the transverse 
magnetisation has decayed to 37% of its initial amplitude. As TE is lengthened, the 
transverse magnetisation becomes weaker. As for TR, the TE can be chosen to 
exploit biological variation in T2 to provide image contrast.  
 
1.6.2.5 The Gradient Echo Sequence 
Gradient echo imaging techniques provide methods of accumulating images in much 
shorter total times than conventional pulse sequences. The gradient echo pulse 
sequence uses a rapidly reversing RF gradient instead of the relatively time 
consuming refocusing 180 degree pulse sequence that is used to form a spin echo. In 
spin echo imaging the 180 degree pulse reverses the direction of all transverse 
magnetisation making the relaxation that occurs between the initial 90 degree RF 
pulse and signal echo immune to fixed magnetic field inhomogeneities. These 
P a g e  | 80 
 
magnetic field inhomogeneities may be static magnetic field non uniformities, any 
un-reversed gradients applied during the time interval TE, or magnetic susceptibility 
inhomogeneities. As a result the transverse relaxation measured in SE sequences is 
related entirely to “true” T2 relaxation effects. In gradient echo imaging, formation 
of an echo by gradient reversal does not eliminate the dephasing effects of magnetic 
field inhomogeneities. Therefore the signal decay between the initial 90 degree pulse 
and the gradient echo depends on true T2 relaxation plus relaxation caused by 
magnetic field inhomogeneities and is governed by T2*, which is shorter than T2. In 
extremely homogeneous magnetic fields and in tissue regions without magnetic 
susceptibility inhomogeneities, T2* values approach T2 times. In voxels where there 
are inhomogeneities T2* can be very much shorter than T2. 
  
Gradient echo sequences are used in the majority of fast scan MRI techniques. 
Typical measuring times for a single two dimensional image are seconds. These scan 
times compare favourably with the time constants of most physiological motion in 
humans and can provide access to functional information such as blood flow. 
 
1.6.2.6 The Inversion Recovery Sequence  
In this sequence, an 180
o
 pulse is applied before the net magnetisation is tipped into 
the transverse plane. The effect of this pulse is to reverse the direction of the initial 
magnetisation. As spin-lattice relaxation occurs and the net-magnetisation starts to 
return toward its equilibrium position aligned along the external magnetic field it 
will reach a point where there is zero net longitudinal magnetisation. If a 90 degree 
pulse is applied at this inversion time (TI) no transverse magnetisation will be 
produced. This sequence is applied to study tissue containing several components 
with differing T1 times. By correct choice of the TI signal from one or more of the 
tissue components can be minimised. This forms the basis of the Fluid Attenuated 
Inversion Recovery (FLAIR) sequence and also the metabolite nulling sequence 
described in section 2.5. 
 
1.6.3 Advanced Magnetic Resonance Imaging (MRI) applications 
MRI is superior to computed tomography (CT) in the detection of the pathology 
underlying focal epilepsies in both adults and children (Kuzniecky et al., 1993b; 
Sperling et al., 1986; Theodore et al., 1986a). The most commonly identified 
abnormalities are hippocampal sclerosis, malformations of cortical development, 
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vascular malformations, tumours, and acquired cortical damage. Due to the rapid 
advances in MRI techniques, abnormalities are not infrequently identified in patients 
who were previously regarded as being 'MRI-negative', and it has become important 
to describe the MRI sequences, MRI field strengths and the criteria by which 
patients are considered 'MRI-negative'. 
 
More advanced MRI techniques such as MRS, diffusion weighted imaging (DWI), 
magnetisation transfer, volumetric analysis and functional imaging (fMRI) may also 
be indicated to characterise the epileptogenic focus and are often applied to the 
assessment of potential surgical candidates. Other modalities such as PET and/or 
SPECT may also be helpful in some subjects. 
 
3D T1-weighted MRI produces images with high anatomical definition which form 
the basis of several quantitative volumetric techniques useful in diagnosing and 
characterising epilepsy. The techniques for reliable detection of hippocampal 
sclerosis by MRI are well established(Jackson et al., 1990;Cook et al., 1992;Duncan 
et al., 1996;Duncan, 1997;Van Paesschen W. et al., 1997a).  Hippocampal atrophy 
identified by MRI correlates well with hippocampal loss, particularly in the CA1 
sub-region(Van Paesschen W. et al., 1997b). Amygdala volumes may be similarly 
determined(Cendes et al., 1993).  Measures may also be derived of cerebral 
hemisphere grey matter and sub-cortical volumes(Sisodiya et al., 1995). Further, the 
distributions of grey and white matter may be compared between groups of subjects, 
between a single subject and a control group using regional measures (Sisodiya et 
al., 1995) and / or voxel based morphometry(Richardson et al., 1997;Woermann et 
al., 1999a). 
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1.7 1H Magnetic Resonance Spectroscopy 
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1.7.1 Introduction 
 
This section introduces the basic physics behind MRS and practical aspects of 
performing a MRS experiment. The most commonly studied metabolite peaks in 
1
H 
MRS experiments are introduced but their relevance to the investigation of epilepsy 
is outlined in more detail in Section 1.8. The metabolism of GABA, glutamate, 
glutamine and lactate has already been discussed in Section 1.2 and is not repeated 
in depth here. 
 
1.7.2 MRS Physics 
In MRI it is generally acceptable to consider that the resonant frequency of any 
particular nucleus depends only on the applied magnetic field (B0). In fact the 
stimulated nuclei are also subject to the local environment. Nearby electrons and 
other nuclei have small but significant effects on the net field to which the nucleus is 
exposed. From the Larmor equation this will alter the frequency at which that 
nucleus will resonate. MRS experiments aim to separate and measure different 
metabolites on the basis of this variation in resonant frequency or chemical shift. 
Most biomedical MRS experiments are performed with 
1
H, 
13
C or 
31
P. 
 
Both 
1
H and 
31
P are naturally abundant isotopes (99.98% and 100%, respectively) 
and are present in sufficiently high concentrations in the brain in biologically 
important compounds. These characteristics have resulted in the widespread use of 
1
H and 
31
P for the study of metabolites in vivo. However, the MR sensitivity of 
31
P 
is only 7% that of 
1
H, so larger volumes of tissue need to be examined for 
31
P MRS 
than for 
1
H MRS, leading to a loss of spatial resolution. For the case of carbon only 
1.1% of the total carbon population consists of the magnetically active isotope 
13
C. 
This factor together with a smaller gyro-magnetic ratio than for 
1
H means that the 
relative sensitivity of 
13
C is 60 times less than that of 
1
H. However the relatively 
small endogenous 
13
C signal can be used to advantage when using 
13
C enriched 
media where the vast majority of the recorded signal will derive from labelled 
13
C.  
 
In practice the poor spatial resolution with
 31
P and 
13
C MRS limits the clinical 
usefulness of such studies although they remain important research tools. The 
remainder of this section will deal with predominantly 
1
H MRS. 
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Figure 1.7.1 Typical short TE 1H MRS spectrum obtained in a healthy volunteer studied 
in the frontal lobes. NAA = N Acetyl aspartate, GLX = glutamate plus glutamine, Cr = 
creatine plus phosphocreatine, Cho = choline containing compounds and Ins = myo-Inositol 
 
1.7.2.1 Chemical Shift 
A proton (or any other resonating atomic nucleus) has a resonant frequency 
proportional to the magnetic field it experiences. This is the sum of the large 
external applied field and the small local field produced by the electrons moving 
around the nucleus. This local field opposes the main applied field, slightly shielding 
the nucleus from the external field B0 such that the effective field experienced by the 
proton is given by: 
 
B = Bo (1-σ)         [Eqn 1.7.1] 
where σ is the shielding constant. The modified Larmor equation is then given by: 
ν = γ/2(1-σ)B0         [Eqn 1.7.2] 
The shielding electrons are therefore said to result in a chemical shift of the resonant 
frequency of the nucleus. The magnitude of the shielding effect and hence the 
magnitude of the chemical shift varies. For example the 
1
H nuclei in water 
molecules (H2O) generally experience less shielding than 
1
H in lipid molecules. 
They therefore experience a larger net magnetic field resulting in a higher resonant 
frequency for the same applied external field.  Usually the X-axes of MR spectra are 
displayed in units of chemical shift, defined as the frequency of resonance relative to 
the resonant frequency of a reference chemical. Chemical shift (δ) is usually stated 
in parts per million (ppm) according to:  
Cho 
Cr 
NAA 
GLX Ins 
2 4 1 ppm 3 
P a g e  | 85 
 
 
δ = 106 (ν sample – ν reference) / ν reference      [Eqn. 1.7.3] 
 
By convention the reference used in proton MRS is the resonant frequency of the 
equivalent 
1
H nuclei in tetramethyl silane (TMS), which by definition resonate at 0 
ppm.  TMS is an appropriate reference because the shielding of protons in this 
compound is greater than in other organic compounds. Consequently MR signals of 
most relevant molecules are shifted in the same direction downfield from TMS and 
have chemical shifts between 0 and 10 ppm. Water has a chemical shift of 4.7 ppm 
whilst aliphatic lipids have chemical shifts of about 1.2 ppm. By convention spectra 
are displayed with chemical shift increasing along the horizontal axis from right to 
left so that the water peak is to the left of the lipid peak. Chemical shift measured in 
ppm is independent of the B0 field and this allows comparison of spectra acquired on 
different scanners and at different field strengths.  The area under the peaks is 
proportional to the number of protons in each environment and with the same 
chemical structure. 
 
1.7.2.2 Free Induction Decay 
In MRS a strong RF pulse is applied that will cause all the nuclear species under 
investigation to resonate. The signal recorded, defined as the free induction decay 
(FID) is a convolution of these individual metabolite resonant frequencies decaying 
exponentially with time. 
 
1.7.2.3 Spin-spin (J) coupling 
It is not only the surrounding electron cloud that has an effect on the resonant 
frequency of a particular nucleus. The obtained spectra may also display the effect 
of line splitting due to field interaction of two nuclear spins on the same molecule. 
For example if a proton (HA) is near another non-equivalent proton (HB) (i.e. HB has 
different chemical shift), in half of the molecules the HA proton will be adjacent to 
an HB aligned with the field and in the other half the HA proton will be adjacent to 
an HB aligned against the field. Thus, half the HA protons in the sample will feel a 
slightly larger magnetic field than they would in the absence of HB and half will feel 
a slightly smaller magnetic field and resultant peak will be split into 2 equal halves.  
Such “spin-spin” coupling is independent of the intensity of the external field B0. 
The distance between the split peaks (in Hz) is called the “coupling constant” and is 
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usually represented by the symbol J. Provided the coupling effect is weak (the 
coupling constant is small compared to the difference in the chemical shifts between 
the coupled nuclei) the final spectrum will be determined by the spin and the number 
of interacting nuclei to produce (2nI + 1) lines (for first order coupling, where I is 
the spin of the adjoining nuclei and assuming n equivalent interacting nuclei) and the 
relative intensities of the multiplet will be given as follows. 
 
e.g. for 
1
H where I = ½. 
 
n = 0     1 
n = 1    1  1 
n = 2   1  2  1 
n = 3  1  3  3  1 
.. 
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The GABA molecule is shown together with the J values for the interacting H nuclei 
(Fig. 1.7.2). The GABA peaks at 3.01, 2.28 and 1.89 ppm are all heavily overlapped 
in the standard spectrum acquired at short TE and therefore GABA cannot be easily 
measured. For this reason techniques have been developed which make use of the J 
modulation to simplify the spectrum and allow GABA peak measurement. The 
double quantum filter technique used in this thesis to measure GABA concentration 
is one such technique. The filter is described in more detail in Chapter 2. Further 
description of the techniques used to simplify the spectrum using J-coupling effects 
is provided in Section 1.7.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7.2 Gamma amino butyric acid. The three pairs of 1H: H1 and H2, H3 and H4, 
H5 and H6 interact with their adjacent pairs as shown in the table below: 
 
 
Resonance Chemical Shift (ppm) J-Coupling (Hz) 
H1 3.0128 H1 – H3 (5.37) H1 – H4 (7.13) 
H2 3.0128 H2 – H3 (10.58)H2 – H4 (6.98) 
H3 1.8890 H3 – H5 (7.76)H3 – H6 (7.43) 
H4 1.8890 H4 – H5 (6.17) H4 – H6 (7.93) 
H5 2.2840  
H6 2.2840  
 
 
Table 1.7.1: Chemical shifts and coupling constants for GABA(Govindaraju et al., 
2000) 
 
 
 
+(H)3N 
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1.7.2.4 T2 and MR visibility 
MRS studies performed at short TE (< 60 ms) will still include some components 
from partially mobile macromolecules and lipids or metabolites with short T2. 
Studies performed at longer TE will not show these compounds. In practice the aims 
of the MRS study will dictate the acquisition TE. Short TE studies can measure a 
greater range of compounds and are less susceptible to changes in T2 in pathological 
tissue. However analysis is more complicated at short TE because the baseline 
contains a series of broad peaks from macromolecules and lipids. Long TE studies 
benefit from the fact that as the TE lengthens there is diminishing presence of these 
broad baseline resonances and direct, “by eye”, qualitative assessment of the ratios 
of the main visible metabolite peaks is possible.  
 
1.7.3 Basic acquisition and processing techniques 
1.7.3.1 Shimming 
The magnetic field inside an ideal magnet will be highly homogeneous. For simple 
solenoids this requires an infinitely long magnet length compared to the diameter of 
the coil in order to minimise the effect of the strong divergence of the field lines at 
the ends of the coil. To compensate for this divergence and to generate a reasonably 
homogeneous field in a bore of an acceptable length that can be incorporated into 
currently available MRI scanners, the coil segments are wound with a smaller radius 
or more turns at the end of the coil than at the centre. Further fine adjustment of field 
homogeneity at the site of interest is called shimming. MRS experiments which 
depend upon detecting the small differences in resonant frequencies corresponding 
to small variations in the local field experienced by each resonating hydrogen 
nucleus are particularly sensitive to field inhomogeneity and shimming procedures 
will usually be applied prior to the commencement of MRS acquisitions from 
prescribed regions of interest. 
 
The field homogeneity is improved by passing current through appropriate gradient 
coils, which generate small magnetic field gradients superimposed on the main B0 
field. These gradients add to, or subtract from, the field at desired points along its 
axis or transverse to it, smoothing out the field non-homogeneities.  
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1.7.3.2 Water suppression  
The water peak dominates the unsuppressed 
1
H MRS spectrum because of the high 
concentration of water in the human brain. Without water suppression the other 
metabolite peaks are hard to measure and the baseline is massively distorted by the 
dominant water peak. In order to visualise the other non-water metabolites it is 
necessary to suppress the signal from the water hydrogen nuclei. A practical 
measure to overcome this is to suppress the water signal immediately prior to the 
time of acquisition. Although suppression of the water signal may be achieved via a 
number of different methods a convenient method entails the prescription of a series 
of chemical shift selective pulses adjusted to the resonant frequency of water that 
transfer the water signal to the transverse plane and are followed by “crusher” 
gradients in the transverse plane that dephase the transverse magnetism before a 
spatially localised spectrum is acquired (see Chapter 2 for pulse sequences used in 
this thesis). 
 
1.7.3.3 Choice of Echo Time (TE)  
Early in-vivo work was generally carried out at long TE. A value of TE = 135 ms 
was often chosen because at this TE the lactate peak is inverted and easily identified. 
Longer TE acquisitions are technically less demanding and produce well defined 
main peaks and a flat baseline. However, as noted above, T2 losses are large and can 
constitute a problem, both because of reduction in the signal to noise ratio (SNR) 
and also because the resulting signal has to be corrected for these losses as part of 
the quantification procedure. More recent work has made use of improvements in 
gradient switching times and the shielding of eddy currents to perform short TE 
studies. Such studies suffer fewer T2 losses and result in higher signal to noise ratio. 
More metabolites are visible at shorter TE but the baseline is now complex and 
irregular as a consequence of broad macromolecule peaks and this has to be 
modelled before quantification of metabolite concentrations is possible. 
 
1.7.3.4 Localisation techniques  
For a detailed review of the developmental history of these techniques please see a 
review by Keevil (Keevil, 2006). In order to allow for a meaningful interpretation of 
MRS results, localisation techniques are employed to acquire spectra from a limited 
pre-defined volume of interest (VOI) only. A number of localisation methods have 
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been developed but for the majority of studies localised spectra are now obtained by 
applying one of the following four methods: 
 
The STimulated-Echo Acquisition Mode (STEAM) was first demonstrated as a 
viable localisation method for proton spectroscopy of the human brain by Frahm and 
was rapidly taken up by other groups(Frahm et al., 1989). The sequence consists of 
three 90 degree selective pulses, each applied in the presence of an orthogonal 
gradient to excite a slice. Because these are 90 degree pulses, gradient refocusing 
lobes must be used. The resulting signal is from the VOI defined by the intersection 
of the orthogonal slices. Although the STEAM sequence is both simple and robust it 
suffers from the fact that the final stimulated echo yields at best only half of the 
possible signal from the VOI.  Also, although it can be used advantageously for 
short TE studies it is not well suited for the study of nuclei with very short T2 values 
(e.g. phosphorus) because of the time required for application of the gradient 
refocusing lobes. 
 
The Point RESolved Spectroscopy (PRESS) localisation experiment(Bottomley, 
1987) consists of a 90-180-180 degree pulse sequence with each pulse applied in the 
presence of an orthogonal gradient so that the final echo comes from the intersection 
of the planes as depicted in Figure 1.7.3. Unlike STEAM the PRESS sequence 
retains the full signal. A disadvantage of PRESS is that the longer sequence 
preparation time makes it less suitable for acquisitions at very short TE. 
 
Figure 1.7.3 The PRESS Sequence. For simplicity, the initial water suppression, outer 
volume suppression are not shown 
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The Image Selected In vivo Spectroscopy (ISIS) experiment also uses frequency 
selective pulses in the presence of orthogonal gradients(Ordidge et al., 1988). 
However the selective pulses are inversion pulses and a fourth non-selective pulse is 
applied for observation of the signal. A series of eight acquisitions with different 
combinations of inversion pulses is required to achieve the localisation of the VOI 
defined by the intersection of the orthogonal slices. Because the signal is received 
immediately after the final RF pulse there is minimal loss from T2 relaxation, and 
ISIS has proved to be a particularly effective localisation experiment for observation 
of nuclei with short T2 values such as 
31
P. The availability of frequency selective 
pulses with immunity to B1 inhomogeneity has made ISIS an important localisation 
experiment for use with surface coil experiments where the B1 field is inherently 
inhomogeneous. 
 
Magnetic Resonance Spectroscopic Imaging (MRSI) (alternatively known as 
Chemical Shift Imaging or CSI) techniques involve spatial encoding by switched 
gradients(Bottomley et al., 1988). The number of encodings required is equal to the 
desired number of pixels in the final spectroscopic image. The spatial encoding in 
spectroscopic imaging is accomplished by phase encoding gradient steps as used in 
conventional MRI methods (Fig. 1.7.4). However to preserve the chemical shift 
information, the data in spectroscopic imaging methods are collected in the absence 
of a readout gradient; this is in contrast to MRI methods in which a readout gradient 
is used to obtain spatial information in one of the dimensions. MRSI methodology is 
discussed in more detail in Chapter 2. 
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Figure 1.7.4 Typical 2D MRSI pulse sequence. Again for simplicity the initial water 
suppression, outer volume suppression, and associated slice-selective crusher gradients are 
not shown 
 
1.7.3.5 T1 and T2 correction  
Nuclear concentration is only proportional to peak area under two conditions. First, 
the longitudinal magnetisation must have had time to fully recover after any 
previous pulses, i.e. it must be fully relaxed (TR >> T1). Second the transverse 
magnetisation must be fully intact at the time of signal acquisition, with no 
transverse magnetisation decay (TE << T2). The first condition is sometimes 
achieved, although data collection times can become very long. The second 
condition is rarely achieved in 1H MRS since an echo is required for the spatial 
localisation schemes. Thus a correction is often made for T1 and T2 decay. This can 
be kept as small as possible, by using long TR and short TE so that small errors in 
the T1 and T2 values used in the corrections do not have a large effect on the 
estimate of concentration. Relaxation times can change in disease, thus corrections 
which assume standard values can be inaccurate. The alternative of measuring T1 for 
each subject is time consuming. T2 measurements may be more desirable when 
correcting long echo time spectra (e.g. TE = 135ms).  
 
 
1.7.3.6 Referencing to a standard solution  
Although the concentration of a metabolite is proportional to its spectroscopic peak 
area, the determination of the constant of proportionality is not trivial. The 
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calculation depends on the receiver gain, the coil loading (which depends on the 
subject or sample), the voxel size and the temperature. 
 
Internal water referencing has been advocated. It is easy to collect a rapid brain 
spectrum that includes water as an internal standard. If the water concentration is 
known, this then calibrates the gain of the spectrometer, establishing the link 
between proton concentration and peak area. Non-uniformity in the receiver 
sensitivity is the same for water and metabolites and therefore need not be corrected 
for. The water signal has a high signal to noise therefore only a few averages are 
required. The difficulty is that the water concentration is usually not known exactly. 
It depends on the proportions of white matter, grey matter and CSF in the voxel, and 
is often increased in disease. It must be measured separately, or some assumption 
made about its value. 
 
For this reason external referencing is frequently used to quantify the metabolite 
signal. The signal from water, or a metabolite of known concentration, can be 
measured in a separate acquisition from a phantom (test object). This overcomes the 
problem of the incomplete information about the water concentration. A “same 
time” external standard can be measured in the same sequence as the subject of 
interest. “Same-place” external standard measurement can also be used. This 
requires that the phantom is measured in the same position within the magnetic field 
as would be occupied by the specimen of interest, for example the centre of the brain 
in a volunteer undergoing a Head MRS study (thus overcoming the major problems 
of spatial non-uniformity). “Same place” scanning must clearly be performed at a 
different time point to the acquisition of the volunteer scan. It is therefore vulnerable 
to changes in coil sensitivity (brought about by the change from loading by a head to 
loading by a phantom), and to receiver instability (whether caused by explicit gain 
changes or unexpected drift). Corrections for RF non-uniformity across the different 
regions in the brain are still needed in principle, although they may be minimal in a 
relatively uniform coil. 
 
An alternative to the above techniques which try to reference the obtained 
metabolite signal to a known internal or external concentration is to choose a stable 
metabolite peak from the produced spectrum; and then to use this peak value as an 
internal standard by reporting the other acquired peaks with reference to this 
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“standard”. This is helpful where one metabolite is known not to vary in 
concentration. In most cases there is no such standard metabolite and the biological 
interpretation of any change in a peak ratio can become very difficult. This last 
method was employed in the majority of the early MRS studies of subjects with 
epilepsy. The creatine plus phosphocreatine (Cr) peak was considered to be 
relatively invariant across brain regions and between pathologies and was used as 
the “standard” peak. However, as discussed in Chapter 3 of this thesis, this use of 
ratios can lead to loss of information as to the true trend to change in metabolite 
concentrations in regions of pathology. 
  
1.7.3.7 Signal to noise ratio and signal averaging 
Metabolite concentrations are usually too low to obtain a satisfactory signal-to-noise 
ratio (SNR) in the spectrum from a single FID or echo signal. By adding together 
many signals before Fourier transformation, the SNR is improved. Signal averaging 
enables the noise to be decreased (since it is random), relative to the signal.  
 
The SNR is given approximately by: 
 
SNR = SNR0 * NEX 
½ 
* VOI      [Eqn. 1.7.4] 
 
Where SNR0 is the SNR for 1cc of tissue in a single acquisition, NEX is the number 
of excitations (averages), and VOI is the volume from which the spectrum is being 
collected (i.e. the total number of protons excited). Thus, from (1.7.5), SNR 
increases rapidly with increasing VOI, and more slowly with increasing NEX (as 
NEX
1/2
). To achieve a given SNR, more NEX (and therefore a longer exam time) is 
required as VOI is reduced. An acceptable SNR can be achieved in about 10 minutes 
for a 2ml voxel at 1.5 Tesla (using short TE PRESS). 
 
1.7.4 Advanced acquisition and processing techniques  
Advanced MRS sequences may be applied to filter or simplify the spectrum to allow 
the identification of a particular peak. In Chapter 2 a Double Quantum Filter 
technique is described. The technique has been employed extensively in this thesis 
and GABA measurement in several different epilepsy syndromes is reported in 
Chapter 3 ([3.2], [3.3], [3.4], and [3.6]). 
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Another technique employed to simplify GABA measurement is the technique of 
spectral editing. This technique has been widely applied by Rothman and co-
workers in order to measure GABA concentrations in a number of studies of 
subjects with epilepsy and the findings of this group are referred to frequently in the 
discussion sections of this thesis. It is therefore instructive at this point to briefly 
describe Rothman and co-workers’ methodology of GABA signal detection by 
spectral editing techniques. 
 
As shown below the 
1
H spectrum of GABA consists of three multiplets at circa. 1.9, 
2.5 and 3.0ppm respectively. Each multiplet is heavily overlapped by other 
metabolite peaks. The C4 GABA resonance at 3.0 ppm (H1 and H2) is a triplet 
arising from J-coupling with the protons bonded to the C3 carbon (protons H3 and 
H4 which resonate at 1.9 ppm). The major overlapping resonance at 3.0 ppm is the 
Cr peak which is a singlet.  
 
 
            
            
  
  
 
Figure 1.7.5 1H MRS spectrum for GABA[from (Govindaraju et al., 2000)] 
 
In spectral editing, a semi-selective refocusing pulse is applied in the first instance 
placed at the C3 GABA resonance at 1.9 ppm. Next, to selectively induce J-
modulation a tailored excitation pulse train is applied to invert the C3 GABA 
resonance and cause the outer sidebands of the C4 GABA triplet to invert. 
Subtraction of a spectrum obtained with this sequence from a spectrum obtained 
without the sequence eliminates signals that are not J-coupled to resonances at 1.9 
ppm and gives an edited GABA spectrum at 3.0 ppm. Specifically, the major 
overlapping Cr peak, which does not exhibit J-coupling, is subtracted out from the 
ppm 
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final spectrum. Since only the outer two peaks of the triplet are detected the 
maximum yield is 50%. 
 
The double quantum filter (DQF) used in this thesis to measure GABA 
concentrations also uses J-coupling effects to remove the overlapping Cr peak at 3.0 
ppm and is described fully in Chapter 2.  Each of these techniques which filter or 
edit the obtained spectra from a volume of interest result in reduced signal to noise 
in the finally obtained spectrum. Whilst equation [1.7.5] demonstrates that this 
reduction in signal can be countered by increasing scan times or by increasing the 
studied volume of interest the final scan sequences applied at conventional magnet 
field strengths will usually require some compromise between signal quality and 
acceptable scan duration and / or spatial resolution.  
 
1.7.5 MRS at Higher Magnetic Field Strengths 
An alternative mechanism to improve the resolution of the separate metabolite peaks 
is to apply a higher external magnetic field. Returning to the Larmor equation (1.7.3) 
it can be seen that increasing the magnetic field B0 will increase the separation of the 
individual metabolites along the frequency axis. High static field MRI scanners are 
now becoming available and several studies have reported good separation of 
overlapping peaks(Gruetter et al., 1998a;Gruetter et al., 1998b;Tkac et al., 2003). 
Increasing B0 will also improve the separation of metabolite peaks by directly 
increasing the SNR. 
 
1.7.6 Biological Significance of Metabolite Peaks 
Several brain metabolites are reliably measured using 
1
H MRS. Three dominant 
signals are visible at both short and long TE. These three metabolites are N-acetyl 
aspartate (NAA), creatine plus phospho-creatine (Cr) and Choline containing 
compounds (Cho). Other brain metabolites are visible only at short TE. These short 
TE visible metabolites include GLX, the complex signal of glutamate plus 
glutamine, GABA and myo-inositol (Ins). Finally lactate is visible at low 
concentration at both short and long TE in some healthy control subjects and is 
visibly elevated in some pathological conditions. A reference library of the spectral 
peaks of some 35 metabolites visible to 1H MRS has been compiled by 
Govindaraju(Govindaraju et al., 2000). 
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1.7.6.1 Principal metabolites: NAA, Cr, Cho 
1.7.6.1.1 NAA 
NAA is a non-essential amino acid and is the most visible metabolite peak of the 
1
H 
MRS spectrum. Within the brain NAA is synthesised primarily in neurons being 
present in concentrations of up to 20mM and representing about 7% of neuronal 
osmolarity. The majority of MRS studies published to date have found NAA to be 
the most sensitive MRS visible metabolite marker of pathological states. The role of 
N-acetyl aspartate in brain tissue, however, has been unclear and although reduced 
level of NAA is commonly referred to as a marker of “neuronal loss or dysfunction” 
the biological explanation for this reduction has also been absent. However, 
evidence has begun to accumulate that NAA synthesis is linked with mitochondrial 
function(Heales et al., 1995;Bates et al., 1996) and that NAA has an important and 
dynamic role in removing neuronal water produced as a consequence of increased 
metabolic activity. NAAG appears to act as a specific transmitter signalling to 
adjacent astrocyte foot processes to increase regional blood flow and uptake of 
glucose. [For more detailed discussion of NAA metabolism see (Baslow, 
2000;Moreno et al., 2001;Barker, 2001;Baslow et al., 2003;Baslow, 2003b;Baslow 
et al., 2007;Baslow and Guilfoyle, 2009)]  
 
NAA metabolism appears to span three metabolically linked compartments. Using a 
combined method of 
13
C MRS and labelled glucose infusion in humans in vivo, it 
has been demonstrated that NAA synthesis is directly coupled to glucose 
metabolism(Moreno et al., 2001). Neurons synthesise NAA in mitochondria and it is 
calculated that 1mol of NAA is synthesized for every 40 mol of glucose oxidized in 
the brain. NAAG is formed from NAA and glutamate. However neither NAA nor 
NAAG can be catabolised within the neuron and must be released to the extra-
cellular fluid (ECF). In this space NAAG interacts with astrocyte foot process 
surface NAAG peptidase producing NAA and glutamate whilst NAA reacts with 
oligodendrocyte surface membrane aspartoacylase which converts it to acetate and 
aspartate. The glutamate formed at the astrocyte surface is thought to provide 
specific signalling to increase blood flow and increase supply of glucose.  
 
Investigations of NAA export from stimulated neurons have estimated that each 
NAA molecule transports with it 32 molecules of obligated water. This can be 
achieved using the NAA system at the relatively low energy cost of about 1% of the 
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brain’s daily energy budget(Baslow and Resnik, 1997). The water removal process 
from the brain would most likely involve diffusion of liberated water down its 
gradient via aquaporin-4 (AQP4), the predominant water channel protein that is 
heavily expressed in astrocytes but not in neurons or oligodendrocytes.  
 
This has led to the theory that NAA probably functions as a molecular water pump 
(MWP)(Baslow, 2003a) to transport neuronal metabolic water to ECF for its 
removal from the brain via aquaporin 4 (AQP4) channels present on the surfaces of 
astrocytes and vascular endothelial cells(Verkman et al., 2006). MWPs are recently 
discovered entities that can actively pump water against its gradient(Meinild et al., 
1998;Zeuthen, 2000;MacAulay et al., 2001). MWP appear to be highly efficient, 
with 1 molecule of MWP solute able to transport as many as 500 water molecules 
during its passage.   
 
Baslow has suggested that the metabolism of NAA is via an inter-compartmental 
shuttle(Baslow, 2002). In humans, NAA turnover in the brain is very rapid, and the 
efflux of NAA is 0.55 µM/g/h from the neuronal compartment into the extra cellular 
space. For equilibrium NAA must be removed from the ECS at the same rate. The 
role of the oligodendrocyte localised amidohydrolase II is to participate in this 
process by hydrolyzing NAA that has been liberated from neurons(Bhakoo et al., 
2001). It follows that the products of NAA hydrolysis, aspartate and acetate, must 
also be removed, at the same rate as NAA hydrolysis, or the action of this hydrolytic 
enzyme would also be compromised. NAA-derived acetate is metabolised by 
oligodendrocytes or astrocytes, and incorporated into many lipid components and 
thus lost from the NAA cycle. The NAA-derived aspartate diffuses towards the 
neuron surface, where it is taken up to complete the shuttle action. Aspartate does 
not easily pass into the brain across the blood-brain barrier, and this conservative 
step ensures a sufficient supply of aspartate for neuron use in the continuous and 
rapid formation and inter-compartmental release of NAA. Conservation of acetate is 
not essential in the brain because it easily passes across the blood brain barrier at 
about the same rate as glucose. 
 
 
These findings would propose that NAA function is linked with neuronal metabolic 
activity both by providing a mechanism for the removal of waste water of 
metabolism as well as a specific signalling pathway to the astrocyte end processes 
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leading to increased glucose uptake. Such proposals seem to be supported by the 
results of functional magnetic resonance spectroscopy (fMRS) studies of the human 
visual cortex in response to visual stimulation(Baslow et al., 2007) which showed 
13% NAA reduction after intense visual activity with complete recovery after a 
subsequent “rest period” and which represents export of preformed NAA with 
activation and recovery following re-synthesis during a period of reduced metabolic 
activity.  
 
The astrocytic surface metabotropic glutamate receptor 3, (GRM3) activation of 
which initiates intracellular calcium transients(Hashemi et al., 2008) and secondary 
astrocyte–astrocyte and astrocyte–vascular system signals that increase focal blood 
flow(Baslow and Guilfoyle, 2007), is the likely target for NAAG(Baslow, 
2008;Baslow, 2009) 
 
Disorders of NAA metabolism are known and are associated with significant 
pathology. Canavan disease is a rare recessive genetic neurodegenerative brain 
disorder associated with many different mutations in the gene encoding 
aspartoacylase and leading to accumulation of NAA and the development of a 
spongiform leukodystrophy. There is also a single human case of apparent lack of 
NAA(Martin et al., 2001) and relatively preserved neurological function and this 
observation of apparently normal function without NAA has yet to be assimilated 
into the theories developed above. 
 
1.7.6.1.2 Creatine plus phosphocreatine (Cr) 
Cr is the second major visible metabolite peak in the 
1
H MRS spectrum at 3.0 ppm. 
It is the combined peak of Creatine (Creat) and phosphocreatine (PCreat) which 
together provide an important buffer system of intracellular ATP levels (see section 
1.2.2).  
 
1.7.6.1.3 Choline containing compounds 
Choline containing compounds (single peak at ~3.22 ppm) include choline, 
phosphocholine and glycerophosphocholine. In adult human controls choline 
concentration does not appear to vary in concentration between grey matter and 
white matter in adult human control frontal and parietal lobes (McLean et al., 2000). 
In early development Cho is high whilst NAA levels are low. With increasing 
maturity Cho falls whilst NAA increases (Tkac et al., 2003). The early high levels of 
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Cho are presumed to be a consequence of rapid cell membrane development(Kreis et 
al., 1993;Kreis et al., 2002;Kok et al., 2002;Girard et al., 2006a;Girard et al., 2006b). 
 
Elevated Cho levels are now widely recognised as a general marker for neoplastic 
tissue in the brain as well as in other tissues. Again, the elevation is likely to be due 
to cell membrane synthesis in rapidly dividing cells(Ross and Michaelis, 
1994;Swanson et al., 2001;Yeung et al., 2002;Mueller-Lisse and Scherr, 
2007;Papanagiotou et al., 2007). Multiple sclerosis brain lesions are associated with 
abnormal Cho levels both in acute lesions and in normal appearing white 
matter(Husted et al., 1994;Rooney et al., 1997) secondary to fluctuations in 
membrane turnover rates due to inflammatory / demyelinating processes(Arnold et 
al., 1990). 
  
Cho levels have also been shown to be elevated in malformations of cortical 
development associated with epilepsy in some studies(Kuzniecky et al., 1997b) 
although normal findings were observed by other groups(Widjaja et al., 2003).  
Elevated Cho in the regions of the primitive brain tissue of MCD may be expected 
from the literature of MRS examinations acquired during early development. 
 
1.7.6.2 Glutamine, glutamate, Myo-inositol 
Early proton MRS studies generally reported only the three principal metabolites. 
Studies performed at shorter TE provide the opportunity to measure additional 
metabolites relevant to the investigation of brain metabolism.  Glutamate and 
glutamine (resolved at 1.5 Tesla as the combined signal GLX) and myo-inositol 
(Ins) may be measured using short TE sequences whilst GABA can be measured 
with advanced pulse sequences that make use of J-modulation effects. As magnet B0 
field strengths and scanner hardware generally improve these metabolites will be 
measured with increasing reliability and further compounds will also become 
resolvable.  
 
1.7.6.2.1 GABA, glutamate and glutamine 
The metabolism of GABA, glutamate and glutamine has been discussed in a 
previous section (Section 1.2). All are visible to 
1
H MRS performed at short TE, 
although visualisation of the spectral peaks is made more complicated by overlap 
with other more dominant peaks and with each other and most researchers have been 
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obliged to report the combined signal of glutamate plus glutamine (GLX) or to 
employ more sophisticated methodologies such as spectral editing or J-resolved 
experiments to measure them directly. There are so far very few reports of the 
separate measurement of glutamate and glutamine in humans although Petroff has 
reported separate measurement in the occipital lobes of human volunteers using 
spectral editing(Petroff et al., 2000) and Garcia has reported separate values in 
human patients with epilepsy taking valproate examined on a 3T system(Garcia et 
al., 2009). Several groups have reported on measurement of GABA. Petroff, 
Rothman and co-workers have published extensively using a spectral editing 
sequence. The findings of this group are considered in Section 1.8.   
 
1.7.6.2.2 Myo-inositol 
Myo-Inositol (Ins) [(cis-1,2,3,5-trans-4,6-cyclohexanehexol], is a carbocyclic polyol 
that is the core component of the increasingly important phosphoinositide family of 
phospholipids. Phosphoinositides act as substrates for the generation of potent 
intracellular second messengers and as activators of other signalling proteins (for 
review see (Hammond and Schiavo, 2007). The central nervous system possesses 
relatively high concentrations of myo-inositol as well as the means to synthesize it 
from glucose 6 phosphate. Myo-Inositol serves not only as a precursor molecule for 
inositol lipid synthesis, but also as a physiologically important osmolyte. 
 
  
 
 
 
      
 
Figure 1.7.6 1H MRS spectrum for myo-Inositol [from (Govindaraju et al., 2000)] 
 
In the first stage of phosphoinositide synthesis Ins is combined with diacylglycerol 
to form phosphotidyl inositol (PI) with later phosphorylation at the 3, 4 or 5 position 
ppm 
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of the inositol ring. The major phosphoinositide in many of the above activities is 
phospatidylinositol 4,5-bisphosphate (PI(4,5)P2). PI(4,5)P2 is hydrolysed by 
PI(4,5)P2 specific phospholipase C (PLC) to yield Ins(1,4,5)P3 (IP3) and 
diacylglycerol (DAG). IP3 acts as a second messenger to mobilize Ca2+ from 
intracellular Ca2+ stores, whereas DAG activates C1-domain-containing proteins, 
such as protein kinase C (PKC) and MUNC-13 which plays a pivotal role in 
controlling synaptic vesicle formation(Brose and Rosenmund, 2002;Irvine, 2003). 
Furthermore, PI(4,5)P2 is also phosphorylated at position 3 to yield PI(3,4,5)P3, 
another important second messenger(Vanhaesebroeck et al., 2001). 
 
Over the past decade a large number of membrane transport proteins have been 
shown to be sensitive to the action of phosphoinositides in the plasma membrane. 
These proteins include voltage-gated potassium and calcium channels, ion channels 
that mediate sensory and nociceptive responses, epithelial transport proteins and 
ionic exchangers. Each of the regulatory lipids is also under multifaceted regulatory 
control(Hammond and Schiavo, 2007). Phosphoinositide modulation of membrane 
proteins in neurons often has a dramatic effect on neuronal excitability and synaptic 
transmitter release. In astrocytes phosphoinositides have been implicated in the 
generation of intracellular [Ca
2+
] oscillations and inter cellular 
signalling(Nedergaard et al., 2003;Nahorski et al., 2003).  
 
The PI system has been the subject of much speculation in parallel with the 
development of a new understanding of the role of astrocytes in nervous system 
tissue(Nedergaard et al., 2003;Oberheim et al., 2006). Glial cells have been shown to 
form non-overlapping domains bordered by small blood vessels. The glial foot 
processes overlap these blood vessels and also the synaptic terminals of neurons 
included within the functional domain. This anatomy places the astrocyte at the 
centre of the interaction between glia, neurons and the blood brain barrier. In this 
position astrocytes have been shown to modulate synaptic activity, take up and 
recycle neurotransmitter compounds released at the synaptic terminal, and to 
regulate the flow of molecules such as water and perhaps glucose through their close 
association with the blood brain barrier. Current understanding of this functional 
unit has encouraged speculation that astrocyte function (and dysfunction) may 
explain a wide range of neurological conditions(De Keyser J. et al., 2008). In 
particular the phenomenon of cortical spreading depression may be explainable in 
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terms of astrocytic Ca
2+
 activation with associated synaptic terminal inhibition and 
this observation together with the release of cyclo-oxygenase by activated astrocytes 
across the blood brain barrier causing a reactive hyperaemia may neatly explain 
many of the manifestations of migraine. Epilepsy associated with K
+
 channel 
disorders would also be a potential consequence of primarily astrocytic dysfunction. 
 
Myo-inositol is visible to proton MRS at magnetic field strengths of 1.5T as a single 
peak at ~3.5 ppm. Early experiments have indicated that this signal is predominantly 
derived from Ins within the glial pool(Brand et al., 1993) although inositol 
concentrations in some neuronal populations may equal or exceed those observed for 
glia. 
 
Interest in the measurement of Ins in humans developed in the field of psychiatry in 
the late 1980s with the observation that lithium administration is associated with 
reduction in measurable Ins levels leading to the proposal of an “inositol depletion” 
theory as a suggested mechanism for the therapeutic effect of lithium(Berridge et al., 
1982;Berridge and Irvine, 1989;Berridge et al., 1989). Lithium reduces Ins levels by 
acting as an uncompetitive inhibitor of inositol monophosphatase (IMPase) resulting 
in an accumulation of inositol monophosphates and a reduction in Ins 
concentrations. Subsequent MRS experiments in vivo revealed that Ins decreases 
following lithium treatment(Moore et al., 1999) and that bipolar patients may have 
elevated pre-treatment levels of Ins(Davanzo et al., 2001). Later work by 
O’Donnell(O'Donnell et al., 2003) in rats and and in vitro work by 
Williams(Williams et al., 2002) showed that both lithium and sodium valproate 
decrease the concentration of Ins, despite the fact that valproate is not known to have 
any effect on the IMPase enzyme. Ding and Greenberg later reported a study of the 
effects of valproate and lithium in saccharoyces cerevisiae yeast. They found that 
the addition of either of these agents brought about a decrease in PI synthesis and to 
a lesser but still significant degree, the steady state relative PI composition(Ding and 
Greenberg, 2003).  
 
Other work has focussed on the role of Ins as an osmolyte in glial cells.  Ins is taken 
up against a steep concentration gradient(Biden and Wollheim, 1986) via the high 
affinity sodium myoinositol co-transporter (SMIT) which appears to be highly 
expressed in astrocytes(Kwon et al., 1992). Chronic exposure to various cell types to 
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hypertonicity leads to up regulation of SMIT(Ibsen and Strange, 1996). This effect 
protects the cell since it increases the intracellular Ins concentrations and thus 
osmolarity without disrupting cellular functioning. Both the activity of SMIT and 
the expression of its mRNA in astrocytes are down regulated in astrocytes with 
chronic ingestion of lithium over a period of 8 days (which is similar to the time 
required for efficacy of the drug).  
 
1.7.6.2.3 Lactate 
Lactate metabolism has also been discussed in Section 1.2. Lactate signal is visible 
to 
1
H MRS. The spin-spin coupling of lactate means that the lactate doublet is in 
phase at TEs of 270ms and mostly in phase at TE less than about 60ms but inverted 
at TE = 135ms. This characteristic pattern has been utilised in a number of studies 
that have reported the presence of visible elevation of lactate in ischemia, status 
epilepticus and mitochondrial encephalopathy(Fazekas et al., 1995;Saunders, 
2000;McKnight, 2004;Bianchi et al., 2007). Elevation in lactate has also been 
reported in healthy volunteers following functional activation(Sappey-Marinier et 
al., 1992). As noted above for glutamate, glutamine and GABA, two dimensional 
acquisition techniques are sometimes used to better visualise the lactate peak. 
 
1.7.7 MRS in Healthy Adults 
Quantitative in vivo single voxel measurements from occipital grey matter and 
parietal white matter(Kreis et al., 1993) identified differences between grey and 
white matter contents of Cr, NAA and Cho. These reports were subsequently 
confirmed in spectroscopic imaging studies in which volumetric image segmentation 
techniques allowed separate determination of metabolite content in white matter and 
grey matter(Hetherington et al., 1996;McLean et al., 2000). McLean measured the 
differences in metabolite concentrations between grey and white matter in normal 
volunteers (n = 13). A positive correlation was found between metabolite 
concentration and grey matter content for most metabolites studied. The estimated 
ratios of metabolite concentration in grey versus white matter were: N-acetyl 
aspartate + N-acetyl aspartyl glutamate (NAAt) = 1.16 +/- 0.11; Cr =1.7 +/- 0.3; 
glutamate + glutamine = 2.4+/- 0.5; myo-inositol = 1.6 +/- 0.3; choline = 0.9 +/- 0.2. 
The ratio of NAAt/Cr was negatively correlated with grey matter content: grey/white 
= 0.69 +/- 0.08. As well as unequal metabolite distribution between grey matter and 
white matter there is also some MRS evidence for spatial distribution of the 
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metabolites through the brain. Pouwels and Frahm(Pouwels and Frahm, 1998) found 
that N acetyl aspartyl glutamate (a metabolite of NAA) was elevated and Cho 
reduced in the occipital lobes compared to the frontal lobes in 34 healthy volunteers. 
 
Based upon these findings it is clear that tissue heterogeneity in spectroscopic 
volumes of interest will impact on the obtained voxel metabolite concentrations. 
Specifically, due to the lower total Cr content in white matter as opposed to grey 
matter, inclusions of significant amounts of white matter in predominantly grey 
matter voxels would lower Cr content and increase NAA/Cr ratio, thereby 
mimicking more healthy tissue and resulting in false negatives. Similarly, volumes 
with substantial grey matter, due to higher Cr content, would artificially bias the 
NAA/Cr downwards, giving the appearance of greater damage. 
 
A number of methodologies have been developed to try to limit the effects of tissue 
heterogeneity. Linear regression analyses have been developed to obtain metabolite 
concentration plots for “pure” grey and “pure” white matter content and ratios of the 
two(Chu et al., 2000). Alternatively volumetric images are acquired and segmented 
using statistical parametric methods to obtain estimates of the relative proportions of 
grey matter, white matter and CSF present in each voxel to allow correction to be 
made for CSF which is considered to return negligible metabolite information and 
evaluation of the obtained metabolite concentrations in the context of known 
information relating to the grey matter: white matter ratio in the volume 
studied(Woermann et al., 1999c;McLean et al., 2000). 
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1.8 Application of 
1
H MRS to the investigation of epilepsy 
 
1.8.1 Introduction 
1.8.2 Ex vivo MRS of epileptic tissue 
1.8.3 Findings in temporal lobe epilepsy 
1.8.4 Findings in extra-temporal lobe epilepsy 
1.8.5 Findings in malformations of cortical development 
1.8.6 Association of MRS findings with seizure history 
1.8.7 Effect of antiepileptic drugs on MRS metabolites 
1.8.8 
31
P and 
13
C MRS findings in epilepsy 
1.8.9 Correlation of MRS findings with other imaging modalities 
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1.8.1 Introduction 
 
Most early studies 
1
H MRS studies of epilepsy reported on only the three main 
metabolites NAA, Cr and Cho expressed as ratios and measured at longer 
TE(NAA/Cr; NAA/(Cr + Cho), NAA/Cho) (see (Duncan, 1996;Kuzniecky, 1999). 
Later investigators performed MRS experiments at shorter TE which provided 
additional information on metabolites such as Ins and GLX that are visible only at 
short TE(Woermann et al., 1999c;Savic et al., 2000a;Savic et al., 2000b;Wellard et 
al., 2003). From this work a number of common findings have emerged although the 
wide range in subject selection criteria, acquisition techniques, acquisition 
parameters and statistical analysis methodology makes integration of these results 
difficult.   
 
1.8.2 Ex vivo MRS of epileptic tissue 
1
H MRS has been successfully applied to the ex vivo investigation of epileptic 
tissue. Measured at very high magnetic field strength the resulting spectrum allows 
the discrimination of metabolite peaks that are heavily overlapped at lower field 
strengths. When such studies have been combined with histopathological techniques 
direct comparison of the observed metabolite concentrations with measurements of 
cell content has been possible.  
 
Petroff and co-workers have studied ex vivo epileptic tissue obtained at surgery for 
medically refractory epilepsy(Petroff et al., 1989;Petroff et al., 1995;Petroff et al., 
2002b;Petroff et al., 2003).  They found that glutamate content and GABA content 
were elevated while NAA content was reduced in ex vivo epileptic cortex compared 
with in vivo measurements in healthy volunteers. After separating the tissue into 
synaptosomes, neuronal cell bodies and glial cell fractions they reported that the 
neuronal fractions were enriched in glutamate whilst the glial cell fractions were 
higher in lactate, glutamine and Ins. MRS of ex vivo hippocampal tissue was 
combined with histopathological examination(Petroff et al., 2002b;Petroff et al., 
2003). Sixteen of 20 hippocampi were abnormal on pre-operative MRI while four 
had had normal MRI. MRS investigation of the tissue showed reduced NAA 
compared to reference levels for healthy volunteers with lowest values obtained for 
those abnormal on MRI. However when NAA, glutamate and Cr concentrations 
were separately correlated with hippocampal neuron loss no relationship was 
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observed suggesting that metabolite concentrations do not simpy reflect neuronal 
numbers. There were similarly no correlations between Cr or NAA and glial cell 
density. Comparisons of NAA versus glutamate and NAA versus Cr showed high 
correlation coefficients. The authors concluded that the findings appeared to support 
the proposal that NAA is directly linked with energy metabolism in the neuron.  
 
Vielhaber and co-workers have applied very high field MRS at 14 T to ex-vivo 
tissue slices from three hippocampal subfields (CA1, CA3, dentate gyrus) in patients 
with mTLE. The authors again found a large variance in NAA concentrations in the 
individual regions but particularly noted that in the subfield CA3 there was marked 
reduction in NAA and elevated lactate despite otherwise moderate preservation of 
cell densities. The authors conclude that this indicated that reduced NAA is not 
directly a measure of neuronal cell loss and support the proposal that NAA is linked 
with mitochondrial function(Vielhaber et al., 2008). This is in agreement with work 
by Hammen and colleagues who performed an analysis of in-vivo metabolite 
concentrations according to hippocampal sub-field histopathological 
findings(Hammen et al., 2008). They also found that cells loss in CA1, CA3 and the 
dentate gyrus was associated with reduced NAAt and further reported that Ins levels 
were positively correlated with astroglial glial fibrillary acidic protein (GFAP) 
expression.  
 
There is a very limited literature concerning ex vivo MRS of MCD. In a study by 
Aasly and co-workers histopathological examination identified mild cortical 
dysplasia in four subjects with associated gliosis in three and MRS examination 
showed reduced NAA and increased Cho (and GABA)(Aasly et al., 1999).  
 
1.8.3 Findings in temporal lobe epilepsy 
A number of excellent reviews of the MRS literature in temporal lobe epilepsy are 
available [(Duncan, 1996;Duncan, 1997;Antel et al., 2002;Hetherington et al., 
2002;Willmann et al., 2006)]. The focus of most studies has been to investigate the 
role of MRS in the surgical pre-assessment of patients with refractory temporal lobe 
epilepsy. The data to date appear to suggest that whilst MRS may be useful as an 
adjunct to other surgical assessments the technique has not become established as a 
primary assessment tool. 
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Other imaging tools such as PET and diffusion weighted MRI have also been much 
investigated in this group of patients. Several authors have compared relative merits 
of these different techniques in the pre-operative assessment of patients with 
epilepsy (see Section 1.8.9) but generally these new techniques have yet to become 
core assessments in pre-surgical assessment protocols. 
Prior to widespread 
1
H MRS availability phosphorus MRS was applied to the study 
of these patients. Weiner and colleagues(Laxer et al., 1992) evaluated the use of 
31
P 
spectroscopy for the lateralization of epileptogenic regions. In these initial studies at 
2.0T, significant alterations in inorganic phosphate (Pi) (73% increase in Pi) and 
brain pH (0.17 unit increase) were reported. Although subsequent studies at 1.5T 
and 4.1T failed to reproduce the reported changes in pH, significant alterations in 
bioenergetic parameters were reported(Kuzniecky et al., 1992;Chu et al., 1996;Chu 
et al., 1998).  
At 1.5T, Kuzniecky reported that PCreat/Pi was reduced by 50% in the ipsilateral 
temporal lobe, whereas it was reduced by 24% in the contralateral lobe(Kuzniecky et 
al., 1992). At 4.1T, Chu later reported that PCreat/Pi was significantly decreased in 
both the ipsilateral (32%) and contralateral lobes (19%). Within this group, 73% of 
the patients were correctly lateralized using the PCreat/Pi ratio(Chu et al., 1998). 
Despite the controversy regarding pH changes, bio-energetic impairment (increased 
Pi and decreased PCreat/Pi) was reported by both groups. Since patients with recent 
seizures were excluded these effects could reflect a chronic impairment of energy 
metabolism. 
Hetherington and colleagues, using a sophisticated multi-compartment model in 
order to minimise extraneous signal inclusion, showed that the largest decrements in 
PCreat/ATP were found overlying the ipsilateral hippocampus(Hetherington et al., 
2001)and Simor and colleagues have shown that the pre-surgical abnormalities seen 
in the contralateral hippocampus are reversible following successful surgery(Simor 
T et al., 1997). 
 
Reduced PCreat/ATP in epileptic tissue which has also been reported in ex-vivo 
studies of epileptic(Williamson et al., 1995) tissue has been explained by description 
of the role of the creatine - phosphocreatine equilibrium in maintaining stability of 
ATP levels by buffering the balance between cellular demand and 
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production(Williamson et al., 2005). As a result, the ratio of PCreat/ATP determined 
inter-ictally has been suggested by some authors to represent a “steady-state” energy 
balance (review Pan(Pan et al., 2008)). 
 
1
H MRS has been used extensively to assess patients with temporal lobe epilepsy. 
Several groups have attempted to correlate in-vivo MRS findings with 
histopathological examination performed on resected epileptic temporal lobe 
tissue(Tokumitsu et al., 1997;Kuzniecky et al., 2001;Cohen-Gadol et al., 
2004;Hammen et al., 2008). Tokumitsu and colleagues used an animal model of 
temporal lobe epilepsy to show reduced NAA and Cr in the presence of neuronal 
loss and gliosis(Tokumitsu et al., 1997). Hammen also found reduced NAA 
particularly in the CA1 hippocampal subfield and the dentate gyrus and found 
correlation of Ins levels with expression of Glial Fibrillary Activated Protein 
(GFAP)(Hammen et al., 2008). Cohen-Gadol and co-workers found no relationship 
between NAA/Cr and neuronal cell loss or frequency or duration of seizures(Cohen-
Gadol et al., 2004). A similar finding was earlier reported by the same 
group(Kuzniecky et al., 2001). 
 
Almost all human in-vivo studies have reported on the three main metabolite peaks, 
have performed investigations at longer TEs and have generally reported metabolite 
peak ratios. Some investigators have considered that a side-to-side asymmetry in 
metabolite ratios can reflect significant pathology whilst other groups have reported 
only on reduced ratios as compared to a control population. The relatively large 
voxel sizes of MRS experiments has resulted in further methodological variance 
amongst experimenters as regions of interest have varied in size, location in tissue 
composition. Findings have generally been concordant but no standard 
methodology, metabolite peak or metabolite ratio has been uniformly agreed. It is 
for these reasons that whilst MRS has been generally informative in the work up of 
patients with TLE the technique has not superceded other imaging modalities or 
EEG in pre-surgical assessment protocols. 
 
Reduction in NAA and NAA / Cr has been consistently reported in the epileptic 
temporal lobe in TLE by most groups using either single voxel or multi-voxel 
techniques and at short and long TE [for example as reported by (Cendes et al., 
1994;Connelly et al., 1994;Gadian et al., 1994;Cendes et al., 1995;Hetherington et 
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al., 1995a;Cendes et al., 1997b;Woermann et al., 1999c;Riederer et al., 2006)]. Most 
reporters have observed that even in subjects with well lateralised epilepsy on 
clinical and electrophysiological grounds and concordant unilateral MRI 
abnormality MRS identifies bilateral reductions in NAA or NAA/Cr in between 20 
and 54% of subjects studied(Connelly et al., 1994;Cross et al., 1996;Achten et al., 
1997;Cendes et al., 1997b;Woermann et al., 1999c). In those studies that have 
compared findings in different regions of the mesial temporal lobe a greater 
sensitivity for abnormality is generally reported in the regions including the anterior 
structures of the hippocampus compared to the more posterior structures(Vermathen 
et al., 2000). This is consistent with MRI evidence that hippocampal sclerosis is 
typically more marked anteriorly(Woermann et al., 1998a). Although most studies 
have been performed on epileptic subjects with mesial TLE secondary to HS a small 
number of studies(Connelly et al., 1998;Woermann et al., 1999c;Hammen et al., 
2006) have studied patients with normal conventional imaging and found reduction 
in NAA or NAA/Cr in between 30 to 60% of cases. Patients with bilateral EEG 
abnormalities seem to have more bilateral 1H MRS abnormalities (Cendes et al., 
1997a) and there is some limited evidence to suggest that the more unilateral the 
EEG finding, the more asymmetric the MRS finding (Cendes et al., 1997b). 
 
Several studies have investigated whether MRS performed prior to temporal lobe 
surgery will provide prognostic information about post-operative seizure control.  
Knowlton found that prognosis depended on the presence or absence of ipsilateral 
hippocampal atrophy but was not influenced by pre-operative MRSI or FDG-PET 
findings(Knowlton et al., 1997).  Antel and co workers reviewed 81 patients selected 
for temporal lobe surgery that had had preoperative MRI and MRSI (TE / TR 
270/2000 ms) and constructed Bayesian predictors of seizure outcome. They found 
that the asymmetry index of NAA/Cr in the mid temporal region together with the 
ipsilateral hippocampal volume and hippocampal asymmetry were predictors of 
“worthwhile” improvement (in 60/63 who had worthwhile improvement)(Antel et 
al., 2002).  
 
Willmann(Willmann et al., 2006) performed a meta-analysis of patients considered 
for surgery in published reports between 1992 and 2003 and included 22 studies 
(Hugg et al., 1993;Cendes et al., 1994;Connelly et al., 1994;Constantinidis et al., 
1996;Knowlton et al., 1997;Achten et al., 1997;Ende et al., 1997;Cendes et al., 
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1997a;Cendes et al., 1997b;Duc et al., 1998;Thompson et al., 1998;Achten et al., 
1998;Kuzniecky et al., 1999;Eberhardt et al., 2000;Li et al., 2000b;Park et al., 
2001;Huijin et al., 2001;Stefan et al., 2001b;Kantarci et al., 2002;Antel et al., 
2002;Suhy et al., 2002) (Vikhoff-Baaz et al., 2001) in adult patients describing over 
600 patients who had in the vast majority of cases MRI evidence of unilateral HS. 
Even within this carefully selected meta-analysis there was substantial variance in 
methodology. Across these studies the post operative interval range was from 3 
months to 78 months whilst age ranged from three years to 66 years.  Chemical shift 
imaging techniques were used in 15 studies whilst 7 used single voxel techniques. 
The TE ranged from 50 to 272ms and the repetition time from 1.5 to 6s. Field 
strengths ranged from 1.5 to 4.1Tand the reporting of abnormality differed between 
sites – usually ratios or asymmetry indexes involving NAA/Cho +Cr, NAA/Cr, 
NAA/Cho, Cr/NAA and occasionally NAA alone. Voxel placement protocols were 
not standardised and in general no attempt was made in these studies to make 
correction for variation in tissue composition within each region of interest. Despite 
this substantial inter-study heterogeneity Willmann and colleagues were able to 
make some statements about the performance of MRS in the assessment of patients 
undergoing surgical resection for TLE. They found that in sixty-four percent of the 
assessed surgical candidates MRS showed a correctly lateralized decrease ipsilateral 
to the side of final surgical decision. They calculated that the positive predictive 
value for good outcome with an ipsilateral reduction in NAA/Cr was 82% and 
calculated an odds ratio of 4.89 in favour of post operative freedom from seizures 
with unilateral compared to bilateral metabolite reductions. Few MRI negative 
studies were included and the authors identified that the data in this group was 
conflicting. Li and co workers(Li et al., 2000b) reported that in a study of 21 patients 
with bilateral hippocampal atrophy at MRI temporal lobe NAA/Cr reduction was 
concordant to the side of major EEG abnormality and surgery in 11 of 16 patients 
with good outcome. None of the five patients with non-concordant MRS temporal 
NAA/Cr reduction had a good outcome. The importance of pre-operative normal 
contralateral temporal lobe NAA/Cr levels has also been noted by other 
authors(Kuzniecky et al., 1999;Eberhardt et al., 1999;Stefan et al., 2001a). In 
contrast, successful surgical outcome for a small number of patients with bilateral 
abnormalities has been reported(Knowlton et al., 1997;Achten et al., 1997). 
However, since the majority of these studies were performed in patients already 
carefully assessed with EEG and MRI the added value offered by MRS has been 
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difficult to quantify(Wallimann et al., 1998). One paper however has indicated that 
MRS might be more sensitive for the detection of subtle MRI negative cortical 
malformations(Stefan et al., 2001b) although higher field strength MRI can be 
expected to now identify more abnormalities in patients with previously labelled 
MRI-negative MCD.  
 
Post-operative normalisation of the NAA/Cr values in the ipsilateral temporal lobe 
after surgery for seizure-free patients and post-operative persistence of abnormally 
low contralateral NAA/Cr values for non seizure free patients has been 
noticed(Cendes et al., 1997a). Non-significant contralateral NAA recovery and 
increases of Cho and Cr after surgery in eight seizure-free and two improved 
patients have been also reported(Vermathen et al., 2002). More abnormal 
contralateral values were observed post-operatively as compared to pre-operatively 
by MRS in another five patients whose seizure control worsened after 
surgery(Eberhardt et al., 1999). Cendes has also reported lower pre-operative 
NAA/Cr value in the temporal lobe contralateral to surgery for well-assessed 
patients who continued to have seizures after surgery as compared to patients who 
became seizure-free(Cendes et al., 1997a). 
 
The value of MRS in predicting medical outcome has been less well studied 
although there is some evidence from work by Briellmann and colleagues that 
factors influencing the response to medical treatment may be the degree of reduction 
in ipsilateral NAA/Cr together with the presence of T2 signal abnormality outside 
the hippocampus(Briellmann et al., 2005). 
 
The argument for the reporting of metabolite ratios had conventionally been that any 
inhomogeneity effects would be expected to affect the numerator and the 
denominator equally. Most ratios involve Cr in accord with the early belief that Cr 
levels were stable across brain regions. However Cr levels in any region of interest 
may well vary according to the inclusion of pathological tissue and may be 
decreased (Ende et al., 1997;Duc et al., 1998) or increased(Connelly et al., 1994) in 
hippocampal sclerosis. Cr levels will certainly also vary with differing tissue 
composition between voxels(McLean et al., 2000). Ex vivo findings(Petroff et al., 
2003) might predict unchanged or reduced Cr concentrations rather than elevation.  
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Concentrations of Cho have rarely been reported in these studies but many 
investigators have used the ratio NAA/(Cr + Cho) to report on metabolite 
disturbances. Choline containing compound (Cho) concentrations also vary across 
brain regions(Noworolski et al., 1999) and according to tissue composition of the 
voxel of interest(McLean et al., 2000). Some groups have reported on Cho levels 
and suggest that concentrations are increased in TLE associated with hippocampal 
sclerosis(Connelly et al., 1994;Hammen et al., 2006). Stefan and colleagues have 
found a high prevalence of co-existence of subtle malformation of cortical 
development and hippocampal sclerosis in surgical specimens from patient 
undergoing temporal lobe surgery for mesial TLE (occurring in 13 or 25)(Stefan et 
al., 2001b) which might  explain the elevated Cho since Cho levels appear to be 
increased in MCD(Kuzniecky et al., 1997b;Aasly et al., 1999). 
 
Few investigators have reported on in vivo concentrations of the metabolites GLX 
(glutamate plus glutamine) or Ins. Woermann and co-workers observed elevation in 
GLX concentrations in subjects with TLE and normal MRI but not in subjects with 
HS(Woermann et al., 1999c) while Savic reported that the ratio GLX/NAA was 
sensitive for identifying abnormality in the sclerotic temporal lobe(Savic et al., 
2000b). Increase in Ins has been reported in the sclerotic hippocampus(Woermann et 
al., 1999c;Wellard et al., 2003) and has been correlated with increased expression of 
GFAP(Hammen et al., 2008). 
 
Pan and colleagues have developed a spectral editing sequence at high field strength 
that can measure hippocampal glutamate concentrations with MRS. This sequence 
performed in a small number of cases showed higher concentrations of glutamate in 
hippocampus and temporal lobe cortex compared to temporal white matter and 
higher glutamate levels in MRI negative patients compared to patients with 
hippocampal sclerosis(Pan et al., 2006). No studies have reported on MRS measured 
GABA concentrations in-vivo in TLE.  
 
Several MRS studies have examined for evidence of metabolic disturbance outside 
the region of seizure localisation(Li et al., 2000a;Mueller et al., 2002;Wellard et al., 
2003). Mueller and colleagues used multi-slice MRSI (1.5T, TE/TR 135 / 1800 ms, 
TI = 170 ms) in patients with unilateral TLE to measure metabolite concentrations in 
frontal grey and white matter and non-frontal grey and white matter. Volumetric 
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images were segmented to determine the tissue composition of the spectroscopic 
voxels. A modest reduction in NAA was identified in the patient group that was 
bilateral and diffuse (observed in frontal grey matter and non-frontal white matter 
regions). Li measured 51 patients with focal epilepsy of whom 21 had TLE, 20 had 
extra temporal lobe epilepsy and 10 had a multi-lobar epilepsy and found reduction 
in NAA / Cr in more than 40 % that extended beyond the epileptogenic zone defined 
by clinico-EEG criteria or the structural abnormality defined by MRI. Vermathen 
has also reported the investigation of 11 subjects with unilateral mesial TLE using 
MRSI. Metabolite concentrations in 13 extra-hippocampal regions were measured 
and diffuse reduction in NAA/(Cr + Cho) observed in the regions of interest 
ipsilateral to seizure onset. A less marked reduction in the metabolite ratio was 
observed in the contralateral hemisphere(Vermathen et al., 2003). Similar changes 
have also been described by Hetherington et al who found reduced NAA/Cr in both 
the ipsilateral and contralateral thalami as well as the contralateral 
hippocampus(Hetherington et al., 2007). 
 
Memory decline and reduced language skills are associated features of TLE. Using 
MRS Namer and co-workers found an association between metabolite 
concentrations (NAA/ (Cr + Cho)) and T2 relaxation time and verbal and visual 
memory tasks but found that the reported seizure frequency correlated only with the 
ipsilateral value of NAA/ (Cr + Cho))(Namer et al., 1999). Sawrie (Sawrie et al., 
2001) and Pauli(Pauli et al., 2000) found that left hippocampal Cr/NAA ratios were 
a sensitive measure of verbal memory dysfunction in TLE and were more predictive 
of dysfunction than hippocampal volume measurements(Sawrie et al., 2001). 
 
Burneo and co-workers have sought to correlate NAA/Cr with the extent of 
metabolic dysfunction or with the duration of epilepsy and found no 
association(Burneo et al., 2004). Other groups have reported association of NAA 
with seizure frequency in both the frontal lobe and the temporal lobe(Garcia et al., 
1997) and Bernasconi has noted that NAA/Cr may be lower in patients with frequent 
generalised convulsive seizures(Bernasconi et al., 2002). 
 
1.8.4 MRS findings in extra-temporal lobe focal epilepsy 
Fewer studies in patients with extra-temporal lobe epilepsy have been reported. 
Whilst it is generally accepted that mesial TLE secondary to HS is usually 
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associated with reduced NAA and that “MR Negative” TLE is associated with 
reduced NAA in approximately one third of subjects, there is no consensus finding 
for NAA, Cr and Cho in other regions of the brain.  
 
Stanley(Stanley et al., 1998) performed MRSI in 20 patients with extra-temporal 
lobe epilepsy and measured the ratios NAA/Cr, NAA/Cho and NAA/(Cr + Cho) in a 
series of voxels in the frontal lobes and in central / post central regions. A diffuse 
reduction in all three ratios was reported throughout the spectroscopic image as 
compared to controls, with greatest reduction in metabolite ratios observed in the 
region of the seizure focus. Wellard et al studied patients with frontal lobe epilepsy 
and found that Ins appeared to be lower in the frontal lobe ipsilateral to seizure onset 
but reduced NAA was not observed(Wellard et al., 2003). 
 
Occipital lobe GABA levels (without concurrent measurement of NAA, Cr or Cho) 
have been reported by several groups using spectral editing techniques. Typically, 
the recruited patients had extra-occipital lobe focal onset seizures although some 
studies have included patients with IGE (Petroff et al., 2000); (Petroff et al., 
1996b;Petroff et al., 1999a;Petroff et al., 2001a;Mueller et al., 2001b). 
 
The major contribution in this area has been by Petroff and co-workers. They have 
reported lower mean occipital GABA levels in patients with focal onset epilepsy 
when compared to healthy volunteers(Petroff et al., 1996b). They have also shown 
correlation of GABA concentration with increasing seizure control(Petroff et al., 
1996b;Petroff et al., 1999a;Petroff et al., 2001a). In their later work they have 
reported separate resolution of GABA containing compounds into GABA and 
homocarnosine. When measured separately Petroff reports that it is homocarnosine 
levels that are particularly linked to seizure control such that levels of this metabolite 
increase with increasing duration since last seizure(Petroff et al., 2001a;Petroff et al., 
2001b). The role of homocarnosine is not established but it is considered likely that 
it acts as a “reservoir” for GABA(Henry and Theodore, 2001). Petroff and 
colleagues have also reported that several antiepileptic drugs including vigabatrin, 
topiramate and gabapentin can increase measured GABA levels in this region 
(discussed further below). 
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1.8.5 MRS findings in IGE 
Savic used short TE STEAM localised MRS without correction for tissue 
composition to measure NAA, Cr, Cho and Ins in prefrontal and occipital cortical 
regions in 15 subjects with JME(Savic et al., 2000a). Reductions in NAA were 
observed in the prefrontal region compared to the occipital region and 23 control 
subjects measured in a matched position. This result was taken to provide supporting 
evidence for the frontal lobe cognitive abnormalities often displayed by patients with 
JME. Cendes and co-workers have also studied patients with JME and measured 
reduced NAA/Cr in the thalami compared to levels in a control population(Mory et 
al., 2003). Using the technique of spectral editing and examining for GABA levels 
in the occipital lobe Petroff has described reduced combined GABA and 
homocarnosine levels in patients with JME with 50% of patients having levels more 
than 2 SD below the control mean. Homocarnosine levels were higher in the JME 
subjects compared to a group of patients with focal onset epilepsy(Petroff et al., 
2001a).  
 
1.8.5 Findings in malformations of cortical development (MCD) 
Several MRS studies have examined for neurochemical abnormality in subjects with 
MCD(Marsh et al., 1996;Kuzniecky et al., 1997b;Li et al., 1998;Simone et al., 
1999b;Woermann et al., 2001b). In general the earlier studies reported metabolite 
ratios at long TE and made variable correction for voxel tissue content. These 
methodological factors limit the conclusions that can be drawn from their findings. 
Correction for voxel tissue content is important because voxels containing MRI 
visible MCD will usually contain a higher proportion of grey matter to white matter 
than homologous voxels in the contralateral hemisphere. Since it is known that most 
metabolites have a higher concentration in grey matter than white matter(Doyle et 
al., 1995;Pouwels and Frahm, 1998;McLean et al., 2000) the composition of the 
voxels can be expected to influence the interpretation of findings. For example 
Marsh reported an MRS examination of a single subject with unilateral heterotopia. 
A “control” voxel was obtained from the contralateral normal appearing hemisphere 
and asymmetry ratios were given for NAA, Cr and Cho which showed no 
asymmetry in NAA but elevation of Cr and Cho levels in the heterotopia. In this 
study it is likely that the heterotopia voxel grey matter proportion would have been 
higher than in the normal appearing voxel and that if correction had been made 
P a g e  | 118 
 
NAA would have been shown to be low in the region of the heterotopia(Marsh et al., 
1996).   
 
Kuzniecky measured 11 subjects with MCD (six with focal cortical dysplasia 
(FCD), three with heterotopia, and two with polymicrogyria (PMG)) at 
4.1T(Kuzniecky et al., 1997b). Spectra were obtained from the MRI visible lesion 
and surrounding grey matter and white matter. The results were presented in the 
form of the ratios Cr/NAA and Cho/NAA.  The subjects with FCD generally showed 
high Cr/NAA in the lesional voxels as did two of the three subjects with heterotopia. 
No abnormalities were observed in the two subjects with PMG. The surrounding 
grey and white matter generally demonstrated a wide variability in Cr/NAA and 
Cho/NAA ratios. Three of the subjects with FCD went on to have surgical excision 
of the lesion. Subsequent histopathological examination showed no correlation 
between cell loss and the preoperative metabolite ratios(Kuzniecky et al., 1997b). Li 
and colleagues reported an MRSI study on a similar group of subjects (FCD = 5, 
heterotopia = 12, PMG = 3, tuberose sclerosis = 2 and one subject with PMG and 
heterotopia). Voxels were analysed in the lesion, contralateral to the lesion and in 
similar brain regions in healthy volunteers and the ratio NAA/Cr measured in each 
area and expressed as a z score with respect to the control population normal range. 
The authors found that for most of the subjects studied there was reduction in 
NAA/Cr in the lesional (mean = -2.2 +/- 0.32) and perilesional (mean = -1.01 +/- 
0.38) voxels. Reduction was most marked for FCD and Heterotopia compared to the 
subjects with PMG(Li et al., 1998). Simone and colleagues also studied a mixed 
group of MCD (PMG = 5, heterotopia = 8, FCD = 4). Single voxels were prescribed 
in the lesion, in the contralateral hemisphere. Grey matter containing voxels and 
white matter containing voxels in healthy controls were also studied. Reduction in 
NAA/Cr and Cho/Cr was observed in the lesional voxels compared to control white 
and control grey voxels. Reduction in Cho/Cr was also seen in the contralateral 
voxels. Across the sub-groups, PMG showed lower NAA/Cr and higher Cho/Cr than 
the other MCD sub-types(Simone et al., 1999b).  
 
Woermann and colleagues(Woermann et al., 2001b) reported a MRSI study 
performed at short TE allowing metabolite quantification. Volumetric MRI studies 
were also acquired and segmented into grey matter, white matter and CSF to allow 
the relative proportions of grey matter and white matter in each voxel to be 
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calculated. Ten subjects with MCD were studied with a mixture of MCD subtypes 
(polymicrogyria / macrogyria = 6, heterotopia = 4). Voxels were analysed from the 
lesion, the perilesional area and contralateral normal appearing tissue. An ANCOVA 
analysis with grey matter proportion as a covariant was performed to correct for 
variation in voxel tissue composition. Variable levels of abnormality were observed 
in all regions. The most consistent abnormality in individual subjects was bilateral 
reduction in NAA, although some voxels showed elevation in NAA. GLX findings 
were variable in both lesional, perilesional and contralateral voxels with some 
subjects showing reduction and others showing elevation. Group analysis showed 
that NAA, Ins and NAA/Cr were reduced in the lesional voxels. 
  
1.8.6 Association of MRS findings with seizure history 
A small number of human in vivo studies have investigated the direct effects of a 
seizure on metabolite concentrations. Seven subjects with TLE were studied in the 
inter-ictal and post-ictal (within 24 hours) period by Maton with no observed 
changes in the metabolite ratios NAA/Cr or NAA/(Cr + Cho) suggesting to the 
authors that this ratio is insensitive to immediate seizure history(Maton et al., 
2001b). Cendes measured NAA/Cr ratios in the temporal lobe in subjects during 
non-convulsive complex partial seizures and in subjects with IGE during a typical 
absence. The authors found no change in the ratio NAA/Cr but noted an increase in 
the ratio Lactate/Cr in the focal group(Cendes et al., 1997c). This finding of elevated 
lactate is consistent with animal studies that have demonstrated elevated brain 
lactate levels following multiple epileptic stimuli, exogenous glutamate 
administration, or chemical convulsant administration(Duffy et al., 1975;Chapman 
et al., 1977;Petroff et al., 1986;Najm et al., 1997;Neppl et al., 2001). Pfund studied 
11 patients with medically intractable partial epilepsy with MRS and FDG-PET in 
the interictal state (N = 11) and later in the ictal / peri-ictal state (n = 4) and found 
reduced interictal glucose metabolism and reduced GLX concentration in the 
epileptic focus compared to the contralateral hemisphere but a correlated increase in 
glucose metabolism and GLX concentrations in the ictal / peri-ictal state suggesting 
glutamate – glutamine cycle coupling with glucose metabolism(Pfund et al., 2000). 
There is also a case report(Fazekas et al., 1995) of elevation of GLX and lactate 
during focal status epilepticus.  
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Li assessed the relationship between seizure history and inter-ictal NAA/Cr values 
and found no relationship between NAA/Cr and; a) seizure duration, b) seizure 
frequency or c) lifetime estimated seizures. The authors also studied 8 subjects with 
a recent diagnosis of epilepsy before / shortly after commencing antiepileptic 
medication and 7 months after treatment had been established in 6. Initial NAA/Cr 
levels were low in 5 of the 8 subjects at the time of the index study and remained 
low in the follow up study, despite 5 of the 6 followed up subjects becoming seizure 
free in the intervening period(Li et al., 2000c). 
    
Neppl and colleagues (2001) performed serial post-ictal MRS studies at 0.5T on four 
adult dogs following induced status epilepticus (duration 30 minutes). They found 
that compared with pre-status studies there was a 24.7% reduction in Cr, a 15.4% 
elevation in GLX, and no significant effect on NAA, but they did not describe the 
time course of metabolite change in the post-ictal period. Possible mechanisms for 
the measured increase in GLX were proposed: 1) an increase in the synthesis of 
glutamate and / or glutamine, 2) an increase in the proportion of the more visible 
glutamine with reduction of the less visible glutamate, and 3) an increase in the MR 
visibility of glutamate. No explanation for the reduction in Cr was advanced. 
 
Vermathen and workers performed MRSI (1.5T, TE/TR 135/1800 ms) on 10 
patients before and after temporal lobe surgery and found a modest increase in NAA 
post surgery in the contralateral temporal lobe as well as increase to above normal 
levels of Cr and Cho(Vermathen et al., 2002). Serles measured NAA/Cr pre and post 
operatively in 16 patients undergoing temporal lobe surgery for refractory TLE. 
Post-operatively the subjects who became seizure free showed higher contralateral 
NAA/Cr ratios than those who did not become seizure free and higher values post 
operatively than pre-operatively. A nonlinear regression model of recovery of 
NAA/Cr was formulated on the basis of these findings which predicted reversal of 
neuronal metabolic dysfunction as an exponential function with half-life of 6 
months(Serles et al., 2001).  
 
1.8.7 Effect of antiepileptic drugs on MRS metabolites 
Several of the newly licensed antiepileptic drugs are thought to modulate GABA 
function. Vigabatrin irreversibly inhibits GABA-transaminase, the enzyme 
responsible for the metabolism of GABA to succinic semialdehyde. Gabapentin is 
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thought to act by increasing the release of GABA from neurons and glia, perhaps by 
reversal of the GABA transporter, while one of the several modes of action of 
topiramate is thought to be via the enhancement of GABAA receptor function. 
Several groups have demonstrated that the administration of each of these 
antiepileptic drugs is associated with a demonstrable elevation in GABA+ (the 
combined signal from GABA + homocarnosine) concentrations(Petroff et al., 
1996a;Petroff et al., 1998;Kuzniecky et al., 1998a;Petroff et al., 1999b;Petroff et al., 
1999c;Petroff et al., 2001b;Mueller et al., 2001b). 
This effect is most clearly demonstrated following the administration of vigabatrin. 
Petroff reported that epileptic subjects taking vigabatrin have GABA+ levels more 
than double the GABA+ levels of epileptic subjects not taking this 
medication(Petroff et al., 1996a). Glutamine levels were also elevated presumably 
due to blocked metabolism into GABA via glutamate in GABAergic neurons. 
Petroff later showed that the increase of GABA+ occurs within hours of ingestion of 
a loading oral dose of vigabatrin and is sustained on continued 
administration(Petroff et al., 1999b). In this study it was also shown that 
homocarnosine levels start to rise 2 – 3 days following the commencement of 
Vigabatrin therapy, which might support the proposal that homocarnosine is a 
“GABA reservoir”. A similarly rapid effect on GABA+ and homocarnosine levels 
was also reported by this group for topiramate(Petroff et al., 2001b), with elevations 
in GABA+ visible within 1 hour of the administration of the first dose of topiramate, 
and elevations in homocarnosine visible within the first day. Gabapentin was also 
shown in a small number of subjects to bring about elevation in GABA+ that was 
more marked at high doses of administered drug(Petroff et al., 2000). Whilst these 
reports did not contain full information about the efficacy of the newly administered 
antiepileptic drugs, support for an association between elevation of GABA and 
improved seizure control was later provided by another group(Mueller et al., 2001b). 
The authors of this study administered vigabatrin to 14 subjects with refractory 
epilepsy and measured the GABA+ level in the epileptogenic hemisphere before 
drug administration and a second time 1 month after the introduction of the drug. 
They were able to separate the subjects into three groups (Responders, Partial 
Responders and Non-responders) in terms of the efficacy of the drug on seizure 
control. The Responders showed an increase in the GABA+/Cr ratio and a low 
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initial value. The Non-responders showed no change in the GABA+/Cr ratio while 
the Partial-responders showed a non-sustained elevation in the GABA+/Cr value.  
 
However if these medications are administered to healthy volunteers elevation of 
GABA+ levels is also seen(Kuzniecky et al., 1998a;Kuzniecky et al., 2002) 
suggesting that the drugs also cause alteration in GABA+ levels that is independent 
of the efficacy of the drug in improving seizure control. 
 
Petroff and colleagues have also measured the effects of some of the more 
established antiepileptic drugs (carbamazepine, phenytoin and sodium 
valproate)(Petroff et al., 1999d). In a small number of subjects with epilepsy who 
were taking carbamazepine, phenytoin or valproate as a mono therapy the authors 
observed similar GABA+ and glutamate concentrations compared with healthy 
volunteers. In the subgroup taking sodium valproate 3 of 5 subjects showed high 
glutamine concentrations. The authors noted that raised plasma ammonia levels are 
observed in some patients taking sodium valproate and that since ammonia is a 
precursor for glutamine this might be a mechanism for the observed elevation in 
glutamine. However no blood levels were available on the studied patients to further 
investigate this possibility. 
 
No drug effects on measured levels of the commonly measured metabolites NAA, 
Cr or Cho have been reported. However a study of rats treated with valproate or 
carbamazepine(van Calker and Belmaker, 2000b) identified that these medications 
reduce measured Ins concentrations.  The mechanism for Ins reduction by valproate 
may be by action on the phosphoinositide Ca
2+
 second messenger system or via 
inhibition of a cell membrane sodium/Ins co-transporter and it is possible that these 
mechanisms are shared by carbamazepine. Whether either of these mechanisms 
could account for some of the anti-seizure efficacy of these drugs has not yet been 
formally studied. 
 
1.8.8 
31
P and 
13
C MRS findings in epilepsy 
31
P MRS has also found widespread application to the investigation of subjects with 
epilepsy (reviewed by (Duncan, 1996)) particularly in the study of temporal lobe 
epilepsy (as discussed above). Animal studies have shown the relative preservation 
of pH and ATP levels at the expense of PCr in the course of prolonged 
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seizures(Petroff et al., 1984;Young et al., 1985). However the necessity for 
prescription of relatively large volumes of interest (compared even with 
1
H MRS) 
results in heterogeneity of included tissue which limits the interpretation of obtained 
results: e.g. studies have shown 50% higher levels of PCr in grey matter than in 
white (Mason et al., 1998). Consequently 
31
P MRS remains a research tool. 
 
13
C MRS techniques are based upon the observation that endogeneous levels of 
13
C 
in the brain are low and produce negligible signal. Consequently if a labelled 
metabolite is introduced, any signal that is observed will have arisen from this 
source. Since 
13
C metabolite peaks have a wider range of chemical shifts than is 
observed for 
1
H MRS these peaks are more easily resolved. 
13
C MRS is therefore an 
appropriate tool for the measurement of flux through different metabolic cycles or 
between cellular compartments.  Rothman and co workers used 
13
C to measure the 
rate of flux through the glutamate – glutamine cycle(Rothman et al., 1999;Rothman, 
2001;Rothman et al., 2003) and reported that the rate of glutamate – glutamine 
cycling between the glial and neuronal compartments is proportional to the total rate 
of glucose consumption(Sibson et al., 1998a;Sibson et al., 1998b;Sibson et al., 2001) 
 
1.8.9 Correlation of MRS findings with other novel imaging modalities 
Kantarci and colleagues compared the sensitivity of diffusion weighted MRI (DWI) 
and MRS for lateralising seizure onset and predicting postoperative seizure control 
in patients with temporal lobe epilepsy. They found that the hippocampal and 
temporal stem apparent diffusion coefficient (ADC) measurements were more 
concordant with electro-clinical findings (correctly lateralising 32/40 and 26/40 
respectively) compared to NAA/Cr (18 of 40). However NAA/Cr ratios were the 
only measures predictive of good surgical outcome (94%)(Kantarci et al., 2002). 
 
Meyer compared 
18
F-fluorodeoxyglucose (FDG)-PET, MRS (NAA/Cr) and MRI 
data in 43 subjects with mesial temporal lobe epilepsy. There were no significant 
differences between the three modalities and their level of concordance with electro-
clinical data. However FDG-PET was more predictive of good post-surgical 
outcome and MRS was more sensitive for abnormality in MR negative cases(Meyer 
et al., 2001). Knowlton has also compared MRS with FDG-PET finding that PET 
was the most sensitive single test for the lateralisation of the seizure focus in 
temporal lobe epilepsy with and without MRI visible abnormality. However, the 
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combination of MRSI and hippocampal volumetry was as sensitive as PET alone for 
lateralisation of the seizure focus(Knowlton et al., 1997). 
 
Cross and colleagues compared MRS with interictal SPECT in 14 children with 
intractable TLE finding hypo-perfusion in one temporal lobe ipsilateral to seizure 
focus in 10 subjects and lateralised NAA/Cr in 8 of these 10. Of the remaining 4 
subjects that showed no regional perfusion abnormality the MRS examination 
revealed bilateral abnormalities in 3 that were non-lateralising. The authors 
concluded that the investigations were complementary and that MRS might be more 
informative in cases where no regional interictal perfusion abnormalities were 
detectable(Cross et al., 1997). 
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2.1 Introduction 
 
Many of the methods relating to subject recruitment, acquisition and segmentation 
of conventional MRI data, basic MRS acquisition and processing strategies, and data 
analysis are common to each of the experiments reported in this thesis. To avoid 
repetition, they are described in detail in the Common Methods section of this 
chapter and referred to where appropriate in subsequent chapters.  
 
Each Results chapter also involves the application of more advanced techniques. 
These more specific methodologies are also described later in this chapter, and again 
referred to where necessary in later chapters. 
 
2.2 Common Methods 
2.2.1 Subject recruitment 
The patients studied were recruited from the epilepsy clinics of the National 
Hospital for Neurology and Neurosurgery, Queen Square, London, UK and the 
National Society for Epilepsy, Chalfont Centre, Chalfont St Peter, UK. Written 
informed consent according to the declaration of Helsinki was obtained in all cases.  
 
All performed experiments had the approval of The Joint Research and Ethics 
Committee of The National Hospital for Neurology and Neurosurgery and The 
Institute of Neurology.  
 
Clinical data and the results of any previous imaging were obtained from the patient 
hospital notes. Current seizure frequency and time since last seizure were obtained 
from patients or carers at the time of scanning.  
 
Normal control subjects were all volunteers recruited from the staff population at 
The National Society for Epilepsy.  All controls were free of any significant medical 
history and in particular reported no personal history or direct family history of 
epilepsy or epilepsy related illness. They were taking no regular neuro-active 
medications. 
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2.2.2 Image data acquisition and analysis 
Patients were scanned on a 1.5 Tesla GE Signa Echospeed scanner at the National 
Society for Epilepsy. Standard departmental epilepsy protocol sequences were 
acquired for all patients unless the patient had recently undergone such a study as 
part of a clinical investigation or as part of a different research project. These studies 
ensured that each patient was given the correct MRI diagnosis and also that there 
had been no recent development of a second MRI evident pathology. All controls 
underwent as a minimum an axial inversion recovery prepared fast spoiled gradient 
echo (IRP-FSPGR) volumetric sequence. The radiological assessment of all the 
images was performed by two experienced Neuro-radiologists, Dr John Stevens and 
Dr Brian Kendall.  
 
The standard epilepsy protocol consisted of: 
 
Sagittal T1 weighted localiser. Conventional spin echo sequence (TE / TR = 14ms / 
640ms), NEX = 1,  slice thickness = 5mm with 2.5 mm gap, field of view (FOV) 
24x24cm with a 256x256 matrix, acquisition time = 2 min 47 s. 
 
Coronal oblique proton density (PD) and T2 weighted. Conventional spin echo, 
TE/TR/NEX 30&120/2000/1, 28 slices of 5mm thickness with 0 mm gap, FOV 
18x24cm with a 256x192 matrix, acquisition time = 1 min 24 s.  
 
Coronal T1 weighted 3D volume. Inversion recovery prepared fast spoiled gradient 
recall (IRPFSPGR), TE/TR/NEX 4.2/15.5/1, time of inversion (TI) 450, flip angle 
20°, 124 slices of 1.5mm thickness, FOV 18x24cm with a 192x256 matrix, 
acquisition time = 6 min 56s. 
 
Coronal oblique fast fluid attenuation inversion recovery (Fast FLAIR). Fast FLAIR 
sequence, TE/TR/NEX 144/11000/1, TI 2600, 28 slices of 5mm thickness with 0mm 
gap, FOV 18x24cm with a 192x256 matrix, and orientated perpendicular to the long 
axis of the hippocampus, acquisition time = 3 min 10s. 
 
To this series was routinely added a further volumetric sequence to allow voxel 
placement and subsequently for segmentation using SPM99 (Statistical Parametric 
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Mapping; Wellcome Department of Imaging Neuroscience, Institute of Neurology, 
University College London). 
 
Axial inversion recovery prepared fast spoiled gradient echo (IRP-FSPGR). Images 
were 124 * 1.5mm thick with field of view (FOV) = 26 cm, and a matrix of 
256*128, TE/TI/TR = 4.2/450/16 ms, flip angle 20
o
, acquisition time = 5 min 47 s. 
 
2.2.2.1Voxel segmentation 
The methodology of SPM segmentation is well described 
[www.fil.ion.ucl.ac.uk,(Ashburner and Friston, 2000)].  For the purposes of this 
programme the MR image is assumed to consist of a number of distinct tissue types 
(clusters) from which every voxel has been drawn. The intensities of the voxels 
belonging to each of these clusters conform to a multivariate normal distribution 
which can be described by a mean vector, a covariance matrix, and the number of 
voxels belonging to the distribution. These parameters are estimated through a series 
of iterative computations by comparison with an a priori approximate knowledge of 
the spatial distributions of these clusters in the form of probability images which 
have been derived from MR images of a large number of subjects. These template 
images were segmented into binary images of grey matter (GM), white matter (WM) 
and cerebro-spinal fluid (CSF) and all normalised into the same space using a nine 
parameter affine transformation. The probability images are the means of these 
binary images so that they contain values in the range of 0 to 1 which represents the 
probability of a voxel being GM WM or CSF after an image has been normalised to 
the same space using a nine parameter transformation. 
 
SPM99 was applied in each of the MRS experiments in this thesis. Classification of 
pixels as CSF, GM or WM was not forced. For example, if a pixel was reported as 
having a 54% probability of being GM, 10% CSF, and 36% WM, the pixel was 
assumed to have contained various tissues in approximately these proportions.  
 
MRS experiments examine a localised volume of interest (VOI) from which the 
concentrations of relevant neuro-metabolites are measured. In order to determine the 
tissue composition of the prescribed VOI the IRP-FSPGR volumetric whole brain 
images are first segmented as above. The co-ordinates of the prescribed VOI are 
then given to a locally developed programme written in SAGE 7.0 (the GE MR 
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spectroscopy software package, based on the Interactive Data Language (IDL: visit 
www.ittvis.com/IDL) that averages the estimated content of GM, WM, and CSF 
from within the VOI. 
 
In the ideal situation a VOI would be sufficiently small to allow for the exclusive 
measurement of a single tissue type. However VOI are limited by the available 
signal to noise ratio (SNR) as outlined in Equation 1.7.5. Therefore at present in 
vivo MRS experiments are limited to a minimum VOI of approximately 5 ml (for B0 
= 1.5 T, scan duration = 5 min) and consequently the prescribed volume will usually 
have a heterogeneous tissue composition. It is important that the effects of this 
heterogeneity are recognised because metabolite concentrations are different in pure 
grey matter compared to pure white matter voxels(Hetherington et al., 1996;McLean 
et al., 2000) and may vary in concentration across brain regions(Pouwels and Frahm, 
1998). The major differences are between GM or WM and CSF since CSF has 
negligible metabolite content(Lynch et al., 1993). Comparison of MRS VOI between 
regions that contain different amounts of CSF can therefore lead to the introduction 
of partial volume error.  
 
Because of this potential error it has become a standard practice of the NSE MRS 
group to correct the obtained metabolite concentrations for the presence of CSF 
which will not have contributed to the final metabolite signal such that: 
 
[Metabolite]corrected = [Metabolite]measured * 1 / (1 – CSFproportion) [Eqn. 2.2.1] 
 
Most metabolites have a higher concentration in grey matter than in white 
matter(Doyle et al., 1995;McLean et al., 2000). In order to correct for this further 
source of partial volume error the GM proportion obtained from the segmentation 
process may be used as a covariant in statistical comparisons that compare subjects 
or groups with different grey matter proportion estimates 
 
2.2.3 MRS data acquisition 
This thesis describes single voxel and multiple voxel MRS acquisitions. All studies 
measured the concentrations of the main metabolites visible at short TE, i.e. NAA, 
Cho, Cr, GLX and Ins obtained with standard acquisition parameters (TE/TR = 
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30/3000 ms). The number of averages varied between studies and depended on the 
trade off between sequence duration and signal to noise requirements in each case.  
 
Voxel placement was from axial volumetric FSPGR images and magnetic field 
inhomogeneities were minimised using automated gradient shim procedures.  
 
Water suppression was achieved using a series of 3 chemical shift selective 
(CHESS) pulses. The CHESS sequence entails the application of a frequency 
selective excitation of water through 90
0
 with subsequent dephasing of the 
transverse magnetisation with a crusher gradient.  
 
VOI localisation was performed using the standard PRESS sequence as described in 
chapter 1.7.3.5. 
 
2.2.4 MRS data processing 
Following localisation the free induction decay (FID) signal is collected without a 
readout gradient. There are several methods of analysing the FID to allow 
visualisation of the metabolite peaks. The data can be analysed in the time or, 
following Fourier transformation, in the frequency domain, and each technique has 
its own relative merits. In this work all spectral processing was performed in the 
frequency domain. The GABA+ signal was analysed by locally written programme 
in SAGE 7 described in Section 2.4. Processing of all other spectra was by the 
application of LCModel which is an established MRS software package that allows 
semi-quantitative estimation of metabolite concentrations(Provencher, 
1993;Provencher, 2001). 
 
2.2.4.1 LCModel 
The LCModel method analyzes an in vivo spectrum as a linear combination of 
model in vitro spectra from individual metabolite solutions. Complete model 
spectra, rather than individual resonances, are used in order to incorporate maximum 
prior information into the analysis. A nearly model-free constrained regularisation 
method automatically accounts for the baseline and line shape in vivo without 
imposing a restrictive parameterized form on them. LCModel is automatic (non-
interactive) with no subjective input. Approximate maximum-likelihood estimates of 
the metabolite concentrations and their uncertainties (Cramer-Rao lower bounds) are 
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obtained. The method has also been shown to deal robustly with a series of potential 
causes for quantification failure such as the inclusion of excessive water signal 
following imperfect water suppression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.2 Typical LCModel output acquired in a patient with IGE examined in the right 
frontal lobe with TE/TR = 30ms/3000ms and showing LCModel estimates for the obtained 
metabolite concentrations in the upper right hand section of the output. The estimated 
baseline is shown below the obtained spectrum as are the residual deviations of the true data 
from the estimated plot (shown above the spectrum).    
 
In order to calibrate the concentrations for local machine performance, and to 
monitor any possible fluctuations, an 8 cm diameter spherical phantom containing 
50 mM NAA was scanned on a weekly basis. It was kept refrigerated between uses 
and always scanned directly after removal from the refrigerator to minimise error 
due to fluctuations in sample temperature. An 8.13 cc PRESS voxel was prescribed 
graphically in the centre of the sphere, which was positioned in the centre of the 
head coil. The acquisition (TE/TR/number of averages/scan time = 30ms/3s/256/13 
min 46s) reported the obtained NAA concentration with a very high SNR (≥100) and 
a low estimated Cramer-Rao uncertainty (<2%). This weekly quality assurance 
measurement was necessary to allow recalibration to correct for any drift in local 
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machine performance over time and to allow the reliable comparison of results 
obtained from repeated scans.  
 
2.2.5 MRS data analysis 
LCModel reports the concentrations of the modelled metabolites for each studied 
VOI. Before statistical comparison can be made these concentrations are then 
corrected for partial volume error due to the inclusion of CSF in the VOI according 
to equation 2.2. Further metabolite concentration correction was made for the multi-
voxel data as described below (Section 2.3). 
 
All statistical comparisons were made using the scientific statistical package 
SPSS9.0. To account for variation in VOI GM/WM relative content, further analysis 
was then made using an ANCOVA analysis using GM as a covariant in two of the 
reported experiments in the next Chapter (Section [3.1] and [3.5]). 
 
2.3 Magnetic Resonance Spectroscopic Imaging (MRSI) 
The term MRSI refers to a technique in which spatial information is encoded by 
magnetic field gradients (phase encoding). The number of encodings required is 
equal to the desired number of pixels in the spectroscopic image. The data is 
encoded in k (phase) space. A multi-dimensional Fourier transformation will then 
return a spectrum for each pixel.  
 
Chapter 3 of this thesis [Section 3.1] reports the findings of an MRSI experiment 
investigating metabolite variation in the temporal lobes in temporal lobe epilepsy. 
The methodology for this study is described in more detail elsewhere(McLean et al., 
2000;McLean et al., 2001) but the main details are outlined here. 
 
Analysis of regions of interest (ROIs) was performed using LCModel 
Interactive(McLean et al., 1999;McLean et al., 2000), a locally developed program 
in Sage/IDL. The program allows the user to define a ROI by drawing with a cursor 
on a reference image and then extracts voxels that are aligned with the VOI for 
analysis using LCModel. This allowed the comparison of anatomically matched 
voxels between hemispheres and between subjects. 
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Figure 2.3.1: Axial T1 weighted images of a control patient showing the hippocampal 
formations bilaterally. The interactive software allowed regions of interest (ROI) to be 
drawn on the reference image using a cursor.  For each ROI, the program then extracted all 
the spectra within its boundaries after voxel shifting in 2 dimensions to maximise inclusion. 
The image on the left shows the chemical shift imaging grid at acquisition prior to voxel 
shifting using LCModel Interactive. The right hand image shows the prescribed volume of 
interest in the right temporal lobe and the final acquired ROIs along the hippocampus and in 
the adjacent lateral temporal lobe. 
 
 
Fourier transformation was performed without zero-filling or apodisation. 
Approximate zero-order phase was applied in order to provide a good starting point 
for LCModel, which optimizes the phase for each individual spectrum. Additionally, 
to account for frequency shifts across the FOV, peak registration was performed on 
the singlet peak of NAA. The size and location of the excitation region (ROI) was 
read from the raw MRSI file header and only spectra within it were extracted for 
processing and the metabolite concentrations for those voxels outside the ROI were 
set to zero. A queuing system was established using LSF (Load Sharing Facility: 
Platform Computing Corporation, http://www.platform.com) in order to send 
LCModel jobs to six SUN computers, two of which had dual processors. After 
completion of peak fitting, another locally developed program was run to read the 
postscript output and produce Sage/IDL datasets of the metabolite concentrations. 
 
Several further corrections to the data were then made. This was necessary because 
the volume of interest was comparatively large and any variation in the slice 
excitation profile across the excitation region could be expected to produce 
artifactual variation in metabolite concentrations. The data was also corrected for 
known chemical shift artefact (CSA) across the region. CSA arises from the 
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differing neuro-metabolite chemical shifts. This causes the excited region of interest 
for one metabolite, for example NAA, to be slightly shifted with respect to the 
excited slice for another with a different chemical shift, for example Ins. The amount 
of this loss of spatial alignment is proportional to the relative difference in their 
chemical shifts. Therefore comparison of metabolite concentrations from a region 
must take into account that the regions of interest evaluated for each metabolite are 
not completely coincident. In most single voxel studies CSA is a small effect and 
can be ignored. However in MRSI studies where the excitation ROI is subdivided 
into smaller voxels of interest this effect can become more important and needs to be 
considered as part of the data interpretation. 
 
To correct for imperfect slice profiles, two images of the MRSI slab were acquired 
using PRESS localisation: one image with the voxel placed as for MRSI, and one 
with the voxel the same size as the FOV. Scanning time was 1:20 per image (TE/TR 
= 35/500, imaging matrix = 256*160, interpolated to 256
2
). The ROI image was 
divided by the FOV image to produce a map of the PRESS excitation profile in two 
dimensions. The average pixel intensity of the excitation profile image over the 
region corresponding to each MRSI voxel, as a fraction of the theoretical maximum 
(FPRESS) was used to correct for signal loss: 
 
[Metabolite]corrected = [Metabolite]/FPRESS            [Eqn. 2.3.1] 
 
To correct for chemical shift artefact (CSA), this image was translated in both in 
plane dimensions by a number of pixels for each metabolite calculated from: 
 
CSA correction = (σB0/G)*(256/FOV)            [Eqn. 2.3.2] 
 
In this equation, B0 is the field strength (1.5T), G is the calculated gradient 
amplitude along the axis in mT/m, and the factor 256/FOV converts from metres to 
pixels.  
 
2.4 Double Quantum Filter (DQF) measurement of GABA 
Despite a 
1
H MRS visible GABA concentration of approximately 1.5mmol/l, in vivo 
GABA can at present only be directly measured at very high magnetic field 
strengths(Tkac et al., 2003). At lower field strengths the three GABA multiplets are 
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heavily overlapped at 1.9 ppm, 2.3 ppm and 3.0 ppm by other metabolites such as 
creatine plus phosphocreatine (Creat) at 3.0 ppm, by glutamate and glutamine at 2.3 
ppm and by NAA at 2.0 ppm and more generally by the macromolecule baseline in 
short TE acquisitions. Therefore a number of different MRS techniques have been 
applied to simplify or edit the spectrum to allow resolution of GABA. The general 
characteristics of these methods have been described in some detail in Section 1.7.  
Most studies have been designed to allow measurement of the γCH2 resonances at 
3.0 ppm. This resonance is most amenable to examination because it is overlapped 
by the singlet Cr resonance which does not exhibit spin-spin (J) coupling. Such 
techniques then use selective modulation of the J-coupling to suppress or subtract 
the Cr resonance. 
 
In this thesis I have applied a double quantum filter (DQF) technique to edit the 
spectrum to measure GABA concentrations in patients with focal epilepsy and 
idiopathic generalised epilepsy. Several regions of the brain have been studied. The 
technique allows a “single shot” measurement of GABA and thus reduces the 
possibility of cancellation errors that may arise following patient movement and 
other instabilities when using subtraction methods. However a filter efficiency of 
only ~30% makes SNR calculations an important factor in the design of the 
experiment. 
 
The resulting “GABA” peak will however include at low intensity other compounds 
such as homocarnosine, glutathione and some macromolecule signal.  The filtered 
GABA measurements are therefore designated as GABA+. GABA concentrations 
obtained by spectral editing similarly include homocarnosine and some 
macromolecule signal. 
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Figure 2.4.1: The Double Quantum Filter GABA+ sequence. For simplicity, the initial 
water suppression, outer volume suppression, and associated slice-selective crusher 
gradients are not shown. The total TE was 68 ms (1/2J for J = 7.35 Hz). The optimum value 
for the time TM between the hard 90° pulse and the centre of the binomial read pulse was 
found to be the minimum obtainable (6 ms). The binomial spacing (BS) was set at 7 
ms(McLean et al., 2002). 
 
 
A simplified version of the DQF pulse sequence is shown above (Figure 2.4.1). 
Multiple quantum coherences are created in the coupled metabolites by the first 
three pulses (90°, 180°, 90°).  
 
After a period of evolution, TM, these multiple quantum coherences are converted 
back to observable single quantum coherences by a frequency selective binomial 90° 
pulse with 7-ms spacing, tuned to the βCH2 GABA resonance at 1.9 ppm to allow an 
increase in theoretical efficiency for the γCH2 by transferring the magnetisation from 
the βCH2 to the desired γCH2 resonance. 
 
The filter gradients, G and 2G, are applied to select only the double quantum 
coherences. The phase of the double quantum coherence evolves twice as fast as a 
single quantum coherence therefore only those spins that experienced the first 
P a g e  | 137 
 
gradient as double quantum coherences will have zero net phase difference when the 
signal is acquired.  
 
This DQF sequence is based upon a sequence reported by Keltner and 
colleagues(Keltner et al., 1997). A full description of the calibration of the filter and 
evaluation of the filter efficiency can be found elsewhere(McLean et al., 2002). The 
filter yield of GABA relative to an unfiltered PRESS experiment at a TE of 136 ms 
was 38.5% with the area of the peak at 2.9 ppm alone estimated to be 16% of the 
total unfiltered GABA area. The Cr singlet suppression factor was found to be on the 
order of 1000.  
 
Although, in vivo, the 3.1 ppm peak of the γCH2 multiplet is partially obscured by 
macromolecular contamination the 2.9 ppm peak is relatively free of 
macromolecular contamination (forming <10% of the measured area). This degree 
of contamination is not negligible, but is less than that found in other spectral editing 
experiments for which macromolecule signal may contribute up to 30% of the 
resulting “GABA+” peak(Rothman et al., 1993). 
 
 
Figure 2.4.2: Typical GABA+ signal following application of DQF sequence 
 
GABA+ 
ppm 
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VOI localisation was achieved using slice selective gradients on the first 90
0
 pulse 
and the two 180
0
 degree pulses. Spectra (TE = 68 ms, TR = 2000ms) were initially 
acquired with the filter off (1 min) then the DQF filter was applied with the same 
TE/TR and 512 averages were collected (scan time = 17 min) to measure GABA+. 
Conventional PRESS localised spectra (TE/TR = 30 / 3000ms) were also acquired 
during the same examination.  
 
The conventional PRESS spectra at TE =30 ms were analyzed using LCModel. The 
spectra acquired at TE = 68 ms without the DQF filter were also analyzed using 
LCModel, in order to obtain a consistent fit to the small baseline still present at this 
TE. However, the DQF spectra could not be analyzed in this way, so the 
concentrations of Cr at TE =68ms reported by LCModel were then converted back 
to peak areas for comparison with DQF spectra.  
 
Since DQF spectra are a mixture of low SNR peaks with varying relative phases it is 
necessary to ensure that the final spectrum is consistently phased before peak 
measurement.  This is achieved by employing a programme written in General 
Electric’s Sage/IDL processing package to automatically phase the spectra by 
maximizing the integrated area between 2.4 and 3.8 ppm. The peaks in this region of 
the DQF spectrum are consistently in phase with the GABA resonance at 3.0 ppm 
(Figure 2.4.2).  
 
Finally, GABA+ is quantified by taking the ratio of the integrated peak at 2.9 ppm 
relative to that of Cr without the filter at the same TE (68 ms), correcting for the 
filter yield and for the number of protons contributing to each resonance (two for 
GABA, and three for Cr). Conversion to mM concentration is then performed by 
taking the concentration of Cr from the short TE LCModel analysis and according 
to: 
 
[GABA+] = [Cr] * (AreaGABA+ / AreaCr) * 3/2 * 1/Yield.  [Eqn. 2.4.1]  
 
Where AreaGABA+ = the integrated area of the GABA+ multiplet peak at 2.9 ppm 
(TE = 68ms), AreaCr = the estimated area of the Cr peak at the same TE and Yield 
was determined from phantom experiments as 16%.  
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In some subjects the quality of the DQF spectrum was not sufficient to allow reliable 
measurement of the GABA+ peak necessitating the development of objective 
exclusion criteria. In this thesis GABA+ measurements were made in several regions 
of the brain, producing DQF spectra of differing quality from region to region. 
Therefore the exact exclusion criteria in each study vary slightly, the details of 
which are provided in the relevant Results chapters. 
 
2.5 Metabolite nulled measurement of glutamate and glutamine 
As described in Chapter 1, performing short TE MRS/MRSI allows the potential 
measurement of metabolites such as glutamate and glutamine that are of interest to 
the study of epilepsy, as well as Ins which may be a an important marker of glial 
activity. However as the TE is reduced the macromolecule baseline becomes more 
difficult to model. There are four broad macromolecule peaks appearing at roughly 
0.9, 1.3, 2.4 and 3.2 ppm and at TE = 30ms the macromolecule signal accounts for 
approximately 30% of the total signal. In particular the 2.4 ppm macromolecule 
peak underlies the glutamate and glutamine signal which reduces the reliability of 
estimation of these metabolites, even as the combined peak GLX(Behar et al., 
1994;Soher et al., 2001).  
 
Suppression of this macromolecule background has been shown to improve 
discrimination of the individual metabolites(McLean et al., 2004). This can be 
particularly useful when VOI are unavoidably placed close to the scalp and the 
resultant spectra incorporates artifactual macromolecule signal from outside the 
VOI. In Section 3.5 I describe the results of GABA+ measurement in the temporal 
lobe of patients with hippocampal sclerosis and TLE. This experiment required 
prescription of large VOI with outer boundary close to the brain surface and to 
minimise this potential source of error the study design incorporated the 
macromolecule suppression sequence (McLean et al., 2004). 
  
This sequence discriminates macromolecule signal from neurochemical signal 
through their different spin-lattice (T1) relaxation times. Macromolecules are 
relatively immobile and consequently their protons have much shorter T1. The 
prescription of an inversion pulse prior to the acquisition sequence can allow either 
the signal due to the macromolecule baseline or the signal due to the small mobile 
metabolites to be suppressed.  
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Practically it is more convenient to suppress the small metabolite signal than the 
macromolecule signal because an inversion pulse tailored to suppressing the 
macromolecule signal would also lead to significant loss of signal for the metabolite 
peaks and the short inversion times needed would be difficult to combine with 
efficient water suppression. 
 
The basic methodology is as follows. Two spectra are acquired for each VOI. The 
first is obtained using a standard MRS acquisition (TE/TR = 30/3000 ms) and 
includes both small metabolites and the broad macromolecular baseline. A second 
acquisition is then performed that is preceded by an inversion pulse calculated to 
minimise the metabolite peaks. The final “macromolecule nulled spectrum” is the 
edited spectrum of the first acquisition minus the second (“macromolecule only”) 
acquisition. The edited spectrum can then be analysed as previously using LCModel. 
 
The timing of the inversion pulse (TI) was determined from a pilot series of in vivo 
acquisitions with variable TI times that had been calculated to be close to the 
theoretical minimum of: 
 
S/S0 = 1 – 2 * exp(-TI/T1) + exp(-TR/T1)       [Eqn. 2.5.1]  
 
Where S/S0 is the fraction of signal that remains for a given inversion time TI and 
metabolites with a given T1 relaxation(McLean et al., 2004). 
 
This method which was validated in 10 healthy volunteers(McLean et al., 2004) has 
been shown to reduce the  LCModel measured Cramer-Rao lower bounds of 
uncertainty for all the metabolites of interest, including glutamate, glutamine and 
GLX.  
 
The method of subtracting the macromolecule signal from the standard spectrum 
does result in loss of SNR. However, in the experiment in which macromolecule 
suppression was used a large VOI was chosen ensuring sufficient SNR in all cases. 
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2.6 Post-ictal MRS 
The final experiment performed in this thesis was an investigation of transient 
metabolite disturbance in the immediate post-ictal period [3.7]. A previous in vivo 
human study had reported that metabolite ratios might show dynamic changes 
during the post-ictal period(Maton et al., 2001b) and one animal study had noted a 
change in individual metabolite concentrations in this period(Neppl et al., 2001). For 
obvious technical reasons only case reports exist of measurement during a seizure 
and these also have suggested that there is dynamic metabolite change (for example 
(Fazekas et al., 1995) 
 
In this experiment an additional sequence was added to the basic protocol. This 
sequence was a standard MRS acquisition performed at longer TE (TE=144ms) than 
was used for the metabolite nulled experiment (TE = 30ms). The addition of this 
sequence allowed the examination of post ictal changes in the ratio: 
 
[Cr]TE=30ms / [Cr]TE=144ms      
 
Recent work had suggested that Creat and PCreat have different T2 relaxation times 
with the phosphocreatine signal decaying faster with increasing TE (T2  for PCreat 
and Creat = 117 +/- 21 ms and 309 +/- 21 ms respectively)(Ke et al., 2002). Since 
Creat and PCreat act to buffer ATP according to: 
 
ATP + Creat ↔ ADP + PCreat       
 
in the immediate post ictal period there is relative shift of this reaction to the left 
with relative reduction of the contribution that phosphocreatine makes to the 
combined concentration of Cr which stays relatively constant. At short TE this 
relative increase in PCreat will make little difference to Cr. However at long TE the 
increased creatine component of Cr will cause it to decay more slowly and show 
relatively more signal compared to the resting state where PCreat and Creat will be 
more evenly balanced. In this circumstance the ratio [Cr]TE=144ms / [Cr]TE=30ms  should 
be increased in the post ictal state compared to the interictal state. 
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An additional advantage of adding this longer TE sequence was to allow for 
comparison of any findings in the study with the limited existent literature which 
used longer TE. 
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Chapter 3: Results 
 
3.1 Multi-voxel MRSI in TLE  
3.2 MRS in the Occipital lobes in IGE and OLE  
3.3 MRS in the Frontal lobes in IGE 
3.4 MRS in Malformations of Cortical Development  
3.5 The effect of Sodium Valproate on MRS Measured Metabolites  
3.6 MRS in TLE post Temporal Lobe Surgery 
3.7 MRS in the immediate post ictal period 
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3.1 A Short Echo Time Proton Magnetic Resonance Spectroscopic 
Imaging Study of Temporal Lobe Epilepsy. 
 
ABSTRACT: 
Purpose: 
Short echo time proton Magnetic Resonance Spectroscopy Imaging (MRSI) was 
used to study metabolite concentration variation through the temporal lobe in 
patients with temporal lobe epilepsy (TLE) with and without abnormal MRI.    
 
Methods: 
MRSI was performed at TE=30ms to study 10 control subjects, 10 patients with 
TLE and unilateral hippocampal sclerosis and 10 patients with TLE and 
unremarkable magnetic resonance imaging (MRI negative). Concentrations of N-
acetyl aspartate + N-acetyl aspartyl-glutamate (NAAt), creatine (Cr), choline (Cho), 
glutamate + glutamine (GLX), and myo-inositol were measured, in the anterior, 
middle and posterior medial temporal lobe (MTL), and in the posterior lateral 
temporal lobe. Segmented volumetric T1 weighted MR images gave the tissue 
composition of each MRSI voxel. Normal ranges were defined as the control mean 
+/-3 SD.  
 
Results: 
In the hippocampal sclerosis group seven of 10 had abnormally low NAAt, in the 
ipsilateral anterior MTL. In the MRI negative group four of 10 had low NAAt in the 
middle MTL voxel ipsilateral to seizure onset. Metabolite ratios were less sensitive 
to abnormality than NAAt concentration. Group analysis showed low NAAt, Cr and 
Cho in the anterior MTL in hippocampal sclerosis. GLX was elevated in the anterior 
voxel contralateral to seizure onset in the MRI negative group. Metabolite 
concentrations were influenced by voxel position and tissue composition. 
 
Conclusions: 
(1) Low NAAt, Cr and Cho were features of the anterior sclerotic hippocampus 
whilst low NAAt was observed in the MRI negative group in the middle medial 
temporal lobe region. The posterior temporal lobe regions were not associated with 
significant metabolite abnormality. (2) The two patient groups demonstrated 
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different metabolite profiles across the temporal lobe with elevated GLX a feature of 
the MRI negative group. (3) Voxel tissue composition and position influenced 
obtained metabolite concentrations. 
 
Published ref: (Simister et al., Epilepsia 2002 43, 1031-1041) 
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3.1.1 Introduction 
 
The value of single voxel proton Magnetic Resonance Spectroscopy (MRS) and 
Magnetic Resonance Spectroscopy Imaging (MRSI) has been demonstrated in the 
evaluation of patients with temporal lobe epilepsy (TLE) (Hugg et al., 1993;Cendes 
et al., 1994;Connelly et al., 1994;Cendes et al., 1995;Hetherington et al., 
1995a;Hetherington et al., 1995b;Cross et al., 1996;Vermathen et al., 1997;Achten et 
al., 1997;Cendes et al., 1997b;Kuzniecky et al., 1998b;Woermann et al., 1999c;Chu 
et al., 2000;Li et al., 2000b) (Cross et al., 1996;Vermathen et al., 1997;Achten et al., 
1997;Kuzniecky et al., 1998b;Woermann et al., 1999c;Chu et al., 2000;Li et al., 
2000b) and may identify more abnormalities than magnetic resonance imaging 
(MRI) volumetry and relaxometry(Cendes et al., 1997b;Kuzniecky et al., 1998b). 
This could provide important information in the pre-surgical evaluation of patients 
who have TLE and normal quantitative MRI and those with apparently bilateral 
pathology(Li et al., 2000b). 
The principal advantage of MRSI is that it offers the opportunity to examine 
regional variation of metabolite concentrations. This may allow improved 
localisation of the pathological focus and an assessment of the extent of metabolic 
abnormality outside the clinical and EEG-defined primary epileptogenic area(Li et 
al., 2000a). There are no other published MRSI studies that report quantification of 
each of the metabolites (NAA, Cho, Cr, Ins and GLX) through the temporal lobe in 
controls and patients with TLE. This is because of the technical difficulties of MRSI 
in this region of the brain, particularly due to the proximity to air spaces, incomplete 
water suppression and field inhomogeneity. The majority of MRSI studies of the 
temporal lobes have also used a longer TE(Vermathen et al., 1997;Cendes et al., 
1997b) or have only reported ratios of the three main metabolites(Hetherington et 
al., 1995a;Kuzniecky et al., 1998b).  
The aim of this investigation was to apply quantitative MRSI to compare metabolite 
concentrations at different positions of the temporal lobe for patients with TLE and 
hippocampal sclerosis (HS) and patients with TLE and normal MRI (MRIN) in 
comparison with healthy volunteers.     
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3.1.2.0 Methods  
3.1.2.1 Subjects 
Ten control subjects and 20 patients with intractable TLE were recruited and 
investigated as outlined in section 2.2. Ten patients had a MRI diagnosis of 
unilateral hippocampal sclerosis and 10 had unremarkable MRI scans on visual 
inspection and according to accepted quantitative criteria(Woermann et al., 1998a). 
In all patients the localisation and lateralisation of the side of seizure onset was 
based on a full clinical assessment, interictal and ictal scalp EEG video monitoring 
and/or intracranial electrodes, neuro-psychometry, MRI and hippocampal volumetry 
and relaxometry. 
 
3.1.2.2 Magnetic Resonance Spectroscopic Imaging 
The subjects were positioned with their necks extended as previously 
described(Woermann et al., 1999c) to allow the long axis of the hippocampus to be 
orthogonal to the long axis of the magnet. The two temporal lobes were studied 
separately to minimise field inhomogeneity effects(Xue et al., 1997) (McLean et al., 
2001). On each side a PRESS volume of interest was prescribed of approximate 
dimension 4.5cm in the Left-Right direction, and 6.5cm in the Anterior-Posterior 
direction. The acquisition matrix was 20*20 phase encodings over a 26cm FOV. The 
slice thickness was 12mm, which yielded a nominal voxel volume of approximately 
2cc. One excitation was acquired, with TE/TR 30/3000, which gave an acquisition 
time of 20 minutes for each side, and a total examination time of 75 minutes.  
The data was processed using LCModel Interactive(McLean et al., 2001) as outlined 
in section [2.3]. The program took the user defined hippocampal area and extracted 
up to three voxels, centred respectively on the head, body and tail of the 
hippocampus are referred to in this paper as anterior, middle and posterior medial 
temporal lobe (MTL).  If the anterior part of the defined hippocampal region was 
narrower than the voxel width, only two voxels would be prescribed and would be 
designated as middle and posterior voxels. Alternatively if the posterior part of the 
defined region was narrower than the voxel width, two voxels designated anterior 
and middle would be prescribed. A second region of interest was defined in the 
lateral temporal lobe (LTL), also resulting in up to three voxels in anterior, middle 
and posterior LTL positions. This process allowed the selection of up to six voxels 
in each lobe that were in matched anatomical positions within each subject and 
between each group.  
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Figure 3.1.1A) Axial T1-weighted localising magnetic resonance imaging scans for: (I) a 
control subject and (II) a patient with left hippocampal sclerosis. In both figures the 
positions of the prescribed anterior (1); middle (2); and posterior (3) medial temporal lobe 
voxels are shown in the image on the right. The position of the prescribed posterior lateral 
temporal lobe voxel (4) is also shown. The prescribed PRESS volume of interest (VOI) is 
demonstrated in (I). The images on the left show the chemical shift imaging grid at 
acquisition prior to voxel repositioning using the locally developed software package, 
LCModel Interactive. 
 
Figure 3.1.1 B) Representative spectra (TE/TR 30/3000ms) are shown from each of the 
above numbered positions.  NAAt = N-acetyl aspartate plus N-acetyl aspartyl-glutamate; 
GLX = glutamate plus glutamine; Cho = choline containing compounds; Cr = creatine + 
phosphocreatine; Ins = myo-inositol.  
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LCModel was used to quantify the metabolite concentrations for GLX, Cho, Cr, Ins 
and NAAt as described in section 2.2.4.1. Data with full width half maximum 
(FWHM) >0.15 PPM were rejected, which occurred for only 3 of 213 spectra. 
LCModel reported for each metabolite a mean SD≤15% at every voxel position, 
which can be considered to indicate reliable determination. The metabolite 
concentrations were corrected for the cerebro spinal fluid (CSF) partial volume 
effect and for the PRESS excitation slice profile as described elsewhere (McLean et 
al., 2000).   
 
3.1.2.3 Statistics 
Data were tested for normality with Kolmogorov-Smirnov tests. The control group 
was investigated for evidence of left versus right temporal lobe asymmetry, using 
the following function: 
 
Asymmetry index (AI) = [(Right - Left)/((Right + Left)/2)]*100%     [Eqn. 3.1.1] 
 
which gave a mean range of between 0 and 11% difference between paired voxels 
 
A one-sample t-test was used to determine that there was no significant difference in 
AI values and zero mean; subsequently mean values of the paired right and left data 
points were used to calculate a normal range for each metabolite in each position. 
The normal range was defined as consisting of this control mean +/-3 standard 
deviations (SD). Individual patient data were compared against the normal range for 
each metabolite and ratio at each voxel position. 
 
Metabolite concentrations and ratios were individually compared along the MTL in 
each group using ANOVA and post hoc comparisons were performed using the 
Least Significant Difference (LSD) test. Similar comparisons were also made across 
the groups (Control, HS, MRIN) and sides (ipsilateral temporal lobe to seizure 
onset, contralateral temporal lobe) in the anterior, middle and posterior MTL voxel 
positions. Due to technical difficulties with data acquisition in the anterior and 
middle LTL regions, inter-group comparisons in the lateral temporal lobe were made 
only for the posterior LTL. 
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3.1.3 Results 
3.1.3.1 Subjects 
The three subject groups (Control, HS and MRIN) were similar in age and gender 
distributions. The handedness distribution of the three groups was similarly matched 
as follows; Control seven right and three left, HS eight right and two left and MRIN 
eight right and two left. No handedness asymmetry effects were identified in the 
control group using Mann-Whitney non-parametric testing, but the group sizes were 
too small for this to be a strong test. No significant differences were noted between 
the HS group and the MRIN group in terms of seizure frequency, lifetime total 
number of secondary generalised seizures or time since last seizure (Table 3.1.1). 
For all the patients with HS the affected side was concordant with the side of seizure 
onset. Six of 10 of the HS group went on to anterior temporal lobe resection. The 
diagnosis of HS was confirmed histologically in all of these cases. One of the MRI 
negative TLE subjects had bi-temporal interictal and ictal epileptiform activity. 
Anti-epileptic drug (AED) therapy was similar in the two patient groups.  
 
3.1.3.2 MRSI in individual patients 
Abnormality of a metabolite concentration was defined as a value more than 3 SD 
distant from the control mean of that variable. The most discriminatory metabolite 
concentration for detecting abnormality in individual patients was NAAt. 
 
3.1.3.2.1 MTL data 
In the defined MTL regions data were obtained from 168 voxels out of a possible 
180. In the HS group nine of 10 patients had abnormally low NAAt in at least one 
ipsilateral MTL voxel. In seven of 10 NAAt was abnormally low anteriorly, in four 
in the middle voxel and in one NAAt was low posteriorly. One patient had low 
NAAt in all 3 ipsilateral voxels. One patient had bilateral abnormalities in NAAt. 
There were no abnormally elevated values for NAAt in the anterior MTL, but one 
patient with ipsilateral anterior low NAAt had bilateral high NAAt in the posterior 
MTL voxels.  
 
In the MRIN group four patients had abnormalities ipsilateral to the epileptic focus. 
All four had low NAAt in the middle voxel and two of these also had low NAAt in 
the anterior voxel. One patient had bilateral low NAAt. One patient with left TLE  
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Table 3.1.1: Description of the three groups of subjects. The healthy volunteer group is 
designated as Control. HS represents the group of patients with temporal lobe epilepsy and 
hippocampal sclerosis; and MRIN represents the group with temporal lobe epilepsy and 
unremarkable conventional MRI. Each group has n=10. AED = anti-epileptic drug. 
 
 Control  HS  MRIN  
Gender male/female 5/5 4/6 4/6 
Age (yrs): median (range) 31 (23-36) 32 (24 – 53) 32 (23- 41) 
Duration of epilepsy (yrs): median 
(range) 
Not applicable 23 (11 – 35) 17 (3 – 22) 
Time since last seizure (days): median 
(range) 
Not applicable 3 (1 - 14) 5 (1 - 14) 
Frequency of complex partial seizures 
/ month: median (range) 
Not applicable 13 ( 2 –60) 15 (2 – 50) 
Secondarily generalised seizures Not applicable 5 6 
Past history of prolonged early 
childhood convulsion. 
0 5 0 
Family History of epilepsy 0 2 0 
Number of AEDs taken: Median 
(range) 
0 2 (2-3) 3 (1-4) 
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had normal NAAt in all the voxels on the left side, but a low NAAt in the middle 
voxel of the right MTL. 
 
Analysis of the other metabolites using this wide normal range showed no clear 
patterns of abnormality. Analysis of ratios of metabolites NAAt/Cr, 
NAAt/(Cr+Cho), NAAt/Ins did not yield any further information over analysis of 
the individual compounds. 
 
If all the MTL voxels were combined for each subject to form a mean value for each 
metabolite, two of 10 NAAt mean values in the HS group were abnormal 
ipsilaterally, with none abnormal bilaterally. In the MRIN group one of 10 was low 
ipsilateral to the epileptic focus and there was no contralateral abnormality. No 
abnormalities were noted with any of the other metabolites. 
 
3.1.3.2.2 Posterior Lateral Temporal Lobe 
Due to the constraints of avoiding artifact arising from the auditory canal, 
satisfactory data was obtained in 27 and 36 voxels from a potential 60 in the anterior 
and middle voxels of the lateral temporal lobe respectively. In the posterior LTL 56 
of the potential 60 were obtained. For this reason only data from the posterior LTL 
voxel was analysed. In this position one of the HS patients and one of the MRIN 
patients had low ipsilateral NAAt. There were no other significant individual 
metabolite or metabolite ratio abnormalities in this region in either the HS or the 
MRIN groups. 
 
3.1.3.3 MRSI Group Comparisons 
There was significant variation of CSF proportion along the MTL in all groups apart 
from the contralateral MRIN. The middle voxel contained the smallest proportion of 
CSF. Across the groups the CSF proportion was generally highest in the HS 
ipsilateral group, most notably in the middle voxels (p<0.01). The grey matter 
proportion was higher in the anterior hippocampal voxels in all the groups (p<0.01) 
and this did not vary significantly between groups (Table 3.1.2). As several of the 
metabolites may have a higher concentration in grey matter than white 
matter(Pouwels and Frahm, 1998;Noworolski et al., 1999;McLean et al., 2000)  each 
metabolite analysis using ANOVA was repeated by incorporating grey matter 
proportion as a co-variate. 
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3.1.3.3.1 Analysis along the MTL 
3.1.3.3.1.1 Control Group 
In the control group(McLean et al., 2001), concentrations of Cho, GLX and Ins were 
higher in the anterior hippocampal voxels (p<0.01, p<0.05, p<0.01 respectively). 
Cho was highest anteriorly (Fig 3.1.2a) and lowest in the posterior voxels. NAAt 
(Fig 3.1.2b) and Cr showed no significant variation. The ratios NAAt/(Cr+Cho), 
NAAt/Ins and NAAt/Cho were dominated by the changes in the concentrations of 
Ins and Cho and were lower anteriorly.  When grey matter content was incorporated 
as a co-variate, Cho, Ins, NAAt/Cho and NAAt/Ins still varied significantly 
(p<0.05), but for NAAt/(Cr+Cho) and GLX there was no longer significant 
variation. 
 
3.1.3.3.1.2 Patient Groups 
Similar patterns of variation to the control group were noted for NAAt/Cr (Fig 
3.1.2c), NAAt/(Cr+Cho) and Ins in the HS ipsilateral MTL. NAAt was non-
significantly lower in the anterior voxel. Cho and Cr were not elevated in the 
anterior voxel. GLX was higher anteriorly (Fig 3.1.2d). Using grey matter as a co-
variate, there was no longer significant metabolite variation. In the contralateral 
MTL a trend for relative reduction in anterior Cr and Cho was observed but was less 
marked than on the ipsilateral side. There was no significant metabolite variation 
along the MTL contralateral to HS when grey matter was used as a co-variate. 
 
In the MRIN ipsilateral MTL GLX, Cr, Cho, and Ins followed the pattern of 
variation noted in the control group. Cr, NAAt/Cr and NAAt/(Cr+Cho) all varied 
significantly in this group and the effect remained after the inclusion of grey matter 
as a co-variate (p<0.05), all a consequence of low Cr values in the middle voxel.  
 
In the MRIN contralateral MTL GLX was more elevated in the anterior voxel than 
was observed for the other groups (figure 3.1.2d). This variation of GLX along the 
MRIN contralateral MTL remained significant (p<0.01) despite correction for grey 
matter. For the other values the pattern of change mirrored that of the control group, 
with Cho higher anteriorly (p<0.01).  
 
 
 
P a g e  | 155 
 
3.1.3.4 Analysis between subject groups 
There was no significant variation of grey matter proportion between the groups in 
any position. NAAt varied significantly in the anterior MTL position (Fig 3.1.2b, 
Table 3.1.2) (p<0.05). This was due to a lower mean value in the HS ipsilateral side 
compared with all other groups apart from the MRIN ipsilateral group. Anterior 
MTL NAAt values in MRIN ipsilateral were not significantly different from 
contralaterals and controls. Cr and Cho were lower in HS ipsilateral than all groups 
(p<0.05) apart from HS contralateral, and were lower in HS contralateral MTL than 
the control values (p<0.05). These effects remained after grey matter was 
incorporated as a co-variate. NAAt/Cr and NAAt/Cho were higher in HS 
contralateral MTL anterior voxels (p<0.01 and p<0.05) than in the anterior voxels of 
any other groups. No significant variation was noted across the middle and posterior 
MTL or the posterior LTL voxels. 
 
The mean MTL NAAt was lower in HS ipsilateral than HS contralateral (p<0.05) 
but not significantly lower than the control population and Cho in the HS ipsilateral 
group was lower than the control group (p<0.05). 
 
3.1.3.5 Comparison of the posterior MTL and the posterior LTL 
For all groups the grey matter proportion was higher in the MTL; Cr was lower and 
NAAt/Cr was higher (p<0.05) in the posterior LTL. In the control group (p<0.01) 
and in both the temporal lobes of the MRIN group (p<0.05), GLX was higher in the 
MTL. This effect was not seen in the HS groups. In the MRIN group NAAt was 
lower in the posterior LTL on the side ipsilateral to the seizure focus (p<0.05).  
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Table 3.1.2: Metabolite concentrations and ratios in medial temporal (MTL) and 
posterior lateral temporal (LTL) lobe voxels, expressed as the group mean and standard 
deviation. The healthy volunteer group is designated as Control. HSips refers to the 
temporal lobe ipsilateral to the side of pathology and seizure onset. HScont refers to the 
contralateral temporal lobe. MRIN refers to the MRI negative group and again ips and cont 
refer to the sides ipsilateral and contralateral to the sides of seizure onset respectively. NAAt 
= N-acetyl aspartate plus N-acetyl aspartyl-glutamate; GLX = glutamate plus glutamine; Cr 
= creatine plus phosphocreatine; Cho = choline containing compounds; Ins = myo-inositol. 
Mean values and SD are provided for each measurement. 
 
 
ANTERIOR MTL Control 
N=9 
HSips 
N=10 
HScont 
N=9 
MRINips 
N=9 
MRINcont 
N=9 
Grey Proportion  0.90(0.07) 0.88(0.06) 0.88(0.06) 0.87(0.08) 0.91(0.03) 
 NAAt 7.8(0.48) 6.4(0.93) 7.6(1.3) 7.1(1.2) 7.7(0.92) 
Metabolites GLX 13.0(2.6) 13.0(3.3) 13.0(2.5) 13.0(1.2) 15.0(1.9) 
(mmol/l) Cho 1.8(0.18) 1.4(0.21) 1.5(0.25) 1.7(0.46) 1.8(0.39) 
 Cr 6.3(0.71) 5.1(0.69) 5.4(1.1) 6.3(1.4) 6.2(0.76) 
 Ins 6.8(0.81) 6.4(1.6) 5.7(1.1) 6.6(2.3) 6.6(2.1) 
 NAAt/Cr 1.2(0.10) 1.3(0.18) 1.4(0.17) 1.2(0.13) 1.3(0.17) 
Metabolite ratios NAAt/(Cr+Cho) 0.96(0.07) 0.98(0.12) 1.1(0.12) 0.90(0.11) 0.99(0.14) 
 NAAt/Ins 1.2(0.15) 1.1(0.34) 1.4(0.25) 1.1(0.25) 1.3(0.31) 
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Table 3.1.2: continued 
MIDDLE MTL Control 
N=10 
HSips 
N=10 
HScont 
N=10 
MRINips 
N=10 
MRINcont 
N=10 
Grey Proportion 0.72(0.10) 0.74(0.07) 0.72(0.10) 0.72(0.10) 0.72(0.11) 
 NAAt 7.9(0.24) 7.4(0.92) 8.0(0.45) 7.6(0.77) 8.0(0.90) 
Metabolites 
GLX 10.0(1.2) 11.0(1.7) 9.7(1.8) 9.4(3.1) 10.0(0.91) 
(mmol/l) Cho 1.5(0.16) 1.3(0.18) 1.4(0.18) 1.4(0.22) 1.5(0.19) 
 Cr 5.8(0.46) 5.6(0.85) 5.7(0.53) 5.3(0.70) 5.6(0.95) 
 Ins 5.1(0.66) 4.7(0.81) 4.6(0.56) 4.5(1.42) 4.3(0.90) 
 NAAt/Cr 1.4(0.13) 1.4(0.19) 1.4(0.12) 1.5(0.22) 1.5(0.14) 
Metabolite 
ratios 
NAAt/(Cr+Cho) 1.1(0.10) 1.1(0.14) 1.1(0.08) 1.2(0.17) 1.2(0.10) 
 NAAt/Ins 1.6(0.23) 1.6(0.29) 1.7(0.24) 2.0(0.97) 1.9(0.50) 
 
POSTERIOR MTL Control 
N=9 
HSips 
N=9 
HScont 
N=8 
MRINips 
N=9 
MRINcont 
N=10 
Grey Proportion 
0.76(0.10) 0.77(0.10) 0.75(0.09) 0.79(0.06) 0.68(0.18) 
 NAAt 8.3(1.1) 7.7(1.8) 8.3(2.3) 8.6(1.8) 8.2(1.0) 
Metabolites 
GLX 12.0(1.4) 9.2(2.0) 10.0(2.3) 11.0(2.3) 11.0(2.1) 
(mmol/l) Cho 1.4(0.10) 1.2(0.44) 1.3(0.28) 1.4(0.30) 1.2(0.14) 
 Cr 6.4(0.84) 5.9(1.4) 6.4(1.4) 7.0(0.90) 6.0(1.0) 
 Ins 5.4(0.59) 4.7(1.03) 5.1(0.54) 4.7(1.5) 4.3(1.2) 
 NAAt/Cr 1.3(0.12) 1.3(0.16) 1.3(0.10) 1.2(0.13) 1.4(0.24) 
Metabolite 
ratios 
NAAt/(Cr+Cho) 1.1(0.09) 1.1(0.13) 1.1(0.10) 1.0(0.10) 1.1(0.18) 
 NAAt/Ins 1.5(0.22) 1.8(0.88) 1.6(0.33) 2.1(1.1) 2.0(0.54) 
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Table 3.1.2: continued 
 
Mean MTL Control 
N=8 
HSips 
N=9 
HScont 
N=8 
MRINipsi 
N=8 
MRINcont 
N=9 
Grey Proportion 0.78(0.08) 0.80(0.06) 0.79(0.07) 0.80(0.05) 0.76(0.10) 
 NAAt 8.0(0.42) 7.2(1.1) 8.1(1.0) 7.8(1.0) 7.9(0.66) 
Metabolites 
GLX 12.0(1.2) 11.0(1.5) 11.0(1.2) 11.0(1.4) 12.0(0.73) 
(mmol/l) Cho 1.5(0.10) 1.3(0.2) 1.5(0.18) 1.5(0.22) 1.5(0.19) 
 Creat 6.1(0.43) 5.6(0.82) 5.9(0.77) 6.2(0.72) 6.0(0.66) 
 Ins 5.8(0.52) 5.4(0.47) 5.3(0.28) 5.5(1.1) 5.2(1.0) 
 NAAt/Cr 1.3(0.08) 1.3(0.11) 1.4(0.08) 1.3(0.08) 1.3(0.14) 
Metabolite 
ratios 
NAAt/(Cr+Cho) 1.0(0.07) 1.0(0.09) 1.1(0.06) 1.0(0.06) 1.1(0.11) 
 NAAt/Ins 1.4(0.15) 1.3(0.20) 1.5(0.17) 1.4(0.19) 1.6(0.31) 
 
POSTERIOR LTL Control 
N=9 
HSips 
N=9 
HScont 
N=7 
MRINips 
N=10 
MRINcont 
N=10 
Grey Proportion 0.26(0.13) 0.32(0.18) 0.18(0.04) 0.28(0.08) 0.24(0.07) 
 NAAt 8.0(0.71) 7.5(1.3) 8.4(1.5) 7.4(1.1) 7.2(1.2) 
Metabolites 
GLX 9.0(1.2) 8.4(1.9) 9.1(4.0) 9.4(2.8) 8.4(1.8) 
(mmol/l) Cho 1.3(0.21) 1.3(0.28) 1.2(0.33) 1.4(0.31) 1.3(0.29) 
 Cr 4.4(0.66) 4.6(1.1) 5.3(1.5) 4.3(0.91) 4.5(0.79) 
 Ins 4.8(0.58) 4.3(1.2) 4.0(1.3) 4.1(1.0) 3.8(1.3) 
 NAAt/Cr 1.8(0.20) 1.6(0.25) 1.6(0.21) 1.8(0.37) 1.6(0.21) 
Metabolite 
ratios 
NAAt/(Cr+Cho) 1.4(0.14) 1.3(0.14) 1.3(0.17) 1.3(0.26) 2.1(0.71) 
 NAAt/Ins 1.7(0.27) 1.7(0.30) 2.3(0.63) 1.9(0.67) 1.3(0.16) 
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Figure 3.1.2: Plots of mean and 95% confidence intervals for: (a) choline containing 
compounds (Cho); (b) N-acetyl aspartate plus N-acetyl aspartyl-glutamate (NAAt); (c) the 
ratio NAAt / Creatine (NAAt/Cr) and (d) glutamate plus glutamine (GLX). Metabolites were 
estimated in the anterior, middle and posterior MTL, in control subjects, patients with 
hippocampal sclerosis (HS) and temporal lobe epilepsy, and patients with temporal lobe 
epilepsy and normal magnetic resonance imaging (MRIN). Ips = MTL ipsilateral to HS and/or 
seizure onset. Cont = MTL contralateral to the side of HS and/or seizure onset. 
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3.1.4 Discussion  
At the time of publication this was the first study to report short TE MRSI measured 
concentrations of NAAt, Cr, Cho, GLX, and Ins through the MTL and the posterior 
LTL in patients with TLE. The study indicated that NAAt is a marker for abnormality 
in both HS and MRIN and found that Cr and Cho concentrations follow the NAAt 
changes in the anterior hippocampi in HS. The concentration of several metabolites 
varied significantly through the MTL and lateral neocortex and interpretation must 
take the grey/white composition and partial volume effects into account.  
 
3.1.4.1 Methodology 
MRSI has been considered to be more difficult in the temporal lobe than single voxel 
spectroscopy, because the anterior hippocampus, where most pathology has been 
observed in HS(Woermann et al., 1998a), may be less accessible to MRSI studies. 
Part of this reasoning was based on results obtained by prescription of a single region 
of interest that included both temporal lobes and resulted in poor field homogeneity in 
the anterior temporal lobe(Xue et al., 1997;McLean et al., 2001). This is generally 
resolved by studying each temporal lobe separately with smaller regions of interest 
localised to the relevant temporal lobe, and also by ensuring that the plane of the 
MRSI grid is aligned along the long axis of the hippocampus, the anterior MTL is 
accessible to MRSI(McLean et al., 2001). However, using this technique, quantitative 
information from the anterior lateral temporal lobe remained inaccessible although 
other MRS studies have shown that metabolite abnormalities might be observed 
here(Meiners et al., 2000).  
The small size of the hippocampus together with the point spread function of 
spectroscopic imaging data means that it is currently not feasible to exclusively 
analyse hippocampal tissue using MRSI on standard 1.5T clinical scanners. In this 
study the term Medial Temporal Lobe (MTL) was used to indicate that the voxels do 
not only contain hippocampal tissue, although they can be considered to be 
predominantly hippocampal tissue particularly in the anterior and middle positions. 
The method of voxel analysis(McLean et al., 2001) allowed spectra to be analysed 
from similar anatomical positions for each group. In common with reports from other 
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groups this study identified that most metabolite concentrations were higher in neo-
cortical grey matter than white matter(Doyle et al., 1995;Pouwels and Frahm, 
1998;Noworolski et al., 1999;McLean et al., 2000).  
CSF proportion was highest in the ipsilateral HS group, reflecting the atrophy in this 
group. CSF is believed to return negligible metabolite signal(Lynch et al., 1993). 
Consequently without the CSF correction, metabolite concentrations, particularly in 
the HS ipsilateral group, would be under-estimated, leading to an over interpretation 
of abnormalities. Correction was also made for potential error due to imperfections in 
the PRESS slice excitation profile, magnetic field inhomogeneity and chemical shift 
artifact at the periphery of the PRESS region of interest(McLean et al., 2000). These 
corrections resulted in Coefficient of Variation (CV) values of mean 13% and range 
6-22%, for the five metabolites in the control group across all 4 voxels. These values 
compare satisfactorily with the CV data that were previously obtained from a 
hippocampal single voxel study(Woermann et al., 1999c) and hence indicate a similar 
reproducibility to that study. The values are also similar to data for voxels outside the 
temporal lobe(McLean et al., 2000). 
 
3.1.4.2 Findings in individual patients 
In agreement with most other studies reduction of NAAt was observed in the region 
of the sclerotic hippocampi(Hugg et al., 1993;Ende et al., 1997;Woermann et al., 
1999c). Bilateral reduction in NAAt was only observed in 1 HS patient. Several 
previous studies have reported bilateral abnormalities in 20-54% of subjects(Connelly 
et al., 1994;Cross et al., 1996;Achten et al., 1997;Cendes et al., 1997b;Woermann et 
al., 1999c). This variation is partly explained by different definitions of metabolite 
abnormality. As described above, most groups have discussed changes in metabolite 
ratios (NAA/Cr, NAA/(Cr +Cho), NAA/Cho) in preference to individual metabolite 
concentrations or have identified abnormality as the presence of significant ipsilateral 
- contralateral asymmetry(Achten et al., 1997;Cendes et al., 1997b). Other groups 
used the individual metabolite concentrations and/or ratios but differed in definition of 
the normal range as control mean +/- 2 SD(Ng et al., 1994;Hetherington et al., 
1995a;Cross et al., 1996). The previous single voxel study undertaken by the NSE 
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MRS group identified that three of 15 patients with HS and unilateral TLE had 
bilateral hippocampal NAA lower than 2.5SD of the control mean(Woermann et al., 
1999c). 
In the MRIN group four of 10 had low MTL NAAt on the side of seizure onset, and 
bilateral reductions were found in one of these. These results are consistent with other 
reports of the frequency of abnormality in the absence of MRI abnormality(Connelly 
et al., 1998;Woermann et al., 1999c). This compares to the findings in the Single 
voxel study of four of 15 TLE patients with low NAAt and with normal 
MRI(Woermann et al., 1999c).  
The pathophysiological explanation for the observed bilateral metabolite changes in 
TLE patients with normal MR imaging or unilateral MR abnormality remains a 
subject of discussion. There is evidence from some authors that NAAt levels do 
correlate with absolute cell loss in hippocampal sub-fields(Vielhaber et al., 
2008;Hammen et al., 2008) whilst others have found no association between neuronal 
cell counts and NAA(Petroff et al., 2002b). Low NAAt may represent functional 
change and / or subtle neuronal loss. Bilateral MRS abnormality may be observed in 
subjects with either unilateral MRI abnormality(Woermann et al., 1999c) or normal 
MRI(Connelly et al., 1998;Woermann et al., 1999c) (Connelly et al., 1998;Riederer et 
al., 2006), and is seen with higher incidence than bilateral EEG abnormality(Maton et 
al., 2001a). In the current study conventional investigation suggested bilateral 
abnormality in only one subject in the MRIN group (bilateral inter-ictal EEG 
abnormality). MRSI investigation of this subject revealed low NAAt in the middle 
MTL region contralateral to the side of seizure onset.   
The current study also provided information about the location of maximal metabolite 
abnormality. In the HS group, low NAAt was most commonly found in the anterior 
voxel. In contrast, in the MRIN group the middle voxel was most commonly 
abnormal. This suggests that studies that concentrate on the anterior position of the 
MTL may miss abnormalities in the middle or posterior MTL. 
In this current study six subjects (one subject with HS, and five subjects with MRI 
negative TLE), were included who had previously participated in the single voxel 
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study reported by our group(Woermann et al., 1999c). For the subject with HS, the 
single voxel study identified ipsilateral reduction in NAAt. In the current MRSI study 
bilateral anterior hippocampal reduction in NAAt was observed. For the five MRI 
negative subjects, two previously showed unilateral and ipsilateral NAAt reduction. In 
the current study both showed ipsilateral reduction in the anterior and middle 
hippocampal voxels. Of the remaining three overlapping subjects, despite normal 
single voxel spectroscopy, one showed reduction in NAAt in the middle hippocampal 
region ipsilateral to the seizure focus and one was contralateral. Although these 
numbers are small there is an indication that the multi-voxel study was more sensitive 
for abnormality and provided spatial information about the position of the region of 
maximal abnormality. 
3.1.4.3 Group comparisons 
Variation was observed within both the control and TLE patient MTL and also across 
these groups in the anterior MTL voxel. Several metabolites co-varied with grey 
matter content.  
 
In the control group Cho concentrations were higher in the anterior MTL. Cr was non-
significantly lower in the middle voxel and NAAt did not vary significantly. This 
resulted in lower NAAt/(Cr+Cho) anteriorly and higher NAAt/Cr in the middle voxel. 
GLX and Ins were higher in the anterior voxel. These effects were reduced by the 
incorporation of grey matter proportion as a co-variate, such that NAAt/(Cr+Cho) and 
GLX no longer varied significantly. Other workers have considered metabolite 
variation in the control temporal lobe. Vermathen et al(Vermathen et al., 2000) used 
MRSI at TE=135ms, and found lower NAA/(Cr+Cho) and higher Cho in the anterior 
control MTL although no correction for grey matter proportion was made. Another 
group has described lower NAA/Cr in the hippocampus than the lateral temporal 
lobe(Wang et al., 2008). Lower NAAt/Cr was also seen in the posterior MTL than in 
the posterior LTL in all the groups, due to a lower Cr in the lateral voxel, without 
significant variation in NAAt or Cho. This is consistent with a study of metabolite 
concentration in grey and white matter in voxels outside the temporal lobe, at the 
same short echo time (TE=30ms)(McLean et al., 2000). In this study the ratio of Cr 
concentrations in grey versus white matter was 1.7, compared with 1.16 for NAAt and 
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0.9 for Cho. This implies that Cr concentration will be most altered by a reduction in 
the proportion of grey matter. The concentration of Ins and GLX were lower in the 
posterior LTL than the posterior MTL in the control group. This would also be in 
keeping with the observed metabolite ratios for GLX and Ins between grey and white 
matter of 2.4 and 1.6 respectively(McLean et al., 2000) implying that there would be 
lower concentrations in regions with lower proportions of grey matter.  
 
In the HS group the anterior ipsilateral voxel showed reduced NAAt, but also low Cr 
and Cho (Figure 3.1.2). Other studies have similarly reported reduction in both NAA 
and Cr in the sclerotic hippocampus(Ende et al., 1997;Duc et al., 1998) and a 
histological examination in an animal model of temporal lobe epilepsy(Tokumitsu et 
al., 1997) identified reduced NAA and Cr in the presence of neuronal loss and gliosis. 
The single voxel study(Woermann et al., 1999c) did not identify significant group 
effects for Cr or Cho but averaged the entire hippocampus, which could have masked 
changes confined to the anterior region. It has been held that in the sclerotic anterior 
hippocampus there is loss of neuronal tissue with consequent loss of NAAt, because 
of the localisation of NAA in neurones(Urenjak et al., 1993), and reactive gliosis, with 
consequent increase in Cr and Cho. This understanding was largely based on single 
voxel studies or MRSI at longer TE. The finding that all three metabolites were 
decreased in this region might indicate that Cr and Cho are sufficiently present in 
neurones to also be affected by the presumed process of neuronal 
loss/dysfunction(Urenjak et al., 1993). 
 
In agreement with the above trends for NAAt, Cr and Cho the ratios NAAt/Cr and 
NAAt/(Cr+Cho) were unhelpful in identifying abnormality in the TLE groups. This 
concurs with the findings of the single voxel study(Woermann et al., 1999c). Other 
groups, however, and usually with longer TE, have found these ratios to be 
sensitive(Cendes et al., 1994;Vermathen et al., 1997;Achten et al., 1997). The reason 
for this difference in findings is not established but these studies were in general 
performed with different acquisition parameters and utilise different descriptions of 
abnormality. At short TE there is improved signal to noise which might make 
quantification more reliable, and although the baseline at short TE is more variable 
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there are established spectral peak fitting programmes that produce reliable and 
repeatable estimates of metabolite concentration. It is also possible that metabolite T2 
might be altered in pathological tissue (e.g. hippocampal sclerosis), in which event 
those studies performed at longer TE would be more likely to introduce metabolite 
measurement error.   
 
The single voxel study identified elevated GLX in the mesial temporal lobe ipsilateral 
to seizure onset in the MRIN group.  In the current study ipsilateral elevation was not 
found but elevation of GLX in the anterior voxel of the MRIN contralateral group was 
observed. It is of interest that both studies identified elevated GLX in patients with 
TLE and normal MR imaging. However several factors limit the interpretation of 
these findings. Firstly GLX represents a signal complex of glutamate plus glutamine 
and it is not currently possible to determine whether elevation in GLX represents 
change in glutamate, in glutamine or in both metabolites. Also GLX is measured less 
reliably than NAAt and in these two studies the number of subjects is relatively small. 
Furthermore the two studies measured GLX in different volumes (total hippocampal 
GLX versus anterior MTL GLX in the current study) with a very limited number of 
subjects participating in both studies.  
 
In the MRIN ipsilateral group NAAt was significantly lower in the posterior LTL than 
in the posterior MTL. This finding might indicate involvement of lateral neo-cortex in 
a pathological process in this group and agrees with a previous MRS study of 
similarly selected subjects which identified extensive metabolite abnormality in the 
temporal lobe ipsilateral to seizure onset compared to healthy controls(Connelly et al., 
1998).   
 
In this study no relationship between NAAt and seizure frequency, total lifetime 
secondary generalised seizures, or time since last seizure was noted. This is consistent 
with the single voxel findings(Woermann et al., 1999c) and also with a longitudinal 
study, which did not observe change in the ratio NAA/Cr in patients who had become 
seizure free on anti-epileptic drug therapy(Li et al., 2000c). Another study(Maton et 
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al., 2001b) identified no consistent changes in metabolite peak ratios between the 
inter-ictal and post-ictal state in TLE. 
 
MRSI has a demonstrated role in the study of subjects with epilepsy. The ideal study 
would provide a full metabolite profile as well as spatial information. This current 
short TE work is the first MRSI study to quantify Ins and GLX as well as NAA, Cho 
and Cr at different positions along the MTL and the lateral temporal lobe, in the 
normal temporal lobe and also in subjects with temporal lobe epilepsy. The study 
identifies how the obtained concentrations are influenced separately by variation in 
voxel position and tissue composition and show how such variability might limit the 
interpretation of metabolite ratios. 
 
3.1.5 Conclusion 
The study indicates that low NAAt is a marker for abnormality in HS and MRIN TLE, 
but the location of maximal abnormality appears to be different, with maximal 
abnormality in the anterior region in HS and in the middle MTL region in MRIN 
TLE. Low Cr and Cho were also a feature of the anterior sclerotic hippocampus. 
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3.2 A Proton Magnetic Resonance Spectroscopy Study of Metabolites in the 
Occipital lobes in Epilepsy. 
 
ABSTRACT: 
Purpose: 
Gamma amino butyric acid (GABA) and glutamate, respectively the principal 
inhibitory and excitatory neurochemicals in the brain, are visible to proton Magnetic 
Resonance Spectroscopy (MRS). In this study GABA+ (GABA plus homocarnosine) 
and GLX (glutamate plus glutamine) concentrations were measured in the occipital 
lobes in patients with idiopathic generalised epilepsy (IGE) and in patients with 
occipital lobe epilepsy (OLE). 
 
Methods: 
Fifteen patients with IGE, 15 patients with OLE and 15 healthy volunteers were 
studied. A single voxel was prescribed in the occipital lobes for each subject. PRESS 
localised short echo time MRS was performed to measure GLX using LCModel. A 
double quantum GABA filter was used to measure GABA+.  Segmented T1 weighted 
images gave the tissue composition of the prescribed voxel. 
 
Results: 
Grey matter proportion, GLX and GABA+ were all elevated in IGE. However, 
analysis using grey matter proportion as a co-variable showed no significant group 
differences. No correlation was observed between GABA+ concentration and either 
seizure frequency or time since last seizure.  
 
Conclusions: 
GLX and GABA+ were elevated in IGE. Elevated grey matter content in the IGE 
group despite normal MRI appearance can be expected to account for some or all of 
this observed elevation of GLX and GABA+. GABA+ concentration did not correlate 
with seizure control or duration since most recent seizure. 
 
Published ref: Simister et al., Epilepsia, 2003 44,550–558
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3.2.1 Introduction 
 
Proton Magnetic Resonance Spectroscopy (MRS) enables non-invasive in-vivo 
estimation of brain metabolites relevant to the study of epilepsy. Most MRS studies 
have typically measured abnormality in the three main visible metabolites; NAA, Cr, 
Cho expressed as simple ratios, or with careful calibration, as concentrations. Recent 
methodological advances also allow detection of neurochemicals, such as glutamate 
plus glutamine (GLX)(Woermann et al., 1999c) (McLean et al., 2000;Woermann et 
al., 2001b;Simister et al., 2002)and GABA(Petroff et al., 1996a;Petroff et al., 
1996b;Petroff et al., 1998;Mescher et al., 1998;Petroff et al., 2000;Petroff et al., 
2001a;Petroff et al., 2001b;Mueller et al., 2001b) that are of fundamental importance 
in the pathophysiology of seizure disorders. 
 
Glutamate is the principal excitatory neuro-transmitter in the mammalian brain. 
Elevated in-vitro glutamate concentrations have been identified in epileptic 
tissue(Sherwin et al., 1988;Petroff et al., 1995) whilst in-vivo micro-dialysis studies 
have shown an increase in extra-cellular glutamate concentration following seizure 
onset in the epileptogenic temporal lobes of patients with refractory temporal lobe 
epilepsy (TLE)(During and Spencer, 1993). Glutamate metabolism is tightly coupled 
with the metabolism of glutamine. Glutamate released from the glutamatergic nerve 
terminal into the synaptic cleft is taken up by surrounding glial cells and converted to 
glutamine by glutamine synthetase (an enzyme exclusively localised to the glial 
cell(Martinez-Hernandez et al., 1977)). Glutamine is subsequently released from the 
glial cells into the extracellular fluid where it is taken up by neurons. Here it is re-
converted into glutamate by the action of phosphate activated glutaminase(Kvamme, 
1998). Although direct quantification of glutamate is not yet reliable via proton MRS 
on clinical scanners, the complex signal GLX (glutamate plus glutamine) is quantified 
at short echo times(Woermann et al., 1999c;McLean et al., 2000) with repeatability 
measures approaching those obtained for the main visible metabolites(Woermann et 
al., 1999c). GLX may be elevated in regions of seizure onset(Woermann et al., 
1999c). 
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GABA is the major inhibitory neurotransmitter in the human brain. Decreases in 
GABA inhibition may cause seizures(Olsen and Avoli, 1997) whereas several potent 
anti-epileptic drugs (AED) such as topiramate, gabapentin and vigabatrin are thought 
to work by enhancement of GABA synthesis or function. Low occipital lobe GABA 
has been found in patients with partial epilepsy of extra-occipital seizure onset(Petroff 
et al., 1996b;Petroff et al., 1999a;Petroff et al., 2000) and in these studies is lowest in 
subjects with poor seizure control(Petroff et al., 1996b). Low occipital GABA is 
found in subjects with JME(Petroff et al., 2001a). Elevation in observed GABA 
concentrations is observed following the administration of several AEDs known to 
modify GABA metabolism or function(Petroff et al., 1996a;Petroff et al., 
1998;Kuzniecky et al., 1998a;Petroff et al., 2000;Mueller et al., 2001b). Levels of 
GABA and homocarnosine, a dipeptide metabolite of GABA and histidine, have been 
positively correlated with seizure control(Petroff et al., 2001a). 
 
The majority of previous GABA MRS studies have been performed on the occipital 
lobe in patients with extra-occipital lobe focal epilepsy or in one study JME. The 
purpose of this current study was to compare the metabolite profiles in the occipital 
lobes of 15 patients with idiopathic generalised epilepsy (IGE), 15 patients with 
occipital lobe epilepsy (OLE) and 15 healthy volunteers. 
  
3.2.2 Methods 
3.2.2.1 Subjects 
15 control subjects and 30 patients with chronic epilepsy were investigated after 
giving informed consent. This study was approved by the Joint Research Ethics 
Committee of the National Hospital for Neurology and Neurosurgery. 15 patients had 
a diagnosis of idiopathic generalised epilepsy (IGE). All fifteen had normal MRI on 
visual inspection. Thirteen of the 15 had photo-paroxysmal responses on current 
electro-encephalogram (EEG). Seven of the 15 had IGE syndromes that were sub-
classifiable as follows; Juvenile Myoclonic Epilepsy (three), Juvenile Absence 
Epilepsy (two), Eyelid Myoclonia with Absences (one), Generalised Tonic Clonic 
Seizures on Awakening (one). In the remaining eight patients sub-syndrome 
classification was not possible. Fifteen patients had occipital lobe epilepsy (OLE). 
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Fourteen of this group had normal MRI. The fifteenth had a porencephalic cyst in the 
right fronto-parietal region and normal occipital lobe appearance. In all patients the 
diagnosis was based upon full clinical assessment, interictal +/- ictal scalp EEG, 
neuropsychometry and MRI. Vigabatrin, topiramate and gabapentin, are reported to 
elevate in vivo GABA levels(Petroff et al., 1996a;Kuzniecky et al., 1998a;Petroff et 
al., 2000). Only three patients were taking one of these medications. The medications 
taken by the IGE group were as follows; valproate (six), lamotrigine (five), 
carbamazepine (two), topiramate (two), clobazam (one), acetazolamide (one). Five 
patients were taking no regular medications. For the OLE group the medications were: 
carbamazepine (six); lamotrigine (five); clobazam (two), oxcarbazepine (one), 
phenytoin (one), gabapentin (one), phenobarbitone (one) and valproate (one). One 
patient in the OLE group was taking no regular medications. Seizure frequency and 
the duration in days since the most recent seizure were noted. In the OLE group only 
those seizures leading to altered level of consciousness were recorded. In the IGE 
group patients recorded seizure frequency and duration since most recent generalised 
tonic clonic convulsive seizure. A history of absence seizures was also recorded 
although this was expected to be less reliably assessed by the subject. 
 
3.2.2.2 Magnetic Resonance Imaging   
The study was performed on a 1.5T General Electric SIGNA Horizon Echospeed 
scanner (Milwaukee, WI) using a standard quadrature head coil for all MRI/MRS 
studies. Axial T1 weighted inversion-recovery prepared fast spoiled gradient recalled 
echo (IRP-FSPGR) images were acquired (TE/TI/TR = 4.2/450/16 ms, flip angle 20
0
; 
matrix 256*128; slice thickness 1.5mm). These images were used both to guide voxel 
placement and subsequently for segmentation using SPM99 (Statistical Parametric 
Mapping; Wellcome Department of Imaging Neuroscience, Institute of Neurology, 
University College London). All the MRI studies were reviewed by two experienced 
neuro-radiologists. 
 
Locally written software in SAGE 7.0 (General Electric, Milwaukee WI) provided 
estimates for the resulting grey matter, white matter and cerebro-spinal fluid (CSF) 
tissue composition of the prescribed MRS volume of interest based on the SPM 
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segmentations. Metabolite concentrations were then corrected for CSF content, which 
is considered to provide negligible signal(Lynch et al., 1993). Since most of the 
observed metabolites have higher concentration in grey matter than white matter 
voxel grey matter fraction was used as a co-variable in inter-group statistical 
comparisons. 
 
3.2.2.3 Magnetic Resonance Spectroscopy  
3.2.2.3.1 Acquisition 
A single voxel was prescribed in the occipital lobe of each subject with approximate 
dimensions 35 by 40 mm in the Anterior-Posterior and Left-Right directions 
respectively and thickness 25mm. (Fig 3.2.1) Conventional PRESS-localised spectra 
were obtained initially with the acquisition parameters (TE/TR = 30/3000 ms) 
matching our previous studies(Woermann et al., 1999c;McLean et al., 2000;McLean 
et al., 2001), so that LCModel(Provencher, 2001) could be used for quantification of 
NAAt, Cr, Cho, myo-inositol (Ins) and GLX.  NAAt is the combined peak of N-acetyl 
aspartate and N-acetyl aspartyl-glutamate. Ins is considered to be localised to glial 
cells(Brand et al., 1993).  Sixteen averages were performed.  
 
Next the double quantum filter (DQF) sequence was applied to the same PRESS-
localised volume(McLean et al., 2002).  For the first acquisition the filter was not 
activated (i.e. normal PRESS, TE/TR = 68/2000 ms), and spectra were acquired with 
and without applied CHESS water suppression gradients (scan time c. 1 minute each). 
Subsequently the filter was activated and 512 averages collected (scan time 17:12) to 
measure GABA+. 
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Figure 3.2.1:A) Axial T1-weighted localising magnetic resonance imaging scan showing the 
position of the prescribed occipital lobe voxel. B) A representative PRESS localised spectrum 
(TE/TR 30/3000ms) with superimposed LCModel fit to metabolite concentrations and 
estimated baseline, and C) a filtered GABA spectrum (TE/TR 68/2000 ms) from the occipital 
voxel of a control volunteer are shown below.  NAAt = N-acetyl aspartate plus N-acetyl 
aspartyl-glutamate; GLX = glutamate plus glutamine; Cho = choline containing compounds; 
Cr = creatine + phosphocreatine; Ins = myo-inositol; GABA+ = gamma amino butyric acid 
plus homocarnosine. PPM = chemical shift in parts per million. 
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3.2.2.3.2 Spectral Processing 
The conventional PRESS localised water suppressed spectra (TE/TR = 30 / 3000 ms) 
were analysed using LCModel. The spectra obtained from the unfiltered DQF 
sequence (TE/TR = 68 / 2000 ms) were also analysed via LCModel in order to 
provide a consistent fit to the small baseline still present at this echo time. The 
LCModel Cr concentration was then converted to a peak area by multiplication with a 
conversion factor derived from phantom studies. The GABA+ concentration was then 
obtained according to equation [Eqn. 2.4.1] as described on page 138. 
 
(Fig 3.2.1) includes a typical DQF spectrum and shows a well resolved GABA+ peak 
with minimal baseline. This allowed for reliable manual integration of the GABA+ 
peak. Poor quality data was rejected by setting a threshold of 4.5 for the signal to 
noise ratio (SNR) of the filtered signal (signal taken as the peak height between 3.5 to 
2.5 PPM and noise 15 to 20 PPM). 
3.2.2.3.3 Statistical Analysis 
Statistical analysis was performed with SPSS 9.0. Metabolite concentrations and 
ratios were individually compared using ANOVA and post hoc comparisons were 
made using the Least Significant Difference Test (LSD). 
 
3.2.3 Results 
3.2.3.1 Subjects 
The three subject groups (Control, IGE and OLE) were similar in age and gender 
distribution (Table 3.2.1). Individual metabolites were correlated against age for each 
group. No metabolite or metabolite ratio correlated with age or gender for any group. 
The two patient groups were acceptably matched for seizure control. 
 
The control group was scanned on two occasions and test-retest repeatability scores 
obtained. The repeatability scores for the individual metabolites were as follows; 
NAAt 16%, Cr 11%, Cho 20%, Ins 18%, GLX 26% and GABA+ 38%. The 
repeatability measure for the obtained grey matter content was 14%. Repeatability 
measures are defined as(Bland JM and Altman DG, 1986); 
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[2*SD(scan1 – scan2)/mean (scan1,scan2)]*100%       [Eqn. 3.2.1] 
 
For the group comparisons the control group data set contemporary in acquisition 
dates to the acquisition of the patient data sets was used. 
 
Table 3.2.1: Description of the three groups of subjects. The healthy volunteer group is 
designated as Control. IGE represents the group of patients with idiopathic generalised 
epilepsy; and OLE represents the group with occipital lobe epilepsy. Each group has n=15. 
 
 Control  IGE  OLE  
Gender: Female / Male 7/8 5/10 8/7 
Age in years: median (range) 27 (13- 40) 27 (17 – 55) 27 (17- 43) 
Duration of epilepsy (years): median 
(range) 
Not applicable 7 (1 - 25) 12 (4 – 31) 
Duration in days since last seizure: 
median (range) 
Not applicable 30 (1 - 1200) 75 (1 – 1000) 
No. of seizures per year: median 
(range) 
Not applicable 12 (<1 - 300) 5 (<1 – 600) 
Duration in days since last 
convulsive seizure (IGE 
only):median (range) 
Not applicable 45 (2 – 1200) Not applicable 
No. of convulsive seizures per year 
(IGE only): median (range) 
Not applicable 1(1 – 50) Not applicable 
Lifetime convulsive seizures: median 
(range) 
Not applicable 10 (1- 50) 17 (4 – 50) 
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3.2.3.2 MRS in individual patients 
Abnormality of a metabolite concentration was defined as a value more than 3 
standard deviations (SD) distant from the control mean of that variable. No significant 
abnormalities were identified for any single metabolite. Several ratios were also 
examined; NAAt/Cr, GLX/Cr, GLX/GABA+, GLX/NAAt and GLX/Ins. Only the 
ratio GLX/Ins showed sensitivity for abnormality in individual patients. Elevated 
GLX/Ins was observed in two of 15 patients in the IGE group and four of 15 in the 
OLE group. No individuals in the control group had elevated GLX/Ins. 
 
3.2.3.3 Group Results  
Comparison was made between the three groups (Table 3.2.2, Fig 3.2.2). No 
significant inter-group variation was observed for NAAt, Cr, Cho or Ins. Significant 
variation was observed for GLX, Grey matter proportion and GABA+ (p<0.05). Post 
hoc analysis was made using the LSD test and showed significant elevation of GLX 
and GABA+ in the IGE group compared to the control population and elevation of 
grey matter content in the IGE compared to both groups. Following re-analysis with 
grey matter content as a co-variable, no metabolite showed significant variation, 
although GLX remained higher in both patient groups than in the control group.  
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Table 3.2.2: Occipital metabolite concentrations and ratios expressed as the group mean and 
standard deviation for healthy volunteers (Control), patients with idiopathic generalised 
epilepsy (IGE) and patients with occipital lobe epilepsy (OLE). NAAt = N-acetyl aspartate 
plus N-acetyl aspartyl-glutamate; GLX = glutamate plus glutamine; Cr = creatine plus 
phosphocreatine; Cho = choline containing compounds; Ins = myo-inositol; GABA+ = 
gamma amino butyric acid plus homocarnosine. Mean values and SD are provided for each 
measurement. 
 
 
 Control 
N=15 
IGE 
N=15 
OLE 
N=15 
Grey matter proportion 0.60(0.06) 0.65(0.04) 0.61(0.07) 
 NAAt 7.43(0.60) 7.74(0.50) 7.48(0.60) 
Metabolites GLX 7.49(1.21) 8.51(0.90) 8.04(1.12) 
(mmol/l) Cho 0.81(0.10) 0.76(0.10) 0.75(0.12) 
 Cr 4.66(0.34) 4.85(0.30) 4.71(0.50) 
 Ins 3.26(0.30) 3.31(0.40) 3.16(0.61) 
 GABA+ 1.35(0.21) 1.53(0.17) 1.45(0.17) 
 NAAt/Cr 1.61(0.20) 1.60(0.01) 1.59(0.13) 
Metabolite 
ratios 
GLX/Ins 2.30(0.30) 2.58(0.40) 2.64(0.64) 
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Figure 3.2.2: Box plots for: (A) N-acetyl aspartate plus N-acetyl aspartyl-glutamate (NAAt); 
(B) glutamate plus glutamine (GLX); (C) gamma-amino butyric acid plus homocarnosine 
(GABA+); (D) grey matter content and (E) GLX/myo-inositol (Ins) in the prescribed occipital 
region. The volunteer group is designated Control. IGE = idiopathic generalised epilepsy 
group and OLE = patients with occipital lobe epilepsy. The ends of the graph boxes fall at the 
upper and lower quartiles, the solid line within the box represents the median, and the 
whiskers the range of the data. Significant inter-group variation (p<0.05) was observed for 
GLX, GABA+ and grey matter content. 
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No associations between metabolite concentrations were identified for the control 
group or the IGE group. However there was a positive association between NAAt and 
GLX for the OLE group (Table 3.2.3).  
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Table 3.2.3: Pearman correlation coefficients and levels of significance for metabolites 
within each group. Levels of significance have been corrected for multiple comparisons 
within each group. Healthy volunteers = Control; patients with idiopathic generalised epilepsy 
= IGE; and patients with occipital lobe epilepsy = OLE. NAAt = N-acetyl aspartate plus N-
acetyl aspartyl-glutamate; GLX = glutamate plus glutamine; GABA+ = gamma amino butyric 
acid plus homocarnosine. A significance level of p=0.05 is corrected to 0.015 for 3 
comparisons. 
 
 NAAt GLX GABA+ 
 
Control: 
NAAt 
GLX 
GABA+ 
 
- 
R
2
=0.03(not sig) 
R
2
=-0.06(not sig) 
 
- 
- 
R
2
=0.01(not sig) 
 
- 
- 
- 
IGE: 
NAAt 
GLX 
GABA+ 
 
- 
R
2
=0.33(not sig) 
R
2
=0.07(not sig) 
 
- 
- 
R
2
=0.01(not sig) 
 
- 
- 
- 
OLE: 
NAAt 
GLX 
GABA+ 
 
- 
R
2
=0.49(0.002) 
R
2
=<0.01(not sig) 
 
- 
- 
R
2
=-0.01(not sig) 
 
- 
- 
- 
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The metabolite ratio GLX/Ins showed post-hoc significant variation between the OLE 
group and the control group only. This was not significant on analysis with grey 
matter as a covariate analysis. No other ratios showed significant variation between 
the groups.   
 
3.2.3.4 Relationship to concurrent anti-epileptic therapy 
Two patients were taking topiramate in the IGE group. GABA+ values for both these 
subjects were within 1SD of the control mean. In the OLE group one patient was 
taking gabapentin. For this patient the GABA+ concentration was also within 1 SD of 
the control mean. Five patients in the IGE group were taking no medications. 
Comparison of GABA+ values in those taking AEDs against those on no AEDs 
showed a trend to lower values in the drug free group however this was not 
significant.  
 
3.2.3.5 Relationship to seizure frequency and duration since the most recent 
seizure 
A correlation analysis for each patient group for each metabolite against seizure 
frequency and duration since the most recent seizure was performed. The OLE group 
showed no correlation with seizure control and GABA+. In the IGE group no 
correlation was observed between GABA+ and either control of convulsive seizures 
or control of seizures of any type.  
 
3.2.4 Discussion 
At the time of publication this was the first study to apply a double quantum filter in 
vivo to measure GABA+ concentration in patients with epilepsy. The study was also 
the first report of in-vivo GABA+ concentrations measured in the region of seizure 
onset in patients with focal epilepsy. Using this technique GABA+ was measured 
with repeatability figures approaching those achievable for GLX. In patients with IGE 
and patients with OLE both GABA+ and GLX were found to be elevated compared to 
the control population. As noted in earlier studies, inter-group variation in grey matter 
composition can affect the significance of any observed metabolite differences and 
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must be taken into account(McLean et al., 2000). However following correction for 
grey matter content there was still a trend to elevated GLX in IGE albeit not 
statistically significant.     
 
3.2.4 Methodology 
The majority of GABA studies in patients with epilepsy have used spectral editing 
techniques. Petroff and co-workers have extensive experience of editing GABA in the 
occipital lobes in patients with partial epilepsy of extra-occipital onset using a 2.1T 
scanner and a surface coil. However their technique is limited at present to 
investigation of fairly superficial regions of the occipital lobes.  
 
Double quantum filters have lower theoretical yield than the spectral editing 
techniques (38%(McLean et al., 2002) versus 100%) but are not prone to subtraction 
errors. At 1.5T reasonable reliability using a standard quadrature head coil was 
achieved. This allowed the examination of GABA concentration in other regions of 
the cerebrum without the limitations of surface coils. However large voxels are 
required (c. 35ml) that are clearly insensitive to local variation in GABA 
concentration. The scan time of 17 minutes per filtered acquisition was also a 
potential cause of patient non-compliance. 
 
The resulting GABA+ signal can be expected to contain some contribution from 
homocarnosine, glutathione and macromolecules. The role of homocarnosine in vivo 
is not well understood. Its localisation appears to be the cytosol of a subgroup of 
GABAergic neurons and it may act as a GABA reservoir(Henry and Theodore, 2001). 
The contribution to the final signal of glutathione is expected to be small, whilst 
metabolite nulled studies suggest that there is limited passage of macromolecule 
through the filter(McLean et al., 2002). Shen and co-workers have reported findings 
with a doubly selective DQF in healthy volunteers(Shen et al., 2002). Using a 2.1T 
magnet, similar sized region of interest (30*30*30 mm) and a surface coil they report 
a slightly lower GABA concentration (1.21 +/- 0.28mmol/L) but similar coefficients 
of variation (23% versus 15% for the current study). These measures compare with 
coefficients of variation for GABA of between 5% and 13% reported by Petroff and 
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co-workers using spectral editing techniques(Petroff et al., 1996b;Petroff et al., 
1999b). 
 
In the control and IGE groups there was no correlation between the obtained 
metabolite concentrations. There was a positive correlation between NAAt and GLX 
in the OLE group (R
2
 = 0.49: p = 0.002). This finding agrees with a recent study that 
identified correlation between NAA and glutamate in specimens of epileptic human 
hippocampus and which proposed a coupled relationship between glutamate synthesis 
and NAA synthesis(Petroff et al., 2002b). 
 
3.2.4.2 Findings in individual patients 
In the patient groups no metabolite concentration was sensitive for abnormality in 
individual patients. Reduction in NAAt is generally considered to reflect neuronal 
loss/dysfunction and is commonly observed in the temporal lobes in patients with 
temporal lobe epilepsy. However in this current study the voxel volume of interest is 
relatively large. Consequently any localised metabolite abnormality at the focus of 
ictal onset in the OLE group would be diluted by inclusion of surrounding unaffected 
tissue. This could account for the relative lack of abnormality in this group compared 
to the control group. 
 
The cerebral concentration of NAAt in IGE has not been extensively reported. Cendes 
and co-workers reported normal NAA/Cr in the temporal lobes in patients with 
absence seizures(Cendes et al., 1997c) whilst published findings in IGE patients 
measured in the frontal lobes(Savic et al., 2000a;Simister RJ et al., 2003b), [Chapter 
3.3] suggest reduced NAA compared to a control population.  
 
The relative sensitivity of the ratio GLX/Ins for abnormality is not simply explained. 
However, GLX has been found to be elevated in regions of ictal onset(Woermann et 
al., 1999c;Neppl et al., 2001), whilst  Ins is thought to be localised to the glia(Brand et 
al., 1993). The ratio GLX/Ins may therefore represent the concentration of an 
excitatory component divided by a term representing glial concentration. There was 
no correlation observed with either ratio and seizure control or duration since most 
P a g e  | 185 
 
recent seizure, so the terms appear to demonstrate no dynamic alteration with 
seizures. Six patients in the IGE group and one patient in the OLE group were taking 
VPA which lowers Ins levels [Chapter 3.5] and this might be expected to contribute 
to the elevation in GLX/Ins. However the obtained metabolite concentrations for Ins 
in IGE and OLE were higher than for the Control group which would argue against a 
significant effect of concomitant AED usage. 
 
3.2.4.3 Group Comparisons 
In the IGE group an increase in voxel grey matter content was observed despite 
normal MRI appearances. This would be consistent with the presence of microscopic 
abnormality of grey and/or adjacent white matter structure. Pathological analysis has 
shown cortical and subcortical dystopic neurons and other microscopic structural 
abnormalities (“microdysgenesis”) in a large percentage of a limited number of cases 
with IGE(Meencke and Janz, 1984). Other studies have not identified structural 
abnormality in IGE(Palmini et al., 1995;Opeskin et al., 2000) although widespread 
cerebral structural changes have been reported in quantitative MRI examination of 
patients with IGE leading to an increased mean normalised grey matter volume 
compared to control subjects(Woermann et al., 1998b).  
 
In the IGE group GLX concentrations were significantly higher than in the control 
group. Following correction for grey matter content a trend to elevation was still 
evident in both patient groups. Elevation of GLX in subjects with temporal lobe 
epilepsy measured in the inter-ictal phase in the region of seizure onset(Woermann et 
al., 1999c) and in the contralateral temporal lobe(Simister et al., 2002) [Chapter 3.1] 
has been previously reported. Whether increased inter-ictal GLX represents elevation 
of glutamate and/or glutamine, or an increase in glutamatergic neurons, is not 
established. Post-ictal measures may also be affected by acute changes in MR 
“visibility” of these metabolites(Kauppinen et al., 1994). In vitro studies of epileptic 
tissue have described elevated glutamate(Sherwin et al., 1988)
 
or elevation of 
glutamate and glutamine(Petroff et al., 1995). One recent animal study reported 
elevated post-ictal GLX following prolonged generalised seizures(Neppl et al., 2001).  
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Anticipated progress in separately resolving glutamate and glutamine will help 
explain these findings further.  
 
AED therapy may also affect the observed concentration of GLX or GABA. 
Valproate and vigabatrin have both been reported to increase glutamine(Petroff et al., 
2000).  However in this study six patients in the IGE group were taking valproate, 
compared to nine patients not taking this medication. Comparison of the two groups 
did not identify a trend to elevation of GLX or GABA+ in the valproate group, and 
although a recent study has suggested that lamotrigine may cause elevation in GABA 
levels(Kuzniecky et al., 2002), a similar comparison showed no effect of lamotrigine 
on GABA+ or GLX levels. 
 
In this study GABA+ concentrations were not observed to be reduced in our patient 
groups. This is contrary to earlier in-vivo MRS reports using spectral editing 
techniques(Petroff et al., 1996b;Woermann et al., 1999c). One study(Petroff et al., 
2001a) has reported separate measurement of GABA and homocarnosine in patients 
with extra-occipital partial epilepsy and in patients with Juvenile Myoclonic Epilepsy 
(JME), a sub group of IGE. In that study, levels of GABA were generally within the 
normal range for the partial epilepsy group (three of 11 having GABA levels less than 
2SD from the control mean) whilst GABA levels in JME were generally low (seven 
of 14 below 2SD). Homocarnosine levels were all within the normal range for both 
groups. These and earlier studies, however, investigated a region that was outside the 
site of seizure onset in patients with partial epilepsy and it was not known whether or 
not the JME group were actively photosensitive at the time of the study. Findings 
might be expected to be different in regions of epileptic neocortex. There was relative 
inhomogeneity in the IGE group with 8 of the 15 having IGE syndromes that were not 
sub-classifiable. All the patients with OLE had occipital ictal focal onset and 13 
patients in the IGE group had active photo-paroxysmal response on EEG at the time 
of imaging. Pathological estimates of GABA concentration, although they are 
interpreted with caution, have not reported low levels of GABA in epileptic 
neocortex(Perry et al., 1975;Sherwin et al., 1988;Petroff et al., 1995). No variation of 
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GABA+ concentration was observed in this study with any taken AED therapy. 
However the numbers taking each medication were small.  
 
There was no correlation between GABA+ and seizure control or interval since most 
recent seizure in the IGE group or in the OLE group. This is in agreement with the 
most recent findings of Petroff(Petroff et al., 2001a) who found no correlation 
between seizure control and GABA levels in patients with JME. That study did also 
report that seizure control in patients with extra-occipital partial epilepsy correlated 
with GABA and with homocarnosine concentrations but did not investigate GABA 
concentration in the region of seizure onset.   
 
3.2.5 Conclusion 
Disorders of GABA and Glutamate regulation are closely linked with seizure 
disorders. Previous work has suggested that MRS detected elevation in GLX is a 
feature of epileptic tissue whilst GABA levels may be affected by anti-epileptic drug 
therapy and seizure control. This current study reports reliable measurement of 
GABA+, by application of a double quantum filter, together with GLX measurement 
in patients with occipital lobe epilepsy and with IGE. Elevation was observed in both 
GLX and GABA+ in IGE and a trend to elevation of GLX in occipital lobe epilepsy. 
However, elevated grey matter content in the IGE group may have been responsible 
for most of the apparent metabolite abnormalities.  
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3.3 Proton MRS Reveals Frontal Lobe Metabolite Abnormalities in Idiopathic 
Generalised Epilepsy. 
ABSTRACT 
Purpose: 
Cortical hyper-excitability may be important in the patho-physiology of idiopathic 
generalised epilepsy (IGE). In the human brain glutamate is the most important 
excitatory transmitter and γ-amino butyric acid (GABA) the dominant inhibitory 
neurotransmitter.  This study reports GABA plus homocarnosine (GABA+) and 
glutamate plus glutamine (GLX) concentrations in the frontal lobes of patients with 
IGE.  
 
Methods: 
Twenty-one patients and 17 healthy volunteers were studied. A single voxel was 
prescribed in each frontal lobe for each subject. PRESS localised short echo time 
MRS was performed to measure GLX and the metabolites N-acetyl aspartate plus N-
acetyl aspartyl-glutamate (NAAt), creatine and phosphocreatine, choline containing 
compounds and myo-inositol. A double quantum GABA filter was used to measure 
GABA+.  Segmented T1 weighted images gave the tissue composition of the 
prescribed voxel.  
 
Results: 
Group comparisons showed elevation of GLX and reduction of NAAt in the patient 
group (p < 0.05). The metabolite ratios GLX/NAAt and GLX/Ins also showed 
elevation in IGE (p = 0.01). No group effect was observed for GABA+, creatine and 
phosphocreatine, or choline containing compounds. Myo-inositol concentrations were 
not significantly reduced in the patient group but were less in the sub-group of 
patients who were taking sodium valproate.  
 
Conclusion: 
The results indicate that IGE is associated with frontal lobe metabolite changes that 
may imply increased excitability or proportion of glutamatergic neurons, and reduced 
NAAt, implying reduced overall neuronal numbers or neuronal dysfunction. 
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3.3.1 Introduction 
 
Elevated glutamate concentrations have been identified in human epileptic 
tissue(Sherwin et al., 1988;Petroff et al., 1995), and in vivo microdialysis studies have 
shown increased extra cellular glutamate in the temporal lobe following a 
seizure(During and Spencer, 1993). GLX can be estimated using proton MR 
spectroscopy (MRS) at short echo times(Woermann et al., 1999c;McLean et al., 2000) 
and may be elevated in regions of seizure onset(Woermann et al., 1999c). 
 
Decreases in GABA inhibition may also cause seizures(Olsen and Avoli, 1997), and 
several AED enhance GABA function. Low GABA has been measured in patients 
with focal epilepsy(Petroff et al., 2000). Levels of GABA and homocarnosine, a 
dipeptide of GABA and histidine, have been shown to increase with improved seizure 
control(Petroff et al., 1996b;Petroff et al., 2000) or following the administration of 
AED that modify GABA metabolism or function(Petroff et al., 2000;Mueller et al., 
2001b;Kuzniecky et al., 2002). 
 
The purpose of the current study was to investigate GABA+ and GLX concentrations 
in patients with idiopathic generalised epilepsy (IGE) compared to healthy volunteers 
measured in the frontal lobes.  The frontal lobes were studied because there is 
evidence for frontal lobe dysfunction(Niedermeyer, 1996;Swartz et al., 1996;Savic et 
al., 2000a) or subtle structural abnormality(Woermann et al., 1999b) in subjects with 
IGE.  
 
3.3.2 Methods 
3.3.2.1 Subjects 
20 control volunteers and 26 patients with IGE were scanned after giving informed 
consent. Following application of exclusion criteria on the basis of quality of 
spectroscopic data, 17 controls and 21 patients were included in the study. Ethical 
approval by the Joint Research Ethics Committee of the National Hospital for 
Neurology and Neurosurgery was obtained. In all patients the diagnosis was based 
upon full clinical assessment, interictal +/- ictal scalp EEG, neuropsychometry and 
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MRI. All subjects had normal MRI on visual inspection. Fifteen of the included 
patients had IGE syndromes that were sub-classifiable as follows: Juvenile Myoclonic 
Epilepsy (seven), Juvenile Absence Epilepsy (six), Childhood Absence Epilepsy (one) 
and Generalised Tonic Clonic Seizures on Awakening (one). In the remaining six 
patients sub-syndrome classification was not possible. The antiepileptic drugs (AED) 
taken by the included patients were as follows; valproate (fourteen), lamotrigine 
(eight), carbamazepine (three), topiramate (two), clobazam (two), phenytoin (two), 
levetiracetam (two), ethosuximide (one). One patient was taking no regular 
medications. A full seizure history was obtained and the frequency of both absence 
and tonic-clonic seizures (GTC) at the time of scanning was recorded. The duration in 
days since the most recent GTC was also recorded. 
 
3.3.2.2 Magnetic Resonance Imaging   
The study was performed on a 1.5T General Electric SIGNA Horizon Echospeed 
scanner (Milwaukee, WI) using a standard quadrature head coil for all MRI/MRS 
studies. Axial T1 weighted inversion-recovery prepared fast spoiled gradient recalled 
echo (IRP-FSPGR) images were acquired (TE/TI/TR = 4.2/450/16 ms, flip angle 20
0
; 
matrix 256*128; slice thickness 1.5mm). These images were used both to guide voxel 
placement and subsequently for segmentation of fractional gray matter, white matter 
and cerebro-spinal fluid (CSF) content using SPM99 (Statistical Parametric Mapping; 
Wellcome Department of Imaging Neuroscience, Institute of Neurology, University 
College London). All the MRI studies were reviewed by two experienced neuro-
radiologists. 
  
3.3.2.3 Magnetic Resonance Spectroscopy  
A single voxel was prescribed in each frontal lobe of each subject with approximate 
dimensions 40 by 35 mm in the Anterior-Posterior and Left-Right directions 
respectively and thickness 25mm (Fig 3.3.1). Voxel placement was prescribed from 
axial images. The voxel was placed with the medial border over the longitudinal 
fissure and the posterior border at the level of the pre-central sulcus. The most rostral 
axial slice that could fully contain the in plane dimensions of the voxel was chosen as 
the superior surface of the voxel. The volume of interest contained pre-motor cortex 
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including the supplementary motor area, cingulate gyrus and dorsolateral prefrontal 
cortex.  
 
Conventional PRESS-localised water suppressed spectra were obtained initially with 
the acquisition parameters (TE/TR = 30/3000 ms) matching previous 
studies(Woermann et al., 1999c;McLean et al., 2000;McLean et al., 2001;McLean et 
al., 2002), so that LCModel(Provencher, 1993) could be used for quantification of 
NAAt, Cr, Cho, Ins and GLX.  The magnetic field in-homogeneities were 
successfully compensated for using the provided first order automated gradient shim 
procedures. Sixteen averages were performed. 
 
Next the double quantum filter (DQF) sequence was applied and the final spectrum 
consistently phased to allow integration of the GABA+ resonance. The GABA+ 
concentration was then calculated relative to Cr [Eqn 2.4.1] on page 138. Finally, 
metabolite concentrations were corrected for CSF content, which is considered to 
provide negligible signal(Lynch et al., 1993).  (This common methodology is fully 
described in Section 2)   
 
Poor quality data was rejected by setting a threshold of 4.0 for the signal to noise ratio 
(SNR) of the filtered signal (signal taken as the highest peak between 3.5 to 2.5 PPM 
and noise 15 to 20 PPM, and rejected data with SNR < 4.0. PRESS localised (TE/TR 
= 30/3000 ms) datasets were also rejected if the manually measured unsuppressed 
water full width half maximum (FWHM) > 0.15 PPM. Only two data sets were 
discarded as a consequence of poor DQF signal to noise, however nine of 92 data sets 
were discarded with FWHM > 0.15 PPM. Finally, only those subjects with both left 
and right frontal data fulfilling these criteria were included in order to allow the 
opportunity to compare right voxel, left voxel and mean concentrations between the 
two groups. This final restriction resulted in the exclusion of two subjects in the 
control group and three subjects in the IGE group. 
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3.3.2.4 Statistics 
Statistical analysis was performed with SPSS 9.0. Metabolite concentrations and 
ratios were individually compared using ANOVA. To investigate for a relationship 
between seizures and metabolite concentration only patient recorded GTC information 
was studied with the expectation that this data was the most accurately recorded. IGE 
subjects with age at the time of the study within the age range for the control group 
were included. Regression analysis was performed for each metabolite against 
duration of epilepsy, number of GTC per year, and the duration in days since the most 
recent GTC. 
 
3.3.3 Results 
3.3.3.1 Group Results 
The SPM estimates of voxel fractional gray matter content were compared between 
IGE subjects and controls and between right and left voxels, since several metabolites 
are predominantly concentrated in gray matter. No group differences were observed.  
 
In the IGE group 21 of the 26 subjects met all the criteria for data inclusion. Paired t-
tests were applied to examine right-left metabolite symmetry. In the control group 
right-left asymmetry was identified for NAAt, Cr, Cho, and GLX.  Concentrations in 
the left frontal voxel were lower than in the right frontal voxel (p<0.05). 
Consequently inter-group comparisons were performed for right (R) and left (L) voxel 
concentrations separately as well as for mean (M) metabolite concentration. Two 
subjects of the Control group were left-handed. 
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Figure 3.3.1: A) Axial T1-weighted localizing magnetic resonance imaging scan showing 
the position of the prescribed frontal lobe voxels. B) A representative PRESS localised 
spectrum (TE/TR 30/3000ms) with superimposed LCModel fit to metabolite concentrations 
and estimated baseline, and C) a filtered GABA spectrum (TE/TR 68/2000 ms) from the right 
frontal voxel of a control volunteer (Vertical scale is increased 100x relative to (B)).  NAAt = 
N-acetyl aspartate plus N-acetyl aspartyl-glutamate; GLX = glutamate plus glutamine; Cho = 
choline containing compounds; Cr = creatine + phosphocreatine; Ins = myo-inositol; GABA+ 
= gamma amino butyric acid plus homocarnosine. PPM = chemical shift in parts per million. 
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Table 3.3.1: Clinical data for the included IGE subjects. Identified IGE sub-types were 
juvenile myoclonic epilepsy (JME), juvenile absence epilepsy (JAE), childhood absence 
epilepsy (CAE) and generalised tonic clonic convulsions on awakening (GTCA). All subjects 
had normal clinical examination and normal MRI. All had EEG demonstrating generalised 
spike and wave (SW) discharge. U = unclassified IGE sub-type. GTC = generalised tonic 
clonic seizure. AED = antiepileptic drug. Cbz = carbamazepine, clb = clobazam, pht = 
phenytoin, eth = ethosuximide, ltg = lamotrigine, lev = levetiracetam, tpm = topiramate, vpa = 
sodium valproate, nil = no regular antiepileptic drugs.  
 
Patient No. 
/Age 
/gender 
/handedness 
Diagnosis  
/AEDs  
Age of onset  
/ Duration  
of epilepsy (years) 
GTC per year  
/ GTC (lifetime)  
/ Duration since last  
GTC (days) 
1/21/M/R JME/ ltg 17/4 2/5/6 
2/19/M/R JAE/ ltg 11/8 2/6/30 
3/17/M/R JME/ cbz, clb 10/7 4/17/30 
4/19/F/R JAE/ nil 13/6 0/1/1000 
5/23/M/R JAE/ cbz 13/10 6/40/7 
6/19/F/R JME/ vpa 15/4 4/6/30 
7/20/F/R U/ vpa 14/6 1/5/60 
8/19/M/R JAE/ lev 9/10 12/40/4 
9/39/F/R U/ vpa, ltg 10/29 3/15/60 
10/31/F/R U/ ltg 10/21 6/30/40 
11/30/F/R JME/ vpa 12/18 6/30/30 
12/32/M/R U/ vpa 15/17 0/3/900 
13/23/M/R JAE/ tpm, eth, vpa, ltg 13/10 22/40/2 
14/40/M/R JAE/ vpa, ltg 6/34 0/17/800 
15/51/F/R JME/vpa 11/40 6/100/30 
16/43/M/R CAE/ vpa, clb, ltg 8/35 4/30/9 
17/32/M/R GTCA/ vpa, pht 17/15 15/100/30 
18/36/F/R U/ vpa, cbz 6/30 0/5/800 
19/22/M/R JME/ vpa 18/4 2/5/42 
20/44/F/R U/ vpa, lev 16/28 0/1/1000 
21/39/M/R JME/ vpa, tpm, ltg, pht 7/32 6/18/30 
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Mean GLX was higher in the IGE group than the controls by 12% (IGEL p= 0.03, 
IGER p = 0.03 IGEM p = 0.04) (Table 3.3.2). Reduction of NAAt was observed in 
IGER by 8% p= 0.01 and in IGEM by 7 % p = 0.01) as well as a trend to reduction in 
the IGEL group that was not significant. Ins was reduced in the IGEL and IGEM 
voxels. No inter-group variation was observed for GABA+.  
 
Both the ratios GLX/Ins and GLX/NAAt were higher in all three IGE voxels (p < 
0.01).  
 
Table 3.3.2: Frontal metabolite concentrations and ratios expressed as the group mean and 
standard deviation for healthy volunteers (Control) and patients with idiopathic generalised 
epilepsy (IGE). R = right frontal voxel. L = left frontal voxel. M = mean frontal voxel. NAAt 
= N-acetyl aspartate plus N-acetyl aspartyl-glutamate; GLX = glutamate plus glutamine; Cr = 
creatine plus phosphocreatine; Cho = choline containing compounds; Ins = myo-inositol; 
GABA+ = gamma amino butyric acid plus homocarnosine. Variation (p  0.05) between IGE 
and Control is indicated by *. Mean values and SD are provided for each measurement. 
 
 
 ControlR 
N=17 
ControlL 
N=17 
ControlM 
N=17 
IGER 
N=21 
IGEL 
N=21 
IGEM 
N=21 
 
Gray matter proportion 0.31(0.03) 0.30(0.04) 0.30(0.03) 0.32(0.05) 0.30(0.04) 0.31(0.04) 
 
 
 
 
Metabolites 
(mmol/l) 
NAAt 7.4(0.6) 7.0(0.7) 7.2(0.6) 6.8(0.4)* 6.6(0.5) 6.7(0.5)* 
GLX 7.4(0.9) 6.3(1.0) 6.9(0.6) 8.4(1.5)* 7.1(1.1)* 7.7(1.1)* 
Cho 1.1(0.1) 1.0(0.1) 1.0(0.1) 1.1(0..2) 0.9(0.2) 1.0(0.2) 
Cr 4.4(0.4) 4.1(0.5) 4.3(0.4) 4.3(0.4) 4.0(0.5) 4.1(0.4) 
Ins 3.1(0.3) 3.0(0.4) 3.1(0.4) 2.8(0.6) 2.5(0.7)* 2.7(0.6)* 
 GABA+ 1.4(0.3) 1.4(0.2) 1.4(0.3) 1.4(0.3) 1.4(0.3) 1.4(0.3) 
 
Metabolite 
Ratios 
NAAt/Cr 1.7(0.2) 1.7(0.2) 1.7(0.1) 1.6(0.2) 1.7(0.2) 1.6(0.2) 
GLX/NAAt 1.0(0.2) 0.9(0.1) 1.0(0.1) 1.2(0.2)* 1.1(0.2)* 1.1(0.2)* 
GLX/Ins 2.4(0.4) 2.1(0.4) 2.3(0.4) 3.1(1.1)* 3.0(1.1)* 3.1(1.0)* 
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Figure 3.3.2: Error bar plots of mean and 95% confidence intervals for Myo-inositol (Ins) 
in patients with idiopathic generalised epilepsy (IGE) and in the control group (Control). VPA 
= subjects taking sodium valproate. No VPA = subjects not taking valproate. Variation (p  
0.05) between VPA and No VPA in the IGE group is indicated by *.  
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3.3.3.2 Relationship to current anti-epileptic therapy 
In this study only valproate (n = 14) and lamotrigine (n = 8) were AED therapies 
taken by more than five patients. There was no effect of valproate therapy on GLX or 
GABA+. Ins was reduced in the valproate taking patients in the mean voxels (p = 
0.05) (Fig 3.3.2) compared to the non valproate taking IGE subjects and this effect 
remained after re-analysis using gray matter proportion as a covariable. There was no 
difference in Ins between the control group and the non valproate taking subjects and 
no effects were observed for lamotrigine. Topiramate was taken by only two patients. 
If the topiramate taking patients were removed from the IGE group, GLX was still 
observed to be elevated in the IGE group.   
 
3.3.3.3 Relationship to seizure frequency and duration since the most recent 
seizure 
There were no significant associations for any metabolite or metabolite ratio against 
tonic-clonic seizure frequency, duration of epilepsy or time since the most recent 
tonic-clonic convulsive seizure (Fig 3.3.3).  
 
3.3.3.4 Relationship to IGE sub-type 
Seven subjects in the IGE group had a diagnosis of juvenile myoclonic epilepsy 
(JME) and six subjects had juvenile absence epilepsy (JAE).  Both sub-groups showed 
elevation in mean GLX and a trend to reduction in mean NAAt compared to the 
control group. A trend to elevation in mean GABA+ and mean gray proportion was 
observed in JAE compared to JME and controls.  
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Figure 3.3.3: Plots of mean GLX, GABA+ and NAAt against (A) age and duration of 
epilepsy, (B) number of generalised tonic clonic seizures (GTC) in the year preceding the date 
of the scan and (C) duration in days since the last GTC for the IGE group. 
 
 
 
100 10 1000 
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3.3.4 Discussion 
The main findings of this study were that GLX was elevated and NAAt was reduced 
in patients with IGE. Ins concentrations were lower in patients taking valproate. 
 
Right–left comparison of the metabolite concentrations in the control group revealed 
lower concentrations of all metabolites in the left frontal voxels. Frontal gray matter 
volumes have been shown to be higher in the right hemisphere in healthy 
volunteers(Amunts et al., 2000;Watkins et al., 2001;Rademacher et al., 2001) which 
would generally be expected to give higher metabolite concentrations(McLean et al., 
2000); however, in this study, the gray matter proportions within the prescribed 
voxels showed no right–left asymmetry. The lateral margins of the prescribed 
volumes of interest were positioned relatively close to the scalp, allowing some 
inclusion of signal from scalp lipids, which may differ in the left voxel as compared 
with the right voxel because of chemical shift artifact and may affect the baseline 
estimation. Therefore, this side-to-side difference most likely arose as a consequence 
of methodology rather than true physiologic difference. 
 
Previous volumetric studies have suggested that IGE may be associated with a relative 
increase in gray matter(Woermann et al., 1998b;Simister RJ et al., 2003a), [Chapter 
3.2] possibly due to a subtle abnormality of the cortical layers(Woermann et al., 
1998b). In this current frontal lobe study, no gray matter increase was observed in the 
IGE group compared with the control group, but this was only a small sample of the 
frontal lobe. 
 
In the IGE group, GLX concentrations were significantly higher than in the control 
group. This is in agreement with prior studies which have reported elevation of GLX 
in the region of seizure onset in partial seizures(Woermann et al., 1999c), and a recent 
animal study has reported elevated post-ictal GLX following prolonged generalized 
seizures(Neppl et al., 2001). Whether increased GLX directly represents increased 
glutamatergic neurotransmission is not yet established. 
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The metabolism of glutamate and glutamine is tightly coupled. After neuronal release 
of glutamate, glutamate action in the synaptic cleft is terminated by glial uptake 
mechanisms and the glutamate is subsequently converted within the glia by glutamine 
synthetase to glutamine. The glutamine is then exported back into the neighbouring 
neuron, where it is reconverted to glutamate. Astrocytic glutamine synthesis also 
occurs. Elevation in GLX may therefore be the consequence of a number of 
processes: increased neuronal glutamate concentrations or glutamatergic neurons; 
increased astrocytic glutamine content as a consequence of increased glutamate– 
glutamine flux or increased glial activity of the tricarboxylic acid cycle; increased 
glial cell numbers; or altered function of glutamine transporters. Post-ictally measures 
may also be affected by acute changes in MR “visibility” of glutamate(Kauppinen et 
al., 1994). In vitro studies of epileptic tissue have described elevated glutamate or 
elevation of glutamate and glutamine(Petroff et al., 1995).  Further studies at higher 
field strengths will help to determine whether GLX elevation in subjects with epilepsy 
is a consequence of glutamate and/or glutamine elevation and also how the relative 
proportion of these metabolites changes following epileptic seizures. Elevated GLX 
would be in keeping with a model of cortical hyperexcitability in IGE but subsequent 
work by Badawy and colleagues indicates that whilst changes in cortical excitability 
do occur around the time of a seizure both increased excitability (prior to the seizure) 
and decreased excitability post seizure are observed(Badawy et al., 2009).  
 
The current study shows reduced NAAt in patients with IGE. A similar result was 
obtained in a study of patients with JME that reported reduction of NAA in the 
prefrontal cortex(Savic et al., 2000a). In comparison no NAAt reduction was observed 
in patients with IGE when measured in the occipital lobes(Simister RJ et al., 2003a) 
[Chapter 3.2]. These findings together support the proposal that IGE might be 
associated with abnormal frontal lobe function. Subsequently published work has 
added to these observations. Several quantitative MRI studies have reported 
abnormally increased grey matter content in medial frontal regions(Betting et al., 
2006;Kim et al., 2007) whilst Hommet and colleagues have reported frontal cognitive 
disturbance in IGE patients(Hommet et al., 2006). 
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In this study, IGE subjects had GABA+ concentrations in the normal range. A similar 
observation was made when IGE subjects were studied using voxels placed in the 
occipital lobe (Simister RJ et al., 2003a) [Chapter 3.2]. Few previous MRS studies 
have included IGE patients, and none has been performed in the frontal lobes. One 
study reported separate measures of GABA and homocarnosine in the occipital lobes 
in subjects with JME(Petroff et al., 2001a). GABA levels were generally low, whereas 
homocarnosine levels were within the normal range. The role of homocarnosine in 
vivo is not well understood. Its localization appears to be the cytosol of a subgroup of 
GABAergic neurons, and it may act as a GABA reservoir(Henry and Theodore, 
2001). 
 
It is possible that concurrent AED therapy may have affected the concentrations of 
GLX and GABA+(Petroff et al., 2000). Valproate has been reported to increase 
glutamine and hence GLX(Petroff et al., 2000), but although 14 of the 21 patients 
included in the IGE group in the current study were taking valproate, neither GLX or 
GABA+ concentrations appeared elevated. 
 
Comparison of patients taking valproate with patients not taking valproate revealed 
lower Ins in the valproate-taking group. Low Ins has been reported in a patient with 
valproate-associated encephalopathy(Ziyeh et al., 2002). Low Ins and raised inositol 
monophosphates have also been reported in rats treated with valproate or 
lithium(O'Donnell et al., 2003). Lithium has no role as an AED, and the relevance of 
these findings to the anti-seizure activity of valproate is not established. The 
mechanism for Ins reduction by valproate may be by an unknown action on the 
phospho-inositide Ca
2+
 second messenger system(O'Donnell et al., 2003) or via 
inhibition of a cell membrane sodium/Ins co-transporter(van Calker and Belmaker, 
2000a). A few studies have reported modulation of the phospho-inositide system in 
epileptic tissue(Dubeau et al., 1992), but whether this is a cause or a consequence of 
seizure activity is not established. 
 
There was no correlation between GABA+ and tonic clonic seizure frequency or 
interval since most recent GTC in the IGE group. This concurs with a recent 
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study(Petroff et al., 2001a) that found no correlation between seizure control and 
GABA in JME patients. That study, however, reported that seizure control correlated 
with homocarnosine concentrations. In the current study DQF measures of GABA+ 
include GABA and homocarnosine, so a direct comparison cannot be made. 
 
3.3.5 Conclusion 
In this study quantitative 1H MRS demonstrated that IGE is associated with elevated 
frontal GLX and reduced NAAt. Sodium valproate appears to be associated with 
reduction in Ins levels in subjects taking this medication. 
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3.4 Proton Magnetic Resonance Spectroscopy of Malformations of 
Cortical Development Causing Epilepsy 
 
ABSTRACT 
Purpose:  
To use proton Magnetic Resonance Spectroscopy (MRS) to measure concentrations of 
Gamma-amino butyric acid (GABA) and glutamate plus glutamine (GLX) in adult 
patients with refractory epilepsy associated with malformations of cortical 
development (MCD). 
 
Methods:  
MRS was used to measure N-acetyl aspartate (NAA), creatine plus phosphocreatine 
(Cr) and choline containing compounds (Cho), as well as GLX, and GABA. Fifteen 
patients with epilepsy attributable to MCD and 15 healthy controls were studied. Nine 
of the MCD group had heterotopia and six had polymicrogyria. Quantitative short 
echo time MRS [echo time (TE) = 30 ms, repetition time (TR) = 3000 ms] was 
performed in the MRI evident MCD and in the occipital lobes of the control group 
and the concentrations of NAA, Cr, Cho, and GLX were measured. GABA plus 
homocarnosine (GABA+) was measured in the same regions using a double quantum 
filter.  
 
Results:  
The dominant abnormalities in the patient group were elevation of Cho and GLX and 
reduction in NAAt compared to the control group. The ratios GLX/NAAt and 
GABA+/Cr were also increased in the patient group whilst the ratio NAAt/Cr was 
decreased. NAAt was significantly lower in polymicrogyria than heterotopia.  
 
Conclusions: 
Large cortical malformations had abnormal levels of both GLX and GABA+/Cr. Low 
NAAt and high Cho were also observed. These results indicate that MCD show 
spectroscopic features of primitive tissue and abnormal metabolism of both inhibitory 
and excitatory neurotransmitters.  
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3.4.1 Introduction 
 
Malformations of cortical development (MCD) are an important cause of refractory 
focal epilepsy. MCD include a heterogeneous range of conditions that arise at 
different points along the process of normal cortical development, which have 
characteristic histopathological features and recognisable appearance on MRI. 
Microscopic structure of these MCD sub-types can range from heterotopic aggregates 
of relatively normal neurons to abnormalities of cortical lamination or neuronal 
differentiation. Invasive EEG studies have demonstrated that MCD are intrinsically 
epileptogenic(Palmini et al., 1995;Mattia et al., 1995;Kothare et al., 1998) or that 
surrounding normal appearing tissue is epileptogenic(Jacobs et al., 1999). 
 
Proton Magnetic Resonance Spectroscopy (MRS) is a sensitive measure of neuronal 
loss or dysfunction(Urenjak et al., 1992;Cendes et al., 1997b;Tasch et al., 1999) or 
neuronal maturation(Simone et al., 1999b;Kreis et al., 2002;Tkac et al., 2003), and a 
number of MRS studies have reported the reliable quantification of metabolites 
relevant to the study of epilepsy(Petroff et al., 2000;McLean et al., 2000;McLean et 
al., 2002). Most MRS studies in subjects with MCD have used long echo times (TE), 
and reported only the ratios of the main visible metabolites, NAA, Cr, Cho(Marsh et 
al., 1996;Kuzniecky et al., 1997b;Li et al., 1998;Simone et al., 1999a;Simone et al., 
1999b;Widjaja et al., 2003). These studies have typically shown reduction in NAA/Cr 
and NAA/Cho in the region of focal cortical dysplasia whilst  heterotopia and 
polymicrogyria may have normal or reduced NAA/Cr(Marsh et al., 1996;Kuzniecky 
et al., 1997b;Li et al., 1998;Widjaja et al., 2003). There is evidence for metabolic 
heterogeneity within the visible lesions as well as within normal appearing 
surrounding tissue(Kuzniecky et al., 1997a). In a quantitative multi voxel MRS study 
of MCD with correction for tissue composition abnormal metabolite concentrations 
were found within MCD, within peri-lesional tissue and also in contralateral normal 
appearing tissue(Woermann et al., 2001b). 
 
Elevation of glutamate is a feature of epileptic tissue(Petroff et al., 1995) and 
elevations in GLX have been observed in the frontal lobes in subjects with idiopathic 
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generalised epilepsy (IGE) (Simister RJ et al., 2003b) [Chapter 3.3] and in the 
temporal lobe in temporal lobe epilepsy(Woermann et al., 1999c). 
  
The role of GABA in the developing brain and in epileptic tissue is the subject of 
much current research. Reduction in GABA inhibition may cause seizures (Olsen and 
Avoli, 1997) and several potent anti-epileptic drugs (AED) enhance GABA function. 
However, in immature or epileptic tissue, activation of GABAergic synapses may be 
excitatory rather than inhibitory(Ben Ari, 2002;Ben Ari and Holmes, 2005). Animal 
models of MCD have shown increased GABAergic function associated with impaired 
GABA transporter function(Calcagnotto et al., 2002), down-regulation of GABAA 
receptors(Prince et al., 1997) or decreased neuronal sensitivity to GABA(Benardete 
and Kriegstein, 2002).  
 
The aim of the current study was to measure the profiles in large MCD of GABA+ 
and GLX concentrations together with concentrations of the other main MRS visible 
metabolites.  
 
3.4.2 Methods 
3.4.2.1 Subjects 
Fifteen controls (seven female, with median age 27 years and range 18 to 40 years) 
and 15 subjects with MCD (five female, with median age 30 years and range 21 to 51 
years) were studied. Ethical approval by the Joint Research Ethics Committee of the 
Institute of Neurology and the National Hospital for Neurology and Neurosurgery was 
obtained, and all subjects gave informed consent.  All 15 patients had refractory focal 
epilepsy, and were taking one or more AED. Diagnosis was based upon full clinical 
assessment, interictal +/- ictal scalp EEG, neuropsychometry and MRI. All control 
subjects had normal MRI on visual inspection. All patients had a single dominant 
MRI evident MCD (Table 3.4.1). Four had bilateral and symmetrical pathology. In 
two of these, voxels were placed in homologous regions in both hemispheres and the 
obtained results averaged. Six subjects had MRI appearance of polymicrogyria (PMG) 
while nine subjects had MRI appearance of heterotopia (HT).  
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3.4.2.2 Magnetic Resonance Imaging 
A 1.5T SIGNA Horizon Echospeed scanner (General Electric, Milwaukee, WI) with a 
standard quadrature head coil was used for all studies. Axial T1 weighted inversion-
recovery prepared fast spoiled gradient recalled echo (IR-FSPGR) images were 
acquired (TE/TI/TR = 4.2/450/15.5 ms, flip angle 200; matrix 256*160; FOV 24 cm; 
slice thickness 1.5mm) to guide voxel placement and for segmentation into fractional 
grey matter, white matter and cerebro-spinal fluid (CSF) using SPM99 (Statistical 
Parametric Mapping; Wellcome Department of Imaging Neuroscience, Institute of 
Neurology, University College London). All MRI studies were reviewed by two 
experienced neuro-radiologists. 
 
3.4.2.3 Magnetic Resonance Spectroscopy 
For each MCD patient a voxel was prescribed from the axial IR-FSPGR images with 
in plane dimensions 40 by 35 mm and thickness 25mm (Fig. 3.4.1). The voxel was 
centred over the major visible MCD. In the controls a single voxel with dimensions 35 
by 40 mm in the Anterior-Posterior and Left-Right directions and thickness 25 mm 
was prescribed in the occipital lobes as previously described(McLean et al., 
2002;Simister RJ et al., 2003a) (Chapter [3.2], [3.3]). This control voxel location was 
chosen to match the high grey matter proportion seen in MCD. 
 
Conventional PRESS-localised water suppressed spectra were obtained with the 
acquisition parameters (TE/TR = 30/3000 ms) as in previous studies(Woermann et al., 
1999c;McLean et al., 2000;McLean et al., 2001;McLean et al., 2002), so that 
LCModel(Provencher, 2001) could be used for quantification of NAA plus N acetyl 
aspartyl glutamate (combined as NAAt), Cr, Cho, Ins and GLX. The double quantum 
filter (DQF) sequence (Keltner et al., 1997;McLean et al., 2002) was used to measure 
GABA concentration. 
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Table 3.4.1: Clinical data for the MCD subjects. M = male; F = female; r. = right; l. = left; 
PMG = polymicrogyria; SCH = sub-cortical heterotopia; SEH = sub-ependymal heterotopia. 
acetazol = acetazolamide; cbz = carbamazepine; clb = clobazam; gbp = gabapentin; ltg = 
lamotrigine; lev = levetiracetam; oxc = oxcarbazepine; pht = phenytoin; prm = primidone; 
tpm = topiramate; vpa = sodium valproate; sec. gen. = secondary generalised. LD = learning 
disability. 
 
 
Patient no. 
/age(years) 
/gender 
Seizure 
onset 
(year) 
CPS 
and 
SGTCS 
/month 
Days 
since 
last 
seizure 
Neurology EEG MRI AED 
1/45/M 6 30 2 r. 
hemiparesis 
Interictal: l 
hemisphere 
l. frontoparietal PMG cbz, prm, tpm 
2/51/M 7 4 30 l. 
hemiparesis 
Interictal and 
 ictal: r. temporal  
r. frontoparietal PMG plus 
l. occipital PMG 
cbz, vpa 
3/46/M 8 8 4 r. 
hemiparesis 
Interictal: l. 
hemisphere  
l.parietoccipital PMG and 
l. HS 
cbz, acetazol 
4/30/M 7 7 7 Normal Interictal and  
ictal:diffuse 
posterior  
r. hemisphere 
Bilateral r > l occipital 
PMG 
clb, vpa 
5/27/F 2 120 3 LD Interictal: 
bilateral r.>l. 
Diffuse bilateral PMG tpm, vpa 
6/28/M 10 15 1 LD Interictal: 
bilateral  
not localised 
Bilateral perisylvian PMG 
r. > l. 
lev, ltg, oxc 
7/51/M 28 0 >350 Normal Interictal:non 
specific 
r. parietal SCH cbz 
8/25/F 2 16 3 LD Interictal: non 
localised 
Bilateral SCH cbz, tpm, pht 
9/31/M 19 20 6 LD Interictal: r. 
temporoparietal 
Posterior r. sided SCH pht 
10/25/M 1 4 3 l. 
hemiparesis 
Interictal and  
ictal: r. 
frontoparietal 
r. frontoparietal SCH clb, cbz, gbp 
11/34/F 4 120 2 Normal Interictal: 
bilateral 
Diffuse bilateral SCH clb, cbz, tpm 
12/31/M 6 300 1 Normal Interictal:bilateral  
diffuse r. > l. 
Occipital SCH cbz, lev, vpa 
13/23/F 13 48 2 Normal  Interictal: r. 
temporal 
Occipital SHE lev, oxc, vpa 
14/21/F 15 3 >350 Normal Interictal:diffuse 
r. parietotemporal 
r. Parietotempero SCH cbz, ltg 
15/25/M 17 40 1 Normal Interictal: diffuse  
focus r. 
hemisphere 
Extensive r. 
temperoparietal SCH 
cbz, pht, tpm 
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Figure 3.4.1: Axial image showing the position of the prescribed voxels A) in the occipital 
lobes in a control and B) in the MRI visible MCD in patient 1. 
 
 
 
 
 
Right Left 
A) 
B) 
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Figure 3.4.2: A) Representative PRESS localised spectrum (TE/TR 30/3000ms) from 
patient 1 with superimposed LCModel fit to metabolite concentrations and estimated baseline, 
and B) a filtered GABA spectrum from the same patient.  NAAt = N-acetyl aspartate plus N-
acetyl aspartyl-glutamate; GLX = glutamate plus glutamine; Cho = choline-containing 
compounds; Cr = creatine + phosphocreatine; Ins = myo inositol; GABA+ = gamma amino 
butyric acid plus homocarnosine. PPM = chemical shift in parts per million.  
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P a g e  | 213 
 
All the obtained data achieved the thresholds for data quality of: A) Full width half 
maximum (FWHM) < 0.15 PPM for PRESS localised (TE/TR = 30/3000 ms) 
unsuppressed water peaks; and B) DQF signal to noise ratio (SNR) > 4.0 (signal taken 
as the peak height between 2.5 to 3.5 PPM and noise 15 to 20 PPM). Finally, 
metabolite concentrations were corrected for CSF content, which is considered to 
provide negligible signal(Lynch et al., 1993). T1 and T2 effects were not corrected for, 
since they can be considered to be minimal at short TE and long TR. 
 
3.4.2.5 Statistical method 
Statistical analysis was performed with SPSS 11.0. Metabolite concentrations and 
ratios were compared between the patient and control groups using the Mann-Whitney 
U test. Comparison between the control group and the sub-group of patients with HT 
was also made for NAAt, Cho, GLX (and GLX/NAAt) and GABA+ (GABA+/Cr). 
Comparison between the two MCD sub types was only made for the main metabolites 
NAAt and Cho because of the small numbers in each sub group. Individual patient 
data was compared against a normal range formulated as the control mean +/- 2 SD.   
  
Sodium valproate (VPA) is associated with reduction of Ins(Simister RJ et al., 2003b) 
[Chapter 3.5] therefore data from the five subjects taking this AED were not included 
in the analysis of Ins. Elevation in GABA+ has been consistently reported with 
Gabapentin and Topiramate(Petroff et al., 2000;Kuzniecky et al., 2002) and therefore 
data from the six subjects taking these AEDs were similarly not included in the 
analysis of GABA+ or GABA+/Cr. 
 
3.4.3 Results 
3.4.3.1 Group Results 
The proportion of grey matter in the studied voxels was similar in both groups (Table 
3.4.2). Inter-group comparison for the individual metabolites identified significant 
variation for NAAt, Cho and GLX. Cho (p < 0.001), GLX (p < 0.05) and GLX/NAAt 
(p< 0.001) were all elevated in MCD. NAAt (p < 0.05) and NAAt / Cr (p = 0.01) were 
reduced in the patient group (Fig 3.4.3).  
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Following removal of patients taking VPA from the Ins analysis and patients taking 
TPM or GBP from the GABA+ analysis no significant variation in Ins was observed 
although levels were generally lower in the patient group. GABA+/Cr levels were 
higher in the patient group (p<0.05) but GABA+ levels showed only a trend to 
elevation (Fig 3.4.4).   
 
Comparison between the control group and patients with HT (n = 9) showed elevation 
in Cho (p = 0.01), GLX (p = 0.05) and GLX/NAAt (p = 0.01). No difference in NAAt 
levels was observed. Comparison of NAAt and Cho levels between the HT group and 
the PMG showed lower NAAt in the PMG group (p < 0.05) but similar Cho. 
 
3.4.3.2 Individual patient results 
Individual patient metabolite concentrations and ratios were compared against a 
normal range (Table 3.4.3). NAAt was reduced in four patients, whilst Cho was 
elevated in seven patients. Four patients showed elevation in GABA+ (all four were 
taking TPM or GBP). Five patients showed low Ins (two of whom were taking VPA) 
and one showed elevated Ins. Seven patients showed elevated GLX/NAAt and six 
patients showed elevation in GABA+/Cr (five with GBP or TPM).  
 
3.4.3.3 Correlation with seizure control 
No correlation was observed between the measured metabolite concentrations or 
ratios and the time since most recent seizure (in days) or seizure frequency (the 
number of complex partial seizures per month).   
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Table 3.4.2: Metabolite concentrations (mmol/L) and ratios expressed as the group mean 
and standard deviation for healthy volunteers (Control) and subjects with malformations of 
cortical development (MCD). NAAt = N-acetyl aspartate plus N-acetyl aspartyl-glutamate; 
GLX = glutamate plus glutamine; Cr = creatine plus phosphocreatine; Cho = choline-
containing compounds; Ins = myo-inositol; GABA+ = gamma amino butyric acid plus 
homocarnosine. *P < 0.05 and ** P < 0.01 between patient group and the control group using 
Mann-Whitney U test. 
†
 patients not taking VPA (N = 10). 
#
 patients not taking TPM or GBP 
(N = 9). GM = voxel grey matter proportion, WM = voxel white matter proportion. Mean 
values and SD are provided for each measurement. 
 
 Control 
N=15 
MCD 
N=15 
GM/(GM+WM) 0.6(0.1) 0.6(0.1) 
NAAt 7.7(0.7) 7.0(0.6)* 
GLX 7.7(1.2) 9.0(1.4)* 
Cho 0.8(0.1) 1.1(0.2)** 
Cr 4.8(0.4) 4.9(0.5) 
Ins† 3.4(0.3) 3.2(0.7) 
GABA+
#
 1.3(0.2) 1.5(0.4)
 
NAAt/Cr 1.6(0.2) 1.4(0.2)* 
GABA+/Cr
#
 0.27(0.04) 0.32(0.06)* 
GLX/NAAt 1.0(0.2) 1.3(0.2)** 
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Figure 3.4.3: Box plots for A) NAAt (mmol/l), B) Cho (mmol/l), C) GLX (mmol/l) and D) 
GLX/NAAt in patients with malformations of cortical development (MCD) and healthy 
volunteers (CTL). The sub-groups of heterotopia patients (HT) and polymicrogyria patients 
(PMG) are also shown. The upper and lower edges of the box represents the upper and lower 
quartile respectively, the thick line within the box the median and the tail and whiskers the 
extremes of the data. Outliers are indicated. The number of subjects included in each group is 
indicated.  
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Figure 3.4.4: Box plots for A) Ins (mmol/l) and B) GABA+ (mmol/l) for patients with 
malformations of cortical development (MCD) and healthy volunteers (CTL). The sub-group 
levels for those patients taking VPA (V) and those not taking VPA (noV), and for those 
patients taking TPM or GBP (G) or not taking these medications (noG) are also shown. The 
upper and lower edges of the box represents the upper and lower quartile respectively, the 
thick line within the box the median and the tail and whiskers the extremes of the data. 
Outliers are indicated. * = P < 0.05 and ** = P < 0.01 between patient group and the control 
group using Mann-Whitney U test. 
 
 
 
 
 
P a g e  | 218 
 
Table 3.4.3: Individual patient data for the MCD subjects.  NAAt = N-acetyl aspartate plus 
N-acetyl aspartyl-glutamate; GLX = glutamate plus glutamine; Cho = choline-containing 
compounds; Cr = creatine + phosphocreatine; Ins = myo-inositol; GABA+ = gamma amino 
butyric acid plus homocarnosine. ↑/ ↓ = metabolite concentration or ratio more than 2 SD 
above / below the control mean. 
†
 patients taking VPA. 
# 
patients taking TPM or GBP. PMG = 
polymicrogyria and HT = heterotopia. 
 
Patient no. 
 
MCD group MRS findings 
1/45/M
#
 PMG ↑Cho ↑GLX ↑GLX/NAAt ↓Ins 
2/51/M
†
 PMG ↑Cho ↓NAAt 
3/46/M PMG ↑GLX/NAAt ↓NAAt ↓Ins 
4/30/M
†
 PMG ↓Ins  ↓NAAt 
5/27/F
†#
 PMG ↑Cho ↑GLX/NAAt ↑GABA+ ↑GLX ↓Ins 
↓NAAt/Cr ↑GABA+/Cr 
6/28/M PMG   
7/51/M HT  
8/25/F
#
 HT ↑GABA+ ↓Ins ↑GABA+/Cr 
9/31/M HT ↑Cho ↑Ins ↑GLX/NAAt ↓NAAt/Cr 
10/25/M
#
 HT ↑Cho ↑GLX/NAAt ↑GABA+ ↑GABA+/Cr 
11/34/F
#
 HT ↑Cho ↑GABA+/Cr 
12/31/M
†
 HT ↑GABA+/Cr 
13/23/F
†
 HT  
14/21/F HT ↑GABA+ ↑GABA+/Cr 
15/25/M
#
 HT ↑GLX ↑GLX/NAAt 
 
 
3.4.4 Discussion 
This study was the first MRS study to measure GABA+ concentrations in MCD in 
vivo. A modest elevation in GABA+/Cr was observed together with more marked 
elevation in GLX, Cho and GLX/NAAt in large MCD. Low NAAt was observed but 
may be a feature of PMG rather than HT. The results indicate highly abnormal 
metabolism in these lesions.  
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 Quantification of GABA+ remains technically difficult and the low sensitivity of the 
DQF method requires relatively large volumes of interest to be studied. This 
necessitated recruitment of subjects whose MRI showed extensive MCD. Such a 
group might be expected to demonstrate a greater level of neurochemical disturbance 
than would be observed in subjects with less extensive structural abnormalities. The 
prescribed volumes of interest included both MRI visible lesion and some surrounding 
normal appearing tissue. Since heterotopia are intrinsically epileptic whilst 
polymicrogyria lesions show perilesional epileptogenicity(Jacobs et al., 1999) the 
volume of interest should have included epileptic tissue in all subjects. In eight, the 
voxels were fronto-parietal and in seven they were parieto-occipital. Findings from 
earlier studies indicate that there is no large difference in metabolite concentrations 
between these regions in control subjects(McLean et al., 2000;Simister RJ et al., 
2003b) (Chapter [3.2] and [3.3]) although other groups have reported some regional 
variation in metabolite concentration(Pouwels and Frahm, 1998). Selection 
requirements resulted in relatively small numbers of patients, particularly within the 
PMG sub-type, and this obviously limits inference about sub-type variation in 
metabolite concentrations. 
 
The majority of previous MRS studies have relied on the use of the ratios NAA/Cr, 
NAA/Cho or NAA/(Cr and Cho)(Kuzniecky et al., 1997b;Li et al., 1998;Simone et 
al., 1999b;Widjaja et al., 2003). However, results from studies performed in healthy 
volunteers indicate that these ratios are sensitive to the tissue composition of the 
prescribed voxel(McLean et al., 2000).  Furthermore, information about the 
pathological variation in concentration of the individual metabolites is lost. In the 
current study this possible confounding effect was limited by comparing the 
individual metabolite concentrations in the patient groups with a control group studied 
in the occipital lobes where voxel grey matter proportion was similar.  
 
MCD form a heterogeneous group, but they share properties of primitive tissue, and 
often underlie refractory epilepsy which might well be reflected in discernable 
abnormalities in GLX and GABA+ metabolism. A low NAAt in MCD probably 
represents an unchanged density of neurones containing very low NAAt, a decrease in 
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the absolute number of neurones which contain normal NAAt, or a combination of the 
two processes.   
 
NAAt was lower in polymicrogyria (PMG) than heterotopia (HT) whilst both sub-
types showed elevated Cho. The histology of polymicrogyria shows abnormal cortical 
organisation and abnormal cells, whilst heterotopia are associated with relatively 
normal neuronal differentiation and organisation. Hence HT NAAt might be expected 
to be less abnormal than in PMG. There is a very limited literature concerning ex vivo 
MRS of MCD(Aasly et al., 1999). In that study histopathological examination 
identified mild cortical dysplasia in four subjects with associated gliosis in three and 
MRS examination showed reduced NAA and increased Cho (and GABA)(Aasly et al., 
1999). The pattern of reduced NAAt and elevated Cho is consistent with immature 
tissue and concurs with a longitudinal study of neurochemical profiles measured in 
healthy rats from postnatal day seven to postnatal day 28 (neurodevelopmentally 
equivalent to the period from 34 weeks gestation to age 2-3 years in the human 
brain)(Tkac et al., 2003). In that study cortical concentrations of NAA, Ins, Cr and 
glutamate increased with increasing age, whilst there was no change in GABA 
concentration and there was reduction in the metabolites making up the Cho signal. 
Studies of development in the human brain have reported similar neurochemicals 
profiles for NAA, Cr, GABA and glutamate but noted no change(Kok et al., 2002) or 
reduction of Ins(Kreis et al., 2002) with increasing development, and no change or 
reduction of Cho.  
 
Glutamate and GABA are predominantly localised to glutamatergic and GABAergic 
neurones respectively. Following release from the pre-synaptic nerve terminal they 
are removed from the synaptic cleft by re-uptake into the neurone or transported into 
neighbouring astrocytes. There they are predominantly metabolised to glutamine 
which is subsequently returned to the neighbouring neurones. One or more of a 
number of mechanisms might be responsible for elevation in the concentrations of 
these compounds. An increase in inter-neuronal connectivity within the neuropil but 
without increase in absolute neuronal numbers has been suggested to be an underlying 
mechanism for epileptogenesis in MCD(Sisodiya et al., 1995;Sisodiya, 1995).  These 
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GABA or glutamate containing neuronal projections might add to the total observed 
concentrations without an associated increase in NAA. Alternatively chronic energy 
depletion may develop as a consequence of structural changes or the subsequent 
development of chronic epilepsy, and lead to partial failure of neurotransmitter 
cycling resulting in neurotransmitter accumulation in the surrounding astrocytes (as 
glutamine) or within the neuronal cytoplasm as glutamate(Petroff et al., 2002a). 
Elevation in glial glutamine levels would also lead to increased GLX or, following 
neuronal metabolism to GABA, an increase in GABA+. Disturbances of uptake could 
also lead to secondary accumulation or mis-regulation of GABA or glutamate.  
 
In this study elevated GABA+/Cr was noted in MCD, which differs from previous 
studies which have shown an association between active epilepsy and low GABA+ 
levels(Petroff et al., 1996b) or unchanged GABA+ levels in IGE or focal 
epilepsy(Simister RJ et al., 2003b) [Chapter 3.2,3.3] in human adults.  The finding in 
this current study is supported by the identification of reduced expression of GABA 
transporters in heterotopic neuronal regions in an animal model, suggesting a reduced 
ability for GABA reuptake(Calcagnotto et al., 2002) and, potentially, abnormal 
accumulation of GABA.  Elevation of GABA+ concentrations is not necessarily 
associated with reduced epileptogenicity. Ex vivo studies of epileptic tissue not 
associated with MCD have shown normal or elevated GABA concentrations(Petroff 
et al., 1995) and several studies have shown reduced GABA receptor function in 
MCD potentially leading to altered GABAergic inhibition(Redecker et al., 2000). 
Furthermore, recent animal studies have shown that GABAergic suppression of 
hippocampal interneurons can enhance seizure activity and spread(Kullmann and 
Semyanov, 2002).  
 
Ex vivo studies have identified elevated glutamate in resected tissue(Petroff et al., 
1995) and in vivo MRS studies have found that NAAt was reduced and GLX and 
GLX/NAAt were elevated in the frontal lobes(Simister RJ et al., 2003b) [Chapter 
3.3] but not the occipital lobes(Simister RJ et al., 2003a) [Chapter 3.2] in subjects 
with idiopathic generalised epilepsy (IGE). Occipital measurement of subjects with 
occipital lobe epilepsy showed no significant variation in any metabolite or metabolite 
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ratio when allowing for variation in voxel grey matter proportion (Simister RJ et al., 
2003a) [Chapter 3.2].  
 
The effects of concomitant AEDs on metabolite concentrations must be considered. 
VPA has been associated with increase in glutamine (and by extension GLX) in a 
proportion of subjects(Petroff et al., 1999d). Previous studies using the same 
methodology have observed no difference in GLX concentrations between subjects 
with IGE taking VPA and those not taking this AED(Simister RJ et al., 
2003a;Simister RJ et al., 2003b) (Chapter 3.2 and [3.3]) and if this effect is present it 
is likely to be small. However VPA has previously been associated with reduction in 
Ins (Simister RJ et al., 2003b) (Chapter [3.3] and [3.5]) and therefore the five 
subjects taking VPA were not included in the group analyses of Ins. This effect of 
VPA on Ins levels was again observed in the current study where Ins levels in the 
excluded patients were generally lower (Figure 3.4.4). Similarly the AEDs TPM and 
GBP have been shown to increase GABA+ concentrations (for example (Petroff et al., 
2000)) in healthy subjects and this effect appears to be present in the current study 
where the GABA+ levels in the excluded patients were higher than the levels in those 
patients not taking these medications.  
 
Previous MRS studies have generally reported the ratios NAA/Cr, NAA/Cho or 
Cho/Cr and have been performed at long TE. These studies have reported that 
heterotopia and polymicrogyria may be associated with normal Cho/NAA and 
Cr/NAA ratios(Kuzniecky et al., 1997b;Widjaja et al., 2003), or normal NAA/Cr in 
polymicrogyria but variable reduction of NAA/Cr in heterotopia (Li et al., 1998). 
Focal cortical dysplasia has been associated with low NAA/Cr and 
NAA/Cho(Kuzniecky et al., 1997b;Li et al., 1998). In an earlier MRSI study in a 
group of subjects with either gyral abnormalities or heterotopia NAA, NAA/Cr and 
Ins were reduced in the MRI visible MCD(Woermann et al., 2001b). This variability 
in reported findings may be influenced by differing methodologies but also clearly 
reflects lesional and perilesional heterogeneity(Woermann et al., 2001a) as well as the 
relatively small number of subjects studied. Studies at higher field strength, and hence 
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improved spatial resolution, may allow better characterisation of the MRS 
appearances of these different MCD sub-types.   
 
In this study no correlation between seizure control and metabolite concentrations or 
ratios was noted. This agrees with earlier observations in cross sectional studies of 
patients with epilepsy(Simister et al., 2002;Simister RJ et al., 2003b) (Chapter [3.1],  
[3.2] and [3.3]) but longitudinal studies of GLX and GABA+ are required before any 
assessment can be made of how sensitive these measurements are to patient seizure 
control. 
 
3.4.5 Conclusion 
In this study quantitative 1H MRS demonstrated that MCD were associated with 
abnormal neurochemical profile. Patterns of abnormality were evident with elevated 
GLX (and GLX/NAAt) and GABA+ and GABA+/Cr together with previously 
described reduction in NAAt and elevation in Cho. 
 
P a g e  | 224 
 
3.5 The Effect of Sodium Valproate on Proton MRS Visible Neurochemical 
Concentrations 
 
ABSTRACT 
Purpose:  
Proton Magnetic Resonance Spectroscopy (MRS) measurements in patients with 
epilepsy may be affected by the use of antiepileptic medications (AEDs). Although 
sodium valproate (VPA) is a widely used AED no longitudinal MRS study has 
investigated the effects of VPA administration on MRS measurements in humans.  
 
Methods:  
A longitudinal quantitative short echo time Proton Magnetic Resonance Spectroscopy 
(MRS) study was performed in 10 patients with epilepsy to investigate the effect of 
the antiepileptic drug (AED), sodium valproate (VPA), on measured metabolite 
concentrations. The patients were studied on two occasions; whilst taking VPA, and 
either before commencing or after withdrawing from VPA. Myo-inositol (Ins), N-
acetyl aspartate plus N-acetyl aspartyl glutamate (NAAt), Creatine plus 
phosphocreatine (Cr) and glutamate plus glutamine (GLX) concentrations were 
measured. 
 
Results:   
Myo-inositol was lower in the VPA taking group, and no significant trends were 
noted for any other metabolite or ratio. No relationship between the change in 
metabolite concentration, VPA dose or seizure control was observed. 
 
Conclusions:  
The results emphasise importance of interpreting MRS findings in the light of 
administered medications.  
 
Published ref: (Simister et al., Epilepsy Research 2007 74, 215—219) 
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3.5.1 Introduction 
 
Analysis in the frontal lobes in patients with idiopathic generalised epilepsy has 
reported that sodium valproate (VPA), may be associated with reduced concentrations 
of Ins in patients compared to subjects not taking VPA(Simister RJ et al., 2003b) 
[Chapter 3.3]. In rats the introduction of VPA has been associated with reductions in 
Ins, NAA and Cr(O'Donnell et al., 2003).  
 
No longitudinal study has measured the effect of the introduction or withdrawal of 
VPA on metabolite concentrations in humans. The aim of the current study was to 
investigate the effects of VPA administration on MRS measurements in patients with 
epilepsy. 
 
3.5.2 Methods 
3.5.2.1 Subjects 
Sixteen healthy controls and 10 patients with epilepsy were included in the study. 
Ethical approval by the Joint Research Ethics Committee of the Institute of Neurology 
and the National Hospital for Neurology and Neurosurgery was obtained, and all 
subjects gave informed consent. All control subjects had normal MRI and were taking 
no regular medication.  
 
Every subject was scanned twice. For each control subject the data was labelled 
CTL1 and CTL2 dependent on the temporal order of the acquisition. For the patients, 
the study performed whilst taking VPA was designated VPA and that performed 
either before commencing VPA or four weeks after withdrawing from VPA was 
designated as noVPA (Table 3.5.1). Eight patients were studied before and after 
commencing VPA and two before and after withdrawing from VPA.  
 
3.5.2.2 Magnetic Resonance Imaging 
A 1.5T SIGNA Horizon Echospeed scanner (General Electric, Milwaukee, WI) was 
used with a standard quadrature head coil. Axial T1 weighted inversion-recovery 
prepared fast spoiled gradient recalled echo (IR-SPGR) images were acquired 
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(TE/TI/TR = 4.2/450/15.5 ms, flip angle 200; matrix 256*160; FOV 24 cm; slice 
thickness 1.5mm) to guide voxel placement and for segmentation into grey matter, 
white matter and cerebro-spinal fluid (CSF) using SPM99 (Statistical Parametric 
Mapping; Wellcome Department of Imaging Neuroscience, Institute of Neurology, 
University College London). 
  
3.5.2.3 Magnetic Resonance Spectroscopy 
For all subjects a single voxel was prescribed from the axial IR-SPGR images in the 
right or the left frontal lobe (40 * 35 * 25 mm)(Simister RJ et al., 2003b) (Fig 3.5.1).  
Care was taken at the time of the second study to assure a comparable spectroscopic 
acquisition to that of the first study.  
 
Conventional PRESS-localised water suppressed spectra (TE/TR = 30/3000 ms) were 
obtained(McLean et al., 2000), so that LCModel(Provencher, 1993;Provencher, 2001) 
could be used for quantification of NAAt, Cr, Cho, Ins and GLX. 
 
Finally, metabolite concentrations were normalized to 100% brain tissue by correcting 
for the CSF content estimated from the images by SPM. 
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Table 3.5.1: Clinical data for the patient group. M = male; F = female; SEH = sub-
ependymal heterotopia. Cbz = carbamazepine; dzp = diazepam; lev = levetiracetam; ltg = 
lamotrigine; pht = phenytoin; vpa = sodium valproate; Sz = generalised tonic-clonic seizures / 
complex partial seizure. IGE = idiopathic generalised epilepsy, FLE = frontal lobe epilepsy, 
xTLE = non-localised extra temporal lobe epilepsy. 
 
 
Patient 
no. 
/age 
(years) 
/gender 
Diagnosis MRI Not Taking VPA Taking VPA 
Last Sz (days) 
/ Sz frequency 
(pa) 
Concomitant 
AEDs 
Last Sz (days) 
/ Sz frequency 
(pa) 
VPAdose 
(mg/kg/day) 
1/19/M IGE Normal 350 / 2 ltg 120 / 1 27.6 
2/40/F IGE Normal 100 / 1 lev 30 / 1 11.9 
3/22/M IGE Normal 48 / 4 cbz, dzp 7 / 2 20.7 
4/33/F IGE Normal 36 / 3 ltg, cbz 6 / 2 7.9 
5/17/M IGE Normal 45 / 2 nil 30 / 1 8.5 
6/35/F IGE Normal 6 / 12 pht 15 / 4 14.8 
7/25/M FLE Normal 4 / 30 Cbz, pht 1 / 36 24.6 
8/46/F xTLE Bilat 
Post 
SEH 
280 / 3 cbz, pht 300/2 11.3 
9/18/M IGE Normal 19 / 9 nil 14 / 4 12.5 
10/40/F IGE Normal 0 / 0 nil 0 / 0 12.5 
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Figure 3.5.1: A) Axial image showing the position of the prescribed voxel in the right or left 
frontal lobe in a patient with idiopathic generalised epilepsy (Patient 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.1: B) Representative PRESS localised spectra (TE/TR 30/3000ms) for Patient 3 
with superimposed LCModel fit to metabolite concentrations and estimated baseline. VPA 
indicates acquisition whilst the patient was taking sodium valproate; and noVPA indicates the 
acquisition performed before commencing this medication. NAAt = N-acetyl aspartate plus 
N-acetyl aspartyl-glutamate; GLX = glutamate plus glutamine; Cho = choline-containing 
compounds; Cr = creatine + phosphocreatine; Ins = myo-inositol. 
 
  VPA       noVPA 
Cho 
Cr 
NAAt 
GLX 
Ins 
2.0 4.0 1.0 
PPM 
3.0 
Cho 
Cr 
NAAt 
GLX Ins 
2.0 4.0 1.0 
PPM 
3.0 
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3.5.2.4 Statistical Analysis 
Statistical analysis was performed with SPSS 11.0. Only acquisitions achieving a 
threshold for data quality of full width half maximum (FWHM) < 0.15 parts per 
million for PRESS localised (TE/TR = 30/3000 ms) unsuppressed water peaks, were 
accepted for analysis. The data in the two groups were compared using paired t-tests. 
Test-retest repeatability measures for the control group were defined as described on 
page 176 according to [Eqn. 3.2.1](Bland JM and Altman DG, 1986). Change in 
metabolite concentration (Δ) between the two scans was also calculated and expressed 
as; 
 
Δ = (noVPA – VPA) / mean (noVPA, VPA)            [Eqn 3.5.1] 
 
A correlation analysis was performed for VPA dose (mg/Kg), change in seizure 
control and Δ for each metabolite using Spearman’s Rho test. During the course of the 
study no changes were made to the concomitant AED treatment.  
 
3.5.3. Results 
All acquisitions achieved the above quality thresholds and were included for analysis. 
 
3.5.3.1 Group Results 
3.5.3.1.1 Control Subjects 
In the control group the median age was 32 years (range 20 to 53 years) and 10 of 16 
subjects were female. There was no difference in voxel grey matter proportion 
between CTL1 and CTL2. Repeatability scores were as follows; NAAt 9%, Cr 10%, 
Cho 13%, Ins 13%, and GLX 22%.  Mean values for CTL1 were NAAt 7.2 (SD = 
0.7) mmol/L, Cr 4.3 (SD = 0.6) mmol/L, Cho 1.1 (SD = 0.1) mmol/L, Ins 3.0 (SD = 
0.3) mmol/L, GLX 6.8 (SD = 1.2) mmol/L and grey proportion 0.29 (SD = 0.03).  
 
3.5.3.1.2 Patient Group 
For the patients the median age was 25 years (range 17 to 46 years) and four subjects 
were female. In the VPA group, seizure frequency (complex partial seizures or 
generalised tonic-clonic convulsions) was median six per year (range 0 to 30) and 
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time since last seizure seven days (range three to 120); whilst the data for the noVPA 
group were eight per year (range 0 to 60) and 20 days (range two to 100). There was 
no significant difference between seizure control in the two groups. Grey matter 
proportion was similar in VPA (0.29) and noVPA (0.30).  
 
Paired analysis showed a 10% lower mean Ins in the VPA compared to noVPA 
group (p = 0.01). No other metabolite concentration changed by more than 3% 
between the two scans, and no significant difference was observed in paired analysis 
for NAAt, GLX, Cr or the ratios NAAt/Cr or GLX/NAAt. Metabolite concentrations 
for noVPA were NAAt 6.8 (SD = 0.6) mmol/L, Cr 4.2 (SD = 0.6) mmol/L, Cho 1.0 
(SD = 0.1) mmol/L, Ins 3.2 (SD = 0.3) mmol/L, GLX 7.0 (SD = 1.2) mmol/L.  
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Figure 3.5.2: Error bars with 95% confidence limits for proportional difference in 
metabolite concentration (Δ) between the two scans for A) N-acetyl aspartate plus N-acetyl 
aspartyl glutamate (NAAt), B) myo-inositol (Ins) and C) glutamate plus glutamine (GLX). 
CTL = control group. PATIENT = patient group. Δ = (noVPA – VPA) / mean (noVPA, 
VPA), (CTL1-CTL2)/mean (CTL1,CTL2). † = significant to p < 0.05. 
 
 
A) NAAt 
B) INS 
C) GLX 
 CTL PATIENT 
  CTL PATIENT 
  CTL PATIENT 
0.0 
-0.1 
0.1 
            
ΔGLX 
  
ΔNAAt 
       ΔINS 
-0.1 
-0.2 
0.0 
0.1 
-0.06 
-0.02 
0.00 
0.04 
0.02 
0.05 
-0.05 
† 
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The inter-scan difference (Δ) in metabolite concentrations did not correlate with the 
dose of VPA taken and there was no correlation with Δ between the measured 
metabolites or change in seizure control.  
 
3.5.4 Discussion 
In this study relatively large voxels were used to allow for accurate estimation of 
metabolite concentrations and followed a similar methodology to an earlier study in 
this thesis (Simister RJ et al., 2003b) [Chapter 3.3]. In that earlier study a difference 
in the macromolecule baseline fit between the left and right frontal lobe voxels was 
observed. In the current study patients and controls were not matched for the side 
examined, precluding a formal cross sectional comparison between patients and 
controls, although there was an expected trend for reduced mean NAAt concentration 
in the patients.  
 
Ins is predominantly concentrated in glia(Brand et al., 1993), perhaps to store Ins for 
subsequent transfer to neighbouring neurons and incorporation into the phosphotidyl 
inositol second messenger intracellular signalling system. Ins may also have a 
significant role as an intracellular osmotic agent via the sodium myo-inositol co-
transporter (SMIT)(van Calker and Belmaker, 2000c). Animal studies(O'Donnell et 
al., 2003) have shown that both lithium and VPA reduce cellular Ins concentrations. 
Lithium has no antiepileptic efficacy and the reduction in Ins in itself does not 
immediately explain the antiepileptic efficacy of VPA. This observation is supported 
in the current study by lack of correlation between change in Ins concentration and 
either VPA dose or change in seizure control. MRS measurement of Ins in epilepsy 
has suggested that Ins might show elevation in epileptogenic tissue either as a 
consequence of the seizure activity, or secondary to a process of reactive 
gliosis(Woermann et al., 1999c;Wellard et al., 2003). The current study shows that 
this effect may be masked if studied patients are taking VPA. 
 
Elevation in GLX has been previously reported with VPA usage in association with 
hyper-ammonemia(Ziyeh et al., 2002). Increased glutamine concentrations are 
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thought to result from removal of ammonia in astrocytes by combination with 
glutamate. Valproate has also been reported to reduce NAA and Cr levels(O'Donnell 
et al., 2003). In the current study GLX concentrations were not elevated in the VPA 
group and NAAt and Cr concentrations were unaffected by VPA usage. 
 
3.5.5 Conclusion 
In this MRS study treatment with VPA was associated with a reduction in the 
concentrations of Ins but unchanged concentrations of NAAt, Cr and GLX in a 
patients with epilepsy. The reduction in Ins was not associated with measured change 
in seizure control suggesting that Ins reduction is not directly linked with the anti-
epileptic properties of VPA. 
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3.6 Proton MR Spectroscopy of Metabolite Concentrations in 
Temporal Lobe Epilepsy and Effect of Temporal Lobe Resection  
 
ABSTRACT: 
Purpose:  
To use proton Magnetic Resonance Spectroscopy (MRS) to measure in vivo temporal 
lobe GABA and glutamate plus glutamine (GLX) concentrations in patients with 
temporal lobe epilepsy (TLE) attributable to unilateral hippocampal sclerosis (HS) 
before and following anterior temporal lobe resection (ATLR). 
 
Methods:  
Quantitative short echo time MRS was obtained in both temporal lobes of 15 controls 
and 16 patients with TLE and HS, and repeat spectra in 10 patients after ATLR. The 
concentrations of N-acetyl aspartate + N-acetyl aspartyl-glutamate (NAAt), creatine 
plus phosphocreatine (Cr), and glutamate+glutamine (GLX) were measured using a 
metabolite-nulled sequence designed to minimize macromolecule artifact. GABA plus 
homocarnosine (GABA+) concentrations were measured using a previously described 
double quantum filter.  
 
Results: 
In patients with TLE, NAAt/Cr was reduced in ipsilateral and contralateral temporal 
lobes. No significant variation in GLX/Cr or GABA+/Cr was evident in any group 
although GABA+/Cr was highest in the ipsilateral temporal lobe in TLE. After ATLR 
there was a trend to normalization of NAAt/Cr but no change in individual metabolite 
concentrations, GLX/Cr or GABA+/Cr compared to pre-surgery levels. 
  
Conclusions:  
Temporal lobe epilepsy was associated with bilateral reduction in NAAt/Cr but not 
significant abnormality in GABA+/Cr or GLX/Cr. Normalization of NAAt/Cr in the 
contralateral temporal lobe was seen following successful ATLR.   
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Published ref: (Simister et al., Epilepsy Research 2009; 83:168-76.) 
P a g e  | 236 
 
3.6.1. Introduction 
 
In the healthy adult hippocampus, GABA pathways tightly control output activity by 
blocking excitatory input and regulating the synchronous discharge patterns of 
hippocampal principal cells (dentate granule cells, CA3 and CA1 pyramidal neurons). 
GABA is the dominant inhibitory neurotransmitter in humans and impairment of 
GABAergic inhibition may be a feature of epileptic tissue. Compounds that enhance 
GABAA receptor mediated inhibition suppress seizures, and epileptiform activity can 
be triggered when GABAA receptor mediated inhibition is blocked. Proton Magnetic 
Resonance Spectroscopy (MRS) experiments in humans with focal onset epilepsy 
have shown low occipital lobe GABA and increase in GABA levels with the 
introduction of GABAergic antiepileptic drugs (AED) or improved seizure 
control(Petroff et al., 1996b;Petroff et al., 1999b;Petroff et al., 2000).  
 
Increased neuronal excitation may be caused by altered glutamatergic function. 
Glutamate is the dominant excitatory neurotransmitter in the human brain and 
temporal lobe ECF glutamate levels have been shown to be increased in the interictal 
period in epileptic temporal lobes(Cavus et al., 2005) and to rise significantly during a 
temporal lobe onset seizure(During and Spencer, 1993) . MRS studies have shown 
elevation in GLX in patients with TLE but without evidence of HS on MRI 
(Woermann et al., 1999c;Simister et al., 2002) [Chapter 3.1] and in the frontal 
lobes(Simister RJ et al., 2003b) [Chapter 3.3] and thalami in idiopathic generalised 
epilepsy(Helms et al., 2006). 
  
Recent observations suggest that the concept of a simple balance between excitation 
and inhibition is inadequate to fully explain epileptic seizures. In particular, 
GABAergic systems may act as an excitatory neurotransmitter in epileptic tissue, 
either by altered connectivity of GABAergic interneurones or through changes in 
GABAA receptor function(Ben Ari and Holmes, 2005;Cossart et al., 2005). 
Furthermore, in the developing brain GABA appears to be primarily excitatory and 
may drive neuronal development and migration(Ben Ari, 2002).  
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MRS experiments have shown that NAA is reduced in the region of the sclerotic 
hippocampus(Cendes et al., 1994;Connelly et al., 1994;Kuzniecky et al., 
1998b;Woermann et al., 1999c) but also in regions distant from the epileptic focus(Li 
et al., 2000a) and in particular is often reduced in the contralateral normal appearing 
hippocampus(Cendes et al., 1995;Woermann et al., 1999c;Simister et al., 2002) 
[Chapter 3.1]. Contralateral temporal lobe NAA/Cr levels have been shown to 
normalize following anterior temporal lobe resection (ATLR) for refractory TLE 
(Hugg et al., 1996;Serles et al., 2001;Vermathen et al., 2002;Cohen-Gadol et al., 
2004).  
 
The acquisition of MR spectra in the temporal lobes has typically required long echo 
times and reporting of  the ratios NAA/Cr or NAA/(Cr + Cho)(Connelly et al., 
1994;Cendes et al., 1995;Hugg et al., 1996;Cendes et al., 1997b;Kuzniecky et al., 
1998b;Vermathen et al., 2000;Serles et al., 2001;Vermathen et al., 2002;Cohen-Gadol 
et al., 2004). However, short echo time experiments have allowed semi-quantitative 
measurement of these three main metabolites, as well as glutamate plus glutamine 
(GLX)(McLean et al., 2000;McLean et al., 2001) and myo-inositol (Ins).  Ins is 
considered to be localised predominantly in glial cells(Brand et al., 1993). GABA+ 
(GABA plus homocarnosine) measurement has been reported in patients with focal 
epilepsy with (Simister et al., 2007) [Chapter 3.4] or without (Simister RJ et al., 
2003a) [Chapter 3.2] MRI evidence of malformations of cortical development and in 
patients with idiopathic generalized epilepsy(Simister RJ et al., 2003b) [Chapter 3.2] 
by application of a double quantum filter in extra-temporal lobe locations.  
 
No previous study has simultaneously measured GABA+ and GLX levels in vivo in 
TLE. The purpose of this study was to examine these metabolites, and NAA, in the 
temporal lobes in patients with TLE prior to ATLR and in the contralateral temporal 
lobe following the surgery.  
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3.6.2 Methods 
3.6.2.1 Subjects 
Twenty-eight control subjects and 35 patients with chronic epilepsy secondary to 
unilateral HS were studied.  Twenty three control subjects were scanned twice to 
assess test-retest repeatability.  The study was approved by the Joint Research Ethics 
Committee of the National Hospital for Neurology and Neurosurgery and all subjects 
gave informed written consent. All patients had had a comprehensive pre-surgical 
evaluation including interictal and ictal scalp video-EEG, neuropsychometry and 
MRI. Thirteen patients underwent ATLR and were re-studied post surgery. 
 
MRS data were subject to quality control (see below). Spectra of adequate ipsilateral 
temporal lobe data quality were obtained in 19 test-retest datasets in the control 
population. Adequate data in both temporal lobe voxels were obtained in 16 TLE 
patients with radiological evidence of hippocampal sclerosis (designated as the HS 
group) and 15 control subjects (designated as CTL). Temporal lobe voxel data from 
the non-epileptic temporal lobe were obtained both before and after temporal lobe 
surgery in 10 patients (designated as SurgicalHS). All 10 had HS confirmed 
histologically, were seizure free following surgery and had no change in medication 
between the two scans. Six TLE patients were included in both the HS and the 
SurgicalHS groups. The frequency of seizures and the duration in days since the most 
recent seizure were noted for all studies. No patient reported an epileptic seizure 
within the twenty four hours prior to scanning. 
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Table 3.6.1: Demographics of the three groups of subjects. The healthy volunteer group is 
designated as Control. HS represents the group of patients with temporal lobe epilepsy and 
hippocampal sclerosis. Surgical HS represents the group of patients with HS studied before 
and after surgical resection. AED = anti-epileptic drug. * indicates data correct at the time of 
the pre-operative scan. 
 
  Control 
N =15 
HS 
N=16 
SurgicalHS 
N=10 
 Gender M/F 8/7 4/12 4/6 
 Age (yrs): median (range) 31(18-45) 33(20 –48 ) 33(24-45) 
 Side of pathology (right / left) Not applicable 7/9 5/5 
 Duration of epilepsy (yrs): median 
(range) 
Not applicable 18(7 – 45) 19(8-33) 
 Time since last seizure  
(days): median (range) 
Not applicable 5(2 - 90 ) 6(2-10)* 
 Frequency of complex partial seizures 
/ month: median (range) 
Not applicable 50(2  – 300) 50(25-120)* 
 Past history of prolonged early 
childhood convulsion. 
0 12/16 10/10 
 Number of AEDs taken: Median 
(range) 
0 2(1-3) 2(1-4) 
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3.6.2.2 Magnetic Resonance Imaging  
The study was performed on a 1.5T General Electric SIGNA Horizon Echospeed 
scanner (Milwaukee, WI, USA) using a standard quadrature head coil for all 
MRI/MRS studies. Axial T1 weighted inversion-recovery prepared fast spoiled 
gradient recalled echo (IRP-FSPGR) images were acquired (TE/TI/TR = 4.2/450/16 
ms, flip angle 20
o
; matrix 256*156; field of view 240x180mm; slice thickness 
1.5mm). These images were used both to guide voxel placement and subsequently for 
segmentation using SPM (Statistical Parametric Mapping; Wellcome Centre for 
Imaging Neuroscience, Institute of Neurology, University College London). All the 
MRI studies were reviewed by two experienced neuro-radiologists. 
 
3.6.2.3 Magnetic Resonance Spectroscopy  
3.6.2.3.1 Acquisition 
A single voxel was sequentially prescribed in each temporal lobe of each subject with 
approximate dimensions 40 mm (Anterior-Posterior), 35 mm (Left-Right) 25mm 
(thickness) (Fig 3.6.1). Two spectra were then acquired for each volume of interest 
according to our previously reported metabolite nulled protocol(McLean et al., 2004). 
Point-resolved spectroscopy (PRESS) localization was used to select the spectroscopy 
volume (TE/TR = 30/3000 ms). Water signal was suppressed using 3 chemical-shift 
selective (CHESS) pulses in both cases, with the flip angle of the final pulse tailored 
to ensure slight under-suppression. Thirty-two transients each were collected, with 
and without an inversion pulse (pulse delay 750ms) along with 16 without water 
suppression used for phasing of the data. The final “metabolite only spectrum” is the 
edited spectrum of the first acquisition minus the second metabolite nulled 
acquisition.  
 
Next the double quantum filter (DQF) sequence was applied to the same PRESS-
localised volume(McLean et al., 2002).  For the first acquisition the filter was not 
activated (ie normal PRESS, TE/TR = 68/2000 ms), and spectra were acquired with 
and without applied CHESS water suppression gradients (scan time c. 1 minute each). 
Subsequently the filter was activated and 512 transients collected (scan time 17:12) to 
measure GABA+. 
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Figure 3.6.1A) Axial T1-weighted localising MRI scans for a patient with right hippocampal 
sclerosis examined before and after anterior temporal lobe resection. Prescribed regions of 
interest are shown in (i) the ipsilateral and (ii) the contralateral temporal lobes prior to surgery 
and in (iii) the contralateral temporal lobe after surgery. 
 
Figure 3.6.1B) Representative spectra (TE/TR 30/3000ms) following application of the 
metabolite nulled protocol are shown for the patient above from regions of interest (i) and (ii) 
prior to surgery and (iii) following surgery as shown. NAAt = N-acetyl aspartate plus N-
acetyl aspartyl-glutamate; GLX = glutamate plus glutamine; Cho = choline containing 
compounds; Cr = creatine + phosphocreatine; Ins = myo-inositol; and GLX = glutamate plus 
glutamine. PPM = parts per million. 
 
Figure 3.6.1C) representative filtered GABA+ measured in the same patient from regions of 
interest (i), (ii) and (iii) as indicated.  GABA+ = GABA plus homocarnosine. PPM = parts per 
million. 
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3.6.2.3.2 Spectral Processing 
The “metabolite only” spectra (TE/TR = 30 / 3000 ms) were analyzed using 
LCModel(Provencher, 1993) quantification of NAAt , Cr, Cho, Ins and GLX.  .  The 
spectra obtained from the unfiltered DQF sequence (TE/TR = 68 / 2000 ms) were also 
analysed via LCModel in order to provide a consistent fit to the baseline. The 
LCModel Cr concentration obtained was then converted back to a peak area for 
comparison with the peak area of GABA estimated using SAGE 7.0 (General Electric, 
Milwaukee WI) as previously described (McLean et al, 2002).  
 
Fig 3.6.1 includes typical DQF spectra and LCModel outputs obtained from a TLE 
patient. Poor quality data was rejected by application of the following criteria: All 
PRESS localised (TE/TR = 30/3000 ms) datasets with unsuppressed water full width 
half maximum (FWHM) > 0.15 ppm were rejected and GABA+ data was rejected if 
the signal to noise ratio (SNR) of the filtered signal (signal taken as the highest peak 
between 2.5 to 3.5 ppm and noise 15 to 20 ppm) was less than 4.0. Preoperative 
patients and controls were only included if there were valid data in both temporal 
lobes.  
 
Locally written software in SAGE 7.0 provided estimates for the resulting grey 
matter, white matter and cerebro-spinal fluid (CSF) tissue composition of the 
prescribed MRS volume of interest based on the SPM segmentations of the IRP-
SPGRs. Metabolite concentrations were then corrected for CSF content, which is 
considered to provide negligible signal.  
 
3.6.2.4 Statistics 
Statistical analysis was performed with SPSS 11.0. In the first analysis the ipsilateral 
temporal lobe (HSips) and contralateral temporal lobe (HScont) patient data were 
compared against a control group (ControlM) for NAAt/Cr, GLX/Cr and 
GABA+/Cr; where ControlM represented the mean of the left and right temporal 
lobe measurements for each control subject.  These metabolite ratios were compared 
using ANCOVA with voxel grey matter content used as a co-variable, and post hoc 
comparisons were made using the Bonferroni Test. In the analysis of GABA+ 
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concentrations, data from patients taking GABAergic medications known to increase 
GABA levels were not included. 
 
In the second analysis data from the contralateral temporal lobe in the surgical group, 
before (PRE) and after ATLR (POST) and from a control group studied in the same 
temporal lobe on two occasions were analyzed. The change in metabolite 
concentration or ratio between the two scans was defined as: 
 
∆ = POST – PRE/Mean (PRE, POST)     [Eqn. 3.6.1] 
 
and for the Control group: 
 
∆ = (SCAN 2 – SCAN1)/Mean (SCAN1, SCAN2)   [Eqn. 3.6.2] 
 
Comparison was made for ∆ between the surgical and control groups. The group 
results for PRE and POST were also compared against the mean control group 
ControlM for the metabolite ratios NAAt/Cr, GABA+/Cr and GLX/Cr (see below). 
 
3.6.3 Results   
The demographics of the controls and patients with data of acceptable quality are 
given in Table 3.6.1. The medications taken by the patients were as follows (HS 
group/surgical group); valproate (3/4), lamotrigine (2/2), carbamazepine (9/6), 
topiramate (3/1), clobazam (5/2), phenytoin (3/1), Oxcarbazepine (3/1), 
phenobarbitone (1/0), levetiracetam (6/3). 
 
3.6.3.1 Control Group 
Nineteen test-retest studies (11 right TL and 8 left TL) were performed with 
acceptable data quality to determine repeatability which was calculated according to 
[Eqn. 2.4.1] on page 176(Bland JM and Altman DG, 1986). Test-retest repeatability 
scores for the control population were : NAAt 17%, Cr 23%, Cho 21%, Ins 23%, 
GLX 32%, GABA+ 43%, NAAt/Cr 25%, GLX/Cr 35% and GABA+/Cr 45%.  
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Data from the right and left temporal lobes were compared in the Control population.  
Concentrations of NAAt, Cr, Cho, GLX, GABA+ were all lower in the right temporal 
lobe. NAAt/Cr, GLX/Cr and GABA+/Cr values showed no side to side variability, so 
ratios rather than concentrations were compared between patients and control 
subjects. 
  
In the group having ATLR, both metabolite concentrations and ratios were compared 
because both measurements for each subject were performed in the same temporal 
lobe. 
 
 
3.6.3.2 Patient Group 
NAAt/Cr was significantly less in the patient than the Control groups (HSips 
p=0.001, HScont p=0.002) and there was no significant difference between patient 
groups. There was no trend to difference noted with GLX/Cr. ANCOVA analysis 
showed increased GABA+/Cr in the HSips group compared to Controls, but this  did 
not reach significance (p = 0.09).  
 
Table 3.6.2: Metabolite ratios in the temporal lobe ipsilateral to hippocampal sclerosis (HSips) and 
in the contralateral temporal lobe (HScont). The healthy volunteer group is designated as Control, 
measured in the right (R) and left (L) temporal lobes and expressed as a mean value (ControlM). 
NAAt = N-acetyl aspartate plus N-acetyl aspartyl-glutamate; GLX = glutamate plus glutamine; Cr = 
creatine plus phosphocreatine; GABA+ = GABA plus homocarnosine. The grey matter proportion in 
the analysed voxels is included. 
§
Patients not taking GABAergic drugs only (N= 11). (** p < 0.005 
compared to ControlM).  Data expressed as mean (standard deviation). 
 
 
 
Temporal lobe Control (R) 
N=15 
Control (L) 
N = 15 
ControlM 
N=15 
HSipsi 
N=16 
HScontra 
N=16 
Grey proportion 0.50(0.03) 0.49(0.03) 0.50(0.03) 0.54(0.11) 0.51(0.04) 
NAAt/Cr 1.6(0.2) 1.6(0.2) 1.6(0.1) 1.4(0.1)** 1.4(0.1)** 
GLX/Cr 1.6(0.2) 1.7(0.3) 1.7(0.2) 1.7(0.2) 1.6(0.2) 
§
GABA+/Cr 0.36(0.1) 0.37(0.07) 0.37(0.07) 0.42(0.08) 0.37(0.11) 
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Figure 3.6.2: Plots of mean and 95% confidence intervals for: (a) NAAt/Cr; (b) GLX/Cr  and (c) 
GABA+/Cr in control subjects (ControlM); patients with hippocampal sclerosis measured ipsilateral to 
the MRI pathology (HSips), and in the contralateral temporal lobe pre-surgery (HScont). NAAt = N-
acetyl aspartate plus N-acetyl aspartyl-glutamate, Cr = creatine plus phosphocreatine, GABA+ = 
GABA plus homocarnosine, and GLX = glutamate plus glutamine. ** p < 0.005. 
 
 
 
** ** 
P a g e  | 247 
 
3.6.3.3 Surgical Patient Group 
No trend to change in metabolite ratios was noted for GLX/Cr or GABA+/Cr. 
NAAt/Cr was significantly higher in the POST than the PRE group (∆NAAt/Cr: 
mean = 0.08, SD = 0.1) when compared against change in the control group (p=0.05). 
No trend to increase was noted for NAAt, GLX or GABA+. Cr was lower in the 
POST group (∆Cr: mean = 0.06, SD = 0.2) but this did not reach significance. 
NAAt/Cr was significantly lower in the PRE but not in the POST group when 
compared to ControlM (p=0.05). No correlation was observed between the changes 
for any metabolite or ratio and prior seizure frequency or interval since the most 
recent seizure. 
 
Table 3.6.3: Table of the 10 analysed patients undergoing TL surgery to treat medically 
refractory seizures. Results show PRE and POST values compared against a mean Control 
group (ControlM). NAAt = N-acetyl aspartate plus N-acetyl aspartyl-glutamate; GLX = 
glutamate plus glutamine; Cr = creatine plus phosphocreatine; Cho = choline containing 
compounds; Ins = myo-inositol; GABA+ = GABA plus homocarnosine. The grey matter 
proportion in the analysed voxels is included. (* p = 0.05). Data are expressed as mean(SD). 
 
Temporal lobe ControlM 
N=15 
PRE 
N=10 
POST 
N=10 
Grey proportion 0.50(0.03) 0.50(0.05) 0.50(0.02) 
 NAAt 6.3(0.4) 5.8(0.8) 5.9(0.8) 
Metabolites 
GLX 6.7(0.6) 6.7(0.5) 6.5(1.1) 
(mmol/l) Cho 0.9(0.1) 0.9(0.2) 0.8(0.2) 
 Cr 4.0(0.4) 4.1(0.5) 3.9(0.7) 
 Ins 3.0(0.4) 3.1(0.6) 3.0(0.7) 
 GABA+ 1.5(0.3) 1.6(0.3) 1.5(0.4) 
 
Ratios 
NAAt/Cr 1.6(0.1) 1.4(0.2)* 1.5(0.1) 
GLX/Cr 1.7(0.2) 1.6(0.2) 1.7(0.2) 
GABA+/Cr 0.37(0.07) 0.40(0.09) 0.39(0.07) 
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Figure 3.6.3: Plots of mean and 95% confidence intervals for: (a) NAAt/Cr, (b) GLX/Cr, (c) 
GABA+/Cr and (d) NAAt (mmol/L) for control subjects (ControlM); patients with 
hippocampal sclerosis measured contralateral to the MRI pathology before (PRE), and after 
(POST) temporal lobe surgery. NAAt = N-acetyl aspartate plus N-acetyl aspartyl-glutamate, 
Cr = creatine plus phosphocreatine, GABA+ = GABA plus homocarnosine, and GLX = 
glutamate plus glutamine. * p = 0.05. 
 
 
 
* 
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3.6.4.0 Discussion  
This was the first MRS study to report in-vivo concentrations of GABA+ in the 
temporal lobes in TLE. A trend to elevated GABA+/Cr levels was observed in the 
ipsilateral temporal lobes but normal levels contralaterally. No change was observed 
in contralateral NAAt, GLX or GABA+ concentrations following surgery, but 
normalization of NAAt/Cr levels was seen. 
 
The measurement of metabolite concentrations in the temporal lobes is difficult due to 
field inhomogeneity and susceptibility artifact. The requirement in the current study 
for a large volume of interest in which to measure GABA introduced further 
challenges to data quality. For the acquisition of the main metabolites these 
difficulties were in part compensated by reporting the metabolite concentrations as 
ratios with respect to Cr and by using techniques to minimise macromolecule 
inclusion in the baseline. Compared to previous studies of GABA+ measurement in 
the occipital and frontal lobes (Chapter [3.2] and [3.3]) there was reduced signal 
intensity and increased DQF signal distortion, resulting in the rejection of a larger 
number of datasets which did not fulfil data quality criteria and potentially poorer 
quality in the datasets included. These problems, however, will have been similar 
between both the control and patient groups and in particular between the pre and post 
operative spectra measured in the same temporal lobe. Despite these technical 
challenges, the test-retest repeatability for the retained datasets in this study are 
comparable to earlier studies; NAAt 17%, GLX 32%, GABA+ 43% in this study 
compared with NAAt 16%, GLX 26% and GABA+ 38% in the occipital 
lobes(Simister RJ et al., 2003a) [Chapter 3.2]. 
 
MRS studies of patients with TLE have generally reported NAA levels expressed with 
respect to Cr and/or Cho with the expectation that Cr in particular acts as an internal 
standard(Connelly et al., 1994;Burneo et al., 2004). In earlier work [Chapters 3.1 – 
3.5] metabolite concentrations as well as ratios were reported(Woermann et al., 
1999c;Simister et al., 2002) [Chapter 3.1]. However in these previous studies no side 
to side variability in metabolite concentrations was noted in the control population 
which allowed the formulation of a normal range for each metabolite that was 
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independent of the temporal lobe studied. In the current study a side to side difference 
in all metabolite concentrations for individual metabolites - but not for the ratios 
NAAt/Cr, GLX/Cr and GABA+/Cr - was evident in the control group, probably due 
to the data quality issues inherent in using larger voxels discussed above. Hence only 
the ratios have been reported in this study for the comparison between controls and 
HSips and HScont. This allows internal adjustment for field inhomogeneity but 
prohibits assessment of individual metabolite variation.  
 
The field inhomogeneity in the anterior and mesial regions of the temporal lobe meant 
that the region of interest could not include the anterior hippocampus where 
metabolite concentrations are most affected in hippocampal sclerosis(Simister et al., 
2002) [Chapter 3.1]. Despite these limitations low NAAt/Cr was observed in both the 
side ipsilateral to the HS and contralaterally. Similar results have been reported by a 
number of authors and this has been taken to represent evidence for neuronal loss or 
dysfunction outside the epileptic focus in TLE(Cendes et al., 1995;Hugg et al., 
1996;Chu et al., 2000;Li et al., 2000a). 
  
GABA+/Cr values were highest in the ipsilateral temporal lobe but did not remain 
significantly increased following correction for voxel grey matter content. Earlier 
work has previously noted that GABA+/Cr levels are increased in malformations of 
cortical development associated with refractory epilepsy(Simister et al., 2007) 
[Chapter 3.4] and these findings would argue against a simple reduction of GABA 
levels as the cause for epilepsy in these patients. However, sensitivity limitations of 
the technique at 1.5T preclude measurement of GABA within the hippocampus, 
where a local effect might be more pronounced and clinically significant.  
 
No abnormality in GLX/Cr was noted in either temporal lobe prior to surgery and no 
change was apparent following surgery. This is in keeping with previous observations 
that GLX levels are not elevated in the hippocampus or surrounding temporal lobe in 
TLE associated with HS (Woermann et al., 1999c;Simister et al., 2002) [Chapter 3.1] 
and also agrees with work performed at higher field strength(Hetherington et al., 
2006). Ex-vivo analysis of temporal lobe tissue from TLE patients with HS found 
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reduced neuronal cell counts and reduced glutamate levels in patients with the most 
severe pre-operative MRI abnormality, but no correlation between glutamate levels 
and cell loss(Petroff et al., 2002b). In some samples with the highest amount of cell 
loss glutamate levels were near normal.  
 
Several studies have measured NAAt/Cr following surgical treatment and found 
normalization of levels in those patients with improved seizure control(Hugg et al., 
1996;Cendes et al., 1997a;Serles et al., 2001). In this current study normalisation of 
NAAt/Cr but no change in NAAt was found. Cr levels were non-significantly lower 
after ATLR, compared with pre-operatively and this accounted for some of the change 
in NAAt/Cr. In previous studies of Cr in TLE a trend to elevation in HS compared to 
control levels has been observed(Connelly et al., 1994). This elevation in creatine plus 
phosphocreatine has been attributed to gliosis, which would appear to be unlikely in 
the current study due to the improved seizure control seen. 
 
As with previous studies no relationship between metabolite concentrations or ratios 
and seizure frequency was found and there was no correlation between pre-operative 
seizure frequency and change in NAAt/Cr or Cr post surgery [Chapters 3.1-3.3]. 
 
3.6.5 Conclusion 
In summary this study again indicates that NAAt and NAAt/Cr are sensitive measures 
of metabolite dysfunction in TLE due to HS. GABA+ levels may be elevated in the 
epileptic temporal lobe but further work is necessary to determine how this might 
reflect hippocampal GABA metabolism. NAAt/Cr but not NAAt appears to normalize 
in the contralateral temporal lobe after ATL. 
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3.7 The Effect of Epileptic Seizures on Proton MRS Visible Neurochemical 
Concentrations 
 
ABSTRACT 
Purpose:  
To investigate post-ictal changes in cerebral metabolites. 
 
Methods:  
We performed a longitudinal quantitative Proton Magnetic Resonance Spectroscopy 
(MRS) study in 10 patients with epilepsy and 10 control subjects. The patients were 
studied on two occasions: immediately following a seizure, and on a second occasion 
at least seven hours after the most recent seizure. Each study measured N-acetyl 
aspartate plus N-acetyl aspartyl glutamate (NAAt), Creatine plus phosphocreatine 
(Cr), Choline containing compounds (Cho) and glutamate plus glutamine (GLX) 
concentrations using a short echo time sequence (TE = 30ms), and NAAt, Cr and 
lactate using a second sequence with longer echo time (TE = 144ms). The control 
group was studied on two occasions using the same sequences. 
 
Results:   
No inter-scan differences were observed for the control group. NAAt and NAAt/Cr 
levels were lower in the patient group at both measured TEs but did not change 
significantly between studies. The ratio of Cr at TE 144ms to TE 30ms (Cr144/Cr30) 
and GLX/Cr were higher and Cho lower in the post ictal scan compared to the inter-
ictal study. Change in Cr144/Cr30 and NAAt144/Cr144 correlated with the post-ictal 
interval. Lactate measurement at longer TE was not informative.  
 
Conclusion:  
Proton MRS is sensitive to metabolite changes following epileptic seizures within the 
immediate post-ictal period. The ratio Cr144/Cr30 is the most sensitive measure of 
metabolic disturbance and is highest in the post-ictal period but appears to normalise 
within two hours of the most recent seizure. 
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3.7.1 Introduction 
 
Magnetic Resonance Spectroscopy (MRS) studies performed in human subjects have 
usually been performed inter-ictally and at least 24 hours after the last seizure. In 
these patients there appears to be no correlation between NAA, NAA/Cr or GLX and 
seizure control, or interval since the most recent seizure(Simister et al., 2002;Simister 
RJ et al., 2003b). GABA levels may rise after administration of several common 
antiepileptic drugs (AEDs) and with improved seizure control(Petroff et al., 
1996b;Petroff et al., 2001a).   
 
The few ictal or post-ictal MRS studies performed in humans have given differing 
results. Ictal elevation in lactate is the most common observation. NAA may be 
reduced or unchanged whilst the choline signal may be increased(Lazeyras et al., 
2000;Mueller et al., 2001a). Post-ictally dynamic changes may be apparent, with 
evidence of increased mobility of choline(Maton et al., 2001b;Flugel et al., 2006) or 
transient generalized reduction in all measured metabolites (Wellard et al., 2004).  In 
animal studies reduction in Cr and elevation in NAA/Cr, GLX and lactate have been 
reported, shortly following stimulated seizures (Najm et al., 1997;Neppl et al., 2001). 
Phosphorous MRS has demonstrated acidosis and reduction in phosphocreatine 
together with stable ATP levels during status epilepticus(Petroff et al., 1984;Young et 
al., 1985).  
 
The Cr signal visible to proton MRS is the sum of creatine and phosphocreatine. In 
mammals ATP levels are tightly controlled according to the reaction below using 
phosphocreatine as an energy store. The relative contributions of creatine and 
phosphocreatine to the combined Cr signal might therefore be expected to change 
dependent on the energy demands on the studied system. During periods of high 
energy demand and increased utilization of ATP the reaction below will be driven to 
the right to restore ATP levels and reduce PCreat stores. 
 
ADP + PCreat ↔ ATP + Creat      
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Phosphocreatine has a shorter T2 relaxation time than Creat (T2  for PCreat and Creat 
= 117 +/- 21 ms and 309 +/- 21 ms respectively)(Ke et al., 2002). At short TE any 
postictal decrease in phosphocreatine will make little difference to the combined 
signal of Cr. At long TE, however, the increased Creat component of Cr will cause it 
to decay more slowly and show relatively more signal compared to the resting state 
where PCreat and Creat are more evenly balanced. This implies that the ratio [Cr]long 
TE / [Cr]short TE should be increased in the immediate post-ictal state compared to the 
inter-ictal state as the equilibrium of the above reaction is driven to the right.  
 
The purpose of our study was to investigate dynamic changes in metabolite 
concentrations in the brain, particularly changes in the ratio [Cr]long TE / [Cr]short TE, in 
the immediate post ictal period, using MRS.   
 
3.7.2 Methods 
3.7.2.1 Subjects 
Ten healthy controls and 10 patients with epilepsy were included in the study. Ethical 
approval by the Joint Research Ethics Committee of the Institute of Neurology and the 
National Hospital for Neurology and Neurosurgery was obtained, and all subjects had 
given prior consent before the onset of the witnessed seizure. All control subjects had 
normal MRI and were taking no regular medication.  
 
Every subject was scanned twice. For each control subject the data was labelled 
CTL1 and CTL2 dependent on the temporal order of the acquisition. For the patients, 
the study performed immediately following a complex partial seizure or generalised 
tonic clonic seizure was designated POST and that performed more than seven hours 
following a witnessed complex partial seizure was designated INTER [Table 3.7.1]. 
During the course of the study no changes were made to patients’ AEDs. 
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Table 3.7.1: Clinical data for the patient group. M = male; F = female; CBZ = 
carbamazepine; CLB = clobazam; DZP = diazepam; GBP = gabapentin; LEV = 
levetiracetam; LTG = lamotrigine; PHT = phenytoin; PRM = primidone, VGB = vigabatrin; 
VPA = sodium valproate; Sz = generalised tonic-clonic seizures or complex partial seizure. 
FLE = frontal lobe epilepsy, OLE = occipital lobe epilepsy, PLE = parietal lobe epilepsy, 
TLE = temporal lobe epilepsy, X-TLE = non-localised extra temporal lobe epilepsy. HS = 
hippocampal sclerosis, MCD = undifferentiated malformation of cortical development and 
WM = white matter. 
 
 
Patient no. 
/age 
(years) 
/gender 
Diagnosis AEDs MRI Post Ictal Scan Inter ictal scan 
Time 
from  
end of sz  
to scan  
(mins)  
Duration  
of sz  
(mins) 
Time since  
last clinical  
seizure (hours) 
Time since 
post ictal 
scan 
(hours) 
1/28/F R. TLE clb, ltg Normal 60 4 34 34 
2/32/F L. X-TLE 
 
clb, cbz, 
gbp, ltg, 
vgb 
L.parieto-
occipital 
MCD 
60 2 24 24 
3/23/F R. OLE vpa Posterior 
heterotopia 
35 2 48 72 
4/23/F L. FLE cbz, gbp L.frontal 
MCD 
25 2 9 816 
5/63/M L. TLE clb, gbp, 
vpa 
 
L. HS 120 4 72 72 
6/45/M R. TLE clb,gbp, 
lev,ltg, prm 
R. HS 50 1 24 24 
7/33/M R. FLE cbz, clb Normal 120 1 26 26 
8/45/F R. X-TLE cbz, prm Multiple 
WM lesions 
120 3 7.5 48 
9/32/F R. TLE lev, ltg Normal 70 1 24 24 
10/26/M R. TLE cbz, lev R. HS 45 2 48 48 
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3.7.2.2 Magnetic Resonance Imaging 
All scanning took place on a 1.5T SIGNA Horizon Echospeed scanner (General 
Electric, Milwaukee, WI) with a standard quadrature head coil. Axial T1 weighted 
inversion-recovery prepared fast spoiled gradient recalled echo (IR-SPGR) images 
were acquired (TE/TI/TR = 4.2/450/15.5 ms, flip angle 200; matrix 256*160; FOV 24 
cm; slice thickness 1.5mm) to guide voxel placement and for segmentation into grey 
matter, white matter and cerebro-spinal fluid (CSF) using SPM (Statistical Parametric 
Mapping; Wellcome Centre for Imaging Neuroscience, Institute of Neurology, 
University College London). 
 
For each patient a single region was investigated, in the frontal lobe ipsilateral to the 
side of seizure onset. A single voxel was prescribed from the axial IR-SPGR images 
with dimensions (40 * 35 * 25 mm)(Simister RJ et al., 2003b) (Figure 3.7.1).  For 
each control subject an otherwise identical acquisition was performed separately in 
both the right and left frontal lobes. Care was taken at the time of the second study to 
assure comparable voxel positions to the first study. 
 
Conventional PRESS-localised water suppressed spectra were obtained, so that 
LCModel(Provencher, 1993) could be used for quantification of metabolite 
concentrations. In the first sequence (TE/TR 30/3000ms) NAAt, Cr, Cho, Ins, and 
GLX were measured and these results are designated by the subscript 30. In the second 
sequence with longer echo time lactate, NAAt and Cr were measured and designated 
with the subscript 144.  
  
Figure 3.7.1: A) Axial T1 weighted MR image showing the position of the prescribed voxel 
in patient 3. B)  Representative PRESS localised spectra with superimposed LCModel fit to 
metabolite concentrations and estimated baseline for the same patient in the post ictal period 
(POST) and inter-ictal period (INTER). Top: (TE/TR 30/3000ms); bottom: (TE/TR 
144/3000ms). NAAt = N-acetyl aspartate plus N-acetyl aspartyl-glutamate; GLX = glutamate 
plus glutamine; Cho = choline-containing compounds; Cr = creatine + phosphocreatine; Ins = 
myo-inositol, Lac = lactate. 
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Finally, metabolite concentrations were normalized to 100% brain tissue by correcting 
for the CSF content within the voxel, estimated from the SPGR images using SPM. 
 
3.7.2.3 Statistical analysis 
Statistical analysis was performed with SPSS 11.0. Only acquisitions achieving a 
threshold for data quality (full width half maximum (FWHM) < 10 Hz for PRESS 
localised (TE/TR = 30/3000 ms) unsuppressed water peaks) were accepted for 
analysis. Group changes in the following concentrations were examined: NAAt30, 
Cr30, Cho30, Ins30, GLX30, NAAt144, Cr144, Lac144, and the following ratios: 
NAAt30/Cr30, NAAt144/Cr144, GLX30/Cr30 and Cr144/Cr30.  
 
Data from the right and left frontal voxels were obtained from each control subject 
and averaged to give a mean metabolite concentration or ratio for that subject 
(CTLM). An ANOVA comparison was then performed between CTLM and the 
patient POST and INTER groups. Bonferroni correction was made in each case to 
allow for multiple comparisons.  
 
Change in metabolite concentration (Δ) between the two scans was calculated for each 
subject, being defined for each patient as: 
 
Δ = (POST- INTER) / mean (POST, INTER)   [Eqn. 3.7.1] 
 
and for each control subject as: 
 
Δ = (CTL1-CTL2) / mean (CTL1,CTL2)    [Eqn. 3.7.2] 
 
Differences were analysed for significance using a one sample t-test. 
 
Finally, we performed a correlation analysis for time since most recent seizure, inter-
ictal interval and Δ for each metabolite and ratio using Spearman’s Rho test.  
 
P a g e  | 260 
 
3.7.3 Results 
All spectra satisfied quality thresholds and were included for analysis. In the control 
group the median age was 35 years (range 28 to 52 years) and four of the 10 subjects 
were female. There was no difference in voxel grey matter proportion between CTL1 
and CTL2 or between right and left frontal lobe voxels. No side to side differences 
were observed for any metabolite between the left and right frontal voxels. No trend 
to inter-scan difference (∆) was noted for any metabolite concentration or ratio.  
 
Metabolite concentrations were lower for patients than controls both in the POST and 
INTER scans for NAAt30 and NAAt144 and for NAAt30/Cr30 and NAAt144/Cr144 but 
following Bonferroni correction only POST NAAt30 (p = 0.05) and INTER 
NAAt30/Cr30 (p=0.05) remained significant compared to the CTLM. Cr144/Cr30 was 
lower for INTER compared to POST (p = 0.05).  
 
Comparison of inter-scan differences (∆) revealed that apparent Cho30 concentration 
was 9% lower post ictally (p = 0.03). No other significant change in concentrations 
was noted. The ratio GLX30/Cr30 was 9% higher (p=0.02) and Cr144/Cr30 7% higher 
(p=0.03) post-ictally. 
 
There was a correlation between Δ(Cr144) and post-ictal interval (R
2
 = 0.5, p = 0.02). 
No other individual metabolite showed an association with post-ictal or inter-ictal 
intervals. There was a significant correlation between post-ictal interval and Cr144/Cr30 
(R
2
 = 0.74, p = 0.001) and NAAt30/Cr30 (R
2
 = 0.6, p = 0.007). Regression analysis 
indicated that these ratios normalised to inter-ictal levels at post-ictal intervals of 
approximately 105 minutes and 85 minutes respectively.  
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Table 3.7.2: showing data for the mean control group (CTLM) measured on two occasions 
(CTL1 and CTL2) and the patient group measured in the post ictal (POST) and inter ictal 
(INTER) periods. NAAt = N acetyl aspartate plus N acetyl aspartyl glutamate, Cr = creatine 
plus phosphocreatine, Lac = lactate, Cho = choline containing compounds, GLX = glutamate 
plus glutamine. Metabolite concentrations measured in mmol/L. (144) TE = 144ms. (30) TE = 
30ms. * significant variation (p < 0.05) when compared against CTLM. 
†
 significant elevation 
in POST compared to INTER levels (p < 0.05). Metabolite and ratio data presented as mean 
(SD). 
 
 CTL1 
N = 10 
CTL2 
N = 10 
CTLM 
N=10 
POST 
N = 10 
INTER 
N = 10 
 Grey 
Proportion 
0.29 0.29 0.29 0.29 0.29 
 
 
 
Metabolites 
(mmol/L) 
NAAt144 4.4(0.4) 4.4(0.4) 4.4(0.4) 4.1(0.3) 4.1(0.4) 
Cr144 1.9(0.1) 1.9(0.1) 1.9(0.1) 1.9(0.2) 1.9(0.2) 
Lac144 0.20(0.12) 0.28(0.08) 0.24(0.09) 0.30(0.10) 0.26(0.16) 
NAAt30 7.0(0.5) 7.1(0.6) 7.1(0.5) 6.5(0.5)* 6.6(0.7) 
Cr30 4.3(0.5) 4.4(0.5) 4.3(0.5) 4.2(0.4) 4.5(0.5) 
Cho30 1.2(0.2) 1.2(0.1) 1.2(0.2) 1.1(0.2) 1.2(0.1) 
Ins30 3.1(0.4) 3.0(0.4) 3.1(0.4) 3.2(0.6) 3.2(0.4) 
 GLX30 6.3(0.9) 6.7(1.0) 6.5(0.8) 6.5(1.0) 6.4(0.8) 
 (NAAt/Cr)144 2.3(0.2) 2.3(0.1) 2.3(0.1) 2.1(0.3) 2.2(0.3) 
Ratios (NAAt/Cr) 30 1.7(0.2) 1.6(0.2) 1.6(0.1) 1.5(0.2) 1.5(0.2)* 
 (GLX/Cr) 30 1.5(0.1) 1.6(0.2) 1.5(0.1) 1.5(0.2) 1.4(0.2) 
 Cr144/C30 0.45(0.05) 0.45(0.04) 0.45(0.04) 0.47(0.04)
†
 0.43(0.03) 
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Figure 3.7.2: Error bars with 95% confidence limits for the change in metabolite 
concentrations between the two scans (Δ) for each subject [where Δ = (POST- INTER) / mean 
(POST, INTER) for each patient and (CTL1-CTL2) / mean (CTL1,CTL2) for each control]: 
A) ∆NAAt30, B) ∆(GLX30/Cr30), C) ∆Cho30, and D) ∆(Cr144/Cr30) where 30 represents studies 
performed at TE = 30ms and 144  represents TE=144ms. CTL = control group. Patients = 
patient group. * = significant to p < 0.05. 
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Figure 3.7.3: Scatter plot and regression curve for A) Cr144/Cr30 and B) NAAt144/Cr144 
against post-ictal interval measured in minutes.  
 
 
 
 
3.7.4 Discussion 
This is the first in-vivo proton MRS study to indicate a time line for recovery of 
metabolite dysfunction following seizures in humans. The results show that 
metabolite disturbances are apparent in the immediate post-ictal period but normalize 
within two hours. Changes in the concentration of the combined Cr signal were 
demonstrated, and were the most sensitive markers for recent seizure activity. 
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No trend to difference was noted for voxel tissue composition or any metabolite 
concentration in the control group between scans, or between the right and left frontal 
lobes. Performing MRS shortly after seizures was challenging, but was possible 
because of the location of the MR scanner within the Epilepsy Assessment Centre. 
Additionally, each patient had consented to participation in the study before the day of 
the seizure. The longer TE sequence was performed second and therefore post ictal 
intervals were slightly longer for this acquisition. All patients included in the study 
had had witnessed complex partial or generalized seizures and approximate seizure 
duration was noted.  
 
As expected, NAAt and NAAt/Cr were low in the patient groups, despite prescription 
of the MRS voxel outside the seizure focus in several cases. Lactate could not reliably 
estimated by LCModel and no significant elevation was seen post-ictally compared to 
the other groups. Previous studies have reported elevated lactate following a 
prolonged seizure(Petroff et al., 1986;Fazekas et al., 1995;Najm et al., 1997;Neppl et 
al., 2001), but it is likely in the current study that the seizures witnessed were too 
short to produce detectable lactate elevation. Similar results were obtained in an 
earlier study(Flugel et al., 2006). 
 
In the patient group, Cho was lower and GLX/Cr and Cr144/Cr30 higher in the post-
ictal study. In the earlier study reduction in Cho post-ictally was not seen(Flugel et al., 
2006), although reduced Cho MTR was identified, indicating alteration in the 
interaction of choline containing moieties with the immobile phospholipid pool. 
Synthesis of phophatidylcholine is impaired by NMDA receptor overactivity before 
phospholipid degeneration occurs(Gasull et al., 2003) and impaired formation of 
phosphocholine from choline is observed during periods of high energy demand and 
excess glutamatergic activity(Gasull et al., 2002). Since the visible choline signal is 
mainly made up of phosphocholine and glycerylphosphocholine, both metabolites of 
phosphatidylcholine, it may not be surprising that there is reduction in this signal 
following brief epileptic seizures. Prolonged seizures with irreversible cell damage 
would be more likely to be associated with phospholipid membrane degeneration and 
release of high concentrations of choline containing metabolites.  In the current study 
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there was no association with the post-ictal interval indicating a slower recovery 
period of choline metabolism than in the post-ictal monitoring period of the current 
study. 
 
Elevation of GLX/Cr was seen post-ictally compared to the inter-ictal period but there 
were no significant changes for GLX itself.  Elevated glutamate has been reported in 
the region of a temporal lobe seizure(During and Spencer, 1993) and in ex-vivo 
analysis of epileptic cortex(Petroff et al., 1995) and it is possible that a similar effect 
here could have been masked by the relative insensitivity of our techniques, which 
cannot distinguish between different metabolite pools within the brain, and the 
unavoidable postictal interval. Subsequent work by Badawy and colleagues has shown 
reduced cortical exciteability in the immediate post ictal period and this finding would 
suggest that intracellular glutamate and glutamine levels may well not be elevated 
post-ictally(Badawy et al., 2009). 
 
NAAt concentrations were similar in the post-ictal and inter-ictal studies, concurring 
with the earlier study(Flugel et al., 2006) and also with post-ictal animal 
studies(Neppl et al., 2001). Other studies have shown reduced ictal NAA in focal 
cortical dysplasia(Neppl et al., 2001), reduced post-ictal NAA in Rasmussen’s 
encephalitis(Wellard et al., 2004) or elevated ictal levels in animals(Najm et al., 
1997). Ex-vivo findings have shown that NAA levels are not directly correlated with 
neuronal cell loss(Kuzniecky et al., 2001;Petroff et al., 2002b) and further work is 
needed to evaluate the patho-physiological correlate of low or high NAA levels. 
However it may not be surprising that NAAt levels were not affected in this study. 
NAA synthesis appears to be linked with the rate of glucose metabolism(Moreno et 
al., 2001). Periods of increased glucose metabolism such as occur during seizures may 
be expected to lead to NAA accumulation whilst periods of neuronal hypo-excitability 
and consequently reduced glucose metabolism as shown to occur in the immediate 
post-ictal period(Badawy et al., 2009) will lead to reduced NAA levels. The exact 
balance between accumulation and reduced synthesis may well vary significantly 
depending on the intensity of metabolic activity during the seizure, seizure duration 
and time since seizure cessation. 
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Cr144/Cr30 was elevated post-ictally and Cr144 was highest in the immediate post-ictal 
period. These findings are consistent with the post-ictal phase being marked by a shift 
of equation (1) to the right and increased proportions of the slower decaying creatine 
signal. Phosphorus MRS studies(Petroff et al., 1984;Young et al., 1985) have reported 
lowered post-ictal phosphocreatine, which is consistent with our findings. The 
advantages of using 1H instead of 31P MRS to monitor this is that proton MRS 
allows potentially much higher spatial resolution and the hardware needed is more 
widely available.  
 
Correlation analysis with the post-ictal interval suggests that these changes will only 
be observed if the patient is scanned within the first 100 minutes following a single 
complex partial or generalized seizure. 
 
The post-ictal interval at which measurements are made is likely to be critical and 
may explain the variation in published findings. One previous in-vivo post-ictal study 
did not find changes in the ratio NAA/Cr post ictally, but generally performed the post 
ictal study after a longer interval(Maton et al., 2001b). Flugel et al. used a similar 
methodology and had a  median post-ictal interval of 70 mins, compared to  60mins in 
the current study, and did not use a longer TE acquisition(Flugel et al., 2006). Post-
ictal MRS animal studies have previously found elevated lactate and NAA/Cr or 
reduced Cr(Najm et al., 1997;Neppl et al., 2001) and low phosphocreatine(Petroff et 
al., 1984;Young et al., 1985) following prolonged stimulated status epilepticus. 
However the metabolic consequences of prolonged seizures would be expected to be 
different to those induced by brief self terminating seizures and it is notable that in 
these studies prolonged elevation in lactate is reported together with histological 
evidence of neuronal loss(Najm et al., 1997).  
 
3.7.5 Conclusion 
In this study MRS demonstrated dynamic disturbances in metabolic function after 
single seizures. The ratio Cr144/Cr30 was the most informative measure and implied a 
change of energy metabolism in the brain that reverted to normal over one and a half 
hours.  
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Chapter 4: Thesis conclusions and Further Work 
 
The work included in this thesis was undertaken with two fundamental aims: The first 
was to apply a standardised MRS methodology in order to gain reproducible semi-
quantitative information about the variation of relevant neurometabolites such as 
gamma amino butyric acid (GABA), glutamate (as glutamate plus glutamine [GLX]), 
N acetyl aspartate (NAA), myo-inositol (Ins) and creatine plus phosphocreatine (Cr) 
within epilepsy syndromes or pathological groups. The second main aim was to test a 
series of hypotheses relating to the regulation of the concentrations of these 
metabolites in the region of epileptic seizures, immediately following seizures and 
associated with particular medical and surgical treatment interventions.  
 
Prior to the period during which this work was undertaken several groups had 
reported MRS findings in patients with epilepsy. These studies, which had generally 
reported on only the major visible metabolites and which had used metabolite ratios 
rather than individual metabolite concentrations, had indicated that MRS may be a 
sensitive tool for the in vivo assessment of biochemical disturbance associated with 
epilepsy. This thesis has built on the evidence from these early studies and has taken 
advantage of the opportunity to measure neurometabolites such as glutamate and γ-
amino butyric acid (GABA) that are of fundamental importance to understanding 
epilepsy. 
 
The thesis was undertaken based upon several hypotheses. Namely that: 
 
Cortical excitability in idiopathic generalised epilepsy (IGE) is associated with 
reduced concentrations of GABA and / or raised concentrations of glutamate and  
glutamine in the cerebral cortex. (Hypothesis I) 
 
In patients with focal seizures, there will be a disturbance in GABA and / or glutamate 
levels in the region of the epileptic focus compared to healthy controls measured in 
the same anatomical region. (Hypothesis II) 
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There will be measurable metabolite abnormalities in epileptogenic malformations of 
cortical development as a consequence of the abnormal development of this tissue. 
(Hypothesis III) 
 
There will be a measurable disturbance of brain metabolites at the site of interictal 
epileptiform activity that will help to characterise the epileptic focus. (Hypothesis IV) 
 
Following focal seizures there will be a transient disturbance in those measurable 
metabolites relevant to cell energetics and neurotransmission such as lactate, GABA, 
glutamate and glutamine and phosphocreatine. (Hypothesis V) 
 
The thesis findings will now be briefly discussed in the context of these hypotheses. 
 
MRS techniques demonstrate metabolite abnormalities in epileptic patients. NAA is 
the most commonly observed metabolite marker of chronic pathology but levels are 
insensitive to recent seizure history. These findings repeat earlier observations of the 
usefulness of NAA measurement in the assessment of chronic epilepsy whilst 
illustrating ongoing uncertainty as to the correct pathophysiological interpretation of 
reduced NAA levels. Low NAA is a feature of 9/10 patients with hippocampal 
sclerosis and temporal lobe epilepsy and 4/10 with MRI negative temporal lobe 
epilepsy. NAA levels were otherwise normal in patients with occipital lobe epilepsy. 
The other measured metabolites are not demonstrated to be sensitive markers for 
inter-ictal abnormality in the region of the epileptic focus. These findings indicate that 
characteristic metabolite disturbance in the region of an epileptic focus is not 
identifiable in occipital lobe epilepsy but that NAA is a good marker of abnormality 
in temporal lobe epilepsy associated with hippocampal sclerosis (IV).  
 
GLX and GABA+ measurement in focal epilepsy did not demonstrate a characteristic 
pattern of disturbance (II). GLX was elevated in the contralateral hippocampus but not 
in the epileptogenic hippocampus [3.1]. GABA+ levels were not reduced in this 
region and instead showed a trend to elevated levels compared to the contralateral 
hemisphere and to the control group [3.6]. In OLE, GLX and GABA+ levels were not 
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altered compared to the control group or to a population with IGE. These findings 
indicate that at the resolution of current MRS techniques GABA and GLX disturbance 
in epileptic foci is not reliably detectable. A probable explanation for this finding is 
that several factors have combined to influence the concentrations obtained. Firstly, at 
the current level of technological development measurement is limited to relatively 
large volumes of interest, long duration acquisitions, and measurement of combined 
signals rather than individual metabolites. These factors will become less significant 
as technology improves. Secondly, the potency of glutamate and GABA molecules at 
synaptic terminals are such that simple imbalances in the concentrations of these 
metabolites that remain present over the time span of an MRS acquisition are 
probably unlikely to be found in patient volunteers well enough to attend for routine 
research studies. Thirdly, MRS is sensitive to free intracellular GABA and glutamate 
and relatively insensitive to extracellular signal and signal contained in synaptic 
vesicles. Consequently, measurement of these signals provides only an indirect 
measure of the metabolism of these compounds. 
 
In contrast MRS appears to have great promise as an investigatory tool for assessment 
of malformations of cortical development (MCD) (III). The finding in this thesis that 
metabolite concentrations demonstrate signal characteristics that show similarities to 
spectra obtained from immature brain tissue fits well with an understanding that MCD 
represent abnormal / blocked development. Both GABA+ and GLX levels were 
abnormal in this tissue which may represent abnormal formations of GABAergic and 
glutamatergic neurons, a highly abnormal metabolic regulation of these compounds, 
and / or a consequence of epileptogenicity. These results would recommend a role for 
MRS in the identification of MCD because the examination should be informative 
both in the region of visible abnormality (to demonstrate the signature of the MCD) 
and in non-adjacent regions (to assess whether these regions are likely to represent 
abnormal tissue even if apparently normal at the resolution of today’s MRI 
sequences). Finally, the observation that different sub-types of MCD may show 
different MRS profiles could recommend a further role for MRS in the sub-
classification of MCD. 
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NAA and GLX/NAA levels were altered in the frontal lobes but not in the occipital 
lobes in Idiopathic Generalised Epilepsy. This finding provides support for frontal 
lobe “cortical hyperexcitability” as a cause or consequence of IGE (I). In contrast 
GABA+ levels were not abnormal in either the frontal or occipital lobes in these 
patients. Reduced frontal NAA would imply abnormal tissue and this finding would 
support pathological observations of microdysgenesis in patients with IGE. The IGE 
group studied in the frontal lobes in this thesis was sufficiently heterogeneous in terms 
of IGE sub-type to preclude any close examination of metabolic profiles within sub-
groups but this would be an interesting follow up study.  
 
Inter-ictal MRS measurements do not appear to be sensitive to recent seizure history. 
In [Chapter 3.3] there was no association between metabolite levels and the time 
since the previous seizure or with seizure frequency. In [Chapter 3.6] NAA levels 
were unchanged in the contralateral temporal lobe after successful surgical treatment 
of mesial temporal lobe epilepsy. However NAA/Cr levels did normalise in this study 
and this has also been reported by other groups. The results from this thesis and in 
particular the results of the post-ictal study [Chapter 3.7] would argue that this 
change may represent alteration in the combined signal of Cr rather than changes in 
NAA. In [Chapter 3.7] I demonstrated that MRS can detect transient alteration of 
metabolite concentrations immediately following an epileptic seizure (V). However, 
rather than GLX, GABA+, lactate or NAA disturbance in this period I found 
alteration of Cr. The finding of high post ictal Cr144/Cr30 levels which normalise 
within minutes appears to fit with our understanding of the role played by the creatine 
/ phosphocreatine buffer system in maintaining ATP levels during periods of brief 
activation. Since the combined Cr signal is a dominant peak that is easily and reliably 
determined in 1H MRS experiments, a functional MRSI study in the immediate 
postictal period would be an interesting follow up of this work. In this study lactate 
was not shown to be elevated in the post-ictal period whereas there is substantial 
evidence that lactate is released during prolonged epileptic seizures. In my experiment 
it is most likely that the ictal events studied were too brief to result in a detectable 
release of lactate. The further work envisaged would be able to reassess this. 
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In addition to these tested hypotheses two further observations can be made on the 
basis of the findings in this thesis. 
 
Firstly, metabolite concentrations are sensitive to the administration of antiepileptic 
medications.  Sodium valproate reduces the levels of MRS visible Ins levels [Chapter 
3.3] and [Chapter 3.5], whilst topiramate and gabapentin appear to be associated with 
higher GABA+ levels [Chapter 3.4]. These findings may find application in the 
assessment of treatment effect in patients with poor response to initiated treatments 
and / or in the investigation of patients with suspected drug resistance genes. The 
obtained Ins signal in 1H MRS experiments is considered to derive from myo-Inositol 
in the glial pool. Thus, the observation of an effect of valproate on a glial marker may 
become particularly interesting in the light of a growing understanding of the role of 
astrocyte dysfunction in a range of neurological conditions which include migraine, 
epilepsy, Alzheimer’s disease, motor neurone disease and stroke. 
 
The second additional observation arising from this work is the difficulty in 
interpreting the conventionally described ratio NAA/Cr. Whilst it is sometimes 
necessary to report this ratio (particularly when signal quality is poor (as in [Chapter 
3.6]) it is now clear that Cr levels do not represent a global “standard” across brain 
regions and pathologies. Cr levels are affected by recent seizures and inter-ictal levels 
may be sensitive to variation in seizure control. More importantly there is wide 
variation in NAA/Cr levels across regions dependent simply on the tissue composition 
[Chapter 3.1]. As long as the majority of papers reporting MRS experiments continue 
to use this ratio, there will remain uncertainty as to the correct role of MRS in the 
assessment of epilepsy and other neurological conditions. 
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Further Work 
 
Further projects suggested by the findings described in this thesis are as follows: 
 
Sub-group analysis of IGE patients to determine whether there is characteristic profile 
within sub-groups / prominent seizure types. 
 
Sub-group analysis of MCD populations to better characterise the profile of MCD 
sub-types. Such a work would incorporate assessment of normal appearing tissue and 
allow correlation with EEG information and / or pathology if available 
 
Functional MRSI assessment could be performed in the immediate post-ictal period to 
determine if it is possible to map seizure activity across brain regions using the ratio 
Cr144/Cr30. 
 
High field examination of GABA, glutamate and glutamine to re-examine whether 
direct observation of these compounds in more localised regions of interest may be 
more sensitive for abnormality in epileptogenic tissue. 
 
Exploration of the effect of valproate on Ins levels in a group of patients with drug 
resistant epilepsy may be informative particularly if this group does not show 
reduction of Ins with administration of valproate
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